Deciphering pre-leukaemic dysregulation caused by mutant C/EBPα at the level of the single cell by Qureshi, Moosa
 
 
Deciphering pre-leukaemic dysregulation 
caused by mutant C/EBPa at the level of 





Moosa Rashid Qureshi 
Department of Haematology 
University of Cambridge 
 
This dissertation is submitted for the degree of 
Doctor of Philosophy 
 
 








This thesis is the result of my own work and includes nothing which is the outcome of work 
done in collaboration except as declared in the Acknowledgments and specified in the text. It 
is not substantially the same as any that I have submitted, or, is being concurrently submitted 
for a degree or diploma or other qualification at the University of Cambridge or any other 
University or similar institution except as declared in the Acknowledgments and specified in 
the text. I further state that no substantial part of my thesis has already been submitted, or, 
is being concurrently submitted for any such degree, diploma or other qualification at the 
University of Cambridge or any other University or similar institution except as declared in the 
Acknowledgments and specified in the text. It does not exceed the prescribed word limit for 












Deciphering pre-leukaemic dysregulation caused by 
mutant C/EBPa at the level of the single cell  
Moosa Rashid Qureshi 
 
C/EBPa is an ideal candidate to explore pre-leukaemic dysregulation of transcriptional 
networks because it is a significant player in normal myelopoiesis, it interacts with other 
transcription factors (TFs) in lineage specification, and the CEBPA gene has been identified as 
an early mutation in acute myeloid leukaemia (AML). N321D is a mutation affecting the 
leucine zipper domain of C/EBPa which has previously generated an aggressive AML 
phenotype in a mouse model. 
 
The first objective of my thesis was to construct a novel in vitro cellular model to recapitulate 
pre-leukaemic changes associated with the CEBPA N321D mutation. The conditionally 
immortalised murine Hoxb8-FL cell line can differentiate into relatively homogenous 
populations of functional myeloid, lymphoid and dendritic cells in appropriate cell culture 
conditions. These cells were transduced with retroviral vectors which expressed either no 
transgene or “Empty Vector” (EV), the CEBPA wildtype (WT) or N321D mutation. CEBPA 
N321D-transduced cells had immature morphological appearance in Flt3L differentiation 
media, proliferated indefinitely, and were characterised by a plasmacytoid dendritic cell 
(pDC)-like immunophenotype. These cells were capable of long-term engraftment in a mouse 
model but did not recapitulate leukaemia for several months after transplantation. 
 
The second objective was to characterise the transcriptional deregulation associated with the 
phenotypes demonstrated by EV, CEBPA WT and N321D-expressing cells in the presence of 
Flt3L. Single cell RNA-seq (scRNA-seq) confirmed phenotypic observations that CEBPA N321D-
transduced cells had a pDC precursor-like gene expression signature when placed in Flt3L 
conditions of differentiation. Single cell analysis also identified transcriptional heterogeneity 






The third objective was to use ChIP-seq to investigate the effect of the N321D mutation on 
C/EBPa’s TF binding profile, and correlate this with scRNA-seq data to identify a set of 
candidate genes (NOTCH2, JAK2, SIRPA, FOS, and others) where gene expression changes 
were associated with direct binding events by the mutant TF.  
 
In addition to characterising the transcriptional effects of the CEBPA mutation, a fourth 
objective was to update and expand the Göttgens group’s CODEX database of TF-binding and 
histone modification data for human blood cells, increasing annotation of the genome to 
14.83%.  This online database now provides significant coverage of the non-coding portion of 











Firstly, I would like to thank my supervisor Bertie Göttgens for his invaluable mentorship and 
support during my PhD, particularly for providing vision at those definitive points when I could 
not myself see a clear path forwards. It has been a real privilege to work under his supervision.  
 
I am indebted to everyone in the Göttgens lab for providing a fantastic environment of 
academic endeavour, but in particular I would like to thank Fernando Calero-Nieto for 
providing me with practical help and advice throughout my scientific apprenticeship, and for 
teaching me the importance of scientific rigour. In addition, I would like to thank Sarah Kinston 
and Iwo Kucinski for their practical help with cloning and single cell work, and the Flow 
Cytometry Team at the CIMR for helping me to develop a workable flow panel and for cell 
sorting. From the Göttgens bioinformatics team, I would like to thank Evangelia Diamanti, 
Fiona Hamey, Xiaonan Wang, and Wajid Jawaid for helping me with R-code, and especially 
Rebecca Hannah who helped enormously with processing my ChIP-seq data and my work on 
the CODEX database. It would be greatly remiss of me not to acknowledge the outstanding 
administrative support I received from Martin Dawes. Regarding collaboration, I would like to 
thank the Huntly group and in particular George Giotopoulos for his help and expertise with 
in vivo work. 
 
Thirdly, I thank the Cambridge Cancer Centre for selecting me for this PhD, and Cancer 
Research UK and the Addenbrooke’s Charitable Trust for supporting my research. In addition, 
I would like to thank the Charles Slater Fund and Queens’ College for funding me to present 
my work at international conferences. 
 
I would also like to thank my father who continues to inspire me, my mother whose memory 
sustains me, and all my extended family. Finally, I express my gratitude to Sara Khalil Ebrahim 
Ali for providing love, intellectual stimulation, asking me questions which I can never answer, 









AML   Acute Myeloid Leukaemia 
APC   Antigen Presenting Cell 
APML   Acute Promyelocytic Leukaemia 
ASAP   Automated Single-cell Analysis Pipeline 
BMDC   Bone Marrow derived Dendritic Cell 
BMS   Bone Marrow Stroma 
BR   Basic Region 
bZIP   basic-region leucine Zipper 
C/EBP   CCAAT/Enhancer Binding Protein 
cDC   Conventional Dendritic Cell 
cDNA   Complementary DNA  
CDP   Common Dendritic cell Progenitor 
CHIP   Clonal Haematopoiesis of Indeterminate Potential 
ChIP   Chromatin Immunoprecipitation 
ChIP-seq  Chromatin Immunoprecipitation Sequencing 
CLP   Common Lymphoid Progenitor 
CMGA   Complex Molecular Genetic Abnormalities 
CML   Chronic Myeloid Leukaemia 
CMP   Common Myeloid Progenitor 
CRISPR   Clustered Regularly Interspaced Short Palindromic Repeats 
CyTOF   Cytometry by Time Of Flight 
DC   Dendritic Cell 
DGE   Differential Gene Expression 
dm   double mutated 
DMEM   Dulbecco's Modified Eagle's Medium 
DMSO   Dimethyl Sulfoxide 
DNA   Deoxyribonucleic Acid 
dNTP   Deoxynucleotide Triphosphates 
dT   Deoxythymine 
EDTA   Ethylenediaminetetraacetic Acid 
ENCODE  ENCyclopaedia Of DNA Elements 





EV   Empty Vector 
FAB   French-American-British (AML Classification System) 
FACS   Fluorescence-Activated Cell Sorting 
FBS   Foetal Bovine Serum 
G-CSF   Granulocyte-Colony Stimulating Factor 
GEO    Gene Expression Omnibus 
GFP   Green Fluorescent Protein 
GM-CSF  Granulocyte Macrophage-Colony Stimulating Factor 
GMP   Granulocyte Macrophage Progenitor 
GO   Gene Ontology 
GRN   Gene Regulatory Network 
GWAS   Genome-wide Association Study 
HEPES   4-(2-Hydroxyethyl)-1-Piperazineethanesulfonic Acid 
HPC-7   Haematopoietic precursor cell-7 
HSC   Haematopoietic Stem Cell 
HSPC   Haematopoietic Stem and Progenitor Cells 
IFN   Interferon 
IL-3   Interleukin 3 
ImmGen  Immunological Genome 
IRES   Internal Ribosome Entry Site 
LIC   Leukaemia Initiating Cell 
LMPP   Lymphoid-Primed Multipotent Progenitor 
LSK   Lin- Sca-1+ c-Kit+ 
LT-HSC   Long-Term HSC 
LZ   Leucine Zipper 
MACS   Model-based Analysis of ChIP-seq 
mChrom1  mouse Chromosome 1 
M-CSF   Macrophage-Colony Stimulating Factor 
MDP   Monocyte/Macrophage Dendritic Cell Progenitor 
MDS   Myelodysplastic Syndrome 
MEP   Megakaryocyte Erythrocyte Progenitor 
MHC   Major Histocompatibility Complex 
MLL   Mixed Lineage Leukaemia 
MLP   Multi-Lymphoid Progenitor 





mRNA   messenger RNA 
NOD SCID  Non-Diabetic with Severe Combined Immunodeficiency Disease 
NGS   Next Generation Sequencing 
NSG   NOD SCID Gamma 
PBS   Phosphate Buffered Saline 
PCA   Principal Component Analysis 
PCR   Polymerase Chain Reaction 
pDC   Plasmacytoid Dendritic Cell 
PBS   Phosphate Buffered Saline 
qPCR   Quantitative PCR 
RNA   Ribonucleic acid 
RPMI   Roswell Park Memorial Institute Medium 
sc   single cell 
SCF   Stem Cell Factor 
Scl   Stem cell leukaemia 
SD   Sequencing Depth 
shRNA   short hairpin RNA 
smFISH  single-molecule Fluorescence In Situ Hybridisation 
SNP   Single Nucleotide Polymorphism 
SNR   Signal-to-Noise Ratio 
ST-HSC   Short-term HSC 
TAD   Transactivation Domain 
TAE   Tris/Acetic Acid/EDTA Buffer 
TBE   Tris/Borate/EDTA Buffer 
TBS   Tris Buffered Saline 
TE   Tris/EDTA 
TF   Transcription Factor 
t-SNE   t-Distributed Stochastic Neighbour Embedding 
TSS   Transcription Start Site 
UCSC   University of California Santa Cruz (Genome Browser) 
UMI   Unique Molecular Identifier 
URE   Upstream Regulatory Element  
WGS   Whole Genome Screening 














Abstract ........................................................................................................................... II 
Acknowledgements ........................................................................................................ IV 
Abbreviations .................................................................................................................. V 
Contents ......................................................................................................................... IX 
List of Figures .................................................................................................................. XI 
List of Tables .................................................................................................................. XV 
List of Figure and Tables in Appendix  ........................................................................... XVI 
1 Introduction ............................................................................................................... 1 
1.1 Normal haematopoiesis ............................................................................................. 1 
1.2 Malignant haematopoiesis ........................................................................................... 7 
1.3 Transcription factor regulation of haematopoiesis ..................................................... 12 
1.4 CCAAT/enhancer binding protein α ............................................................................ 15 
1.5 The Single Cell: A New Paradigm ................................................................................ 24 
1.6 Thesis Aims ................................................................................................................. 27 
2 Materials and Methods ........................................................................................... 29 
2.1 Molecular biology ....................................................................................................... 29 
2.2 Cloning ........................................................................................................................ 31 
2.3 Cell culture .................................................................................................................. 34 
2.4 Cell biology ................................................................................................................. 36 
2.5 In vivo mouse model ................................................................................................... 45 
2.6 Bioinformatics ............................................................................................................ 46 
3 Construction and phenotypic characterisation of a stable retroviral expression system 
for CEBPA WT and CEBPA N321D .................................................................................... 51 
3.1 Construction of retroviral expression system ............................................................. 51 
3.2 Characterisation of transduced cell lines in self-renewal conditions .......................... 53 
3.3 Characterisation of transduced cell lines upon differentiation ................................... 59 
3.4 Differentiation of CEBPA N321D cell line for extended time period in Flt3L suggests Hoxb8- 
independent immortalised pDC progenitor phenotype ......................................................... 65 
3.5 In vivo potential of Hoxb8-independent CEBPA N321D cells....................................... 70 





4 Single cell gene expression analysis reveals heterogeneity in CEBPA N321D-transduced 
cells and dysregulation of HSPC and DC transcriptional programs .................................79 
4.1 Background.................................................................................................................. 79 
4.2 Experimental design .................................................................................................... 83 
4.3 Flow cytometry confirms CD11b phenotype before scRNA-seq ................................... 84 
4.4 Analysis of single-cell data using the Automated Single-cell Analysis Pipeline ............ 85 
4.5 Discussion .................................................................................................................. 107 
5 ChIP-seq reveals the effect of CEBPA N321D mutation on genome-wide binding of 
C/EBPα  and identifies direct targets for transcription ……………………………………………..115 
5.1 Introduction............................................................................................................... 115 
5.2 Experimental design .................................................................................................. 118 
5.3 Confirmation of ChIP enrichment by qPCR and ChIP-seq read quality ....................... 118 
5.4 Binding events for exogenous mutant C/EBPα, but not endogenous C/EBPα, are markedly  
increased during differentiation of mutant cells in Flt3L ...................................................... 121 
5.5 Intersection of differential gene expression and C/EBPα binding events .................. 125 
5.6 Intersection of FLAG binding events and DGE between cell lines at Day 5 ................ 133 
5.7 Intersection of chromatin accessibility profile and C/EBPα binding events……………. 137 
5.8 Discussion .................................................................................................................. 140 
6 Restructuring, curating and expanding ChIP-seq datasets in CODEX database: New 
insights into cell-intrinsic and TF-mediated effects during human haematopoiesis ..... 145 
6.1 Introduction............................................................................................................... 145 
6.2 Manual curation of human blood cells in HAEMCODE ............................................... 146 
6.3 Constructing global heat maps for human blood cells reveals pairwise correlations between 
cell types in TF-binding data but not in histone modification data ....................................... 148 
6.4 Constructing heat maps for normal and malignant human blood cells reveals distinct clusters 
in normal human blood cells but loss of pairwise correlation in malignant cells .................. 153 
6.5 Constructing heat maps for progenitor, myeloid and lymphoid compartments suggests 
altered TF binding profiles for different cell compartments, and an association beween AML and 
pDCs …… ............................................................................................................................... 155 
6.6 Constructing heat maps for myeloid and lymphoid subsets within normal and malignant 
compartments ………………………………………………………………................................................... 158 
6.7 Discussion .................................................................................................................. 161 
 
7 Conclusions ............................................................................................................ 165 
References .................................................................................................................... 173 









List of Figures 
 
Figure 1.1 Clonal relationships. ......................................................................... 10 
Figure 1.2 Boolean model of core TF networks active in common myeloid 
progenitors. ...................................................................................................... 14 
Figure 1.3 Gene expression activity of CEBPA in 39 distinct haematopoietic cells.
 ......................................................................................................................... 16 
Figure 1.4 Structure of C/EBPα.......................................................................... 17 
Figure 1.5 Schematic representation of C/EBPα isoforms . ................................ 18 
Figure 1.6 Schematic representation of mutant CEBPA alleles. ......................... 20 
Figure 1.7 Kaplan-Meier survival analysis of mice receiving transplants of BM cells 
transduced with C-terminal mutations.............................................................. 20 
Figure 3.1 Mutated CEBPA in the CEBPA N321D cell line. .................................. 52 
Figure 3.2 Comparison of c-kit, CD11b, XCR1 and SIRPα expression in cell lines 54 
Figure 3.3 Two subpopulations observed in CEBPA WT-transduced cells in the 
presence of estradiol. ....................................................................................... 55 
Figure 3.4 Differentiation profile of transduced cell lines at Day 10 in the presence 
of Flt3L and estradiol. ....................................................................................... 56 
Figure 3.5 Morphological appearances of cell lines in presence of Flt3L and 
estradiol ........................................................................................................... 57 
Figure 3.6 Competition assay of Hoxb8-FL cells after transduction with retroviral 
vectors. ............................................................................................................. 58 
Figure 3.7 Logarithmic growth chart for transduced cell lines ........................... 59 
Figure 3.8 Differentiation profile of transduced cell lines at Day 5 in the presence 
of GM-CSF, IL-3, M-CSF and Flt3L ...................................................................... 60 
Figure 3.9 Differentiation profile of transduced cell lines at Day 5 in the presence 
of Flt3L and withdrawal of estradiol .................................................................. 61 
Figure 3.10 Differentiation profile of transduced cell lines at Day 10 in the 






Figure 3.11 Morphological appearances of cell lines after differentiation in Flt3L 
for 5 days. ......................................................................................................... 64 
Figure 3.12 Logarithmic growth chart for transduced cell lines. ........................ 65 
Figure 3.13 Indefinite expansion of CEBPA N321D cell line in Flt3L without 
estradiol. .......................................................................................................... 66 
Figure 3.14 CEBPA N321D-transduced cells after 56 days of differentiation in 
Hoxb8 media F+e- ............................................................................................. 66 
Figure 3.15 Differentiation profile of CEBPA N321D-transduced cells after 
extended time period in Hoxb8 media F+e- ...................................................... 67 
Figure 3.16 Flow cytometry shows progression of CEBPA N321D-transduced cell 
line into a c-kit low CD11c+ B220+ phenotype ...................................................... 68 
Figure 3.17 Differentiation profile of CEBPA N321D-transduced cells at Day 31 in 
Hoxb8 media F+e- ............................................................................................. 69 
Figure 3.18 Circulating Ly 5.1 cells in C57BL/6J mice ......................................... 71 
Figure 3.19 Bone marrow profile of C57BL/6J mice infected with CD 45.1 cells . 71 
Figure 3.20 GFP+ cells in bone marrow and spleen after gating for CD45+ leucocyte 
compartment .................................................................................................... 72 
Figure 3.21 CEBPA N321D-transduced cells persist in bone marrow and spleen,  
and express B220, CD11b and Gr1 .................................................................... 72 
Figure 4.1 CD11b expression for 3 biological replicates of transduced cells before 
index-sorting ..................................................................................................... 85 
Figure 4.2 Distribution of gene expression in each cell after normalisation. ...... 86 
Figure 4.3 scLVM fit of technical noise .............................................................. 86 
Figure 4.4 Variable genes identified after scLVM fit of technical noise. ............. 86 
Figure 4.5 ASAP t-SNE visual representation of scRNA-seq experiment ............. 88 
Figure 4.6 ASAP single cell data plotted using ggplot2. ...................................... 89 
Figure 4.7 Gene expression signatures correlate with DC subtypes. .................. 91 
Figure 4.8 ASAP shows IRF8 and IRF4 expression of transduced cells. ............... 92 
Figure 4.9 Number of genes differentially expressed for cell lines differentiated 
for 5 days in Flt3L, excluding genes differentially expressed in CEBPA WT......... 97 
Figure 4.10 ASAP shows two cohorts of CEBPA N321D-transduced cells after 





Figure 4.11 Number of genes differentially expressed for two cohorts of CEBPA 
N321D-transduced cells and all EV-transduced cells ....................................... 103 
Figure 4.12 Violin plot showing normalised counts for RUNX2. ....................... 105 
Figure 4.13 Violin plot showing normalised counts for JUNB. .......................... 106 
Figure 4.14 Violin plot showing normalised counts for CDK6 ........................... 106 
Figure 5.1 Schematic of ChIP-seq. ................................................................... 116 
Figure 5.2 qPCR evaluation of ChIP enrichment .............................................. 119 
Figure 5.3 UCSC shows ChIP-seq binding events at SPI1 and CEBPB loci .......... 120 
Figure 5.4 Read count comparison for global binding events using C/EBPα and 
FLAG antibodies. ............................................................................................. 122 
Figure 5.5 DNA regions which show four-fold increased/decreased read counts 
for C/EBPα-binding in first biological replicate ................................................ 123 
Figure 5.6 DNA regions which show four-fold increased/decreased read counts 
for C/EBPα-binding in second biological replicate ........................................... 124 
Figure 5.7 High confidence regions after intersection of DNA regions. ............ 124 
Figure 5.8 Schematic of first strategy to analyse qualitative variations in genome-
wide binding profiles between EV and CEBPA N321D-transduced cells ........... 126 
Figure 5.9 Schematic of second strategy to analyse qualitative variations in 
genome-wide binding profiles between EV and CEBPA N321D-transduced cells
 ....................................................................................................................... 133 
Figure 5.10 C/EBPα-bound regions enriched four-fold with high confidence ... 137 
Figure 5.11 Regions enriched two-fold by H3K27Ac-binding ........................... 139 
Figure 6.1 Summary of numbers of ChIP-seq experiments in previous iteration of 
CODEX and additional data incorporated during my review ............................ 148 
Figure 6.2 Heat map showing pairwise correlations between ChIP-seq profiles for 
TFs in all human blood cells on CODEX ............................................................ 149 
Figure 6.3 Heat map showing pairwise correlations between ChIP-seq profiles for 
histone modifications in all human blood cells on CODEX ............................... 151 
Figure 6.4 Heat map showing pairwise correlations between ChIP-seq profiles for 
histone modifications in all human blood cells on CODEX after excluding 





Figure 6.5 Heat map showing pairwise correlations between ChIP-seq profiles for 
transcription factors in non-malignant human blood cells on CODEX. ............. 153 
Figure 6.6 Heat map showing pairwise correlations between ChIP-seq profiles for 
transcription factors in malignant human blood cells on CODEX ..................... 154 
Figure 6.7 Heat map showing pairwise correlations between ChIP-seq profiles for 
transcription factors in human haematopoietic progenitor cells on CODEX .... 155 
Figure 6.8 Heat map showing pairwise correlations between ChIP-seq profiles for 
transcription factors in human myeloid cells on CODEX .................................. 156 
Figure 6.9 Heat map showing pairwise correlations between ChIP-seq profiles for 
transcription factors in human lymphoid cells on CODEX ................................ 157 
Figure 6.10 Heat map showing pairwise correlations between ChIP-seq profiles 
for transcription factors in normal myeloid cells on CODEX ............................ 158 
Figure 6.11 Heat map showing pairwise correlations between ChIP-seq profiles 
for transcription factors in normal lymphoid cells on CODEX .......................... 159 
Figure 6.12 Heat map showing pairwise correlations between ChIP-seq profiles 
for transcription factors in malignant myeloid cells on CODEX ........................ 160 
Figure 6.13 Heat map showing pairwise correlations between ChIP-seq profiles 
for transcription factors in malignant lymphoid cells on CODEX ...................... 161 
Figure 6.14 UCSC genome browser confirms similar binding profiles for CTCF at 







     
     






List of Tables 
 
 
Table 2.1 Primers for original CEBPA N321D plasmid .................................................... 32 
Table 2.2 Primers for Gibson assembly of CEBPA WT plasmid ....................................... 32 
Table 2.3 PCR primers and conditions to add FLAG tag and restriction sites  ................ 33 
Table 2.4 Primers to sequence ligation junctions in retroviral constructs ...................... 34 
Table 2.5 Primers for Sanger sequencing along length of CEBPA WT and N321D  ......... 34 
Table 2.6 Basic panel of antibodies for flow cytometry ................................................. 38 
Table 2.7 Advanced panel of antibodies for flow cytometry ......................................... 38 
Table 2.8 RT thermocycler conditions for Smart-seq2 protocol ..................................... 39 
Table 2.9 PCR pre-amplification thermocycler conditions ............................................. 40 
Table 2.10 PCR amplification thermocycler conditions.................................................. 41 
Table 2.11 qPCR primers ............................................................................................... 43 
Table 2.12 qPCR amplification thermocycler conditions ............................................... 44 
Table 2.13 PCR amplification thermocycler conditions during ChIP library preparation 44 
Table 3.1 Flow cytometry panel to evaluate differentiation .......................................... 53 
Table 4.1 Quality control for single cell RNA-seq experiment ........................................ 84 
Table 4.2 Genes differentially expressed for each cell line in differentiation media ...... 94 
Table 4.3 Gene atlas and ontology from gene enrichment of top 100 genes ................. 95 
Table 4.4 Upregulated genes in N321D overlap with Mouse Gene Atlas ....................... 97 
Table 4.5 Upregulated genes in EV overlap with Mouse Gene Atlas .............................. 98 
Table 4.6 Downregulated genes in EV and N321D overlap with Mouse Gene Atlas ....... 99 
Table 4.7 Up and down regulated genes in WT overlap with Mouse Gene Atlas ........... 99 
Table 4.8 Genes switched on/off by N321D overlap with Mouse Gene Atlas ................ 101 
Table 4.9 Up/downregulated genes (78 N321D cells) overlap with Mouse Gene Atlas .. 103 
Table 4.10 Up/downregulated genes (5 N321D cells) overlap with Mouse Gene Atlas .. 104 
Table 5.1 Peak distribution of regions enriched by C/EBPα-binding .............................. 138 








List of Figure and Tables in Appendix 
 
Figure 1 Vector map for MSCV-CEBPA-IRES-eGFP ......................................................... 201 
 
Table 1 Upregulated genes on Day 2 WT vs EV-transduced cells ................................... 201 
Table 2 GO biological processes from upregulated genes in Table 1 ............................. 204 
Table 3 Downregulated genes on Day 2 WT vs EV-transduced cells .............................. 204 
Table 4 GO biological processes from downregulated genes in Table 3......................... 206 
Table 5 Up/downregulated genes on Day 2 N321D vs EV-transduced cells ................... 206 
Table 6 Genes upregulated during culture in Flt3L differentiation media ...................... 207 
Table 7 Genes downregulated during culture in Flt3L differentiation media ................. 212 
Table 8 Genes switched on and off by the N321D mutation.......................................... 218 
Table 9 Genes upregulated during culture in Flt3L differentiation media ...................... 220 
Table 10 Genes downregulated during culture in Flt3L differentiation media ............... 227 
Table 11 Genes upregulated in EV cells which have associated C/EBPα peak ................ 240 
Table 12 Genes from Table 11 which are also upregulated in N321D cells .................... 242 
Table 13 Genes from Table 12 which are also bound by FLAG ....................................... 243 
Table 14 Genes from Table 13 which are downregulated on DGE of N321D vs EV ........ 244 








My PhD thesis undertakes single cell analysis of pre-leukaemic transcriptional dysregulation 
caused by CEBPA N321D, and describes a dendritic cell phenotype following expression of this 
mutation during early haematopoiesis. In this introductory chapter, I first present current 
paradigms of normal and malignant haematopoiesis, focusing on early progenitors and 
leukaemia initiation, and placing my cellular model and dendritic cells within this framework. 
I then present a general synopsis of the transcriptional control of haematopoiesis, before 
undertaking a detailed examination of C/EBPα’s role in that process.  Finally, I give a brief 
overview of how single cell technology is changing current paradigms of haematopoiesis and 
its transcriptional regulation. 
 
1.1 Normal haematopoiesis 
1.1.1 Haematopoietic stem cells and progenitor populations 
Haematopoetic stem cells (HSCs) are defined by dual properties of multipotency and self-
renewal as demonstrated by serial transplantation experiments, whereas haematopoietic 
progenitor cells are characterised by lineage restriction and limited self-renewal capacity in 
irradiated mouse models (Weissman et al, 2001, Oguro et al, 2013). This paradigm of normal 
haematopoiesis was heralded by Till and McCulloch’s seminal finding that rescuing irradiated 
mice with bone marrow transplantation led to splenic “bumps” capable of reconstituting 
heterogeneous haematopoietic lineages (Till et al, 1961), and experimental proof of clonality 
in these splenic colonies (Becker et al, 1963). Over the following decades, it was established 
that normal haematopoiesis is regulated by intricate combinatorial networks (Wilson et al, 
2010) which maintain self-renewal, lineage specification, differentiation, and apoptotic 
programs to maintain a steady state with physiologically advantageous populations of blood 
cells.  
 
Initial characterisation of haematopoiesis by flow cytometry of bulk cell populations employed 
cell surface markers to define a strictly hierarchical tree structure, starting with Lin- Sca-1+ c-
kit+ (LSK) CD150+ CD48- long-term HSCs (LT-HSCs) at the top of the hierarchy (Kiel et al, 2005), 
differentiating down to LSK CD34+ short-term HSCs (ST-HSCs) (Yang et al, 2005), and then 
making a cell fate decision to bifurcate into either a common lymphoid precursor (CLP) (Lin- 





7R- Sca-1- c-kit+ FcγRlo CD34+ ; Akashi et al, 2000). Further cell fate choices to differentiate into 
either megakaryocyte erythroid progenitor (MEP) (CD16/32lo CD41- CD150+ CD105lo ; Pronk et 
al, 2007) or granulocyte monocyte progenitor (GMP) (CD16/32hi CD41lo ; Akashi et al, 2000) 
cells were followed finally by terminally differentiated cells. This series of discrete steps was 
redefined as additional surface markers were identified, by the identification of macrophages 
and dendritic cells arising from early lymphoid progenitors (Doulatov et al, 2010), the finding 
of lymphoid-primed multipotent progenitor (LMPP) cells in the LSK  Flt3+ compartment lacking 
erythro-megakaryocytic potential (Adolfsson et al, 2005), and the classification of  functionally 
distinct lineage-primed multipotent progenitors (MPPs) (Pietras et al, 2015). 
 
In fact, alongside these bulk population studies, more precise experiments were redefining 
the architecture of the haematopoietic landscape from as early as 2013, when single cell 
transplantation studies suggested that lineage restriction can be found in mouse HSCs (Naik 
et al, 2013, Yamamoto et al, 2013). John Dick and colleagues confirmed this effect in humans 
by observing divergence of erythro-megakaryocytic lineage from bone marrow HSC-MPPs 
(Notta et al, 2016). Extensive granddaughter-tracing experiments have found that most cells 
inherit ancestral lineage bias from early progenitor cells including HSCs, that bias is amplified 
by bias-inheriting progeny, but also that lineage bias switching can infrequently be observed  
(Lee et al, 2017). This same study suggested that dendritic cell lineage bias can be identified 
in HSCs, is characterised by specific transcriptional programs correlated with relative 
IRF8:PU.1 ratios, and is heritable and reinforced over progressive cell division.  
 
It is important when performing in vitro experiments to recognise that cell-extrinsic signalling 
from the bone marrow microenvironment also plays a significant role in HSC differentiation 
pathways. HSCs home in to distinct endosteal (Calvi et al, 2003) and vascular (Kiel et al, 2005) 
niches with varied cell composition such as osteoblasts and mesenchymal stromal cells. This 
leads to heterogeneous HSC-niche interactions with diversity provided by extra-cellular signals 
from cytokines, cytokine-receptor profiles of individual HSCs, and cell-to-cell interactions.  
Cytokine-mediated modulation of HSC cell fate decisions is well characterised, for instance 
thrombopoietin signalling is essential for megakaryocyte-biased HSCs (Sanjuan-Pla et al, 
2013). In addition, the biophysical properties of the niche are heterogeneous throughout the 
bone marrow, and it has been shown that LSK HPC cell fate can be modulated by varying the 






1.1.2 LMPP cells  
Downstream of HSCs, the Jacobsen group identified LSK Flt3+ LMPP cells, challenging the 
prevailing consensus position that HSCs committed strictly to common myeloid or common 
lymphoid progenitor lineages (Adolfsson et al, 2005). Human LMPP cells are Lin- CD34+ CD38- 
CD90 -/lo CD45RA+ CD10 - and have granulocytic, monocytic and lymphoid potential, but lack 
erythro-megakaryocytic potential. More recently, human LMPP cells have been divided by 
CD10 and CD45RA cell surface markers into two subpopulations, one with almost entirely 
lymphoid potential and another one with lympho-myeloid potential  (Karamitros et al, 2018). 
In the same study, single cell RNA-seq has suggested heterogeneity in human lympho-myeloid 
progenitors at the level of the single cell, and that the transcriptional signature of LMPP cells 
exists in a continuum with granulocyte-macrophage progenitor (GMP) and multi-lymphoid 
progenitor (MLP) populations (Karamitros et al, 2018).  
 
1.1.3 Hoxb8-FL cells 
The Hoxb8-FL cell line has been employed in our experiments to model pre-leukaemic 
changes, and it is therefore useful to place it within the hierarchical model of haematopoiesis 
and characterise its phenotype and functionality. Hoxb8-FL cells demonstrate phenotypic and 
functional similarities to LMPP cells, but have a distinct lin- Sca-1- c-kit+ cd34+ Flt3+ cell surface 
marker profile, suggesting that they lie downstream of Sca-1+ LMPP cells (Redecke et al, 2013). 
Principal component analysis (PCA) of microarray-based gene expression clusters Hoxb8-FL 
cells in between myeloid and lymphoid branches extending down from LMPP cells (Redecke 
et al, 2013). Conditional Hoxb8 expression by fusing the N terminus of Hoxb8 to the estrogen-
binding domain of the estrogen receptor and expressing the fused cDNA in lineage-negative 
progenitor cells as a retroviral expression vector was first published in 2006 as a method to 
immortalise neutrophil or macrophage progenitors in medium containing stem cell factor 
(SCF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) (Wang et al, 2006). 
Redecke et al cultured these cells in the presence of estrogen and Flt3L, and found that these 
conditions promoted exponential growth of blast-like Hoxb8-FL cells (Redecke et al, 2013). 
Upon withdrawing estradiol, Hoxb-FL cells differentiated over 6 days into a bi-phenotypic 
dendritic cell (DC) population of CD11b+ CD11c+ MHC class II+ B220 - PDCA1- conventional 
dendritic cells (cDCs) and CD11b- CD11c+ MHC class II+ B220+ PDCA1+ plasmacytoid dendritic 





Removing estradiol and replacing Flt3L with GM-CSF caused Hoxb8-FL cells to differentiate 
into a mixed population of CD11b+ CD11c+ MHC class II+ B220 - dendritic cells and Gr1high CD11c- 
MHC class II– granulocytes, whereas replacing Flt3L with macrophage-colony stimulating 
factor (M-CSF) resulted in adherent cells with a CD11b+ Gr1- MHC class II - cell surface marker 
profile. Hoxb8-FL cells were cultured continuously over 6 weeks and their lineage potential 
tested by clonal assays and limiting dilution assays, and were found to constitute a 
homogenous population of cells which maintained multilineage potential stably (Redecke et 
al, 2013). 
 
Furthermore, the multi-lineage cells differentiated from the Hoxb8-FL cell line were 
functionally validated by the Häcker group. Functional analysis of Hoxb8-FL cells showed that 
CpG-DNA-mediated stimulation caused pDCs to produce interferon alpha (IFNa) and cDCs to 
produce IL-12 p40. Type 1 and 2 cDCs triggered proliferation of MHC class II and MHC class I-
restricted T cells after incubation with soluble ovalbumin antigen. M-CSF-driven Hoxb8-FL-
derived macrophages demonstrated phagocytic properties and nitric oxide production upon 
provocation with lipopolysaccharide and IFN-g (Redecke et al, 2013). 
 
In vivo transplantation of Hoxb8-FL cells into lethally irradiated mice generated three 
populations of CD11b+ cells with variable Gr1 expression, CD11b- CD11c- B220+ B lymphocytes 
and CD3+ T lymphocytes in peripheral blood, and also demonstrated myeloid and lymphoid 
potential in vivo in an organ-specific and time-dependent manner. Characterisation of Hoxb8-
FL-derived immune cells from spleen and peripheral blood demonstrated that Hoxb8-FL-
derived cells in vivo corresponded functionally to primary LMPP-derived cells. The LMPP-like 
phenotype was further confirmed by absent megakaryocyte and erythroid potential after 
seeding cells in medium which supported development of these cell lines. Loss of immature 
cells over time suggested that Hoxb8-FL cells do not have self-renewal capacity. 
 
In summary, the Häcker group has developed a remarkably robust and plastic LMPP-like cell 
line which is conditionally immortalised, recapitulates myeloid and lymphoid phenotype, and 
is capable of stable integration of mutant gene constructs which can be employed to study 







1.1.4 Dendritic cells  
Hoxb8-FL cells can differentiate in Flt3L conditions into both conventional and plasmacytoid 
DCs, however it should be emphasised that the characterisation of DC identity, subtypes and 
function continues to evolve rapidly. It is therefore useful to summarise current understanding 
of DCs and DC subsets, DC function, and DC transcriptional signatures, as well as how recent 
work including scRNA-seq is redefining the classical hierarchy of DC identities. 
 
Dendritic cells can broadly be defined in functional terms as ubiquitous sentinel cells which 
are capable of sensing early danger signals through a broad array of pattern recognition 
receptors, and which can bridge the innate and adaptive immune systems by de novo 
processing and presentation of antigen (Guermonprez et al, 2002). The classical hierarchical 
model of haematopoiesis describes MPP commitment to the DC lineage by differentiation into 
the DC-restricted common DC progenitor (CDP), followed by further DC specification into cDC 
or pDC subsets (Fogg et al, 2006, Onai et al, 2007, Onai et al, 2010). Type 2 CD4+ CD11b+ SIRPα+ 
cDCs specialise in phagocytosis and endocytosis of foreign peptides before presenting 
exogenous antigen via MHC class II pathways to CD4+ helper T cells, initiating antigen-specific 
antibody production by B cells (Pooley et al, 2001). By contrast, type 1 CD8+ XCR1+ cDCs 
capture endogenous peptide antigen from intracellular cytosolic degradation of proteins and 
typically present endogenous epitopes on MHC class I molecules to CD8+ cytotoxic T cells. In 
addition, type 1 cDCs are specialised for antigen cross-presentation, permitting the 
presentation of exogenous antigens (including tumour), which are normally presented on 
MHC class II molecules, to activate cytotoxic T cells through MHC class I pathways (Belz et al, 
2005, Hildner et al, 2008, Bachem et al, 2012). IRF8+ B220+ BST2+ pDCs are also capable of 
antigen presentation but are specialised for response to viral infection and produce large 
quantities of interferon-alpha (IFN-α) in response to stimulation via Toll-like receptors 7 and 
9 (Reizis et al, 2011).  
 
TF networks participate in differentiation programs associated with DC cell fate decisions. For 
instance, the ID2/E2-2 axis regulates differentiation towards pDCs and cDCs (Swiecki et al, 
2015). In addition, TFs play significant roles in DC function, such as RUNX2-mediated egress of 
pDCs from the bone marrow (Sawai et al, 2013, Chopin et al, 2016). Type 1 cDCs are regulated 
by Gata2, PU.1, Gfi1, Irf8 and Batf3 (Onodera et al, 2016, Carotta et al, 2010, Rathinam et al, 





KLF4 (Murphy et al, 2016, Guilliams et al, 2016). Key roles in DC lineage specification are 
played by PU.1, Irf8 and C/EBPα. Elevated PU.1 levels cause higher order chromatin 
remodelling to bring a -50 kb IRF8 enhancer into close contact with the IRF8 promoter, 
favouring DC lineage commitment (Schonheit et al, 2013). Reprogramming of committed T 
cell progenitors to macrophages and dendritic cells by C/EBPα and PU.1 respectively 
demonstrates the developmental plasticity of cell identity (Laiosa et al, 2006). More recently, 
Rosa et al have used PU.1, Irf8 and Batf3 TFs to reprogramme mouse and human fibroblasts 
into DCs which can cross-present antigen to T cells (Rosa et al, 2018). The Tenen group has 
demonstrated that C/EBPα is necessary for differentiation from HSPCs to dendritic cell 
populations both in vitro and in vivo, and discovered C/EBPα-dependent genes (eg ELANE, 
CYBB, GATA3) which are required for early DC differentiation (Welner et al, 2013).  
 
The Immunological Genome (ImmGen) consortium has employed large data sets to decipher 
transcriptional programs of DC lineage specification in mouse cells. Affymetrix microarray 
expression profiles of cells in the ImmGen database have identified Ikaros and Flt3 as essential 
TFs for the differentiation of pDCs and cDCs, as well as TFs which regulate DC diversification 
into type 1 cDCs (BATF3, IRF8), type 2 cDCs (IRF4, NOTCH2) and pDCs (E2-2, SPI-B, IRF8) (Miller 
et al, 2012). In addition, the same study has established a core cDC signature of 24 genes 
which are differentially expressed in cDCs compared to macrophages, as well as unique gene 
signatures associated with pDCs and cDCs. Furthermore, Miriam Merad and colleagues from 
ImmGen found that most of the TF genes which increased expression during commitment of 
macrophage-dendritic cell progenitors (MDPs) to CDPs but not to monocytes, also encoded 
TFs such as RUNX2 and KLF8 which are known to control pDC lineage specification, suggesting 
that CDP differentiation into pDCs constitutes a ‘default’ pathway (Miller et al, 2012). The 
ImmGen gene expression dataset has also been used derive gene expression modules for DC 
subsets (Pandey et al, 2013).  
 
By contrast with the ImmGen consortium approach, Lin et al obtained MPPs, CDPs, cDCs and 
pDCs by FACS sorting mouse bone marrow cells, and then analysed gene expression and PU.1 
binding/histone modification at distinct stages of DC differentiation. This approach revealed 
that stage-specific changes in gene expression for key DC regulators such as IRF8 and TCF4 are 






Recent work has challenged traditional hierarchical DC identities. Lee et al analysed the 
quantitative potency of 2,247 HSC and MPP clones derived from CD34+ human cord blood 
cells, and found no evidence of significant populations correlating with MDPs or CDPs, but 
rather found lineage priming of DCs marked by IRF8 expression during early haematopoiesis 
(Lee et al, 2017). The Tamura group have recently employed IRF8 knock-in and knock-out mice 
to identify epigenetically-primed DC lineage bias in IRF8+ LMPP cells mediated by altered 
chromatin accessibility (Kurotaki et al, 2019). Of particular interest, FACS sorting of DCs and 
monocytes from peripheral blood mononuclear cells of healthy donors, followed by single cell 
RNA-seq of single DCs using the Smart-seq2 protocol, identified a novel Axl+ Siglec6+ DC subset 
which was phenotypically and functionally distinct from classical pDCs (Villani et al, 2017). 
 
1.2 Malignant haematopoiesis 
1.2.1 Pre-leukaemic cell of origin 
Leukaemogenesis is a stepwise process which requires sequential mutations and clonal 
expansion to cause disease. 10% of elderly patients have clonal haematopoiesis of 
indeterminate potential (CHIP), defined as somatic mutations in the haematopoietic 
compartment but no evidence of haematological malignancy (Steensma et al, 2015).  
Predictive models have been developed to distinguish cases of age-related clonal 
haematopoiesis which are more likely to progress to AML, finding that TP53 mutations are 
more likely to predict AML than DNMT3A or TET2 mutations in healthy individuals. It has been 
suggested that a predictive model based on somatic point mutations and variant allele 
frequencies can predict AML years or even a decade before clinical diagnosis (Abelson et al, 
2018). In addition, pre-leukaemic mutations which persist in remission are necessary but not 
sufficient to recapitulate leukaemia, predisposing individuals to relapse (Rothenberg-Thurley 
et al, 2018). 
 
Gene mutations, rearrangements and altered expression profiles are instructive with regard 
to the stepwise leukaemic evolution of AML. Nerlov and colleagues employed a knock-in 
mouse model to show that CEBPA mutations cause pre-malignant expansion in 
haematopoietic stem and progenitor cell (HSPC) compartments prior to the development of 
overt leukaemia (Kirstetter et al, 2008). In familial AML, germline mutations in the N-terminal 





mutations in the C-terminal domain as second events (Pabst et al, 2008).  Furthermore, several 
groups have shown that patients with CEBPA-mutated AML carry the same bi-allelic mutations 
on relapse (Shih et al, 2006, Kirstetter et al, 2008), suggesting that CEBPA mutations represent 
an early pre-leukaemic event.  
 
MLL gene rearrangements have been identified in pairs of monozygotic twins, suggesting that 
pre-leukaemic events can exist in utero (Ford et al, 1993). Similarly, there is evidence for the 
prenatal origin of the t(8;21) AML1-ETO translocation (Wiemels et al, 2002). In addition, the 
translocation t(8;21) persists in patients with  long-term remission (Miyamoto et al, 2000), 
suggesting that this gene rearrangement is a pre-leukaemic event in the sequential acquisition 
of mutations.  
 
Besides mutations and gene rearrangements, both GATA1 knockdown (Shimizu et al, 2004) 
and reduced PU.1 expression (Rosenbauer et al, 2004) have generated pre-leukaemic 
phenotypes in mouse models. Similarly, epigenetic modifications such as hypermethylation 
play a role in pre-leukaemic changes such as HSC expansion, as evidenced by experimental 
data from DNMT3A, TET2 and IDH1 mutation models (Challen et al, 2011, Moran-Crusio et al, 
2011, Sasaki et al, 2012). 
 
1.2.2 Leukaemia initiating cells 
John Dick and colleagues transplanted lineage-negative CD34+ CD38- AML cells into non-obese 
diabetic mice with severe combined immunodeficiency disease (NOD/SCID mice) and found 
that they homed to the bone marrow and proliferated with a leukaemic cell morphology 
similar to that seen in patients (Lapidot et al, 1994). Bonnet and Dick then established a 
hierarchical model of cancer, where the SCID leukaemia-initiating cells (LIC) in all sub-types of 
AML were CD34+ CD38 -, suggesting that the leukaemic clone originated in normal primitive 
cells  rather than in committed progenitor cells (Bonnet et al, 1997).  
 
The emergence of more immunodeficient mouse strains, including NOD SCID Gamma (NSG) 
mice which lack natural killer (NK) cells, permitted further characterisation of LICs. Taussig et 
al showed that CD34- CD38+ progenitors sorted from patients with NPM-mutated AML were 
able to recapitulate a leukaemic phenotype in an IVIG-treated NOD/SCID/IL2rγ−/− mouse 





heterogeneous, for instance the Weissman group retrovirally transduced sorted HSC, CMP 
and GMP populations with MSCV/MLL-ENL-IRES-GFP and transplanted them into irradiated 
mice, showing that myeloid progenitors as well as HSCs were capable of generating a 
leukaemic phenotype (Cozzio et al, 2003). Krivtsov et al found that introduction of the MLL-
AF9 fusion gene into GMPs resulted in LICs with a global gene expression profile and 
immunophenotype very similar to normal GMPs but with a leukaemia self-renewal signature 
(Krivtsov et al, 2006). Similarly, GMPs were identified as candidate LICs in blast-phase chronic 
myeloid leukaemia (CML) (Jamieson et al, 2004).  
 
More recently, Paresh Vyas and colleagues have shown that ~80% of leukaemic stem cells 
from CD34+ AML demonstrate the immunophenotype and gene expression profile of  LMPP-
like or GMP-like progenitors, rather than of HSCs, suggesting that most leukaemic stem cells 
in primary CD34+ AML are progenitor cells which acquire aberrant self-renewal capacity 
(Goardon et al, 2011). We therefore hypothesise that LMPP-like Hoxb8-FL progenitor cells 
provide a stable and reproducible cellular model that can be used to study gene expression 
changes implicated in leukaemia initiation. 
 
1.2.3 AML as a clinical entity 
Acute myeloid leukaemia (AML) is the most common adult leukaemia with an incidence of 15 
per 100,000 at age 75 and a median age at diagnosis of 67 years (Roug et al, 2014). Our 
understanding of leukaemia has evolved significantly since Alfred Donné’s speculation in 1844 
that the “mucous globules” he observed microscopically in a patient with splenomegaly were 
due to differentiation arrest of white blood cells (Kampen, 2012). Since those early 
descriptions, apart from progress in clinical and morphological diagnosis, major advances have 
unfolded from the 1970s onwards in diagnostics, prognostics, and therapeutic options. Today 
we understand that AML results from the stepwise acquisition of somatic mutations (Figure 
1.1) which lead to dysregulation of cell cycle control, limitless replicative potential, genomic 
instability, altered micro-environment, and ultimately the clonal expansion of immature 







Figure 1.1 Clonal relationships (adapted from 
Aparicio et al, 2013) 
 
 
AML represents a haematological emergency and morphology can provide an immediate 
diagnosis in the acute clinical setting, with the World Health Organization (WHO) definition in 
most cases requiring 20% myeloid blast cells in peripheral blood or bone marrow (Vardiman 
et al, 2002). Initial classification of AML continues to employ the French-American-British 
(FAB) morphological criteria established in 1976 (Bennett et al, 1976). The identification and 
quantification of myeloid blasts is now commonly confirmed by flow cytometry to identify 
human AML-associated immunophenotypes including CD13, CD33 and CD117 (Bene et al, 
1995). Cytogenetic abnormalities such as inv(16) and t(15;17) provide a diagnosis of AML even 
in the absence of 20% myeloid blasts on morphological examination.  
 
More recently, molecular mutations have been assimilated into diagnostic criteria for AML 
(Roug et al, 2014), with NPM1 and CEBPA mutations designated as AML entities in the 2008 
WHO classification and the addition of RUNX1 mutations in its 2016 revision (Vardiman et al, 
2009, Arber et al, 2016). In addition, whole genome sequencing (WGS) of patients with AML 
has uncovered mutations affecting epigenetic machinery, including DNMT3A (Ley et al, 2010) 
and IDH1 (Mardis et al, 2009). WGS of 200 patients with AML identified approximately 23 





which suggested that AML may comprise a simpler mutational model than solid tumours 
(Tenen, 2003). More recently, Peter Campbell and colleagues described 5234 driver mutations 
across 76 genes or genomic regions, with two or more driver mutations identified in 86% of 
patients with AML (Papaemmanuil et al, 2016). The challenge of the post-genomic age is to 
elucidate elegantly how these gene perturbations interact with each other within 
transcriptional networks to generate leukaemic phenotypes. 
 
Prognostic information guides clinicians in risk-adapted therapeutic decisions after induction 
of remission, with poor-risk patients who are fit for aggressive therapy proceeding to stem 
cell transplantation. By contrast, favourable-risk patients normally proceed to consolidation 
chemotherapy after successful first remission. Cytogenetics remains the most important 
disease-specific risk factor for AML, and poor-risk karyotypes include t(9;22), monosomy 5 and 
complex karyotype (Grimwade et al, 1998). However, approximately 60% of patients have 
intermediate risk cytogenetics, and in this cohort of patients molecular mutations provide 
important prognostic information: NPM1 and CEBPA with double mutation (CEBPAdm) carry 
favourable prognosis, whereas FLT3-ITD carries poor prognosis (Papaemmanuil et al, 2016). 
Wakita et al have described the concept of Complex Molecular Genetic Abnormalities 
(CMGAs) in AML (Wakita et al, 2016), arguing that the poor prognosis of FLT3-ITD is not an 
intrinsic effect of the mutation itself but rather is because FLT3-ITD commonly co-exists in 
CMGAs with multiple concurrent mutations, whereas the converse is true of CEBPAdm 
mutations.  
 
Therapeutics pose a significant challenge in the management of AML. Initial induction of 
remission continues to be by a combination of antimetabolite and anthracycline 
chemotherapy which was first proven to have efficacy in 1973 (Yates et al, 1973). Relapse 
remains a significant clinical problem with current therapies, due either to the founding clone 
expanding through therapy or else the development of additional mutations in the founding 
clone (Ding et al, 2012).  Unfortunately, progress in diagnostics and prognostication has not 
been matched by the emergence of effective targeted molecular therapies for AML. In this 
regard, WGS has uncovered the significant driver mutations which initiate AML, but fails to 
address the complex transcriptional dysregulation by which initial mutational simplicity brings 





patients with AML at 5 years remains low for younger patients and dismal for patients over 
the age of 60 who constitute the majority of patients with AML (Dickson et al, 2016). 
 
Molecular therapies such as the FLT3 inhibitor Quizartinib are currently undergoing 
development in phase III clinical trials (Cortes et al, 2019). Pharmacological inhibition of 
transcription has traditionally been problematic, but the emergence of therapies such as BET 
inhibitors (Zuber et al, 2011) suggests that transcriptional dissection can lead to novel 
therapeutics as well as an increased understanding of the pathogenesis of AML. The 
effectiveness of immunotherapy in leukaemia has thus far been limited. Allogeneic stem cell 
transplants provide evidence that T lymphocytes can eradicate leukaemic cells, and donor 
lymphocyte transfusions were able to treat relapsed CML before the development of tyrosine 
kinase inhibitors (Kolb, 1998). More recently CAR T-cell therapy has been licenced for use in 
refractory B-ALL (Rose, 2017), comprising an antibody-like domain targeting a specific antigen 
such as CD19, a transmembrane domain, and an intracellular signalling domain which 
activates T-cells. Early excitement around DC vaccination was generated by the finding that a 
single injection of antigen-pulsed DCs in healthy subjects was able to induce a T-cell response 
(Dhodapkar et al, 1999), and myeloid malignancies were seen as a prime target (Schurch et al, 
2013, Tesfatsion et al, 2014, Pyzer et al, 2014). Broadly speaking, DC vaccine therapy 
comprises of isolating autologous or allogeneic DCs, incubating with peptides or tumour cells 
to load MHC molecules on the surface of the DCs with antigen, and then delivering DCs to the 
lymph nodes to engage a T cell response. Clinical trials of DC therapy in the setting of AML 
have mostly focused on adjuvant therapy post-allogeneic transplant (Wang et al, 2018), on 
treatment of refractory/relapsed AML where conventional therapy has failed (Li et al, 2006), 
or on delaying relapse for patients in remission (Khoury et al, 2017). Overall, these studies 
have demonstrated limited clinical response in patients with AML, and work is ongoing to 
develop DC-based therapies with increased immunostimulatory activity. 
 
1.3 Transcription factor regulation of haematopoiesis 
Despite the fact that relatively few recurrently mutated genes have been identified in patients 
with de novo AML (Cancer Genome Atlas Research Network, 2013; Papaemmanuil et al, 2016), 
leukaemic phenotypes are enormously diverse. To some extent, this can be explained by 





burst kinetics (Raser et al, 2004, Suter et al, 2011) and by malignant perturbation of intricate 
gene expression networks which regulate cell state stability of haematopoietic stem cells and 
progenitors during normal haematopoiesis (Schutte et al, 2016). 
 
The mechanism for transcriptional regulation derives from the interaction between 
transcription factors (TFs) and cis-regulatory elements on DNA, whereby TFs program cellular 
phenotypes. Indeed, it has been established that a single TF can reprogram cells, for instance 
converting fibroblasts to contracting myocytes (Davis et al, 1987). However, increasingly, the 
attention of the scientific community has focused on the transcriptional paradigm as a 
network of TF combinations which are spacio-temporally interconnected and which often act 
as TF complexes rather than in isolation (Wilkinson et al, 2017). Riddell et al, for instance, used 
six TFs to reprogram mature pro-B cells into HSC-like cells in a mouse model (Riddell et al, 
2014).  
 
Two distinct, but mutually complementary, approaches have been developed to analyse the 
topology of Gene Regulatory Networks (GRNs). Firstly, a ‘bottom-up’ approach typically 
establishes a single TF-DNA interaction by functional studies, and then either builds outwards 
from this central hub or else places it as a new node within an existing network paradigm. An 
example of this process was the Stem cell leukaemia (Scl) node, required for HSC specification, 
being placed within a highly recursive gene regulatory circuit involving GATA2, FLI1 and the 
enhancers SCL +19 and FLI1 +12 (Pimanda et al, 2007). Secondly, technology such as 
Chromatin ImmunoPrecipitation with massive parallel DNA Sequencing (ChIP-seq) combined 
with computational approaches has enabled a ‘top-down’ approach where genome-wide 
binding maps suggest novel TF interactions which can then be confirmed by functional studies. 
This process led, for instance, to the identification of regions mapping to sixteen TF genes as 
targets of the basic helix-loop-helix TF SCL in Haematopoietic precursor cell-7 (HPC-7) cells, 
and then functional in vivo validation of these putative regulatory elements by inserting them 
into lacZ reporter constructs in a transgenic mouse model (Wilson et al, 2009). More recently, 
a ‘top-down’ approach has permitted analysis of combinatorial transcriptional control by ten 
major TFs in blood stem/progenitor cells, including a novel protein-protein interaction 
between GATA2 and RUNX1 which was functionally validated by demonstrating the non-
viability of GATA2/RUNX1 compound heterozygous mice (Wilson et al, 2010). Increasingly, 





patterns of behaviour within complex TF networks [Figure 1.2], but these models continue to 
require functional validation by in vitro and in vivo experiments. 
 
Figure 1.2 Boolean model of core TF networks active in common myeloid 
progenitors (adapted from Moignard et al, 2013) 
 
Perhaps as challenging as the vast possibilities of transcriptional network interactions 
presented by approximately 25,000 protein-coding genes in the murine or human genome, is 
the intriguing question of the relatively small number of cell fates which result from these 
interactions. This can be partially explained by network motifs which control information flow 
within GRNs and which can be inferred by perturbation studies. Notwithstanding, ChIP-seq 
clearly describes an extraordinary number of binding interactions between TF and DNA. The 
observation that binding patterns for a given TF can differ widely with cellular context led to 
the proposition that the majority of binding events are ‘opportunistic’ and only those patterns 
which are constant between cellular contexts are ‘functional’ (Wei et al, 2011). However, work 
on transcriptional interactions in two distinct cell types has suggested that cell type-specific 
binding regions, far from being redundant, demonstrate specific patterns of consensus 
sequence motifs which may participate in DNA accessibility to shared TFs within a given 
cellular context (Calero-Nieto et al, 2014). The emerging picture is of a complex interplay of 
TF networks operating at more than one level which permits intrinsic master regulator TFs to 
give consistent cell fates in an extrinsic cellular context. It has further been observed that ChIP-
seq presents an excess of putative target genes when data is analysed for single TFs but that 
biological functionality is more easily established when statistical analysis is employed to 
identify binding patterns between DNA and TF complexes (Ottersbach et al, 2010). Intuitively, 





must produce limited cell fates by acting within TF complexes which operate in defined 
network motifs and which have mechanisms to deal with varied cellular context. 
 
Single cell studies have given additional useful information regarding the interactome. 
Gottgens and colleagues have demonstrated that TF expression is heterogeneous within LT-
HSC, LMPP, MEP, GMP and CLP populations, with expression levels being more constant in 
specific TFs (for instance, RUNX1) than in others (Moignard et al, 2013). This suggests a limited 
tolerance for variation within TF networks. Furthermore, Index Sorting permits mapping of 
cells back to their original sort location and retrospective interrogation of heterogeneous 
flow-sorted populations (Schulte et al, 2015). Thirdly, single cell studies can go further than 
positively correlating the expression of two genes, and can suggest whether two genes share 
a common regulatory mechanism or whether one gene upregulates expression of the other 
(Moignard et al, 2014). For instance, genes X, Y and Z may be upregulated in a cell population, 
but single cell analysis may indicate that genes X and Z are upregulated in the same single 
cells, and gene Y is upregulated in distinct single cells within that population, suggesting that 
genes X and Z are more likely to have a shared regulatory mechanism than gene Y (Bengtsson 
et al, 2005). 
 
Ideally an increased appreciation for the topology of GRNs will encourage and direct the 
process of developing targeted therapies. For instance, TF network analysis has established 
MYC as a central hub in the B cell transcriptome (Basso et al, 2005), and potentially a promising 
target for therapy (Soucek et al, 2008). In any case, it is clear that the phenotypic output of a 
given TF, and the consequences of its mutation, can only be understood in the context of its 
network interactions with other TFs and with cis-regulatory elements on DNA. 
 
1.4 CCAAT/enhancer binding protein (C/EBP)α 
1.4.1 C/EBPα overview 
C/EBPα is the product of an intronless gene located on chromosome 19q in humans and on 
chromosome 7 in mice. It functions as a bZIP TF and originally was found to regulate 
hepatocyte and adipocytes genes in rat liver (Cao et al, 1991). Pabst et al first identified 
dominant negative CEBPA mutations in human AML (Pabst et al, 2001) and intense research 





arrest (Timchenko et al, 1996, Wang et al, 2001). Interestingly, although CEBPA is described 
as a tumour suppressor gene (Reckzeh et al, 2010), CEBPA expression at the GMP stage [Figure 
1.3] is required for myeloid lineage commitment and hence for the generation of AML 
(Ohlsson et al, 2016). Furthermore, evidence suggests that C/EBPα may act as a pioneer factor, 
opening up chromatin and increasing accessibility for other TFs (Ohlsson et al, 2016).  
 
  
Figure 1.3 Gene expression activity of CEBPA in 39 distinct highly purified murine haematopoietic 
cells, based on varied microarray data as a common reference (from 
https://gexc.riken.jp/models/3/genes/Cebpa ; Seita et al, 2012) 
 
 
1.4.2 C/EBPα structure and function 
CEBPA produces a full 42-kDa C/EBPα isoform (henceforth referred to as p42) which contains 
two transactivation domains (TADs) to activate transcription at the N-terminus, as well as 
basic region (BR) and leucine zipper (LZ) domains, for DNA-binding and dimerisation 
respectively, at the C-terminus [Figure 1.4]. p42 is the primary physiological isoform, but a 
distinct 30-kDa isoform (p30) can also be translated from an alternative ATG start codon 
within CEBPA. p30 has intact BR-LZ DNA-binding function, but reduced transactivation 
properties. Specifically, p30 omits the first 117 amino acids of p42, and therefore lacks TAD1 
which in p42 interacts with the TATA-Binding Protein and hence with the RNA polymerase II 









Figure 1.4 Structure of C/EBPα showing transactivation domains, basic region, 
leucine zipper, initiating AUG residues, protein modifications and protein 
interactions (from Friedman, 2015) 
 
Dimerisation is an intrinsic feature of the C-terminal basic zipper (bZIP) structural motif found 
in C/EBPα. Hydrophobic leucine residues in an α-helical structure interdigitate with parallel 
residues in a partner protein at their respective LZ domains, and the two dimerised proteins 
then bifurcate at their BR domains to bind the major groove of DNA. The standard model for 
C/EBPα is the p42 homodimer, but functional diversity is provided by an alternative p30 
homodimer and by heterodimerisation with other LZ transcription factors including IRF8 
(Kurotaki et al, 2014) and AP-1 (Cai et al, 2008). Co-immunoprecipitation studies suggest that 
C/EBPα favours homodimerisation or heterodimerisation with C/EBPβ over JUN or FOS TFs 
(Cai et al, 2008).  Noncovalent interactions push a protein towards homodimerisation or 
heterodimerisation, and a single amino acid variation in LZ structures can select for a 
particular dimerisation profile (Pogenberg et al, 2014). Each configuration binds specific DNA 
sequence motifs and hence generates a distinct expression profile. 
 
The first major function of C/EBPα is to instruct cell fate within transcriptional regulatory 
circuits. For instance, both a conditional knock-out mouse model of CEBPA (Hasemann et al, 
2014) and deletion of the +37 kb CEBPA enhancer (Avellino et al, 2016, Guo et al, 2016) 
resulted in loss of LT-HSCs. C/EBPα plays a critical role in the differentiation pathway from 
Common Myeloid Progenitors (CMPs) to Granulocyte-Monocyte Progenitors (GMPs) (Nimmo 
et al, 2015). Correspondingly, CEBPA -/- mice are deficient in granulocytes and monocytes 





is evidenced by C/EBPα-mediated reprogramming of fibroblasts into myeloid progenitors 
(Feng et al, 2008). The Tenen group have shown that DC progenitor cell fate is also C/EBPα-
dependent in a knock-out mouse model (Welner et al, 2013). 
 
The second major function is cell cycle control. CEBPs as a TF family act as tumour suppressors 
in a wide range of malignancies, including AML, lung cancer, skin cancer, hepatocellular 
carcinoma and breast cancer (Nerlov, 2007). C/EBPα represses the E2F cell cycle regulatory 
complex, thereby controlling cellular proliferation but also inducing terminal differentiation 
(Porse et al, 2001). C/EBPα may also inhibit the cell cycle by interfering with Cyclin Dependent 
Kinases CDK2 and CDK4 (Wang et al, 2001), although deletion of the CDK2/CDK4 binding 
domains of CEBPA in mice did not alter cell proliferation (Nerlov, 2004). 
 
1.4.3 CEBPA mutations 
AML has been characterised as a collaboration of class I ‘signalling mutations’ which activate 
signal transduction pathways and confer a proliferative advantage on haematopoietic cells, 
with class II mutations which affect transcription or nuclear function and impair differentiation 
(Gilliland, 2002). CEBPA class II mutations are classified as N-terminal or C-terminal mutations, 
and each have general properties which can be related to biological structures coded by the 
CEBPA gene [Figure 1.5]. 
 
 
Figure 1.5 Schematic representation of C/EBPα isoforms occurring naturally and  
as a result of AML-associated mutations (from Bereshchenko et al, 2009). N-
terminal mutations are frame-shift mutations that block the translation of the 42 
kDa isoform (p42) while allowing the 30 kDa isoform (p30) to be expressed. C-
terminal mutations generate in-frame insertions/deletions within the basic region-






N-terminal frame-shift mutations preserve p30 but prematurely truncate the p42 isoform. 
Increased p30 expression then inhibits wildtype p42 in a dominant negative fashion (Pabst et 
al, 2001). The overall effect is reduced transactivation function. In fact, most N-terminal 
mutations lie downsteam of the ATG which initiates synthesis of p42 and therefore lead to 
expression of p30. In addition, bi-allelic mutations preferentially form p30 homodimers 
(Ohlsson et al, 2016), and therefore p30 is the most common isoform to result from mutated 
CEBPA. To investigate the phenotypic effects of p30 dominance, specific ablation of p42 
translation was carried out in a Cre-Lox knock-in mouse model. This resulted in AML with 
death between 9 and 14 months (Kirstetter et al, 2008). Interestingly, GMPs were seen in this 
disease model, indicating that p30 alone is sufficient for the CMP to GMP transition. 
 
C-terminal in-frame mutations have varied effects on transactivation, but are characterised 
primarily by altered DNA-binding by the bZIP region of C/EBPα. The C-terminal N321D 
mutation is located at the 321st codon which lies within the leucine zipper (LZ) domain. LZs are 
characterised by hydrophobic leucine residues at every d position in a (abcdefg)n  amino acid 
repeat, and they are configured in an a-helical structure which interdigitates with parallel 
residues from a partner protein at their respective LZ domains. Asparagine residues can 
specify dimer formation (Zeng et al, 1997), and in addition dimerisation profiles are 
particularly affected by amino acids at positions a, e and g in the LZ heptad repeat 
(Schuermann et al, 1991). CEBPA N321D causes asparagine to be replaced by aspartate at 
position a in the heptad repeat, and therefore it would be reasonable to hypothesise that this 
causes LZ reconfiguration and altered DNA-binding with associated transcriptional effects. 
 
In a seminal study by Bereshchenko et al, after generating knock-in ‘L’ (Lp30) and ‘K’ (K313 
duplication) alleles to achieve competitive transplantation of fetal hepatic cells with both N 
and C-terminal mutations into lethally irradiated mice [Figure 1.6], homozygous C-terminal 
mutations were found to skew HSC differentiation towards erythroid lineage, with absence of 
GMPs (Bereshchenko et al, 2009). Nevertheless, LSK cells were increased in comparison to 
homozygous N-terminal mutations, suggesting that C-terminal mutations expand the HSC 
pool (Bereshchenko et al, 2009). Of note, this same study suggested a syngenic mechanism 
for bi-allelic N-terminal and C-terminal mutations, comprising the most common CEBPA 









Figure 1.6 Schematic represent-
ation of mutant CEBPA alleles 
Closed triangles, LoxP sites; open 
box, neomycin Resistance cass-
ette; duplicated lysine residue 
seen in K313KK C-terminal 
mutation (from Bereshchenko et 
al, 2009) 
 
In a study by Togami et al, 32Dcl3 cells were retrovirally transduced with three different C-
terminal CEBPA mutations and a mock control, then exposed to IL-3 and six days of 
granulocyte-colony stimulating factor (G-CSF) treatment (Togami et al, 2015). The control cells 
differentiated into neutrophils but the three mutants remained immature, with the K313 
mutation inhibiting differentiation most strongly. Subsequently, sublethally irradiated mice 
were transplanted with mononuclear cells infected with retroviruses harbouring the same 
mutations. Transplantation with C-terminal mutated cells resulted in leukaemia in all mice, 
with the shortest median survival time for the N321D mutation [Figure 1.7].  
 
 
Figure 1.7 Kaplan-Meier analysis for the survival of mice receiving transplants of BM cells 
transduced with C/EBPα-299_304dup, (299_304dup; n=13), C/EBPα-K313dup (K313dup; 






The fact that K313 inhibited differentiation most powerfully but the N321D mutation induced 
a more aggressive leukaemia suggests that C-terminal mutations can cause proliferation as 
well as inhibit differentiation. 
 
Bereshchenko et al’s report that C-terminal mutations in a knock-in mouse model caused 
expansion of pre-malignant HSCs but required cooperating N-terminal mutations to promote 
myeloid differentiation into a leukaemic phenotype (Bereshchenko et al, 2009) appears to 
contradict findings by Togami et al that retroviral infection of BM mononuclear cells with C-
terminal mutations followed by transplantation is able to recapitulate AML in vivo without 
cooperating N-terminal mutations (Togami et al, 2015).  In another study by Kato et al, serial 
colony assays demonstrated that cells infected with a C-terminal mutation are able to form 
colonies after 6 rounds of replating and produce a leukaemic phenotype within 4 to 12 months 
of competitive transplantation into irradiated mice (Kato et al, 2011). These divergent results 
may be reconciled to some extent by hypothesising that the latency of the leukaemic effect 
found by Kato et al suggests additional cooperating mutations. However, the leukaemic 
phenotype induced by the CEBPA N321D C-terminal mutation in work by Togami et al had a 
relatively short latency, and it may be that the divergence in reported results is impacted by 
different experimental models. Knock-in mouse models express the CEBPA mutation via an 
endogenous promoter, in contrast to retroviral models which transduce exogenous 
promoters into cells before transplantation. Secondly, knock-in models replace the wildtype 
(WT) allele with a knock-in mutant allele, rather than integrate a gene mutation into a genome 
with two WT alleles. Thirdly, semi-random retroviral integration can cause unexpected cellular 
effects including insertional mutagenesis (Hacein-Bey-Abina et al, 2003, Braun et al, 2014, 
Stein et al, 2010). However, transplantation models arguably model disease pathology more 
accurately because only some cells express the mutant whereas knock-in models express the 
mutation in all haematopoietic cells.  In addition, it is also important to remember that CEBPA 
mutant effects can be cell context-specific, for instance a C-terminal mutant has been 
reported to suppress G-CSF expression and granulocytic differentiation specifically in 
haematopoietic 32Dcl3 cells and not in 293T cells (Kato et al, 2011). Interestingly, the Bonnet 
group found that intrinsic differences between human and mouse progenitor cells resulted in 
distinct self-renewal phenotypes on lentiviral transduction of C-terminal mutated CEBPA 






In addition to general characterisation of N- and C-terminal CEBPA mutation profiles, two 
important observations have been made by mouse models. Firstly, CEBPA -/- mice lack mature 
granulocytes but they do not develop AML, suggesting that some degree of CEBPA expression 
is required for the myeloid leukaemic process (Ohlsson et al, 2016). Secondly, transplantation 
of HSC and progenitor cell fractions with CEBPA mutations has shown leukaemic engraftment 
exclusively in committed myeloid cells (Kirstetter et al, 2008), suggesting that the leukaemia-
initiating cells in CEBPA-mutated AML are found downstream of HSCs. 
 
1.4.4 Alternative mechanisms of C/EBPα-mediated AML 
Gene silencing through hypermethylation of the CEBPA promoter can cause a similar 
expression profile to CEBPA mutations. Interestingly methylation rather than mutation is 
found commonly in Myelodysplastic Syndromes (MDS) which often presage AML (Wen et al, 
2015). Post-translational modifications are seen, such as ERK1/2-mediated phosphorylation 
at serine 21 which changes the conformation of transactivation domains in C/EBPα (Ross et 
al, 2004), thereby altering lineage commitment. Lastly, the interaction between C/EBPα and 
CXCR4 is relevant to AML phenotype, with wildtype p42 binding to the CXCR4 promoter region 
(Kuo et al, 2014). Mutated p30 does not bind to this promoter on ChIP and may downregulate 
CXCR4, increasing AML susceptibility to chemotherapy (Kuo et al, 2014). 
 
1.4.5 Combinatorial interactions with other TFs 
C/EBPα promotes myeloid transcriptional programs by binding to regulatory elements 
(promoters or enhancers) for myeloid genes including KLF5 and CSF3R (Federzoni et al, 2014), 
and reintroduction of C/EBPα in leukaemic CD34+ stem cells can partially restore myelopoiesis 
(Schepers et al, 2007). It has been noted that CEBPA mutations upregulate genes of erythroid 
differentiation and downregulate genes of myeloid differentiation and homeobox genes 
(Pabst et al, 2009). However, more interestingly for computational analysis, C/EBPα interacts 
with other TFs in relatively small core circuits which can be hypothesised to participate in 
larger more complex GRNs (Pimanda et al, 2010). 
 
C/EBPα regulates alternative monocyte or neutrophil cell fate in partnership with IRF8. 
Specifically, IRF8 prevents C/EBPα from binding to its target sequence in monocyte-dendritic 
cell progenitors, impairing transcription and thereby preventing neutrophil differentiation 





immunoprecipitation suggests that IRF8 inhibits C/EBPα activity by interacting with its DNA-
binding domain (Kurotaki et al, 2014). In line with these results, IRF8 -/- mice demonstrate 
absent monopoiesis and aberrant over-production of neutrophils (Kurotaki et al, 2014). By 
contrast, IRF8 associates with PU.1 to promote monocyte differentiation (Kurotaki et al, 
2013). In turn, C/EBPα enhances PU.1 expression by directly binding to its promoter and -14 
kb enhancer, and represses PU.1 activity by displacing its co-factor JUN (Reddy et al, 2002). 
C/EBPα can dimerise via its LZ domain with AP-1 proteins and thereby interact with alternative 
DNA elements which promote monocyte differentiation. In fact, C/EBPα heterodimers with 
JUN induce monocyte lineage commitment more efficiently than C/EBPα or JUN homodimers 
(Cai et al, 2008). In this regard, one mechanism of increased efficiency may be that the 
C/EBPα:JUN heterodimer binds and activates PU.1 (Cai et al, 2008). Thus IRF8, PU.1, JUN and 
C/EBPα interact in recursive core circuits to promote monocyte or neutrophil lineage 
specification and/or differentiation.  
 
Other network motifs remain to be elucidated. For instance, CEBPAdm AML has high levels of 
mutant WT1 and GATA2 (Fasan et al, 2014), suggesting a possible transcriptional circuit. More 
recently a novel activation pathway mediated by p53 and KLF4 has been identified with 
deregulation of the p53-KLF4-C/EBPα axis in AML (Seipel et al, 2016). 
 
1.4.6 C/EBPα as a pioneer factor 
Evidence is building that C/EBPα may have the ability to interact with closed chromatin, 
remodelling chromatin and enabling access by other TFs at key regulatory elements. Transient 
pulsed C/EBPα expression prior to co-expression by TFs OCT4, SOX2, KLF4 and MYC enhances 
reprogramming of B cells into induced pluripotent stem cells, and C/EBPα pulses after 
expression of these factors is ineffective (Di Stefano et al, 2014). Hasemann et al found that 
conditional acute deletion of CEBPA results in histone modifications of genes involved in stem 
cell function (Hasemann et al, 2014). More precise evidence of C/EBPα-mediated chromatin 
accessibility has recently been provided by Thomas Graf and colleagues who found that pulsed 
CEBPA expression in pluripotent cells generates a cluster of de novo ATAC peaks on ATAC-seq, 
which enriches for the KLF4 motif, and that interplay between C/EBPα and KLF4 induces 
chromatin accessibility to the Yamanaka pluripotency factors (Di Stefano et al, 2016). These 
studies suggest that C/EBPα may act as a ‘pioneer factor’, opening up chromatin for TFs to 





1.4.7 Clinical features of CEBPA-mutated AML 
Incidence and prevalence studies need to be interpreted carefully, as recent evidence 
suggests that incidence can alter significantly both with age (Libura et al, 2015) and with 
ethnicity (Gou et al, 2016). Nevertheless, in general, single and double mutations of CEBPA 
account for approximately 7 to 15% of de novo cytogenetically normal AML (Preudhomme et 
al, 2002). Of these, about 30% of cases have single allele CEBPA mutations, and 70% have bi-
allelic mutations most commonly with a N-terminal mutation in one allele and a C-terminal 
mutation in the second allele. There is consensus that CEBPA dm gives a favourable prognosis 
in AML (Pabst et al, 2009, Wouters et al, 2009), recognised in the WHO disease classification 
(Arber et al, 2016). In clinical practice, these patients are therefore more likely to be treated 
with chemotherapy in the first instance rather than allogeneic stem cell transplantation. By 
contrast, single-mutated CEBPA (CEBPA sm) carries no prognostic significance.  
 
1.5 The Single Cell: A New Paradigm 
Cell fate decisions are made by single cells, including rare stem and progenitor cells, and 
therefore require single cell analysis for precise characterisation. In addition, bulk analysis 
cannot map cancer heterogeneity, which is one of the principal challenges for developing 
effective targeted cancer treatments. AML provides an ideal conceptual model for deciphering 
heterogeneity during clonal evolution because it is characterised by relatively few mutations, 
particularly at pre-leukaemic phase. Interestingly, heterogeneity also underlies the fact that 
dendritic cells remain poorly characterised and understood despite playing pivotal roles within 
the immune system. 
 
Single cell RNA-seq isolates individual cells from a bulk population, lyses those cells to acquire 
RNA, reverse transcribes RNA into cDNA, and then amplifies the cDNA to generate genome-
wide sequencing libraries. Due to the reduced quantity of starting material in each individual 
cell, the major QC challenge of this technique is technical bias, including accuracy and 
sensitivity. Cost, numbers of cells, and sequencing depth are other questions which need to 
be considered in experimental design (Baron-Gale et al, 2018). A variety of scRNA-seq 
methods and protocols have developed to meet these challenges, and the comparative 
strengths and weaknesses of each method (Ziegenhain et al, 2017) need to be considered with 





and therefore is less prone to manual handling bias, it employs unique molecular identifiers 
(UMIs), and it applies a 3’-tag or 5’-tag sequencing method. By contrast, Smart-seq2 often 
captures more genes per cell, it uses spike in controls for RNA normalisation, and can capture 
full-length RNA. 
 
In addition to the range of available scRNA-seq protocols, several combinatorial technologies 
have emerged to increase the versatility and power of single cell analytical pipelines. For 
instance, combining scRNA-seq with mass cytometry or Cytometry by Time Of Flight (CyTOF) 
offers significant advantages over flow cytometry, including the employment of non-
fluorescent metal isotopes to conjugate antibodies, which excludes compensation, and the 
significantly increased number of markers which can be evaluated for each single cell. The 
Scadden group have recently employed single cell CyTOF to analyse 32 proteins and define 28 
subsets of bone marrow stromal cells in homeostatic conditions (Severe et al, 2019). Single 
cell intravital imaging offers new insights into spatial relationships between haematopoietic 
cells and the microenvironment, showing that leukaemic T-ALL cells are highly motile 
(Hawkins et al, 2016), in contrast with MLL-AF9-driven AML cells where chemoresistance 
confers an altered migratory phenotype (Duarte et al, 2019). By contrast, Long Cai and 
colleagues have characterised single cells in their spatial environment by computationally 
integrating data from scRNA-seq and single-molecule fluorescence in situ hybridisation 
(smFISH) (Zhu et al, 2018). Integration of scRNA-seq data with ChIP-seq data has been used to 
infer epigenetic reprogramming and deregulation of TFs in ageing HSCs (Adelman et al, 2019), 
but single cell epigenetic technology has proven more challenging because ChIP-seq is difficult 
with fewer than 103 to 104 cells. In this regard, ATAC-seq has emerged as a technology which 
evaluates chromatin accessibility at the level of the single cell (Buenrostro et al, 2015). Finally, 
CRISPR-seq integrates scRNA-seq with CRISPR-pooled screens to infer causality by gene 
perturbations at the level of the single cell (Jaitin et al, 2016). 
 
Functional characterisation of cells undergoing scRNA-seq remains another important 
objective to consider during experimental design, and broadly speaking can be achieved by 
retrospective or prospective methods. The Göttgens group and others have employed flow 
cytometry to index sort individual cells and facilitate retrospective analysis after lysing cells to 
acquire RNA (Schulte et al, 2015, Macaulay et al, 2016, Psaila et al, 2016, Knapp et al, 2019). 





into the endothelial-to-haematopoietic switch (Baron et al, 2018). Secondly, a library of 
cellular barcodes can be lentivirally integrated into the genomes of single cells to follow them 
prospectively during differentiation (Naik et al, 2013). Lentiviral insertion of barcodes is non-
physiological and may alter the biology of single cells, but prospective viral barcoding has 
introduced fundamental reconfigurations of the haematopoietic tree, such as Naik et al’s 
proposal of DC lineage imprinting during early haematopoiesis (Naik et al, 2013). 
 
The evolution of single cell RNA-seq has led to paradigm shifts in our understanding of 
haematopoiesis. Gene expression analysis of HSC and progenitor populations at the level of 
individual cells has suggested that lineage-restricted cells emerge directly from a continuum 
of low-primed undifferentiated HSPCs (Velten et al, 2017). This differs conceptually from the 
hierarchical and stepwise classical model of haematopoiesis, but it remains challenging to 
reconcile this transcriptome-driven model with the phenotypic observation that populations 
of blood cells with distinct functional behaviours are readily identifiable with distinct cell 
surface markers. It can be hypothesised that transcriptional programs characterise intrinsic 
cell properties, but that discrete phenotypes result from epigenetic modifications or 
downstream translational processes.  
 
Interestingly, Belluschi et al have employed scRNA-seq to identify lymphoid commitment in 
the 49f+ human LT-HSC compartment and observed three distinct transcriptional states, 
speculating that the continuum of transcriptional states observed in HSCs may reflect a 
common HSC-wide quiescent profile which disguises underlying discrete transcriptional 
signatures (Belluschi et al, 2018). The classical hierarchical model has now given way to a new 
paradigm of lineage priming during early haematopoiesis, where phenotypically-defined 
discrete populations of cells do not represent crossroads of cell fate decision-making, but 
rather they constitute transient phenotypic meeting points for distinctly-primed cells which 







1.6 Thesis aims 
The Göttgens group combines wet lab functional studies of perturbations within 
transcriptional networks with rigorous bioinformatics analysis of gene expression data. The 
group has already constructed computer models of myeloid leukaemia based on TF 
interactions (Sive et al, 2016). 
 
C/EBPα is a significant player in normal myelopoiesis and CEBPA is commonly mutated in AML. 
Furthermore, it interacts significantly with other TFs and is not currently characterised in our 
group’s GRN models. N321D is a C-terminal mutation of CEBPA identified in human patients 
with AML (Papaemmanuil et al, 2016) and described as highly lethal in mouse models (Togami 
et al, 2015), and therefore may provide an efficient model to evaluate the effects of CEBPA 
mutation on myeloid transcription. Hoxb8-FL cells are a robust LMPP-like cell line which lies 
upstream of the CMP to GMP junction, and therefore represent a cellular model for studying 
pre-leukaemic changes induced by mutant CEBPA. CEBPA-mutated AML has been extensively 
studied in cellular and mouse models, however there is comparatively poor understanding of 
how mutant CEBPA is involved in early leukaemogenesis.  In summary, our model is designed 
to characterise pre-leukaemic changes caused by mutant CEBPA, on the basis that leukaemia-
initiating cells are found downstream of HSCs in CEBPA mutations (Kirstetter et al, 2008), and 
that the N321D mutation has been shown to recapitulate AML when retrovirally transfected 
into BM mononuclear cells (Togami et al, 2015).   
 
In this context, my thesis has the following aims: 
 
§ Establish a cellular model of CEBPA-mutated pre-leukaemia using EV and CEBPA WT 
comparators, by transducing  Hoxb8-FL cell lines with retroviral gene expression 
constructs, and culturing them in cytokine conditions designed to recapitulate early 
haematopoietic differentiation; 
 
§ Analyse the gene expression profile of CEBPA-mutated pre-leukaemia at the level of the 
single cell, aiming to characterise rare transcriptional profiles which cannot be visualised 






§ Examine the genome-wide TF binding and histone modification profile of the CEBPA 
N321D mutation, and correlate this with single cell RNA-seq data to identify candidate 
genes which may play significant roles in pre-leukaemic changes caused by mutant CEBPA, 









2. Materials and Methods  
Unless otherwise stated, all experiments were performed by the author of this thesis. 
 
2.1 Molecular biology 
2.1.1 Agarose gel electrophoresis 
DNA fragments were separated by electrophoresis in 1 to 1.5% agarose gel. Agarose (Sigma) 
was prepared in 1 x Tris-Borate EDTA (TBE) electrophoresis buffer and Ethidium Bromide (100 
ng/ml) was added as intercalating agent. DNA was mixed with gel loading buffer 
(bromophenol blue, xylene cyanol, and glycerol) and loaded into wells alongside DNA 
Hyperladder II (Bioline). Electrophoresis was carried out at 80 to 100 volts (Bio-Rad PowerPac) 
until DNA had migrated a sufficient distance and fragments were cut out under UV 
transillumination. 
 
2.1.2 DNA gel extraction 
DNA was extracted from agarose gel using the QIAquick Gel Extraction Kit (Qiagen) according 
to manufacturer’s instructions and eluted in 30 to 50 µl elution buffer. 
 
2.1.3 DNA PCR purification 
PCR fragments were purified using the QIAquick PCR Purification Kit (Qiagen) according to 
manufacturer’s instructions and eluted in 30 to 50 µl elution buffer. 
 
2.1.4 DNA restriction  
Restriction enzymes and buffers from New England BioLabs were used for all digestion 
reactions, according to manufacturer’s instructions. Digests were performed for 1 to 4 hours 
at 37°C. 
 
2.1.5 Dephosphorylation of DNA fragments 
Antarctic phosphatase enzyme and buffer (New England BioLabs) were used to remove the 5’ 








2.1.6 Blunting of single-stranded overhands in restriction digests 
Where required, T4 polymerase (New England BioLabs) was employed to fill in and blunt 
restriction digest overhangs, as per manufacturer’s instructions. 
 
2.1.7 Ligation of DNA fragments 
The Promega website http://www.promega.com/a/apps/biomath  was used to calculate 
molar ratio of DNA Insert and plasmid vector, and ligation was performed using the T4 DNA 
ligase enzyme (New England BioLabs) as per manufacturer’s instructions at 16°C overnight. 
 
2.1.8 Preparation of electro-competent DH10β E. Coli 
DH10β Escherichia coli was streaked out onto Luria Bertani (LB) agar without antibiotics and 
incubated at 37°C overnight. One colony was then picked into 5 ml of LB broth without 
antibiotics and incubated at 37°C overnight with shaking. The 5 ml was then inoculated into 
500 ml of LB without antibiotics and incubated again at 37°C with shaking for 2 to 3 hour until 
Optical Density (OD600) reached 0.5. The bacterial culture was then divided into pre-cooled 
50 ml falcon tubes, and bacteria was harvested by centrifuging at 3200 x g for 10 minutes at 
4°C. The supernatant was discarded and the bacteria were resuspended in ice-cold ultra-pure 
water and centrifuged twice. Finally, bacteria were resuspended in water, 10% glycerol and 1 
mM HEPES pH 8.0, made up into 50 µl aliquots, snap-frozen in liquid nitrogen and stored at    
-80°C. 
 
2.1.9 DH10β E. Coli transformation 
50 µl of Electro-competent DH10β E. coli were first thawed on ice, then 2 µl of plasmid DNA 
was added, and the transformation mixture was placed in a 2 mm cuvette before 
electroporation at 2.5 kilovolts (25 µF, 250 Ω) on the MicroPulser Electroporator (Bio-Rad). 
The mixture was then washed with 300 µl of 2 x Tryptone Yeast extract and incubated at 37°C 
for 45 minutes on a thermo-shaker. Transformed bacteria were plated on LB agar with 
kanamycin at 37°C overnight. 
 
2.1.10 Plasmid purification by maxi prep 
Single bacterial colonies were inoculated into 100 ml of LB with 100 µg/ml of ampicillin, then 





using the Plasmid DNA Purification Kit (Macherey-Nagel), as per manufacturer’s instructions, 
and the final DNA pellet was dissolved in 1 x TE buffer or sterile water. 
 
2.1.11 Plasmid purification by mini prep 
Alkaline lysis mini prep was performed to isolate small quantities of plasmid DNA. Single 
colonies of transformed bacteria were inoculated into 2 ml of LB medium with the appropriate 
antibiotic, and then incubated at 37°C overnight with vigorous shaking. The culture was then 
transferred to 1.5 ml Eppendorf tubes, centrifuged at 16,000 x g for 60 seconds, before 
removing the supernatant. The pellet was then processed with S1 Resuspension buffer, S2 
Lysis buffer and S3 Quenching buffer from the NucleoBond Xtra Maxi Kit (Macherey-Nagel), 
before centrifuging the plasmid DNA in the supernatant at 16,000 x g for 10 minutes and then 
transferring to a fresh tube. 1 volume of isopropanol was added to precipitate nucleic acids 
from the supernatant, the solution was vortexed and allowed to stand at room temperature 
for 2 minutes, before centrifuging at 16,000 x g for ten minutes, washing once with 70% 
ethanol, and leaving the pellet to air dry. Finally the purified DNA was resuspended in 20 µl of 
ultra-pure water. 
 
2.1.12 DNA sequencing 
The Sanger method was used for DNA sequencing, and performed by Source Bioscience.  
 
2.2 Cloning 
Cloning was performed by the author of this PhD and S Kinston. 
 
2.2.1 Original CEBPA N321D Plasmid construction 
The construct containing the CEBPA N321D mutation was assembled from synthetic 
oligonucleotides and provided by GeneArt (Life Technologies) as an insert into a kanamycin-
resistant vector with restriction sites for BlpI and BstAPI (pMK-T CEBPalpha N321D). 
 
2.2.2 Original CEBPA N321D Plasmid sequencing 
Sanger sequencing was carried out by GeneService (Bioscience) and analysed using 
SerialCloner software to verify the nucleotide sequence of the expression construct. The 






Table 2.1 Primers for original CEBPA N321D plasmid 
 
Forward primer 5' TCAGAAACAACTTTGGCACA 3' 
Reverse primer 5' GTTATCCTCCTCGCCCTTGCTC 3' 
 
2.2.3 CEBPA wild-type (WT) plasmid 
pMK-T CEBPalpha N321D construct was digested with BlpI and BstAPI restriction enzymes to 
release the 52 bp region containing the CEBPA N321D mutation. The -3368 bp fragment 
containing the vector and most of CEBPA was gel extracted using the QIAquick Gel Extraction 
Kit (Qiagen), as per manufacturer’s instructions. 
 
Complementary primers (Table 2.2) were then used to replace the region containing the 
mutation with the WT version of the gene. The primers were denatured at 100°C for 10 
minutes and then left to cool slowly to room temperature in the presence of annealing buffer 
(10 mM Tris, 50 mM NaCl, 1 mM EDTA) for them to reanneal. The annealed product was then 
ligated to the gel extracted band using Gibson assembly cloning strategy with 0.2 U of T5 
exonuclease (Epicentre, T5E4111K), 12.5 U of Phusion polymerase (NEB, M0530S), 2000 U of 
Taq Ligase (NEB, M0208S), and 100 µl of 5X Isothermal (ISO) reaction buffer. 
 
Table 2.2 Primers for Gibson assembly of CEBPA WT plasmid 
 
Primer Sequence 
CEBPa Repair oligo FW AGCAGCGCAACGTGGAGACGCAGCAGAAGGTGCTGGAGCTGACCAGTGAC
AATGACCGCCTGCGCAAGCGGGTGGAACAGCTGAGCCGCGAACTGGACAC
GCTGCGGG 




Resulting ligations were then transformed and purified by mini prep, and the presence of the 
wildtype version of the gene was verified by Sanger Sequencing. 
 
2.2.4 Construction of EV, CEBPA WT and CEBPA N321D retroviral vectors 
pMSCV-MLL-ENL-IRES-eGFP retroviral vector was obtained from S Basilico (Göttgens 
laboratory) and digested with Sal I and Bgl II restriction enzymes. This released MLL-ENL and 





isolated with the QIAquick Gel Extraction Kit (Qiagen). The ends of this fragment were then 
blunted and re-ligated to generate the control vector or “Empty Vector” (EV). 
 
The CEBPA WT and CEBPA N321D insert cDNAs were amplified by PCR using KAPA HiFi Hotstart 
mix. To this end, we designed a forward oligo that contained the recognition sequence for 
BamHI followed by the codon of a methionine, in-frame FLAG tag and CEBPA (including the 
methionine codon). The reverse primer contained the sequence of the last coding codon of 
CEBPA. Of note, both primers contained 30 nucleotides of homology with the backbone vector 
to allow for Gibson assembly cloning strategy, including the region upstream of BamHI site for 
the forward primer and the IRES region for the reverse primer. The following primers were 
used: 
 








Stage Temperature  Time Cycles 
Denaturing 98°C 3 minutes 1 
Annealing 98°C 5 seconds 10 
60°C 15 seconds 
72°C 30 seconds 
Extension 98°C 5 seconds 25 
72°C 60 seconds 
72°C 5 minutes  
 16°C Hold - 
 
 
The CEBPA WT and N321D inserts with FLAG tags and restriction sites were then isolated by 
gel electrophoresis, joined to the pMSCV-IRES-eGFP control vector by Gibson assembly, 
transformed into electrocompetent DH-10β cells, and ampicillin-resistant colonies were 
selected by growth on agar with ampicillin. Plasmid DNA was then isolated by Alkaline Lysis 
mini prep, and the following primers were used to sequence junctions for the CEBPA inserts 






Table 2.4 Primers to sequence ligation junctions in EV, CEBPA WT and CEBPA N321D retroviral 
vectors 
Primer Sequence 
Cebpa junction Forward primer CAGACCACCATGCACCT 
Cebpa junction Reverse primer GTCGATGTAGGCGCTGATG 
IRES Reverse AGGAACTGCTTCCTTCACGA 
 
In addition, a number of primers (Table 2.5) were required for Sanger Sequencing along the 
length of the CEBPA WT and CEBPA N321D inserts, to ensure that plasmid DNA was composed 
of the correct and complete nucleotide sequence for the wildtype and mutant inserts.  
 
Table 2.5 Primers for Sanger sequencing along the length of CEBPA WT and CEBPA N321D inserts 
Primer Sequence Position 
Forward primer GGCGGCGACTTTGACTAC 344 
Forward primer CAGCAGGAGAAGGCCAAG 322 
Forward primer TACCTGGACGGCAGGCT 475 
Reverse primer CAGGTGCATGGTGGTCTG 683 
Reverse primer GTGCGCGATCTGGAACT 706 
 
The completed vector map is shown in Appendix Figure 1. 
 
 
2.3 Cell culture 
2.3.1 Conditions 
Cells were incubated at 37°C in 5% CO2 and cell culture was performed using standard aseptic 
technique in a BioMAT2 class II laminar flow cabinet with unidirectional flow of HEPA-filtered 
air. 
 
2.3.2 B16 cell line 
B16 cells were thawed and seeded into 10 cm dishes with 10 ml culture media: RPMI 1640 
(Sigma R8758) with 10% foetal bovine serum (FBS), 0.1% 2-mercaptoethanol, 1% 
Penicillin/Streptomycin and 1% Glutamine. Cells were cultured for 2 to 3 days, then 
transferred to 175 cm2 flasks and incubated until confluent. Flt3L conditional media was 
harvested from the supernatant by pooling supernatant, centrifuging and passing through a 






2.3.3 293T cell line 
293T cells (Graham et al, 1977) were cultured in Dulbecco’s Modified Eagle’s Medium DMEM 
(Sigma Aldrich D6429), 10% FBS and 1% Penicillin/Streptomycin. These cells were adherent 
and grown in a monolayer in 10 cm cell culture dishes. They were subcultured and dissociated 
with Trypsin EDTA (Sigma T3924) in log phase every 2 to 3 days to maintain 30% to 90% 
confluence. 
 
2.3.4 Hoxb8-FL cell line 
The murine cell line Hoxb8-FL (Redecke et al, 2013) was kindly donated by Hans Häcker as 
mouse bone marrow cells infected with ERHBD-Hoxb8 virus. Cells were cultured in RPMI 1640 
medium (Sigma R8758) supplemented with 10% Hyclone FBS, 5% Flt3L conditioned media, 1% 
Penicillin/Streptomycin, 2 mM L-glutamine, 50 mM 2-mercapto-ethanol, and 1 µM β-estradiol 
(henceforth termed ‘Hoxb8 media F+e+’).  
 
Cells in full media had lymphoblast-like spherical cell morphology, were non-adherent and 
could be grown in suspension within sterile tissue culture treated flasks with gas-permeable 
caps. Cells were subcultured in fresh medium every 2 to 3 days to maintain a concentration of 
0.3 to 1.2 x 106 cells/ml. 
 
2.3.5 Parental EV, CEBPA WT and CEBPA N321D cell lines 
The Hoxb8-FL cell line was infected with one of the following three retroviral plasmids to 
generate three cell lines: (i) pMSCV-IRES-eGFP which carries no human transgene, (ii) pMSCV-
CEBPAWT-IRES-eGFP, and (iii) pMSCV-CEBPAN321D-IRES-eGFP. For experiments requiring 
transduced cells only, transduction was followed by cell sorting (Flow Facility, CIMR, 







2.4 Cell biology 
Retroviral transduction, differentiation and flow cytometry were performed by the author of 
this PhD. Cell sorting was performed by the CIMR Flow team and Smart-seq2 protocol was 
performed by I Kucinski. ChIP-seq was performed by the author of this study and F Calero-
Nieto. 
 
2.4.1 Retrovirus production by transfection of 293T cells 
2 x 106 293T cells were plated in a 10 cm dish at 16 to 20 hours before transfection, aiming for 
70% to 80% confluence at time of transfection. 5 µg of plasmid DNA and 5 µg of Psi packaging 
vector (obtained from the Huntly group) was made up to 10 µl with H2O and added to 500 µl 
of plain DMEM, before adding drop-wise to 30 µl of TransIT-LT1 Transfection Reagent (Mirius 
MIR2300). This was incubated at room temperature for 30 minutes, before distributing drop-
wise and evenly over 10 cm dishes containing 293T cells. The transfection mixture was 
incubated for 24 hours at 37°C in 5% CO2 and culture medium was then replaced with fresh 
medium (5 ml RPMI, 10% Hyclone FBS, 1% Penicillin/Streptomycin, 1% glutamine). Retroviral 
supernatant was recovered after a further 24 hours of culture and passed through a 0.45 μm 
filter to remove cellular debris, fresh medium was added to the 293T cells and supernatant 
was recovered again after a further 24 hours. 
 
2.4.2 Retroviral transduction of Hoxb8-FL cells 
In each well of a 6-well plate, 1.5 x 106 Hoxb8-FL parental cells were placed in 2 ml Hoxb8 
media F+e+ and 24 µl polybrene (Sigma) was added to a final concentration of 8 µg/ml, before 
adding 1 ml of retroviral supernatant. The 6-well plate was then centrifuged at 779 x g for 90 
minutes at 32°C, then incubated for 90 minutes at 37°C in 5% CO2. 1.5 ml of media was 
removed carefully to avoid disturbing transduced cells lying at the bottom of the wells, and 
replaced with 2.5 ml of fresh Hoxb8 media F+e+ before incubating overnight at 37°C in 5% 
CO2. 2 ml of Hoxb8 media F+e+ was added at 24 hours post-transduction, and cells were 







2.4.3 Differentiation assays 
EV, CEBPA WT or CEBPA N321D-transduced cells were cultured for 7 days in Hoxb8 media 
F+e+, then washed twice in PBS, and resuspended at a concentration of 0.1 x 106 cells/ml in 
differentiation medium.  
 
Differentiation medium was prepared by adding appropriate growth factors to RPMI 1640 
medium (Sigma R8758) supplemented with 10% Hyclone FBS, 1% Penicillin/Streptomycin, 2 
mM L-glutamine, and 50 mM 2-mercapto-ethanol. The growth factors consisted of either 5% 
Flt3L conditional medium, 7 ng/ml murine granulocyte-macrophage colony stimulating factor 
(GM-CSF) (PeproTech), 10 ng/ml murine macrophage colony stimulating factor (M-CSF) 
(PeproTech), or 10 ng/ml murine IL-3 (PeproTech). Cells were cultured in 6-well plates at 37°C 
in 5% CO2. Differentiated cells were adherent and therefore dissociated enzymatically with 
trypsin-EDTA (Sigma T3924) prior to further processing. 
 
2.4.4 Cytospin and Romanowsky staining 
Cytospin was performed by loading Cytofunnels with 50 µl to 100 µl of cells in liquid culture 
and centrifuging for 2 minutes at 700 rpm on the Shandon Cytospin3, depositing monolayers 
of cells on Cytoslides. Cells were stained by using a Rapid Romanowsky Stain Pack as per 
protocol (TCS Biosciences, HS705). Microscopic photographs were taken using Zen Pro 
software on Axio Imager.Z2 (Zeiss). 
 
2.4.5 Murine haematopoietic progenitor cell staining 
Cell staining was performed by using either a Basic Panel (Table 2.6) or an Advanced Panel 
(Table 2.7). Cells were centrifuged at 300 x g and washed in PBS, then centrifuged again and 
Fc-blocked using purified anti-CD16/32 antibody (BioLegend). In the case of the Advanced 
Panel, Fc-block was made up in BD Horizon Brilliant Stain Buffer to prevent staining artefacts 
caused by the presence of multiple BD Horizon Brilliant fluorescent polymer dyes. Fc-block 
was carried out for 5 minutes at room temperature, and cells were then conjugated with 
fluorophore-labelled antibodies in FACS buffer (PBS with 2% Hyclone FBS) for 30 minutes at 
4°C.  
 
Cells were washed twice with FACS buffer and then resuspended in 500 µl of FACS buffer with 





viability dyes for the Basic and Advanced Panels respectively. OneComp compensation beads 
(Thermo Fisher) were processed alongside cells for use as compensation controls. 
 
Flow cytometry analysis was carried out on the BD LSRFortessa Cell Analyzer (BD Biosciences), 
and flow cytometry data was processed using FlowJo software. 
 
Table 2.6 Basic Panel of antibodies used for initial flow cytometry and for FACS of mouse cells 
Antibody Clone Supplier Catalogue Dilution 
CD 16/32 (Fc block) 93 Invitrogen 14-0161-85 1:100 
c-kit (APC/Cy7) 2B8 BioLegend 105826 1:100 
Ly-6G (PB) 1A8 BioLegend 127612 1:100 
B220 (APC) RA3-6B2 BioLegend 103212 1:400 
CD11b / MAC-1 (PE) M1/70 BD Pharmingen 553311 1:200 
 
 
Table 2.7 Advanced Panel of antibodies used for further flow cytometry of mouse cells 
Antibody Clone Supplier Catalogue Dilution 
CD 16/32 (Fc block) 93 Invitrogen 14-0161-85 1:100 
c-kit (APC/Cy7) 2B8 BioLegend 105826 1:100 
Ly-6g (BV510) 1A8 BioLegend 127633 1:100 
B220 (AF 700) RA3-6B2 BioLegend 103232 1:100 
CD11b (BV711) M1/70 BioLegend 101242 1:200 
CD11c (PE/Cy7) N418 BioLegend 117318 1:100 
SIRPα (PE) P84 BD Biosciences 560107 1:100 
XCR1 (APC) ZET BioLegend 148206 1:100 
BST2 (BV421) 927 BD Horizon 566431 1:100 
F4/80 (BUV395) T45-2342 BD Horizon 565614 1:100 
MHC class II (PerCP/Cy5.5) M5/114.15.2 BioLegend 107626 1:400 
 
2.4.6 Murine haematopoietic progenitor cell sorting 
Cell sorting was performed on a BD Influx Cell Sorter using BD FACS Software, and cells were 
sorted into appropriate culture media. For single cell sorting, eight-peak rainbow beads 
(Spherotech) were employed for laser alignment and BD Accudrop beads were used for 





lysis buffer (SUPERase-In RNase Inhibitor, 10% Triton X-100, Rnase-free H2O), vortexed for 30 
seconds, centrifuged at 700 x g for 60 seconds at 6°C, and then stored at -80°C. Each plate 
contained thirty-two EV, CEBPA WT and CEBPA N321D-transduced single cells from a distinct 
biological replicate at one of two time points. 
 
2.4.7 Single cell RNA sequencing 
Single cells were processed by a modified Smart-seq2 protocol. Firstly, the oligo-dT primer 
was hybridised to the polyA tail of the mRNA molecule by placing 2 µl of the annealing mixture 
(1 µl free dNTPs (10mM), 0.1 µl tailed oligo-dT oligonucleotides (100 µM), and 0.1 µl ERCCs 
diluted in 0.8 µl DEPC-treated dH2O) into each well, centrifuging the plates at 700 x g for 60 
seconds, incubating at 72°C for 3 minutes, placing immediately on ice, and then centrifuging 
again at 700 x g for 60 seconds.  
 
Reverse transcription was then performed by adding 5.7 µl of RT mixture to each well, 
centrifuging at 700 x g for 60 seconds, and then applying RT thermocycling conditions (Table 
2.8). The RT mixture for each well consisted of 0.5 µl Superscript II RT (200 U/µl), Rnase 
inhibitor (20U/µl), 2.0 µl 5x superscript II first strand buffer, 0.5 µl DTT (100 mM), 2 µl Betaine 
(5M), 0.06 µl MgCl2 (1M), 0.1 µl TSO (100 µM), and 0.27 µl DEPC-treated dH2O.  
 
Table 2.8 RT thermocycler conditions 
Stage Temperature  Time Cycles 
RT and template switching 42°C 90 minutes 1 
Unfolding of RNA secondary structures 50°C 2 minutes 10 
Completion/continuation of RT and template switching 42°C 2 minutes 
Enzyme inactivation 70°C 15 minutes 1 
 4°C Hold - 
 
Following RT, plates were spun at 700 x g for 60 seconds at 6°C and PCR pre-amplification was 
carried out by adding 15 µl of PCR mix (12.5 µl of 2x KAPA HiFi Hotstart ReadyMix, 0.25 µl of 
IS PCR primer (10 µM) and 2.25 µl of nuclease-free dH2O) to each well and applying 







Table 2.9 PCR pre-amplification thermocycler conditions 
Stage Temperature  Time Cycles 
Denaturing 98°C 3 minutes 1 
Denaturing 98°C 20 seconds 21 
Annealing 67°C 15 seconds 
Extension 72°C 6 minutes 
Extension 72°C 5 minutes 1 
 4°C Hold - 
 
The PCR products were then purified as follows: Ampure XP beads were equilibrated to room 
temperature for 15 minutes, vortexed, centrifuged at 700 x g for 60 seconds and added to 
each sample at a volume ratio of 1.0:0.6 for DNA:beads. The mixture was pipetted until 
homogenous, and transferred to a 96-well plate, then incubated for 8 minutes at room 
temperature to allow the DNA to bind to the beads. The plates were then placed on a 
compatible magnetic stand for 5 minutes so that the beads separated from the supernatant, 
and the liquid carefully removed without disturbing the beads. The beads were then washed 
twice with 200 µl of freshly made 80% ethanol. The beads were then dried completely, the 
plates were removed from the magnet stand, and the beads were resuspended in 23 µl of 
elution buffer before incubating for 2 minutes. The plates were then put back on the magnet 
for 2 minutes to separate the beads from the solution of eluted PCR products, and 20 µl of the 
solution was carefully collected without disturbing the beads. 
 
Quality check of the cDNA library was performed by checking size distribution on an Agilent 
high-sensitivity DNA chip. Quantification was performed using the Scientific Quant-iT™ 
PicoGreen ® dsDNA Assay Kit. 
 
Library preparation and tagmentation was performed using the Illumina Nextera XT DNA 
sample preparation kit as per manufacturer’s protocol. Samples were diluted to between 0.1 
and 0.15 ng/µl cDNA per single cell, 1.25 µl of amplified cDNA was transferred to a new plate, 
tagmentation mix (2.5 µl Tagmentation DNA buffer, 1.25 µl Amplicon Tagment Mix) was 
added to each well, plates were centrifuged at 700 x g for 60 seconds, tagmentation reaction 
was carried out at 55°C for 10 minutes, 1.25 µl of NT buffer was added to each sample to 
neutralise the tagmentation reaction, and plates were centrifuged again at 700 x g for 60 
seconds. Finally, preparation of the sequencing library was completed by adding 3.75 µl of 





each row of the plate, 1.25 µl of Index Primer 2 (S501-S508) to the corresponding well of each 
column of the plate, sealing the plate, centrifuging at 700 x g for 60 seconds, and then 
performing PCR amplification as described in Table 2.10: 
 
Table 2.10 PCR amplification thermocycler conditions 
Step Temperature  Time Cycles 
1 72°C 3 minutes 1 
2 95°C 30 seconds  
3 95°C 10 seconds 21 
55°C 30 seconds 
72°C 60 seconds 
4 72°C 5 minutes 1 
5 10°C Hold - 
 
Libraries were then pooled from each sample, the total pooled volume was measured, and 
Ampure XP beads were added firstly in 1.0:0.5 volume ratio, and then in 1.0:0.2 volume ratio 
for DNA:beads. This double clean-up was designed to remove fragments larger than 600 bp 
and fragments smaller than 400 bp respectively. The DNA:bead mixture was incubated at 
room temperature for 5 minutes, placed on a magnetic stand for 2 minutes, and supernatant 
was removed carefully without disturbing the beads before adding 1ml of freshly prepared 
80% ethanol and incubating for 30 seconds on the magnetic stand. Ethanol wash was applied 
twice, the beads were allowed to dry after each wash, and DNA was then eluted from the 
beads with elution buffer. 
 
Agilent High-Sensitivity DNA BioAnalyzer chip was employed to check library size distribution 
between 42 bp and 3561 bp, and the KAPA library quantification kit was used to quantify the 
pooled library. Libraries were submitted as 10 to 20nM in a volume of at least 15 µl in a 1.5ml 
Eppendorf. Single cell RNA sequencing was performed by CRUK Cambridge Institute Genomics 
Core using single-end 50 bp read length, processing 6 plates (576 cells) in 3 lanes on Illumina 
HiSEq 4000. 
 
2.4.8 ChIP-seq (ChIP, qPCR, library prep and sequencing) 
2.4.8.1 Chromatin immunoprecipitation 
ChIP nuclei were prepared from EV and CEBPA N321D-transduced cells which were collected 
both before differentiation in Hoxb8 media F+e+ (EV 40 x 106 cells, CEBPA N321D 80 x 106 





F+e-’) (EV 80 x 106 cells, CEBPA N321D 160 x 106 cells) for 5 days. Cells in F+e+ media were 
free floating in suspension but differentiated cells in Hoxb8 media F+e-  were trypsinised for 
1 minute at 37°C before quenching with original media. Cells were centrifuged at 335 x g for 
5 minutes at room temperature, cross-linked with formaldehyde 1% (Sigma 47608), stirred 
with gentle agitation for 10 minutes, and then quenched with 2M glycine. Cells were then 
stirred for 5 minutes at room temperature, and centrifuged at 300 x g for 5 minutes at 4°C.  
 
Cross-linked cells were then lysed with cell lysis buffer (10 mM Tris pH 8.0, 10 mM NaCl and 
0.2% NP-40, and protease inhibitors), nuclei recovered by centrifugation at 600 x g for 5 
minutes at 4°C, and nuclei lysates were resuspended in nuclei lysis buffer, protease inhibitors 
and 10 mM NaBu. Chromatin was then fragmented by sonication on Diagenode Bioruptor 
UCD-200 for five cycles (30 seconds on, 30 seconds off) before diluting chromatin fragments 
at a 1:5 ratio of nuclei lysis buffer to IP dilution buffer.  
 
Non-specific chromatin-antibody binding was pre-cleared by incubating in 50 µg of rabbit IgG 
(Sigma I5006) at 4°C for one hour, then incubating with protein G sepharose beads at 4°C for 
two hours, permitting separation of IgG-beads complexes from the chromatin in solution.  
 
Precipitation of specific antibody-bound chromatin was then performed: Chromatin from the 
EV cells was divided into anti-C/EBPα antibody (rabbit polyclonal IgG; Santa Cruz sc-61x), anti-
H3K27Ac antibody (rabbit polyclonal IgG; Abcam ab4729), IgG antibody control (rabbit serum; 
Sigma I5006) and Input sample, whereas CEBPA N321D chromatin was divided into anti-
C/EBPα antibody (rabbit; Santa Cruz sc-61x), anti-H3K27Ac antibody (rabbit; Abcam ab4729), 
anti-FLAG M2 antibody (mouse monoclonal IgG; Sigma F3165), IgG antibody control (rabbit)  
and IgG antibody control (mouse serum; Sigma I5381) and Input sample. The appropriate 
antibodies were then added (7 µg antibody for TF/IgG and 5 µg antibody for H3K27Ac) to the 
chromatin, and the samples were incubated on a roller at 4°C overnight. 60 µl of protein A/G 
sepharose beads were then added per condition, followed by rotation for 2 hours at 4°C. The 
sepharose / IgG pellets were centrifuged at 5300 x g for 2 minutes, then washed twice with 
pre-cooled low salt buffer (20 mM Tris pH 8.1, 2 mM EDTA, 150 mM NaCl, 1% Triton X100, 
0.01% SDS), once with Lithium Chloride buffer (10 mM Tris pH 8.1, 1 mM EDTA, 0.25 M LiCl, 






The DNA-protein-antibody complexes were then eluted from the beads by adding elution 
buffer (100 mM NaHCO3, 1% SDS) twice in succession and combining the two elutions. 
 
Cross-links were reversed by adding 1 µg RNaseA and 0.3 M NaCl to both immunoprecipitated 
samples and Input samples, before incubating at 67°C overnight. Endogenous nucleases were 
then removed by application of 60 µg Proteinase K at 45°C for 2 hours, before purifying DNA 
with the QIAquick PCR Purification Kit (Qiagen) and eluting in 50 µl elution buffer.  
 
To check that sonication had resulted in correct size distribution of DNA fragments (300 to 
500 bp), 0.005 µg of Input DNA was loaded onto the Agilent 2100 BioAnalyzer using the Agilent 
High Sensitivity DNA Kit as per manufacturer’s instructions. 
 
2.4.8.2 Real-time quantitative PCR 
Quantitative PCR was performed using Brilliant II SyBr Green QPCR Low ROX Master Mix 
(Agilent, 600830) on a Stratagene Mx3000P instrument. Input EV F+e+ was used for the 
standard curve, with dilutions in 1 x TE buffer at 2 ng/µl, 0.4 ng/µl, 0.08 ng/µl, 0.008 ng/µl, 
and H2O. Enrichment was assessed at two regulatory elements known to be bound by C/EBPα 
(SPI1 -14 and NFE2) as well as a negative control region on mouse chromosome 1 (Calero-
Nieto et al, 2010). ChIP products were diluted to 1:4 in 0.1 x TE buffer. Primers (Table 2.11) 
and thermocycler conditions (Table 2.12) are given below: 
 
Table 2.11 qPCR primers 
 
 PCR forward primer PCR reverse primer 
SPI1 -14 GCTGTTGGCGTTTTGCAAT  GGCCGGTGCCTGAGAAA 
NFE2 TCACACCAGTAGGCAATCCA GTGGCTAGAGGTGGAACCAG 
Negative control region 











Table 2.12 PCR amplification thermocycler conditions 
Step Temperature  Time Cycles 
1 95°C 10 minutes 1 
2 95°C 30 seconds 40 
60°C 60 seconds 
95°C 60 seconds 
3 55°C 30 seconds 1 
4 95°C 30 seconds 1 
5 4°C Hold - 
 
MxPro QPCR software (version 4.10) and Microsoft Excel 2016 were used to analyse data. Fold 
enrichment levels were calculated relative to IgG. 
 
2.4.8.3 ChIP library preparation and sequencing 
Libraries were constructed using TruSeq ChIP Library Preparation Kit Set A and Set B (Illumina,  
IP-202-1012 and IP-202-1024) to supply 24 indexed Illumina adapters for multiplexed 
sequencing. Briefly, ChIP enriched DNA was end repaired, purified with the DNA Clean and 
Concentrator-5 Kit (Zymo Research, D4014) and eluted in 11 µl of elution buffer (Qiagen). A-
nucleotide bases were then added to the 3’ end of the DNA fragments by incubating with A-
tailing mix, before ligating the relevant RNA adapter index and repeating DNA purification. 
PCR amplification of the elution product was carried out as per Table 2.13: 
 
Table 2.13 PCR amplification thermocycler conditions 
Step Temperature  Time Cycles 
1 98°C 30 seconds 1 
2 98°C 10 seconds 18 
60°C 30 seconds 
72°C 30 seconds 
3 72°C 5 minutes 1 
4 4°C Hold - 
 
Both the PCR product and 10 µl of 100bp Hyper Ladder II (BioLine) were then run on 2% 
agarose gel (100 ml 1 x TAE buffer) infiltrated with 10 µl of Sybr Green (Invitrogen), and 
fragments between 250 and 450 bp were selected, taking care to exclude adapter-dimers at 
126 bp. DNA was recovered by using the MiniElute Gel-Extraction Kit (Qiagen) to elute into 11 
µl of elution buffer. Fragment size was confirmed on the Agilent 2100 BioAnalyzer using the 
Agilent High Sensitivity DNA Kit as per manufacturer’s instructions. DNA concentration was 





at dilutions 1:20, 1:2000, 1:200,000, 1:2000,000 and 1: 200 x 106. Libraries were combined 
into two equimolar mixtures of 45 nM and 38 nM, and sequenced on the Illumina HiSeq 2000 
platform at the Genomics Core Facility, Cambridge. 
 
2.5 In vivo mouse model 
Cell extraction was performed by the author of this PhD and F Calero-Nieto. In vivo work was 
performed by G Giotopoulos (Huntly group). 
 
2.5.1 Mice 
Six-week old C57BL/6J mice were housed in a pathogen–free animal facility and were allowed 
unrestricted access to sterile food and water. Experiments were conducted under a UK Home 
Office project license, as per UK Home Office regulations. This research has been reviewed by 
the University of Cambridge Animal Welfare and Ethical Review Body, and is compliant with 
the Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012. 
 
2.5.2 Cell extraction from bone marrow compartment 
Bone marrow CD45.2+ ‘helper’ cells were extracted from tibias, femurs and iliac crests of 
C57BL/6J mice by making an incision just above the bone marrow compartment and using a 
21G needle (BD Microlance 3 0.8 x 40 mm) to flush 5ml of 1 x PBS very slowly through the 
bone, repeating until the marrow becomes pale. The bone marrow exudate was then passed 
through a strainer, centrifuged at 300 x g for 7 minutes, incubated with 5 ml of RBC lysis buffer 
for 10 minutes at room temperature, and centrifuged again at 300 x g for 7 minutes. Cells 
were then resuspended in 6 ml of 1 x PBS. 
 
2.5.3 Infection with EV and CEBPA N321D-transduced cells 
Prior to infection, both cell lines were confirmed negative for mycoplasma by PCR at Surrey 
Diagnostics. Cells were transplanted via tail vein injection into a total of ten lethally irradiated 
(10 Gray in split dose) C57BL/6J mice. Five mice were infected with EV-transduced cells and 
five mice were infected with CEBPA N321D-transduced cells. In each case, 5 x 105 CD45.1+ 
GFP+ plasmid-transduced cells and 2.5 x 105 CD45.2+ helper cells were transplanted into the 
CD45.2+ mouse. Peripheral blood was withdrawn by tail vein at weekly intervals for the first 





1 method or by exsanguination under terminal general anaesthetic. In addition to peripheral 
blood samples in vivo, bone marrow and splenic tissue was collected from animals ex vivo. 
Chimerism was evaluated by CD45.1, CD45.2 and GFP markers on flow cytometry. 
 
2.6 Bioinformatics 
2.6.1 Analysis of single cell gene expression data 
Alignment and mapping of single cell expression data was performed by I Kucinski and E 
Diamanti. Data was uploaded and analysed on ASAP by the author of this PhD. Further analysis 
was performed using R language code written by the author with input from W Jawaid. 
 
2.6.1.1 Alignment and mapping 
Reads were aligned using GSNAP to the GRCm38 genome and reads spanning exons (ENSEMBL 
m38.81) were counted using HTSeq. The genome and annotation files were augmented with 
sequences for External RNA Controls Consortium (ERCC) spike-ins, GFP, human CEBPA and 
pMSCV backbone sequences. It should be noted that alignment to human CEBPA did not 
reliably distinguish the single point mutation between human CEBPA WT and 
human CEBPA N321D. Reads were mapped to gene features with HTseqcount. 
 
2.6.1.2 QC 
FastQC was then used to apply the following quality control metrics: 200,000 < total reads < 
3,000,000; 0.15 < fraction mapped; 1800 < highly expressed genes (defined as counts per 
million > 50); ERCC fraction < 0.12; and mitochondrial gene fraction < 0.2. Cells which fell 
outside these parameters were classified as outliers and excluded from further analysis. 
 
2.6.1.3 Data normalisation 
For the Automated Single-cell Analysis Pipeline (ASAP), data was normalised using the single-
cell Latent Variable Model (Buettner et al, 2015). Technical noise was excluded using ERCC 
spike-ins and the statistical method of Brennecke et al (Brennecke et al, 2013).  
 
2.6.1.4 Dimensionality reduction 
t-distributed Stochastic Neighbour Embedding (tSNE) was performed using ASAP software 
with Perplexity 25 and Theta 0.5. Results were downloaded from ASAP and plotted in three 






2.6.1.5 Differential expression 
ASAP’s DESeq2 function was used to perform differential expression between cell types and 
conditions on normalized data after filtering. 
 
2.6.1.6 Violin plots 
For the generation of Violin Plots, which is not a function provided by ASAP, single cell RNA-
seq data was processed on R version 3.5.2 (http://bioconductor/biocLite.R). Briefly, raw 
counts were parsed in to a dataframe, the dataframe was converted to a matrix, and this was 
correlated with metadata from cells which passed QC. From the DESeq2 package (version 
1.22.2), the function estimateSizeFactorForMatrix was then employed to normalise raw 
counts. GFP expression data was specifically removed before calculating size factor as it would 
skew normalisation. Normalised counts were then log transformed and zero values were 




The online gene set enrichment analysis tool Enrichr (Kuleshov et al, 2016) was used to analyse 
gene sets identified by differential expression (https://amp.pharm.mssm.edu/Enrichr/). 
 
2.6.2 Analysis of ChIP-seq data 
R Hannah performed bioinformatic analysis of ChIP-seq data including genome alignment, 
peak calling, and read count quantification. The author of this PhD analysed peaks using UCSC 
genome browser. 
 
2.6.2.1 Genome alignment and peak calling 
Raw data in FASTQ format was run through FASTQC to exclude overrepresented sequences 
and identify adapters. TRIMGALORE was then used to trim adapter sequences from data. The 
raw reads were then mapped to the mm10 genome using bowtie2 to generate a SAM file. The 
SAM file was then converted to BED format by using the sam2bed program from the 
SAMTOOLS suite, before formatting and extending reads to 200 base pairs. The BED file was 
then converted to a BEDGRAPH density profile, before converting this in turn to compressed 






Peaks were called by running MACS2 (Zhang et al, 2008) on the BED file data, using the IgG 
track as a control, and employing a spread of p-value stringencies. Tracks for multiple 
stringencies were then visually inspected on UCSC Genome Browser to identify optimal p 
values for counting genuine peaks only in each ChIP-seq track. An in-house Perl script was 
then used to modify the peaks to 400 base pairs centred on peak summits.  
 
2.6.2.2 Read count quantification 
ChIP-seq was performed for all conditions on two separate occasions, and BEDTOOLS was 
used to perform intersects and identify a union of peaks at regions bound in both experiments. 
Read coverage was calculated in regions of union for each condition, and then normalised for 
peak length and total read counts per 10 million reads. For H3K27Ac, the entire genome was 
split into 200 bp windows and read coverage was calculated over each of these regions. 
Counts were normalised to total read counts per 10 million reads, as well as using the S3norm 
method (Xiang et al, 2018) to normalise signal-noise ratio. Scores were then log2 transformed 
and plotted using gplots. 
 
2.6.2.3 Peak distribution analysis 
An in-house script mapped a peak to a gene if within a known promoter region as defined by 
the mammalian promoter database, or if directly overlapping a gene body based on Refgene 
coordinates. For intergenic peaks, the script mapped peaks to the nearest gene within 50 
kilobases on either side, so that it was possible for an intergenic peak to map up to two genes.  
 
2.6.3 Analysis of CODEX data 
The author of this PhD performed manual curation of the CODEX database, adding samples 
identified by the CODEX webcrawler and also manually searching GEO datasets. R Hannah 
then processed this data using the CODEX pipeline (Sanchez-Castillo et al, 2015), and 
performed bioinformatic analysis to construct heat maps for both transcription factor and 
histone profiles.  
 
2.6.3.1 CODEX pipeline 
Briefly, public data was converted from SRA format to FASTQ format by using the SRA toolkit. 
Quality control was performed by FASTQC, and overrepresented sequences and adapters 





human reference genome GRCh37 (hg19), and produce a SAM file, then transformed to an 
intermediate BED file before converting to a bigWig read density profile. Peaks were called 
using MACS2 software (Zhang et al, 2008) for a range of p-value stringencies, at which stage 
tracks were manually inspected to identify the optimal stringency. 
 
2.6.3.2 CODEX heat maps 
For transcription factors, a matrix was constructed from a master list (the union) of peaks 
between all samples, based on binary presence or absence of each peak in each sample. Each 
region (row) was then scored across all samples (columns) in the matrix to give coverage 
scores for how many reads overlapped a given peak region. Regions with entirely zero 
coverage scores across all samples were removed from the matrix, and remaining regions 
were normalised per sample to the total read number of that sample. The samples in the heat 
maps were clustered based on pairwise correlation between binding patterns across these 
regions. 
 
For histones, instead of a master peak list, the entire genome was divided into 200 bp windows 
and the S3norm package (Xiang et al, 2018) was used to normalise coverage scores for both 
sequencing depth and signal-to-noise ratio.  
 
Further processing was performed using in-house Perl and Shell scripts and the R package. 
Hierarchical clustering was performed  in R  using the log2 of the coverage scores, comparing 
pairwise the binding of each sample (column) across all given regions (rows) in the matrix and 
then clustering based on similarity of those patterns. The DICE coefficient was used on the 
discrete data in the binary TF matrix, and Euclidean distance was used for the continuous data 
(coverage scores for histone binding). This data was then plotted using R libraries and 











3. Construction and phenotypic characterisation of a 
stable retroviral expression system for CEBPA WT and 
CEBPA N321D 
 
3.1 Construction of retroviral expression system 
My research hypothesis is that the expression of mutant CEBPA will cause transcriptional and 
phenotypic alterations in a cell line which replicates an early stage of haematopoiesis. 
Therefore I set out to construct and validate a retroviral expression system for both CEBPA 
WT and CEBPA N321D. 
 
3.1.1 Empty Vector (EV), CEBPA WT and CEBPA N321D plasmids 
The CEBPA N321D mutation was constructed from synthetic oligonucleotides and provided by 
GeneArt (Life Technologies) as an insert into a pMK-RQ (kanR) vector with restriction sites for 
BLPI I and BstAP I. The plasmid was transformed into DH10β competent cells, colony expanded 
on agar with kanamycin, and then inoculated into Luria Bertani broth. DNA was purified, then 
digested by BLPI I and BstAP I restriction enzymes, followed by Gibson Assembly with forward 
and reverse primers to substitute a single nucleotide base for CEBPA WT. PCR was used to 
amplify and add restriction sites and FLAG tag to both the CEBPA WT and N321D inserts (see 
Figure 3.1), and the products were then ligated into a pMSCV-neo retroviral vector with an 
IRES-eGFP insert provided by the Huntly lab. In addition, an Empty Vector (EV) for the MSCV 
plasmid was established by digesting an existing stable retroviral expression vector (provided 
by S Basilico) with Sal I and Bgl II restriction enzymes to excise the transgene but preserve GFP, 
purifying the plasmid backbone, blunting and then annealing the two ends.  
 
The retroviral expression system is a bicistronic vector where C/EBPα is translated using a cap-
dependent ribosome scanning mechanism with its own 5’-UTR, and translation of GFP is by 
way of cap-independent IRES-mediated recruitment of ribosomes (Jang et al, 1988, Stoneley 
et al, 2004). This mechanism facilitates co-expression of C/EBPα and GFP, although there is 
evidence to suggest that IRES-mediated co-expression can vary with cellular context 






































Figure 3.1 Mutated CEBPA in the CEBPA N321D cell line. (A) cDNA, and (B) amino acid 
sequences. In-frame single nucleotide substitution shown after 321st codon, resulting in 
mutation from asparagine AAT to aspartate GAT. (C) Mutation shown in model of C/EBPα 
protein which characterises TransActivation Domains (TAD) 1 and 2, DNA Binding Domain 
(DBD) and Leucine Zipper Domain (LZD). (D) shows cDNA sequence of forward oligonucleotide 
for Gibson PCR assembly of restriction sites and FLAG tags onto CEBPA WT and N321D inserts, 
with yellow vector (Sal I is underlined), FLAG tag no colour and underlined, green CEBPA. (E) 
shows cDNA sequence of  reverse oligonucleotide for Gibson PCR with yellow vector (Bgl II is 
underlined) and green CEBPA template sequence. 
 
 
3.1.2 Verification of integration of CEBPA sequences into retroviral model 
Successful integration of the CEBPA WT and N321D sequences together with FLAG tags was 
confirmed by Sanger sequencing. Primers were designed specifically to verify CEBPA WT and 
N321D mutation sequences. 
 
3.1.3 Retroviral transduction of Hoxb8-FL cell line 
293T cells were transfected with Psi packaging vector and the vector containing the cDNA 
from either the EV, CEBPA WT or CEBPA N321D plasmids. The viral supernatant was recovered 





parental cells to produce cell lines which expressed EV, CEBPA WT and CEBPA N321D. 
Together with non-transduced parental control cells, these three cell lines were then 
examined for variation in cell growth, immunophenotypic profile and morphological 
appearance under different cytokine conditions.  
 
3.2 Characterisation of transduced cell lines in self-renewal 
conditions 
 
Hoxb8-FL cells contain a fusion construct of the hormone-binding domain of the estrogen 
receptor and the N-terminus of Hoxb8 (Wang et al, 2006), and in the presence of Flt3L and 
estradiol are maintained in an early non-differentiated progenitor state with stable growth, 
conditional immortalisation and multi-lineage potential (Redecke et al, 2013). Transduced cell 
lines were examined in the presence of both Flt3L and estradiol to evaluate if the CEBPA-
transduction affected Hoxb8-mediated programs of differentiation arrest (Knoepfler et al, 
2001). 
 
3.2.1 CEBPA WT-transduced cells overcome Hoxb8 effect in the presence of estradiol 
Expression of myeloid, lymphoid and dendritic cell markers was tested to look for evidence of 
differentiation within any of the transduced cell lines, using parental Hoxb8-FL cells as a 
control. The following flow cytometry panel included markers employed by Redecke et al in 
their characterisation of Hoxb-FL cells and additional markers designed to further elucidate 
dendritic cell (DC) lineage: 
 
Table 3.1 Flow cytometry panel designed to evaluate differentiation of Hoxb8-FL cells 
and transduced cell lines  
CD marker Cell type 
c-kit/CD117 Haematopoietic stem cells and progenitors 
Ly6g/Gr-1 Granulocytes 
B220/CD45R B lymphocytes, plasmacytoid dendritic cells 
CD11b Granulocytes, monocytes/macrophages, dendritic cells 
CD11c Dendritic cells 
XCR1 Conventional dendritic cell type 1 
SIRPα Conventional dendritic cell type 2 
BST2/PDCA1 Plasmacytoid dendritic cells 
F4/80 Monocytes/macrophages 






Importantly, it was noted that the parental cells and the EV transduced cells had very similar 
profiles on flow cytometry in the presence of estradiol, suggesting that the plasmid itself does 
not have an effect and that effects seen on flow cytometry are due to the CEBPA insert.  
 
Interestingly, the CEBPA WT-transduced cells demonstrated increased expression of CD11b 
and SIRPα in the presence of estradiol at Day 2 post-transduction (see Figure 3.2), suggesting 
that these cells were differentiating down a conventional dendritic cell (cDC) pathway. 
Expression of CEBPA N321D prevented the acquisition of dendritic cell markers. By Day 5, the 
decreased proportion of CEBPA WT-transduced cells made it difficult to continue 
characterising them by flow cytometry, but no marked difference was seen in any of the other 
transduced cell lines up to and including Day 18 in the presence of estradiol.  
 
The CEBPA WT-transduced cells form two subpopulations: one which is c-kit high and does not 
express CD11b or SIRPα, and the other which is c-kit low and does express CD11b and SIRPα. 
When these two subpopulations are evaluated separately for GFP expression, it is clear that 
the first subpopulation expresses less GFP than the second subpopulation (see Figure 3.3). 
One explanation for this observation is that the CEBPA WT-transduced cells which show a 
dendritic cell phenotype in the presence of estradiol may comprise only those cells which 
incorporate a higher number of plasmid copy numbers. 
 
Figure 3.2 Comparison of c-kit, CD11b, XCR1 and SIRPα expression in cell lines. CEBPA WT-
transduced cells show increased expression of CD11b and SIRPα in F+e+ media following 








Figure 3.3 Two subpopulations are observed in CEBPA WT-transduced cells in the 
presence of estradiol. Increased GFP expression is seen in cells which are c-kit low and which 
express CD11b and SIRPα. 
 
One interesting observation is that the few cells persisting from the CEBPA WT-transduced 
cell line, which expressed CD11b and SIRPα in the presence of Flt3L and estradiol from as soon 
as Day 2 post-transduction (see Figure 3.2 above), no longer show any significant difference 
from other cell lines at Day 10 (Figure 3.4). The discrepancy between Day 10 and Day 2 
expression profiles of CEBPA WT-transduced cells in the presence of estradiol may be 
explained by the observation at Day 2 (see Figure 3.3) that it is only a subpopulation of CEBPA 
WT-transduced cells expressing more GFP, presumably having incorporated a higher number 
of CEBPA WT plasmid copies, which differentiate into a dendritic cell phenotype. It is possible 
that these cells have fully differentiated and progressed to cell death by Day 10, leaving behind 
only Hoxb8-FL cells which incorporated single CEBPA WT plasmid copies and which have a 








Figure 3.4 Differentiation profile of transduced cell lines at Day 10 in the presence of Flt3L 
and estradiol. All cell lines are c-kit high and fail to express lineage markers at Day 10 in the 
presence of estradiol. (1 replicate for all cell lines, 3 additional replicates showed parental, EV 
and CEBPA N321D only; example shown is representative). 
 
 
3.2.2 Morphological examination of CEBPA WT-transduced cells confirms differentiation in 
the presence of estradiol 
Following the finding that a population of CEBPA WT-transduced cells demonstrated a distinct 





whether this was reflected by a difference in morphological phenotype. Due to the rapid 
decrease in CEBPA WT-transduced cells as a proportion of total cells after transduction, cell 
sorting was carried out to isolate GFP+ EV, CEBPA WT and CEBPA N321D-transduced cells at 4 
days post-transduction. Cytospin was performed (span at 700 rpm for 2 minutes, cells were 
allowed to dry) and then stained using Rapid Romanowsky Stain Pack (TSC Biosciences). 
Photographs were taken using Axio Imager for bright field microscopy (see Figure 3.5). The EV 
and CEBPA N321D-transduced cell lines showed poorly differentiated cells with immature 
dispersed chromatin and high nuclear:cytoplasmic ratio reflecting their early haematopoietic 
progenitor status. By contrast, CEBPA WT-transduced cells showed denser clumped chromatin 
and plentiful vacuoli in the cytoplasm (Figure 3.5). 
 
  
EV cell line CEBPA N321D-transduced cell line 
  
CEBPA WT-transduced cell line 
Figure 3.5 Morphological appearances of GFP+ cells in presence of Flt3L and estradiol EV and 
CEBPA N321D-transduced cells are poorly differentiated in comparison with mature clumped 








3.2.3 Cell growth suggests that CEBPA WT and N321D transduced cells have a competitive 
disadvantage to EV-transduced Hoxb8-FL cells in the presence of estradiol 
Hoxb8-FL cells transduced with EV, CEBPA WT and CEBPA N321D all continued to grow 
indefinitely in the presence of Flt3L and estradiol, however the proportional growth rates of 
the transfected GFP+ compartment showed significant variation between cell lines. Initial 
transduction rate for EV cells was around 70% at Day 2, and this increased to nearly 90% by 
Day 20. By contrast, the CEBPA WT cells were approximately 10% transduced at Day 2, and 
this decreased to 0.5% by Day 5 which was then maintained long-term despite expanding the 
cells every 2 to 3 days. The CEBPA N321D cells showed 25% transduction at Day 2, which 
gradually decreased to 10% by Day 20. 
 
This demonstrated a functional variation between the three cell lines. The EV-transduced cells 
maintained the Hoxb8-FL growth pattern, whereas the CEBPA WT and N321D transduced cells 
had a competitive disadvantage (see Figure 3.6). This suggests that both CEBPA WT and N321D 




Figure 3.6 Competition assay of Hoxb8-FL parental cells after transduction with 
retroviral vectors. Decreased proportion of GFP+ CEBPA WT and N321D-transduced 
cells, contrasting with stable growth of EV-transduced cells. 
 
 
Graphical representation of logarithmic growth in the three transduced cells lines also 































Figure 3.7 Logarithmic growth chart for transduced cell lines. Constant growth rates  
seen for Hoxb8-parental cells transduced by EV, CEBPA WT and CEBPA N321D. 
 
3.3 Characterisation of transduced cell lines upon differentiation 
Hoxb8-FL cells have multi-lineage potential and can be differentiated into myeloid and 
lymphoid cell types upon withdrawal of estradiol. Transcriptionally, they are most similar to 
LMPP cells (Redecke et al, 2013). Specifically, they are able to differentiate into cDCs and 
plasmacytoid dendritic cells (pDCs) in the presence of Flt3L, into DCs and granulocytes in the 
presence of GM-CSF, and into macrophages in the presence of M-CSF. In addition, it is known 
that granulopoiesis can be rescued in C/EBPα -/- mice in the presence of exogenous IL-3 (Hirai 
et al, 2006). The EV, CEBPA WT and CEBPA N321D-transduced cell lines were therefore 
differentiated in these four cytokine conditions for 5 days. 
  
3.3.1 Flow cytometry characterisation of transduced cell lines upon differentiation in GM-
CSF, IL-3, M-CSF, and Flt3L 
EV and CEBPA N321D-transduced cells maintained in Flt3L and estradiol remained c-kit high and 
expressed no lineage markers up to Day 10 (Figure 3.4). This was in keeping with the behaviour 
of Hoxb8 parental cells which are conditionally immortalised in the presence of estradiol. 
 
Differentiation was then performed by removing estradiol and culturing cells in the presence 
of GM-CSF, IL-3, M-CSF and Flt3L cytokines, and comparing the flow cytometry profile of GFP+ 
transduced cells with GFP- non-transduced cells (Figure 3.8). This initial experiment was 
performed with a simplified flow panel using markers of granulocytic (Gr1), dendritic (CD11b), 
or lymphocytic (B220) differentiation (Figure 3.8). There was no significant phenotypic 
difference between the three transduced models in GM-CSF, IL-3 or M-CSF, to suggest that 


































macrophage development of Hoxb8-FL cells during differentiation. Rather, this initial 
exploratory data suggested that an important early haematopoietic effect of the CEBPA 
N321D mutation was related to dendritic differentiation pathways, and it was decided to 





Figure 3.8 Differentiation profile of transduced cell lines at Day 5 in the presence of (A) 
GM-CSF, (B) IL-3, (C) M-CSF, and (D) Flt3L.  CEBPA N321D-transduced cells show marked 
reduction in CD11b expression when cultured in Flt3L. (2 replicates for all cell lines, 1 






By Day 5 of differentiation in Flt3L, the EV-transduced cells showed marked expression of 
CD11b, SIRPα, CD11c and BST2, and showed no expression of XCR1 (Figure 3.9).   
 
Figure 3.9 Differentiation profile of transduced cell lines at Day 5 in the presence of Flt3L 
and withdrawal of estradiol. CEBPA N321D-transduced cells show decreased expression of 
CD11b, SIRPα, CD11c and BST2 at Day 5 of differentiation. (1 replicate for all cell lines and 
full panel as shown, 3 additional replicates for EV and CEBPA N321D cell lines and full marker 





This confirmed the data demonstrated by Redecke et al in their original description of Hoxb8-
FL cells, suggesting that this cell line differentiates into both cDCs and pDCs in Flt3L, although 
our additional characterisation of these cells as SIRPα+ XCR1- suggests that they are type 2 
cDCs. Interestingly, the CEBPA WT-transduced cells showed a similar profile to EV cells after 5 
days of differentiation in Flt3L. By contrast, the CEBPA N321D-transduced cell line 
demonstrated reduced expression of both conventional (CD11b, CD11c, SIRPα) and mature 
plasmacytoid (CD11c, BST2) DC markers, in comparison with EV and CEBPA WT-transduced 
cells (Figure 3.9).  
 
By Day 10, CEBPA N321D-transduced cells were also characterised by decreased expression 






Figure 3.10 Differentiation profile of transduced cell lines at Day 10 in the presence of Flt3L 
and withdrawal of estradiol. (1 replicate for all cell lines, 3 additional replicates for EV and 







3.3.2 Morphological examination shows that CEBPA N321D-transduced cells display 
differentiation defect compared to EV-transduced cells in the presence of Flt3L 
Flow cytometry was repeated on cells differentiated in Flt3L during two separate collections 
of ChIP nuclei and demonstrated a similar profile as described above. CEBPA WT-transduced 
cells rapidly decreased to less than 0.5% of total cells after differentiation, and therefore 
morphological examination of GFP+ sorted cells was performed only on EV and CEBPA N321D-





Figure 3.11 Morphological appearances of cell lines after differentiation in Flt3L for 5 days. 
(A) EV-transduced cell lines are morphologically more differentiated than (B) CEBPA N321D-
transduced cells after withdrawal of estradiol. (2 replicates, examples shown are broadly 
representative). 
 
Differentiated EV and CEBPA N321D-transduced cells demonstrated a clear morphological 
difference with differentiation block evident on morphological examination of the CEBPA 
N321D-transduced cells. The EV transduced cells had relatively small nuclei and vacuolated 
cytoplasm, and some cells suggested pre-DC appearances consisting of lateralised reniform 
nuclei, typical Golgi regions and a few prominent dendritic projections. By contrast, the CEBPA 
N321D-transduced cells had larger nuclear:cytoplasmic ratio and no evidence of dendritic 
differentiation (see Figure 3.11). 
 
3.3.3 Cell growth shows that CEBPA N321D-transduced cells are immortalised 
independently of Hoxb8 expression 
Unsurprisingly, the distinct differentiation profile of EV and CEBPA N321D-transduced cells 
resulted in very different growth profiles. By Day 12 post-differentiation, not many live viable 





to grow in the absence of estradiol in the media. We kept these cells in culture up to Day 56 
without any signs of reduction in growth capabilities (see Figures 3.12 and 3.13). 
 
 
Figure 3.12 Logarithmic growth chart for transduced cell lines. CEBPA N321D-




3.4 Differentiation of CEBPA N321D cell line for extended time period 
in Flt3L suggests Hoxb8-independent immortalised pDC progenitor 
phenotype 
 
Having established in multiple transduction experiments that the CEBPA N321D-transduced 
cells under-expressed markers of dendritic cell maturation at Day 5 of differentiation in Flt3L, 
the next question was to follow mutant transfected cells in Flt3L without estradiol and 
investigate their growth and phenotype over an extended period of time. 
 
CEBPA N321D-transduced cells in Hoxb8 media F+e- were vigorously pipetted, centrifuged, 
and cells were then resuspended in fresh F+e- media every 2 to 3 days. Cells continued to 




































Figure 3.13 Indefinite expansion of CEBPA N321D cell line in Flt3L without estradiol. (A) Percentage 
of GFP+ cells over time. (B) Log (10) of GFP+ cells over time. 
 
CEBPA N321D-transduced cells in Flt3L therefore appeared to demonstrate a Hoxb8-
independent immortalised phenotype. Morphological appearance suggested differentiation 
arrest with cytoplasmic vacuoles, Golgi regions, indented and occasionally reniform nuclei 




Figure 3.14 CEBPA N321D-transduced cells 
after 56 days of differentiation in Hoxb8 
media F+e-. (1 replicate only). 
 
Furthermore, flow cytometry of the immortalised cell line at Day 56 demonstrated a 
dramatically different phenotype from the phenotype described at Days 5 and 10 above. 
These cells were c-kit negative, expressed no cDC markers, but did express markers suggestive 


























































Figure 3.15 Differentiation profile of CEBPA N321D-transduced cells after extended time 
period in Hoxb8 media F+e- . CEBPA N321D-transduced cells are CD11c+ and B220+ at Day 56 
of differentiation in Flt3L, in comparison with EV and mutant cells differentiated for 8 days. (1 
replicate, 1 additional replicate of CEBPA N321D-transduced cells at Day 31 of differentiation 






Intriguingly, the differentiation profile of the mutant cells has switched from reduced 
expression of cDC markers at week one, to a pDC progenitor-like phenotype at week eight. It 
was then decided to repeat differentiation of CEBPA N321D-transduced cells in Hoxb8 media 
F+e-  and perform flow cytometry every 7 days from Day 3 to Day 31. This confirmed a gradual 
progression in the immunophenotype of mutant cells (see Figure 3.16). 
 
 
Figure 3.16 Flow cytometry shows progression of CEBPA N321D-transduced cell line through 
4 weeks into a final c-kit low CD11c+ B220+ phenotype. (1 replicate only). 
 
Flow cytometry at Day 31 with this biological replicate, originating from a distinct transfection 
of Hoxb8-FL cells with CEBPA N321D, demonstrated a similar profile as was previously 






Figure 3.17 Differentiation profile of CEBPA N321D-transduced cells at Day 31 in Hoxb8 
media F+e- . CEBPA N321D-transduced cells are confirmed as CD11c+ and B220+ at Day 31 of 
differentiation in Flt3L, using unstained GFP Hoxb8 parental cells in Flt3L and estradiol as a 
control. (1 replicate, 1 additional replicate of CEBPA N321D-transduced cells at Day 56 of 






3.5 In vivo potential of Hoxb8-independent CEBPA N321D cells  
Our in vitro results suggested that CEBPA N321D-transduced Hoxb8 cells were immortalised 
as a pDC progenitor-like cell line in the presence of Flt3L and in the absence of estradiol-
mediated expression of HOXB8. We then sought to recapitulate these findings in an in vivo 
model. Hoxb8-FL cells were originally generated by Redecke et al from C57BL/6J mice and 
were able to transiently repopulate lethally irradiated mice in a time-dependent manner but 
did not demonstrate self-renewal capacity, leaving the bone marrow by Day 38. In addition, 
in a separate experimental model, bone marrow mononuclear cells were infected with 
retrovirus harbouring the CEBPA N321D mutation and induced a rapid leukaemic phenotype 
when transplanted into C57BL/6J mice (Togami et al, 2014).  
 
We therefore decided to introduce Empty Vector and immortalised CEBPA N321D-transduced 
Hoxb8 cells into two cohorts of an in vivo study with five C57BL/6J mice in each cohort. EV-
transduced cells in F+e+ media and CEBPA N321D-transduced cells at Day 38 of differentiation 
in Hoxb8 media F+e- were confirmed negative for mycoplasma before transplantation. Six-
week old Ly 5.2 C57BL/6J mice were lethally irradiated and then injected with 5 x 105 Hoxb8-
FL Ly 5.1 GFP+ cells and 2 x 105 Ly 5.2 C57BL/6J bone marrow ‘helper’ cells via tail vein. 
Peripheral blood was withdrawn from the tail vein, initially weekly, to monitor engraftment 
and repopulation.  
 
By Day 7 post-injection, the Ly 5.1 GFP+ EV cells were undetectable in peripheral blood 
whereas the CEBPA N321D-transduced cells comprised about 9% of peripheral blood. 
However, the percentage of CEBPA N321D-transduced cells decreased steadily so that by Day 
28 the mutant cohort showed <1.0% Ly 5.1 circulating cells (see Figure 3.18).  
 
Mice from both cohorts demonstrated no Ly 5.1 cells in peripheral blood at Day 120, and 
exhibited no altered body weight, physical appearance or measurable clinical signs. It was 
therefore decided to sacrifice one mouse from each cohort at Day 149 post-infection. The 
mouse injected with CEBPA N321D-transduced cells demonstrated a distinct population of 








Figure 3.18 Circulating Ly 5.1 cells in C57BL/6J mice. Percentage of 
CD 45.1 cells in both cohorts of mice injected with EV and CEBPA 






Figure 3.19 Bone marrow profile of C57BL/6J mice infected with CD 45.1 cells. (A) Mouse 
infected with EV-transduced Hoxb8-FL cell shows no long-term engraftment. (B) Mouse 
infected with CEBPA N321D-transduced cells demonstrates 6.2% engraftment of bone 
marrow cells at Day 149.  
 
On Day 264, one of the mice reached humane end-point (weight loss, lethargy, hunched 





white cell count was normal (HGB 10.7 x 109/L, WBC 5.8 x 109/L, platelets 100 x 109/L). 
Necropsy revealed a marginally enlarged spleen (0.386 gr) and a normal sized liver (1.48 gr). 
In order to isolate leucocytes, particularly in the spleen, we gated on CD45+ cells and found 
that these cells were 80.2% and 99.1% GFP+ respectively in the bone marrow and spleen 
(Figure 3.20). Further characterisation of these GFP+ cells demonstrated that they were B220 
high, CD4 low, CD11b high and Gr1 high (Figure 3.21). 
 
 
Figure 3.20 GFP+ cells in bone marrow and spleen of mouse culled at Day 264. Cells were 
gated for CD45+ leucocyte compartment, and demonstrated >20% infiltration of bone 
marrow and spleen with GFP+ cells.  
 
 
Figure 3.21 CEBPA N321D-transduced cells persist in bone marrow and spleen of mouse 








This was a small preliminary study of two cohorts each of five mice infected with EV and CEBPA 
N321D-transduced cells respectively. None of the mice infected with EV cells showed evidence 
of engraftment during 12 months follow-up. In addition, none of the mice infected with CEBPA 
N321D-transduced cells demonstrated GFP+ cells in peripheral blood at 4 months. However, 
one mouse was sacrificed from each arm of the study at 5 months post-infection, and the 
mouse infected with mutant cells showed evidence of long-term engraftment with 6.2% 
CD45.1+ cells in the bone marrow, in comparison with no CD45.1+ cells in the mouse infected 
with EV cells. As previously described, at 9 months one of the mice infected with CEBPA 
N321D-transduced cells demonstrated 80.2% and 99.1% infiltration of the CD45+ leucocyte 
compartment in bone marrow and spleen respectively (Figure 3.20), showing markers 
consistent with DC phenotype (Figure 3.21). A third mouse infected with mutant cells died at 
month 11, and was found to have evidence of leukaemic infiltration of the bone marrow (data 
not shown).  The two remaining mice infected with CEBPA N321D-transduced cells were culled 
at month 13: one showed expansion of GFP+ cells >20% suggestive of leukaemia, but the other 
showed no evidence of long-term engraftment. Overall, these observations suggest that the 
CEBPA N321D-transduced cells are capable of long-term engraftment in vivo, but do not cause 
frank leukaemia on peripheral blood counts or significant organomegaly during 12 months of 
follow-up. In addition, the length of time required for leukaemic infiltration of the bone 
marrow suggests that additional hits by co-operating mutations may be required for a 




3.6.1 Cellular model of CEBPA expression 
Our retroviral system is designed to answer the following question: What are the early 
changes associated with CEBPA-mutated pre-leukaemia? We have aimed to improve on 
previous cellular models of mutated CEBPA where the starting point has not been well-
characterised, and consequently it has been difficult to compare start and end points. The 
Hoxb8-FL cell line was selected because it has significant advantages when building a cellular 
model of pre-leukaemia. Firstly, it is a conditionally immortalised cell line, with a fusion 
construct between EHRBD and Hox8 which provides a constant supply of near identical 
haematopoietic progenitor cells at a permissive temperature. Secondly, it is a robust cell line 





functional equivalent of LMPP-like cells, with the potential to differentiate into myeloid, 
lymphoid and dendritic cells in vitro. This contrasts with previous myeloid-committed 
progenitor cell lines employed by the Göttgens group such as the 416b cell line (Schutte et al, 
2016) and the HPC7 cell line (Wilson et al, 2010).  
 
The retention of identical mutation patterns in patients who relapse with CEBPA-mutated 
AML (Shih et al, 2006) suggests that these mutations are early events, and therefore it is useful 
to employ a cellular model which lies upstream of the CMP to GMP transition point. In 
addition, Naik et al have tracked developmental fates of early progenitor cells at single cell 
resolution by lentiviral-mediated barcoding, and identified not only lineage restriction in most 
LMPP cells, but also imprinting of B-cell, myeloid cell and DC lineages (Naik et al, 2013), 
suggesting that cell fate decisions occur in  early haematopoiesis. Our hypothesis is that 
Hoxb8-FL cells can recapitulate the pre-leukaemic phenotype of early haematopoietic 
progenitors in a cellular model of mutated CEBPA. 
 
The requirement for CEBPA expression at the CMP to GMP junction is well-characterised, with 
CEBPA deletion resulting in absolute loss of GMPs (Zhang et al, 1997) and macrophages (Heath 
et al, 2004). In addition, the Tenen group have demonstrated that CEBPA deletion causes 
severe depletion of dendritic cells when introduced into the LSK or GMP fraction, but has no 
effect when introduced into common dendritic progenitor cells (Welner et al, 2013). 
Interestingly, we find no significant distinction between the EV, CEBPA WT or CEBPA N321D-
transduced cell lines on differentiation of early LMPP-like cells in either GM-CSF or IL-3, 
suggesting that GM-CSF receptor signalling may not be implicated in the pre-leukaemic stages 
of CEBPA N321D-mutated AML. Similarly, the lack of a distinct CD11b-related phenotype for 
CEBPA N321D-transduced cells in M-CSF implies that macrophage pathways are not disturbed 
by the N321D mutation at this stage of haematopoiesis. By contrast, the marked variation in 
phenotypic profile on differentiation of transduced Hoxb8-FL cell lines in Flt3L implicates a 
novel dendritic cell-mediated mechanism as an early effect of the CEBPA N321D mutation. It 
is important to bear in mind that this is one of many C-terminal mutations of CEBPA which are 
implicated in AML, that these mutations can affect functionally distinct leucine zipper or DNA-
binding structures and that N-terminal mutations are likely to have very different effects on 





phenotype, suggesting that expression of CEBPA N321D in progenitors distinct from the Hoxb8 
model used here, may generate a different phenotype. 
 
3.6.2 CEBPA N321D mutation 
The CEBPA N321D mutation is found in human patients with AML (Papaemmanuil et al, 2016) 
and has previously been shown to induce rapid onset of aggressive leukaemia when 
lentivirally-transduced into BM mononuclear cells and injected into a mouse model (Togami 
et al, 2015). This C-terminal mutation gives rise to the p42 isoform of C/EBPα, preserving both 
transactivation domains and the DNA-binding domain. Single nucleotide substitution by 
N321D results in the in-frame mutation of asparagine to aspartate within the leucine zipper 
(LZ) domain of C/EBPα. The LZ is a three-dimensional structural motif formed from a heptad 
repeat [abcdefg]n where hydrophobic residues fall at positions a and d (typically leucine 
residues occur at position d), and polar/charged residues fall at positions e and g.  A single 
residue can affect the configuration of the coiled coil structure of the leucine zipper, for 
instance the N321D mutation encodes aspartate in place of asparagine at the 321st codon, and 
asparagine residues prefer to pair at a-a’ positions which can in turn reconfigure helix 
orientation (Grigoryan et al, 2008). The hydrophobic and polar interactions between these 
residues govern the helical topology of bZIP transcription factors and indeed engineered 
mutations within the LZ region of the MafB transcription factor have been shown to alter 
dimerisation properties and DNA-binding profile (Pogenberg et al, 2014). Given that the DNA-
binding region of bZIP transcription factors is generally conserved and that combinatorial 
versatility is provided by the LZ region, it is likely that the N321D mutation confers altered 
selectivity for homo- and/or hetero-dimerisation profiles of C/EBPα, and that this in turn 
dysregulates CEBPA-mediated regulatory networks. 
 
3.6.3 Novel pre-leukaemic dendritic cell phenotype induced by CEBPA N321D mutation 
Dendritic cells (DCs) are exquisitely sensitive mononuclear phagocytes which bridge the innate 
and adaptive immune systems, responding to Toll-like receptor signalling, capturing proteins 
and presenting their peptide antigens to lymphocytes via MHC class I and MHC class II 
complexes. Conventional dendritic cells include type 1 cDCs which are CD8+ IRF8+ XCR1+ and 
which specialise in cross-presentation of exogenous antigen to CD8+ cytotoxic T cells, in 
addition to type 2 cDCs which are CD8- SIRPα+ and which stimulate CD4+ helper T cells (Gurka 





and secrete type 1 interferon on viral stimulation. Single-cell RNA-seq on human dendritic cells 
has recently identified novel DC subtypes and resolved functional inconsistencies by isolating 
a ‘pure’ pDC population (Villani et al, 2017). 
 
The differentiation pathways of dendritic cells have proven challenging to decipher, with early 
work suggesting that cDCs and pDCs can develop from both myeloid and lymphoid-committed 
progenitors (Karsunky et al, 2003; Shigematsu et al, 2004; Ishikawa et al, 2007). The 
expression of Flt3 receptor for Flt3 Ligand is required for DC formation (Karsunky et al, 2003) 
but transcription factors such as IKAROS (Allman et al, 2006), GFI1 (Rathinam et al, 2005), and 
PU.1 (Carotta et al, 2010) also play essential roles. More recently, Schonheit et al showed that 
PU.1 remodels chromatin structure at the IRF8 gene to initiate DC commitment, Lee et al 
showed lineage bias dependent on IRF8/PU.1 ratios in HSCs and LMPPs, and separately 
Welner et al showed that C/EBPα is required for early myeloid DC differentiation (Schonheit 
et al, 2013, Lee et al, 2017, Welner et al, 2013). IRF8, PU.1 and C/EBPα cross-talk informs cell 
fate decisions between neutrophil and monocyte lineages including DC lineages (Kurotaki et 
al, 2014). Core binding factors CBFβ and RUNX1 are required for the development of all Flt3+ 
DC progenitors (Satpathy et al, 2014), whereas RUNX2 is required for terminal differentiation 
of pDCs (Sawai et al, 2013, Chopin et al, 2016). In addition, the Immunological Genome 
(ImmGen) Project has generated a compendium of microarray data which has allowed the 
identification of core gene signatures for cDCs, pDCs and other DC subsets (Miller et al, 2012). 
 
It has been previously shown that Hoxb8-FL cells in Hoxb8 media F+e-  differentiate by Day 6 
into biphenotypic populations of conventional (defined as CD11b+ CD11c+ MHC class II+ B220- 
BST2-) and plasmacytoid (CD11b- CD11c+ B220+ BST2+) dendritic cells. Our results do not 
replicate these findings exactly, in particular we do not identify B220+ cells within 10 days of 
differentiation of the EV-transduced cells. This may reflect biological variability as Flt3L media 
was derived from pooled supernatant collected after seeding of B16-FLT3 melanoma cells, 
rather than from recombinant Flt3L. However, we do detect all other markers of cDCs and 
pDCs on differentiation of EV-transduced Hoxb8-FL cells, and our experiments identify that 
the cDCs are SIRPα+ type 2 cDCs rather than XCR1+ type 1 cDCs.  
 
CEBPA WT-transduced cells immediately promote a dendritic cell phenotype in Flt3L even in 





cells is able to override the differentiation arrest caused by estradiol-mediated expression of 
HOXB8. Our results suggest that this phenotype is restricted to a subpopulation of CEBPA WT-
transduced cells which express more GFP and therefore may be transduced with more plasmid 
copies, and that these GFP high cells differentiate, leaving behind cells transduced with lower 
numbers of CEBPA WT plasmid copies which persist in estradiol and behave phenotypically 
like Hoxb8 parental cells. EV and CEBPA N321D-transduced cells remain c-Kit+ and fail to 
express other markers of myeloid, lymphoid or dendritic cell maturation in F+e+ media. Both 
the CEBPA WT and N321D-transduced cells demonstrate a growth disadvantage in 
competitive assay with Hoxb8-FL parental cells over time, but persist at low titres long-term. 
 
On withdrawal of estradiol, both EV and CEBPA WT-transduced cells rapidly differentiate into 
cDCs and pDCs, and eventually are undetectable by Casy Cell Counter. By contrast, CEBPA 
N321D-transduced cells demonstrate maturation arrest within 5 to 10 days, which is 
characterised by markers of cDC (CD11b, SIRPα) but also pDC (CD11c, BST2) lineage 
specification. Importantly, the CEBPA N321D-transduced cells appear to become 
immortalised in a Hoxb8-independent fashion, and gradually undergo phenotypic 
transformation with a CD11c+ B220+ pDC-like profile on flow cytometry by Day 24 of 
differentiation. These immortalised cells are BST2-, which may reflect a pDC progenitor status. 
Interestingly, our result of an initial cDC phenotype progressing to a late pDC progenitor 
phenotype reverses observations made in early studies which suggested that pDCs could 
differentiate into cDCs in vitro (Grouard et al, 1997). Grouard et al’s observations have 
subsequently been interpreted as short-lived pDCs declining and differentiating cDCs coming 
to dominate in cell culture, whereas our observations reflect the dominance of an 
immortalised pDC-like progenitor and the gradual decline of differentiating cDCs. An 
important question not addressed by our experimental work is how this immortalised pDC 
progenitor may contribute mechanistically to the myeloid leukaemic phenotype seen in AML. 
In particular, mouse models have shown that IFN-α is essential for T-cell priming and tumour 
elimination via antigen cross-presentation to CD8+ T-cells (Diamond et al, 2011) and several 
clinical trials have shown evidence that IFN-α has anti-leukaemic effects (Smits et al, 2013; Mo 
et al, 2018). In addition, there is emerging evidence of pDC and cDC cross-talk in cancer 
immunity (Noubade et al, 2019) and there is the possibility that our pDC progenitor phenotype 
deregulates cancer antigen presentation by conventional dendritic cells.  Future experiments 





would be interesting to verify whether CpG-mediated stimulation of immortalised pDC 
progenitor cells promotes secretion of IFN-α or if co-culture with CD4+ T-cells promotes T-cell 
proliferation.  
 
On transplantation, the CEBPA N321D-transduced cells are capable of long-term engraftment 
in an in vivo C57BL/6J mouse model. However, initially on sacrificing a mouse at 5 months, 
there are no circulating cells in peripheral blood, blood counts are normal and there is no 
splenomegaly. Long-term follow-up of transplanted mice shows increased Ly 5.1 cells 
consistent with leukaemia in the bone marrow and splenic compartments at a relatively late 
stage in three out of five mice, but little effect on peripheral blood counts or organomegaly, 
suggesting that additional cooperative mutational hits may be required for leukaemic 
phenotype. Interestingly, this varies from the leukaemic phenotype demonstrated on 
transplantation of C57BL/6J mice with cells infected with retroviruses harbouring the CEBPA 
N321D mutation by Togami et al. However, there is evidence that C/EBPα influences cell fate 
decisions in a highly state dependent fashion (Zhang et al, 2004) and it should be remembered 
that Togami et al transduced a heterogeneous population of BM mononuclear cells, whereas 
our experiment infects LMPP-like cells. In addition, Togami et al employed a different 
retroviral model which may well have had different transduction efficiency resulting in 
different expression levels compared to our approach. By contrast, the Nerlov group found 
that a knock-in model of bi-allelic C-terminal mutations expanded the HSC pool and skewed 
lineage programming of HSCs but did not cause leukaemia (Bereshchenko et al, 2009). It 
seems reasonable to speculate that CEBPA N321D-mediated maturation arrest in the dendritic 
cell compartment may represent a pre-leukaemic initiating event which requires secondary 
mutations for the development of leukaemia in a multi-step process. Double transgenic 
mouse models of CEBPA N321D with either a N-terminal mutation of CEBPA or alternatively 
with mutations known to commonly cooperate with single-mutation CEBPA in human AML 
(Fasan et al, 2014) may validate this hypothesis, and it would also be interesting to perform 
secondary transplants of leukaemic cells in vivo to see if a more proliferative leukaemic effect 
is generated in secondary recipients, but both these potential projects are beyond the scope 
of this study. To our knowledge, this is the first time that a dendritic cell mechanism has been 






4. Single cell gene expression analysis reveals 
heterogeneity in CEBPA N321D-transduced cells and 
dysregulation of HSPC and DC transcriptional programs 
 
4.1 Background 
4.1.1 Global gene expression in a cellular model of mutated CEBPA 
Our hypothesis is that a mutated version of CEBPA will perturb C/EBPα-dependent regulatory 
networks and that the changes can be characterised by performing single cell RNA-seq. For 
this purpose, we used LMPP-like cells transduced with retroviruses harbouring Empty Vector 
(EV), CEBPA WT and CEBPA N321D. Initial characterisation by microscopy and flow cytometry 
identified that differentiation in the presence of Flt3L demonstrated the most significant 
phenotypic effects, and therefore this condition merits more detailed exploration at the level 
of the single cell. 
 
Transcriptional regulation plays an intrinsic role in the cell fate decisions which determine the 
differentiation of self-renewing multipotent HSCs through progressive stages of lineage 
restriction into distinct subsets of mature blood cells. The potency of this transcriptional 
machinery has been demonstrated by TF-mediated reprogramming of differentiation 
pathways from mature somatic cells to pluripotent stem cells (Takahashi et al, 2006).  
 
RNA-seq has become ubiquitous in transcriptomics since it was first described in 2008 
(Nagalakshmi et al, 2008). It has a number of advantages over previous microarray technology 
including a higher signal-to-noise ratio, a larger range of expression values, and the ability to 
map gene expression against the entire genome. RNA-seq can be combined with fluorescence 
activated cell sorting (FACS) to describe transcription profiles of distinct populations within 
the haematopoietic tree. 
 
RNA-seq workflows are designed to favour either annotation of novel transcriptomic data or 
alternatively differential gene expression (DGE). It is important to identify a hypothesis before 
designing an experimental workflow, for instance DGE workflows prioritise sequencing depth 
(Tarazona et al, 2011) and biological replicates (Hansen et al, 2011). DGE experiments aim to 





therefore have to account for variances within complex biological systems. Even isogenic cells 
are subject to biological variance from transcriptional burst kinetics due to factors such as 
chromatin environment (Dey et al, 2015), DNA looping (Bartman et al, 2016), histone 
modifications (Wu et al, 2017) and the affinity of regulatory elements (Suter et al, 2011). 
Biological replicates can account for variance and are essential for the interpretation of RNA-
seq data on differential expression. 
 
RNA-seq experimental protocols commence with disruption of the cell membrane, followed 
by RNA extraction using either organic solvents or solid-phase extraction. Targeted 
enrichment of mRNA is achieved typically by hybridisation of poly-adenyl tails to oligo-
deoxythymines (oligo-dTs). RNA fragments are then used as templates for reverse 
transcriptase-mediated cDNA synthesis. The ends of the cDNA fragments are then ligated with 
sequencing adapters, which can include indexed barcodes for pooling in multiplex libraries. 
The cDNA libraries are quantified before sequencing, and data is then run through an RNA-
seq analysis pipeline which typically includes filtering, mapping to a reference genome, 
normalisation, multivariate statistical analysis, and data visualisation.  
 
4.1.2 Single-cell analysis 
Single-cell technology presents significant advantages over previous genomic tools which 
analysed bulk tissue samples and inferred cell types and trajectories from averaged datasets 
derived from millions of cells. 
 
Firstly, single-cell technology permits transcriptional analysis in the presence of paucity of 
cells, particularly during early developmental biology. For instance, Scialdone et al studied 
1,205 single cells to identify early lineage diversification points at the epithelial-to-
mesenchymal transition (Scialdone et al, 2016). 
 
Secondly, evaluating transcription profiles at the level of the single cell can dramatically 
increase our understanding of differentiation pathways and their deregulation, based on the 
premise that cell fate decisions are essentially unicellular. This premise was originally 
demonstrated by transplantation of single HSCs (Osawa et al, 1996). Retroviral integration of 
reporter genes (Turner et al, 1987) and cell-specific viral DNA barcoding (Lu et al, 2011) 





pathways elucidated by single-cell RNA-sequencing (scRNA-seq) include the early 
diversification between mast cell and basophil progenitors (Dahlin et al, 2018). Cancer stem 
cells are single malignant clones (Quintana et al, 2008), and therefore intuitively single-cell 
technology presents significant opportunities for understanding oncogenesis. For instance, 
single cell technology has described a subset of CML stem cells which are selected out for 
survival during prolonged therapy (Giustacchini et al, 2017).  
 
Thirdly, scRNA-seq provides a powerful tool to explore heterogeneity within cell populations 
that appear homogenous using cell surface markers. For instance, massively parallel scRNA-
seq characterised 19 novel subpopulations amongst myeloid progenitors after index sorting 
by conventional surface markers (Paul et al, 2015). More recently this technology has been  
applied to human dendritic cells (DCs) to identify a novel subset of DCs and redefine 
plasmacytoid dendritic cells (pDCs) (Villani et al, 2017). This transcriptional heterogeneity can 
then be probed for functional relationships, for instance scRNA-seq was followed by 
functional studies to demonstrate that the first wave of IFN-a production depends on cues 
from the microenvironment and is limited to a subset of early responder pDCs (Wimmers et 
al, 2018). Haematological malignancies comprise particularly interesting candidates for single-
cell analysis because intratumoral heterogeneity underpins fundamental mechanisms of 
cancer evasion. For instance, single leukaemic cells from AML patients with Quizartinib 
resistance demonstrate significant clonal diversity (Smith et al, 2017). 
 
Single-cell technology is rapidly evolving with a range of scRNA-seq methods such as Smart-
seq2 (Picelli et al, 2013), Drop-seq (Macosko et al, 2015) and commercial platforms such as 
10x Genomics Chromium. Each technique has advantages and disadvantages including 
sensitivity, precision, multiplexing, the addition of unique molecular identifiers (UMIs), RNA 
processing, and cost-efficiency. Smart-seq2 is widely used for small numbers of single cells 
because it is highly sensitive, accurate, has lower dropout probability, and enables full-length 
capture of mRNA, although with significant 3’ bias during cDNA generation by oligo-dT 
primers. Disadvantages include the difficulty in adding UMIs to account for amplification bias, 
and that the manual procedure requires careful experimental design to avoid batch effects.  
 
Single-cell RNA-seq data analysis differs from bulk RNA-seq because each single cell is 





deal with amplification bias and gene dropouts between libraries. ERCC spike-in are commonly 
employed in Smart-seq2 to improve normalisation. Differential expression and clustering can 
be carried out using methods originally developed for bulk RNA expression analysis such as 
DESeq2 (Love et al, 2014), but novel tools including SCDE (Kharchenko et al, 2014) and 
DESingle (Miao et al, 2018) have evolved specifically to analyse scRNA-seq data. Performance 
is equivalent for both bulk and single cell analytical tools (Soneson et al, 2018). 
 
Data visualisation of single-cell transcriptomic data typically involves analysis by 
dimensionality reduction and clustering algorithms. Principal Component Analysis (PCA) 
resolves high-dimensional data onto lower-dimensional linear space (typically 2 or 3 
dimensions) by establishing orthogonal projections along which the variance of data is high 
(Hotelling, 1933). The first principal component is the direction in space along which data 
points have the largest variance, the second principal component is the direction which 
maximises variance among all projected data points orthogonal to the first, and so on. The 
PCA analysis creates as many components as there are variables (in this case, genes with read 
counts) and each component is a linear combination of all variables, but normally only the 
first two or three principal components are used to visualise gene expression data because 
they explain most of the variability between cells. This statistical method can be employed to 
explicitly map and project complex genomic data onto lower dimensions for visualisation. 
However, PCA-based projections are restricted to linear transformations of high-dimensional 
data and therefore can fail to project datasets where data is not linearly correlated, for 
instance if data points lie upon a spiral-like manifold. Furthermore, the complex structure of 
gene expression data is often better captured in 2 or 3 dimensions by non-linear methods 
(Bartenhagen et al, 2010). In this regard, t-Distributed Stochastic Neighbour Embedding (t-
SNE) converts high-dimensional data into a matrix of pairwise similarities between all cells, 
and visualises the similarity data by first specifying a limited number of components to 
represent the data, and then identifying positions for cells in these components that preserve 
these similarities between pairs of cells (van der Maaten et al, 2008).  t-SNE employs Euclidean 
distances or other similarity measures to learn about discrepancies between pairs of data and 
is therefore better able to preserve local data architecture and cluster cells which are 
transcriptionally similar. For these reasons, it is unsurprising that transcriptomic relationships 
and variances within clusters at the level of the single cell are often better visualised using t-





data visualisation method that preserves global data architecture as well as preserving local 
neighbour relations, and SPRING generates k-nearest neighbour graphs to visualise data using 
force-directed layouts which are more reproducible than t-SNE and better able to visualise 
continuous expression topologies (Weinreb et al, 2018). 
 
Lastly, scRNA-seq can be employed combinatorially with other technologies to further 
characterise gene expression at the level of the single cell. Methods such as Perturb-Seq (Dixit 
et al, 2016) and CRISPR-Seq (Tothova et al, 2017) combine single-cell transcriptome analysis 
with gene perturbations. Similarly, scRNA-seq can be combined with chromatin accessibility 
data to construct a chromatin accessibility landscape of haematopoiesis and establish novel 
differentiation trajectories (Buenrostro et al, 2018). 
 
4.2 Experimental design 
Hoxb8 parental cells were thawed and cultured for 7 days, and then transduced with retroviral 
supernatant to prepare three biological replicates each of EV, CEBPA WT and CEBPA N321D, 
as described in Chapter 3. Cells were then taken at Day 2 post-transduction for differentiation, 
washed twice in PBS, placed in wells at 1 x 105 cells/ml in 2 ml of Hoxb8 media with Flt3L and 
no estradiol (F+e-), and cultured for a further 5 days until Day 7 post-transduction. Single cell-
sorting of 32 cells per replicate at two time points (Days 2 and 7 post-transduction, or Days 0 
and 5 post-differentiation) was performed on a BD Influx cell sorter running BD FACS software, 
alongside flow cytometry with a basic panel of markers (c-kit, Ly6g, CD11b, and B220), and 
the 576 single cells were then processed as one batch using a modified Smart-seq2 protocol 
described by Picelli et al (Picelli et al, 2014). Replicates were evenly sorted into 6 plates and 
evenly distributed in 3 lanes on HISeq4000, aiming to reduce sources of technical variation by 
employing a balanced block design (Baran-Gale, 2018). Following scRNA-seq, transcripts were 
aligned to the mouse genome using GSNAP and Ensembl archive 81, with specific additional 
annotation for GFP and for human CEBPA. It should be noted that alignment to human CEBPA 
did not reliably distinguish the single point mutation between human CEBPA WT and human 
CEBPA N321D. Quality control was then applied with the following criteria: 3,000,000 > total 
reads > 200,000; fraction mapped > 0.15; highly expressed genes (defined as counts per 






Only the 479 cells that pass quality control were kept for subsequent analysis. The cells were 
distributed as follows: 
 
 




















EV-R1-D2 63362912 33712501 0.5 0.03 3571.91 0.08 30 
CebpaWT-R1-D2 49475555 20977838 0.41 0.04 2912.39 0.07 25 
CebpaN321D-R1-D2 51183404 24131687 0.44 0.04 3018.58 0.1 25 
EV-R2-D2 49320596 26084451 0.52 0.03 3306.53 0.09 29 
CebpaWT-R2-D2 50558382 26811977 0.5 0.05 2893.85 0.08 29 
CebpaN321D-R2-D2 66548088 37163956 0.55 0.02 3745.58 0.07 31 
EV-R3-D2 68018455 37955758 0.54 0.02 3713.91 0.08 31 
CebpaWT-R3-D2 41734500 20796897 0.43 0.06 2416.3 0.09 21 
CebpaN321D-R3-D2 41423878 20898580 0.46 0.05 2827.26 0.1 24 
EV-R1-D7 57308244 28164329 0.44 0.08 2241.38 0.11 24 
CebpaWT-R1-D7 40481057 15880198 0.28 0.15 1480.82 0.11 12 
CebpaN321D-R1-D7 60829038 29085480 0.42 0.07 2649.77 0.1 23 
EV-R2-D7 43098006 21604380 0.48 0.06 2614.69 0.08 26 
CebpaWT-R2-D7 66943615 37563159 0.55 0.03 3257.55 0.06 33 
CebpaN321D-R2-D7 79005298 42265521 0.52 0.03 3220.39 0.07 30 
EV-R3-D7 53470150 28480222 0.51 0.03 3182.84 0.06 28 
CebpaWT-R3-D7 52445696 27880078 0.51 0.03 3092.15 0.04 30 
CebpaN321D-R3-D7 56999382 31592893 0.52 0.04 3198.39 0.06 28 
 
 
4.3 Flow cytometry of sorted cells confirms CD11b phenotype before 
scRNA-seq 
Cells from each replicate were stained for c-kit, Ly6g, CD11b and B220, and then processed 
with BD FACS software. In line with the results described in Chapter 3, the only cell surface 
marker which showed a significant effect was CD11b, which was upregulated in all replicates 
of the CEBPA WT-transduced cells at Day 2 post-transduction and showed reduced expression 






Figure 4.1 CD11b expression (normalized to mode) for 3 biological replicates of EV, CEBPA WT and 
CEBPA N321D-transduced cells at Days 2 and 7 post-transduction before index-sorting 
 
 
4.4 Analysis of single-cell data using the Automated Single-cell 
Analysis Pipeline (ASAP) 
ASAP is a web-based platform for the analysis and visualisation of single-cell RNA-seq data 
(Gardeux et al, 2017). It provides a visual web-based interface for a single-cell pipeline which 
allows the user to analyse data after genome alignment. It performs QC, provides different 
normalization methods, allows visualisation including PCA and t-SNE, resolves cells into 
clusters, and calculates differential expression between defined clusters. It also provides gene 
enrichment by Gene Ontology or KEGG. One important limitation is that it can only perform 
differential expression against the genome of a defined species, and is unable to process 
exogenous gene inserts such as GFP, but nevertheless it provides a rapid and flexible tool for 
non-bioinformaticians to analyse single-cell data. 
 
4.4.1 Normalisation of single-cell data 
The single-cell Latent Variable Model (scLVM) was used to normalise data and account for 
confounding factors such as cell cycle variation which can introduce noise into single-cell data 
sets (Buettner et al, 2015). Gene expression was evenly distributed across cell samples after 





and the method of Brennecke et al (Brennecke et al, 2013) was employed to infer 10,456 












Figure 4.2 Distribution of the expression of genes in each cell after normalisation 
 
Figure 4.3 scLVM fit of technical noise 
 





4.4.2 Single-cell data identifies distinct distributions of CEBPA WT and N321D-transduced 
cells and subpopulations within CEBPA N321D-transduced cells 
Transcription profiles of single cells can be employed to cluster cells and annotate novel cell 
types by dimensionality reduction and unsupervised hierarchical clustering. ASAP facilitates 
PCA as a classical linear scaling method for dimensionality reduction, and t-SNE for non-linear 
dimensionality reduction (van der Maaten et al, 2008). Both techniques were employed, but 
it was found that t-SNE gave a more informative visual representation of distinct cell 
populations. Cell identities were manually defined, and t-SNE was performed with perplexity 
25 and theta 0.5 to visualise the data both within ASAP’s own internal visualisation function 
(Figure 4.5), and also by downloading the data for visualisation using the R-package ggplot2 
(Figure 4.6). 
 
Several observations can be made from visual representation of the single-cell data. Firstly, 
EV-transduced cells demonstrate a distinctive transcriptional signature in their non-
differentiated state (corresponding phenotypically to Hoxb8-FL LMPP-like cells) as compared 
to after 5 days of differentiation in Flt3L, with no overlap between the two conditions. This 
conforms with the distinct cell surface marker phenotype with upregulated CD11b in 
differentiated EV cells described in Chapter 3.  
 
Secondly, at Day 2 post-transduction, in conditions which normally maintain Hoxb8-FL cells in 
a non-differentiated state, it is clear that the CEBPA WT-transduced cells form a distinct cluster 
on t-SNE which is very different to EV cells maintained at Day 2 in Flt3L and estradiol. This 
correlates with flow cytometry data described in Chapter 3 where the CEBPA WT-transduced 
cells express CD11b and SIRPα even before abolishing estradiol-mediated nuclear 
translocation of Hoxb8, whereas the EV and CEBPA N321D-transduced cells express no lineage 
markers in the presence of Flt3L and estradiol. Therefore, expression of CEBPA WT pushes 
Hoxb8-FL cells towards a distinctive transcriptional state.  
 
Thirdly, it becomes difficult to visually distinguish CEBPA WT-transduced cells from EV cells by 
t-SNE after 5 days of differentiation, which again correlates with flow cytometry data. This 
suggests that the overexpression of human WT CEBPA in Hoxb8-FL cells cannot by itself 
overcome endogenous mechanisms of Flt3L-mediated dendritic cell (DC) differentiation 






Figure 4.5 ASAP web-based t-SNE visual representation of EV, CEBPA WT and CEBPA N321D-transduced single cells at Days 0 and 5 of differentiation 












Fourthly, CEBPA N321D-transduced cells demonstrate a similar transcriptional profile to EV 
cells in the presence of estradiol, suggesting that CEBPA N321D cannot push Hoxb8-FL cells 
towards the altered transcriptional profile reached by CEBPA WT-transduced cells in the 
presence of nuclear Hoxb8.   
 
Fifthly, CEBPA N321D-transduced cells diverge from both EV and CEBPA WT-transduced cells 
after 5 days of differentiation in Flt3L, and again this corresponds to their very distinct 
expression profile on probing with fluorescent-labelled antibodies.  Furthermore, following 
the withdrawal of estradiol, two distinct subpopulations can be identified within the CEBPA 
N321D-transduced cell population, with the majority of cells distributed proximally within the 
Day 5 differentiated cells, but a much smaller cluster of 5 CEBPA N321D-transduced single 
cells distributed amongst or very close to the Day 0 non-differentiated EV-transduced cells.  
 
In summary, the exogenous expression of CEBPA WT pushes LMPP-like cells towards a distinct 
transcriptional state in the presence of nuclear Hoxb8 but does not interfere with endogenous 
mechanisms of differentiation when Hoxb8 translocates to the cytoplasm, whereas the 
exogenous expression of CEBPA N321D cannot disrupt Hoxb8 transcriptional effects but is 
able to alter the endogenous differentiation trajectory of LMPP-like cells in the presence of 
Flt3L. 
 
4.4.3 The gene expression profiles of Hoxb8-FL cells differentiated in Flt3L correspond to 
ImmGen gene expression modules for pDCs and a specific cohort of cDCs 
Phenotypic data from flow cytometry experiments described in Chapter 3 has demonstrated 
that EV-transduced Hoxb8-FL cells differentiated in Flt3L express antigens for CD11b and 
SIRPα but not XCR1 after 5 days of differentiation, suggesting a conventional dendritic cell 
(cDC) subset which have been variously described as CD8a- or type 2 cDCs. However, CEBPA 
N321D-transduced cells demonstrate reduced expression of CD11b and SIRPα antigen from 
Day 5 of differentiation in Flt3L, and gradually take on a CD11c+ B220+ BST2- pDC precursor-
like phenotype. scRNA-seq presents the opportunity to correlate this immunophenotype with 
gene expression data. 
 
The ImmGen Consortium has employed a multicentre strategy to build a comprehensive gene 





with significant co-expression (http://www.immgen.org/ModsRegs/modules.html). The 
modules F150, F156 and F152 show substantial upregulation in pDCs, cDCs and CD8a+ CD103+ 
cDCs respectively (Miller et al, 2012), and expression profiles for key genes in these modules 
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Figure 4.7 Gene expression signatures correlate with DC subtypes. (a) EV-transduced Hoxb8-FL 
cells after 5 days of differentiation in Flt3L. (b) (c) (d) and (e) show gene expression of cd300c, 
Siglec-H, Slc46a3 and Tspan33 respectively at Day 5 of differentiation. 
 
 
CD300c and the canonical pDC gene Siglec-H are both found in module F150 in the ImmGen 
Consortium database and show convincing gene expression profiles which correlate with EV-
transduced Hoxb8-FL cells differentiated in Flt3L. The genes Slc46a3 and Tspan33 are less well-
established markers for DC expression but are derived from the ImmGen database F156 
module and show some correlation with Day 5 differentiated cells. By contrast, none of the 
genes in the F152 module are highly expressed in any of the Hoxb8-FL transduced cell lines, 
confirming our preliminary findings from XCR1 antigen-negativity that CD8a+ type 1 cDCs are 






For over 10 years, IRF8 and IRF4 expression have been known to distinguish between DC 
subtypes (Tamura et al, 2005). IRF8 expression is elevated in both pDCs and CD8a+ type 1 
cDCs, whereas IRF4 expression has been thought to be elevated in type 2 cDCs. Interestingly, 
our gene expression data suggests that Hoxb8-parental cells differentiated in Flt3L express 






Figure 4.8 ASAP shows (a) IRF8 and (b) IRF4 expression of transduced Hoxb8-parental cells after 
5 days of differentiation in Flt3L 
 
This seems to contradict our previous findings on flow cytometry that Hoxb8-parental cells in 
Flt3L differentiate into CD11b+ SIRPα+ type 2 cDCs. However, it is important to recognise that 
our understanding of DC lineages and gene expression profiles is rapidly evolving. For 
instance, recent work has demonstrated that type 2 cDCs in humans are heterogeneous and 
include a subpopulation of CD5low DCs which demonstrate decreased expression of IRF4 (Yin 
et al, 2017). The co-expression of CD11c, CD11b and SIRPα in both our flow cytometry and our 
scRNA-seq studies is strongly indicative that transduced Hoxb8 cells exhibit a type 2 cDC 
phenotype at Day 5 of differentiation, whereas the expression of IRF8 in the absence of XCR1 
suggests the presence of pDCs. 
 
4.4.4 LMPP-like cells transduced with CEBPA N321D lose the ability of CEBPA WT-transduced 
cells to overcome Hox-mediated differentiation arrest  
Gain-of-function studies with overexpression of Hox genes have indicated that the Hox family 
of transcription factors expand haematopoietic stem and progenitor cell (HSPC) populations 
and arrest lineage differentiation programs (Pineault et al, 2002, Fischbach et al, 2005, 





immortalised in Flt3L by estradiol-mediated translocation of Hoxb8 from the cytoplasm to the 
nucleus where it can bind to and transcribe DNA. Previous work on Hoxb8-FL cells shows that 
in the presence of Flt3L and estradiol these cells are negative for Gr1, CD11b, B220 and MHC 
class II (Redecke et al, 2013).  
 
Differential expression was performed on cells that passed QC using ASAP’s DESeq2 package 
between CEBPA WT and EV-transduced cells at Day 2 post-transduction, with an FDR (adjusted 
p-value) ≤ 0.05 and a fold change ≥2. It is well-established that CEBPA expression is required 
for granulocyte differentiation at the CMP to GMP junction (Zhang et al, 2004). Interestingly, 
the integration of exogenous human CEBPA WT into Hoxb8-FL cells causes a dramatically 
altered transcriptional profile at an early LMPP-like stage with 636 upregulated and 429 
downregulated genes (Appendix, Tables 1 and 3 respectively). 
 
Enrichr (http://amp.pharm.mssm.edu/Enrichr/) is an online interactive gene list enrichment 
analysis tool designed by the Ma’ayan group (Chen et al, 2013, Kuleshov et al, 2016). Genes 
differentially upregulated in CEBPA WT-transduced cells express both neutrophilic and 
antigen presentation ontogenies when analysed on Enrichr, for instance GO biological 
processes are characterised by neutrophil degranulation and neutrophil activation, but also 
by TLR4 signalling (Appendix, Table 2).  
 
The 636 upregulated genes include genes which are known to play significant roles in 
granulocyte-monocyte characterisation and function, including CD33, GCA, CHIT1, LY6C,  
SIRPA, and ITGAM (Ripperger et al, 2015). Enrichr analysis of the 429 downregulated genes 
suggests enrichment in cell ontologies on Mouse gene atlas which include HSCs, MEPs and 
CMPs (Appendix, Table 4). This confirms that the EV-transduced cells remain in a primitive 
state in the presence of estradiol, whereas the CEBPA WT-transduced cells overcome Hoxb8-
mediated differentiation block and progress towards differentiation in the granulocyte 
lineage. In addition, these results signify that it is difficult to compare the trajectories between 
Days 2 and 7 of EV or CEBPA N321D-transduced cells with the trajectory between Days 2 and 
7 of CEBPA WT-transduced cells, because the CEBPA WT-transduced cells start with very 






By contrast, the transcriptional signatures of EV and CEBPA N321D-transduced cells are 
remarkably similar to each other at Day 2 post-transduction before the removal of estradiol, 
as demonstrated by the low number of genes (15 upregulated and 5 downregulated) 
differentially expressed by CEBPA N321D-transduced single cells versus EV-transduced cells at 
this time point (see Appendix, Table 5). Unsurprisingly, differential expression of CEBPA WT 
versus CEBPA N321D-transduced cells at Day 2 gives 745 genes which suggest enrichment for 
GO biological processes including neutrophil degranulation and 292 downregulated genes 
which Enrichr analysis correlates with HSPC ontologies. This confirms and further 
characterises the transcriptional signatures visualised in t-SNE, that exogenous CEBPA WT is 
able to overcome Hoxb8-mediated maturation arrest by downregulating expression of HSPC-
associated genes and upregulating genes associated with neutrophil cell ontology, and 
furthermore that N321D-mutated CEBPA cannot replicate these WT transcriptional effects in 
the presence of Hoxb8 nuclear translocation. 
 
4.4.5 Differential expression identifies genes up and downregulated in EV, CEBPA WT and 
CEBPA N321D-transduced cells during differentiation in Flt3L 
Differential expression was then performed on the cells which passed QC using ASAP’s DESeq2 
package on each cell line between Day 7 and Day 2 post-transduction, with an FDR (adjusted 
p-value) ≤ 0.05 and a fold change ≥ 2.  The results of differential expression can be found in 
Table 4.2: 
 
Table 4.2 Differential expression for each cell line during 5 days in differentiation media 
(Flt3L without estradiol) 
 
 Upregulated genes Downregulated genes 
EV-transduced cells 1400 1340 
CEBPA WT-transduced cells 1167 738 
CEBPA N321D-transduced cells 594 418 
 
The CEBPA N321D-transduced cells clearly have the lowest number of upregulated and 
downregulated genes during 5 days of differentiation. Interestingly, CEBPA WT-transduced 
cells have a lower number of genes differentially expressed than EV-transduced cells, but it 
should be remembered that flow cytometry and differential expression data indicated 
evidence of differentiation before the removal of estradiol, and this may account for the more 






The altered expression signature in CEBPA WT cells at Day 2 post-transduction is also 
important because these cells start with a different transcriptional status to the EV or CEBPA 
N321D-transduced cells, and therefore genes which are differentially expressed in CEBPA WT-
transduced cells are not directly comparable to genes derived from differential expression of 
the other subsets. 
 
4.4.6 Gene enrichment suggests pDC gene ontology for CEBPA N321D-transduced cells 
differentiated in Flt3L 
ASAP has several gene enrichment tools based on its own unique enrichment method which 
is based on a Fisher Exact Test. By default, it enriches the top 100 genes ranked by fold-change. 
The following gene enrichment data is acquired by enriching the top 100 upregulated genes 
identified by differential expression between datasets from CEBPA N321D-transduced cells at 
Days 7 and 2 (Table 4.3): 
 
Table 4.3 Gene enrichment of top 100 genes ranked by fold-change provides gene atlas and gene 
ontology for CEBPA N321D-transduced cells 
 
Gene Atlas 
Annotation OR Adjusted p-value 
dendritic_plasmacytoid_B220+ 11.59893455 0.000106858 
macrophage_peri_LPS_thio_0hrs 5.723928707 0.006772816 
RAW_264_7 7.00752457 0.009999595 
macrophage_bone_marrow_0hr 7.106759907 0.021267311 
macrophage_peri_LPS_thio_1hrs 3.756913022 0.037620484 
 
GO Biological Processes 
Annotation Description OR Adjusted p-value 
GO:0002250 adaptive immune response 9.647636039 0.000107661 
GO:0019221 cytokine-mediated signalling pathway 9.524060414 0.000595797 
GO:0002449 lymphocyte mediated immunity 10.82278481 0.000595797 
GO:0006935 chemotaxis 7.013919095 0.000595797 
GO:0042330 taxis 6.984405458 0.000595797 
GO:0071345 cellular response to cytokine stimulus 7.043805165 0.001256338 
GO:0002443 leukocyte mediated immunity 8.290459604 0.002432459 
GO:0048002 antigen processing and presentation of 
peptide antigen 
22.77316161 0.002960939 
GO:0009615 response to virus 7.37755102 0.013946116 
GO:0060326 cell chemotaxis 8.471471471 0.016538952 
GO:0002495 antigen processing and presentation of 






GO:0050778 positive regulation of immune response 5.779032018 0.021975521 
GO:0002504 antigen processing and presentation of 
peptide or polysaccharide antigen via 
MHC class II 
45.60622837 0.022476632 
GO:0030595 leukocyte chemotaxis 9.50174216 0.022476632 
GO:1903708 positive regulation of haemopoiesis 9.225010574 0.024244182 
GO:0019882 antigen processing and presentation 12.31674361 0.024244182 
GO:0051607 defense response to virus 7.220702754 0.025565976 
GO:0050900 leukocyte migration 7.137351547 0.025883188 
GO:0002573 myeloid leukocyte differentiation 8.6218853 0.027668663 
GO:0002478 antigen processing and presentation of 
exogenous peptide antigen 
32.29411765 0.037621686 
 
GO Molecular Functions 
Annotation Description OR Adjusted p-value 
GO:0004896 cytokine receptor activity 27.61865086 2.50E-06 
GO:0042287 MHC protein binding 73.19444444 1.68E-05 
GO:0019955 cytokine binding 20.93680556 4.78E-05 
 
Interestingly in the context of CEBPA’s role in myeloid differentiation, myeloid leukocyte 
differentiation is identified as one of the biological processes in CEBPA N321D-transduced cells 
after 5 days of differentiation in Flt3L. Nevertheless, ASAP’s gene enrichment tools all coincide 
to suggest a cell ontology which is characterised by mechanisms of the adaptive immune 
response such as cytokine binding and antigen presentation. Gene Atlas annotation suggests 
that these cells correlate with the gene expression profiles of B220+ pDCs. Therefore it appears 
that the CEBPA N321D mutation switches on a pDC transcriptional program in Hoxb8-FL cells 
as early as Day 5 of differentiation in Flt3L, although phenotypic cell surface markers cannot 
be detected by flow cytometry until much later. 
 
Genes of particular interest are the genes up and downregulated during differentiation 
(between Days 7 and 2 post-transduction) of CEBPA N321D-transduced cells, which are not 
identified during differentiation of EV-transduced cells. Bearing in mind that the CEBPA WT 
trajectory is not directly comparable to the trajectories of EV or CEBPA N321D-transduced 
cells during differentiation in Flt3L, for reasons aforementioned, these genes of interest 
should not take into consideration genes differentially expressed in CEBPA WT-transduced 
cells between Days 7 and 2. Differentially expressed genes can be intersected by using the 










Figure 4.9 Number of genes differentially expressed for cell lines differentiated for 5 days in Flt3L, 
and not taking into consideration genes differentially expressed in CEBPA WT-transduced cells. 
(A) Upregulated genes, (B) Downregulated genes. (Appendix, Tables 6 and 7 respectively). 
 
ASAP’s gene enrichment tools allow only global gene set analysis based on differential 
expression between defined clusters of cells. Furthermore, it does not provide the identities 
of specific genes. Therefore, web-based Enrichr gene set enrichment analysis was performed 
on the 151 genes identified as differentially upregulated exclusively in the CEBPA N321D-
transduced cells. Enrichr calculates a Combined Score by taking the log of the p-value from 
the Fisher Exact Test and multiplying it by the z-score of the deviation from the expected rank: 
 
Table 4.4 Enrichr calculates Combined Score and identifies  upregulated genes which overlap with 
top ten entries in Mouse Gene Atlas after differential expression analysis of CEBPA N321D-
transduced cells at Day 7 v Day 2 






mast_cells_IgE+antigen_1hr 3.279761749 D8ERTD82E;GFOD1;CD93;SLC44A1 
Baf3 2.537389426 FBXW4;EGFL7;BCL2;2310001H17RIK;CLEC
2I;CBFA2T3;OCEL1 
macrophage_bone_marrow_0hr 2.523596016 DGKD;CD93;TM6SF1;DUSP7 
dendritic_cells_myeloid_CD8a- 2.451664086 TIFAB;TRAPPC5;BMF;CBFA2T3 












This analysis confirms a pDC cell ontology in CEBPA N321D-transduced cells differentiated for 
5 days in Flt3L, and identifies 5 upregulated genes which are associated with the pDC 
phenotype: SLC44A1,TRAPPC5, MGAT1, FNDC3A, IFFO1, RUNX2, and RAB33B. Interestingly, it 
also suggests that differentiation of CEBPA N321D-transduced cells upregulates genes (TIFAB 
and KCNK12) associated with GMP cell ontology. 
 
4.4.7 Gene enrichment suggests that Empty Vector and CEBPA WT-transduced cells have 
gene ontologies which are distinct from CEBPA N321D-transduced cells differentiated in 
Flt3L 
Enrichr analysis of the 956 genes exclusively upregulated in EV-transduced cells during 
differentiation in Flt3L suggests a distinct gene ontology: 
 
Table 4.5 Enrichr calculates Combined Score to identify upregulated genes 
which overlap with top ten entries in Mouse Gene Atlas after differential 
expression analysis of EV-transduced cells at Day 7 v Day 2 
Term Combined Score Genes 
macrophage_peri_LPS_thio_7hrs 113.42 134  
dendritic_cells_myeloid_CD8a- 15.67 32 
macrophage_peri_LPS_thio_0hrs 14.73 56 
follicular_B-cells 9.52 58 
macrophage_bone_marrow_6hr_LPS 9.25 80 
macrophage_peri_LPS_thio_1hrs 7.85 59 
macrophage_bone_marrow_24h_LPS 7.63 58 
macrophage_bone_marrow_0hr 6.97 31 
macrophage_bone_marrow_2hr_LPS 4.44 45 
dendritic_cells_lymphoid_CD8a+ 4.27 22 
 
 
Furthermore, a direct comparison between cell ontologies on Mouse Gene Atlas of genes 
downregulated exclusively during differentiation of EV and CEBPA N321D-transduced cell lines 






Table 4.6 Enrichr identifies Mouse Gene Atlas cell ontologies with Combined Scores for 
downregulated genes after differential expression analysis of EV and CEBPA N321D-transduced 
cells at Day 7 v Day 2 





embryonic_stem_line_V26_2_p16 13.79 mast_cells_IgE+antigen_1hr 5.82 
embryonic_stem_line_Bruce4_p13 11.62 thymocyte_SP_CD4+ 3.04 
mega_erythrocyte_progenitor 9.65 bone_marrow 2.89 
Baf3 6.01 bladder 2.46 
stem_cells__HSC 4.02 macrophage_peri_LPS_thio_0hrs 2.41 
nih_3T3 2.99 embryonic_stem_line_Bruce4_p13 2.36 
common_myeloid_progenitor 1.73 mast_cells 1.71 
granulo_mono_progenitor 1.05 mega_erythrocyte_progenitor 1.62 
mIMCD-3 0.43 macrophage_peri_LPS_thio_1hrs 1.58 
adipose_brown 0.32 mast_cells_IgE+antigen_6hr 1.45 
 
Genes up and downregulated during differentiation of CEBPA WT-transduced cells in Flt3L 
should be considered separately from gene sets identified in EV and CEBPA N321D-transduced 
cells, as their differentiation trajectories start from a different transcriptional state at Day 2 
post-transduction. Gene set enrichment analysis by Enrichr of 1167 upregulated and 738 
downregulated genes identified by differential expression analysis of CEBPA WT-transduced 
cells at Days 7 and 2 in Flt3L demonstrate the following cell ontologies in Mouse Gene Atlas: 
 
Table 4.7 Enrichr identifies Mouse Gene Atlas cell ontologies with Combined Scores for up and 
downregulated genes identified by differential expression analysis CEBPA WT-transduced cells at 
Day 7 v Day 2 





macrophage_peri_LPS_thio_7hrs 113.65 adipose_brown 8.38 
follicular_B-cells 23.03 bone 8.01 
macrophage_bone_marrow_6hr_ 
LPS 
17.12 stem_cells__HSC 6.2 




macrophage_peri_LPS_thio_0hrs 12.28 granulo_mono_progenitor 2.64 
macrophage_peri_LPS_thio_1hrs 9.46 granulocytes_mac1+gr1+ 1.87 
dendritic_plasmacytoid_B220+ 9.2 3T3-L1 1.76 
macrophage_bone_marrow_2hr_ 
LPS 
5.38 Baf3 1.24 






In summary, gene set enrichment analysis for upregulated genes differentially expressed 
during differentiation of EV-transduced cells in Flt3L gives cell ontologies which differ 
markedly from CEBPA N321D-transduced cells (Table 4.4), with prominence of cDC type 2 cell 
ontology and the exclusion of B220+ pDC cells from the top ten statistically significant cell 
ontologies (Table 4.5). Gene enrichment analysis from differential expression of CEBPA WT-
transduced cells needs to be interpreted with more caution because their differentiation 
trajectory starts from a distinct transcriptional state, but upregulated genes demonstrate a 
similar cell ontology to EV-transduced cells, and genes associated with myeloid CD8a- DCs 
have higher statistical significance than genes associated with B220+ pDCs (Table 4.7). Perhaps 
more significantly from the perspective of the leukaemic phenotype demonstrated by the 
CEBPA N321D mutation in vivo, the CEBPA N321D-transduced cells fail to downregulate gene 
sets associated with HSPC cell ontology which are downregulated by both EV (Table 4.6) and 
CEBPA WT (Table 4.7) -transduced cells. 
 
4.4.8 Intersection of differentially expressed genes in N321D and EV subsets suggests 
transcriptional reprogramming activated by mutated CEBPA 
Phenotypically, EV-transduced cells proceed rapidly to terminal differentiation whereas 
CEBPA N321D-transduced cells do not acquire features of terminal differentiation and can be 
cultured for long periods of time in the presence of only Flt3L. It would therefore be useful to 
identify genes which are upregulated exclusively in EV-transduced cells after 5 days of 
differentiation in Flt3L (956 genes) and intersect those genes with the 633 genes which are 
downregulated on differential expression between CEBPA N321D and EV-transduced cells at 
Day 7. This would provide us with a list of genes that characterise the differentiation of EV 
cells and which fail to be upregulated in CEBPA N321D-transduced cells. 
 
Remembering that EV-transduced cells represent the normal pattern of differentiation and 
lineage restriction by LMPP-like Hoxb8-FL cells, it is also useful to identify the 1060 genes 
downregulated exclusively in EV cells during differentiation in Flt3L and intersect them with 
the 224 genes which are upregulated on differential expression between CEBPA N321D and 
EV-transduced cells at Day 5. 
 
By intersecting these data subsets, we are able to construct a list of 385 EV differentiation 





alternatively a list of 133 genes switched off in differentiated EV-transduced cells which are 
switched on by CEBPA N321D-transduction (Appendix, Table 8). These two gene sets can then 
be analysed by Enrichr:  
 
Table 4.8 Enrichr identifies Mouse Gene Atlas cell ontologies with Combined Scores for genes 
“switched on” and “switched off” after intersection of gene subsets extracted from differential 
expression of CEBPA N321D and EV-transduced cells  









mega_erythrocyte_progenitor 2.18 macrophage_peri_LPS_thio_1hrs 15.05 
Baf3 2.1 macrophage_bone_marrow_0hr 11.91 
stem_cells__HSC 1.58 dendritic_cells_myeloid_CD8a- 7.79 




nih_3T3 0.92 microglia 4.5 
osteoblast_day21 0.72 osteoclasts 3.67 
osteoblast_day14 0.6 macrophage_peri_LPS_thio_0hrs 3.48 
 
Enrichr cell ontology of CEBPA N321D-mediated “switched off” genes (Table 4.8) suggests that 
mutant CEBPA dedifferentiates macrophages and myeloid dendritic cell or cDC ontology, but 
not pDC ontology. Interestingly, some of these genes encode known partner TFs of wildtype 
C/EBPα such as C-FOS and C-JUN (Hong et al, 2011). By contrast, “switched on” genes include 
CDK6 and give cell ontology of HSCs, MEPs and CMPs on Enrichr.  
 
Essentially, CEBPA N321D-transduced cells differentiated at Day 5 in the presence of Flt3L 
seem to “switch on” or fail to switch off a HSPC transcriptional program. Ideally this 
intersectional analysis should include CEBPA WT-transduced cells to demonstrate that these 
two transcriptional programs are derived specifically from the N321D mutation rather than 
from overexpression of CEBPA WT, but this is difficult due to the altered transcriptional state 
of CEBPA WT-transduced cells at Day 2 post-transduction. However, phenotypic features of 
CEBPA WT-transduced cells, including cell growth and cell surface markers, strongly suggest 






4.4.9 A small subset of CEBPA N321D-transduced cells demonstrate a divergent 
transcriptional signature on differential expression against EV-transduced cells 
t-SNE visualisation of single-cell expression profiles reveals that the majority of the CEBPA 
N321D-transduced cells cluster proximal to the Day 5 differentiated EV and CEBPA WT-
transduced cells after five days of  differentiation in Flt3L. The most significant finding on the 
level of the single cell is that a rare subpopulation of 5 CEBPA N321D-transduced cells diverge 








Figure 4.10 ASAP shows two cohorts of CEBPA N321D-transduced cells after differentiation for 5 
days in Flt3L. (A) 78 single cells which are distributed proximally but close to EV and WT-transduced 
cells differentiated in Flt3L, and (B) 5 single cells which diverge from Day 5 populations and cluster 
close to the Day 0 non-differentiated populations  
 
 
Differential expression with DESeq2 confirms that the two cohorts of CEBPA N321D-
transduced cells differentiated at Day 5 express divergent transcriptional signatures. Genes 
upregulated and downregulated in the 78 and 5 cells were identified by applying DESeq2 
separately to cells from each cohort against the 82 CEBPA N321D-transduced cells at Day 0. 
The differentially expressed genes were then intersected with genes differentially expressed 










Figure 4.11 Number of genes differentially expressed between Day 5 versus Day 0 for two cohorts 
of 78 and 5 CEBPA N321D-transduced and all EV-transduced single cells differenti ated inFlt3L, 
and not taking into consideration genes differentially expressed in CEBPA WT-transduced cells. 
(A) Upregulated genes, (B) Downregulated genes. See Appendix Tables 9 and 10 for full lists of 
genes. 
 
Enrichr analysis was then performed for genes which were upregulated (171 and 12) and 
downregulated (108 and 1577) respectively in the 78 (Table 4.9) and 5 (Table 4.10) single 
CEBPA N321D-transduced cells: 
 
Table 4.9 Enrichr identifies Mouse Gene Atlas cell ontologies with Combined Scores for up and 
downregulated genes identified by differential expression analysis of 78 CEBPA N321D-
transduced cells at Day 7 v all 82 CEBPA N321D-transduced cells at Day 2, excluding genes 
differentially expressed in EV-transduced cells between the same time points 
 





follicular_B-cells 6.90 mast_cells_IgE+antigen_1hr 5.10 
NK_cells 6.34 embryonic_stem_line_Bruce4_p13 3.17 
dendritic_plasmacytoid_B220+ 3.54 stem_cells__HSC 2.11 
mast_cells_IgE+antigen_1hr 2.62 thymocyte_SP_CD4+ 1.98 
osteoblast_day5 2.13 macrophage_peri_LPS_thio_7hrs 1.89 
macrophage_bone_marrow_0hr 2.05 embryonic_stem_line_V26_2_p16 1.78 
dendritic_cells_myeloid_CD8a- 1.97 B-cells_GL7_positive_KLH 1.77 
Baf3 1.78 lens 1.74 
mammary_gland_non-lactating 1.70 mega_erythrocyte_progenitor 1.65 







Table 4.10 Enrichr identifies Mouse Gene Atlas cell ontologies with Combined Scores for up and 
downregulated genes identified by differential expression analysis of 5 CEBPA N321D-transduced 
cells at Day 7 v all 82 CEBPA N321D-transduced cells at Day 2, excluding genes differentially 
expressed in EV-transduced cells between the same time points 
 





microglia 3.27 bone_marrow 1.43 
macrophage_peri_LPS_thio_0hrs 0.00 follicular_B-cells 1.41 
macrophage_bone_marrow_24h
_LPS 
0.00 macrophage_peri_LPS_thio_0hrs 0.84 
  adipose_brown 0.81 
  B-cells_GL7_positive_Alum 0.69 
  B-cells_GL7_positive_KLH 0.60 
  mast_cells 0.50 
  B-cells_GL7negative_Alum 0.50 
  mast_cells_IgE 0.45 
  spleen 0.38 
 
 
The 78 single CEBPA N321D-transduced cells which cluster within the proximal aspect of the 
Day 5 differentiated cells upregulate genes which enrich for mononuclear phagocyte cell 
ontologies including pDCs, cDCs, macrophages and mast cells, and downregulate genes which 
enrich for HSC ontologies. By contrast, the 5 single cells which diverge from the Day 5 
differentiated cell populations do not display this transcriptional signature. In fact, the 5 single 
cells upregulate only 12 genes compared to the Day 0 cells, after excluding genes upregulated 
by EV during differentiation (Figure 4.11). Interestingly, although they downregulate 1577 
genes, the low Combined Scores of enriched cell ontologies associated with those 1577 genes 
(Table 4.10) suggests that the enriched gene sets are relatively non-specific. 
 
Experimentally, the small cluster of 5 single cells all originate from one single plate which 
raises questions of bias from a plate effect, however the majority of CEBPA N321D-transduced 
cells from the same plate cluster with cells from other plates. Bearing in mind that the Day 0 
Hoxb8-FL cells, in the presence of Flt3L and estradiol-mediated Hoxb8 DNA-binding, are 
conditionally immortalised and capable of exponential growth, one can hypothesise that it is 
in fact the rare smaller population of 5 CEBPA N321D-transduced single cells which are 
immortalised when estradiol is withdrawn and enjoy a selective survival advantage. This 





from an initial obvious reduction in CD11b and SIRPα expression to a CD11c+ B220+ cell line 
characterised by exponential growth.  
 
4.4.10 Validation of ASAP gene expression data using geometric size factor normalisation 
and ggplot2 
To validate gene expression data from ASAP, it was decided to use the function 
estimateSizeFactorsForMatrix (R version 3.5.2, DESeq2 version 1.22.2) on genomic data for 
cells which passed QC. GFP expression data was specifically removed before calculating size 
factor as it would skew normalisation. Size factors were then applied to raw counts to 
normalise them, before log transforming the results and filtering out zero counts. The R-
package ggplot2 version 3.1.0 was then employed to construct violin plots and compare gene 













Figure 4.13 Violin plot showing normalised counts for JUNB in all cells which passed QC 
 
 







These violin plots provide convincing visual validation that RUNX2 is upregulated exclusively 
in CEBPA N321D-transduced cells, that CEBPA N321D “switches off” genes associated with 
macrophage programs such as JUNB, and that it “switches on” genes including  CDK6 which 
give cell ontology of early haematopoietic precursors. 
 
4.5 Discussion 
My cellular model is designed to evaluate early pre-leukaemic changes induced by the CEBPA 
N321D mutation, by employing Hoxb8-FL cells which are phenotypically similar to LMPP cells 
and therefore present an opportunity to characterise CEBPA-mutated cells before the CMP to 
GMP junction where CEBPA is known to be highly expressed.  
 
The original rationale for examining CEBPA WT-transduced cells was to provide a comparator 
to exclude effects from over-expression of CEBPA, such that genes dysregulated exclusively 
by CEBPA mutation can be identified. This comparison was complicated by the fact that CEBPA 
WT-transduced cells transition into a distinct transcriptional state in Hoxb8-FL conditions. The 
rationale for performing the single-cell experiment was that it enables the identification of 
rare cell populations and cell-to-cell variations, which are important when studying early 
haematopoiesis or pre-leukaemic transcriptional signatures. To our knowledge, the gene 
expression signature of CEBPA-mutated cells has never previously been evaluated at the level 
of the single cell. 
 
4.5.1 Role of C/EBPα in myeloid differentiation and DC biology, and the single-cell 
expression profile of CEBPA WT-transduced Hoxb8-FL cells in conditions which favour 
immortalisation 
C/EBPα plays a key role in myeloid differentiation, and is able to cause growth arrest and 
myeloid differentiation when lentivirally inserted into CD34+ AML cells (Schepers et al, 2007). 
It is expressed at a low level in HSCs, incrementing at the stage of pre-GPs or CMPs, and then 
increasing markedly in GMPs (Zhang et al, 2004).  
 
The role of C/EBPα in HSC biology is complex, with the Tenen group reporting that deletion of 
C/EBPα increases HSC proliferation and promotes HSC expansion through an N-Myc 





in HSC exhaustion and a marked reduction of haematopoietic reconstitution after competitive 
transplantation into lethally irradiated recipient mice (Hasemann et al, 2014). The apparent 
contradiction in these findings may relate to the timing of C/EBPα excision in these two 
experimental models, and it is possible to integrate these apparently divergent results by 
hypothesising early HSC expansion followed by HSC exhaustion and loss of self-renewal.  
 
Regarding lineage restriction, initial studies suggested that C/EBPα was required for the 
transition from CMPs to GMPs, based on the observation that Sca-1- progenitor cells 
accumulated in adult CEBPA -/-  mice (Zhang et al, 2004, Hasemann et al, 2014). However, gene 
expression data has recently mapped CEBPA -/- pre-GMP cells more closely to LSK cells, 
suggesting that the maturation block caused by CEBPA deletion lies just downstream of LSK 
cells when Sca-1 expression is downregulated (Pundhir et al, 2018 ).  
 
Both HSC self-renewal (Hasemann et al, 2014) and myeloid differentiation are mediated by 
C/EBPα acting in partnership with other TFs including PU.1, RUNX1 and IRF8. In particular, 
PU.1 and C/EBPα have been characterised as master regulators of monopoiesis and 
granulopoiesis respectively with the PU.1: C/EBPα ratio instructing lineage specification (Dahl 
et al, 2003). C/EBPα interacts physically with PU.1 at DNA binding domain (DBD) locations, 
displacing the PU.1 co-activator C-JUN, and functionally C/EBPα blocks PU.1-induced DC 
development (Reddy et al, 2002). However, C/EBPα also acts cooperatively with PU.1, 
mediating chromatin accessibility at myeloid-specific enhancers (Heinz et al, 2010). Deletion 
of the CEBPA +37 kb enhancer in mouse models gives phenotypic effects which are identical 
to CEBPA knock-out (Avellino et al, 2016, Guo et al, 2016) whereas deletion of the -14 kb 
enhancer of the SPI1 locus causes significant reduction in SPI1 expression (Rosenbauer et al, 
2004). Interestingly, C/EBPα can induce monocyte lineage commitment by binding at the 
same -14 kb enhancer, suggesting that SPI1 expression is C/EBPα-dependent (Yeamans et al, 
2007). More recently, the coordination of granulocyte monocyte (GM) enhancer activity by 
C/EBPα:PU.1 interplay during successive stages of GM-lineage differentiation (LSK, preGM, 
GMP, and neutrophilic granulocyte populations) has been analysed through integration of 
genome-wide chromatin accessibility profiles, ChIP-seq at different stages of maturation, and 
functional studies of preGM-KO cells from  CEBPA -/- mice. These analyses suggest a more 
active role for C/EBPα than previously thought, acting as a pioneer factor for PU.1 at later 






Furthermore, RUNX1 binds to the CEBPA promoter and regulates the +37 kb enhancer to 
favour granulopoiesis (Cooper et al, 2015), and RUNX1 deletion favours monopoiesis over 
granulopoiesis by reducing CEBPA transcription (Guo et al, 2012). By contrast, IRF8 physically 
interacts with C/EBPα via its DBD, blocks C/EBPα from binding to chromatin, and inhibits 
neutrophil differentiation (Kurotaki et al, 2014). IRF8 also forms a heterodimer with PU.1 
which activates an enhancer signature to promote monocyte and DC differentiation (Kurotaki 
et al, 2013). In line with these findings, IRF8 -/- mice demonstrate absent monopoiesis and 
aberrant over-production of neutrophils (Kurotaki et al, 2014). Besides these direct physical 
interactions with partner TFs, C/EBPα can exert indirect effects, for instance it favours 
neutrophil differentiation by inducing microRNA-30c which in turn downregulates NOTCH1 
(Katzerke et al, 2013).  
 
In addition to its pivotal role in granulocyte differentiation, C/EBPα plays a significant role in 
commitment to mononuclear phagocyte lineages. In this regard, studies have demonstrated 
that C/EBPα and PU.1 act both synergistically and antagonistically in a cell type-specific 
manner. For instance, C/EBPα synergises with PU.1 to reprogram differentiated B cells into 
macrophages (Xie et al, 2004). By contrast, fully-committed pre-T cells can be reprogrammed 
by C/EBPα and PU.1 acting antagonistically, with C/EBPα expression converting them to 
macrophages and PU.1 inducing them to form myeloid DCs (Laiosa et al, 2006).  
 
Interestingly, the Graf group found that NOTCH1 partially inhibited and completely inhibited 
C/EBPα-mediated and PU.1-mediated T cell reprogramming respectively, and suggested that 
C/EBPα inhibits the ability of NOTCH1 to inhibit PU.1 (Laiosa et al, 2006). In DC progenitor 
cells, Carotta et al showed that DC differentiation cannot be induced in Flt3L cytokine 
conditions when PU.1 is conditionally ablated. This was partially explained by their finding that 
PU.1 directly controls FLT3 gene expression in DC progenitors, although enforced Flt3 
expression in PU.1-deficient progenitors was unable to rescue DC differentiation (Carotta et 
al, 2010).  
 
Regarding DC biology, the Tenen group found that C/EBPα is required for early DC 
differentiation both in vitro and in vivo in a transplantation model, although C/EBPα excision 





addition, microarray of C/EBPα-deficient and wildtype DC progenitors identified gene 
expression changes for TFs known to be essential for DC differentiation, and ChIP-seq for 
C/EBPα on sorted DC progenitors confirmed direct binding of C/EBPα to associated regulatory 
elements (Welner et al, 2013).  Recent single-cell studies of 5000 human CD34+ cord blood 
cells have demonstrated that DC lineage bias starts from HSCs and is defined by transcriptional 
programs which correlate with IRF8:PU.1 ratios (Lee et al, 2017). This single-cell analysis did 
not elucidate the role of C/EBPα in IRF8-mediated transcriptional programs during early 
lineage bias, but given that C/EBPα expression mediates HSC self-renewal (Hasemann et al, 
2014), that IRF8 interacts with C/EBPα in monocyte-DC progenitors to prevent neutrophil 
differentiation (Kurotaki et al, 2018), and the known transcriptional wiring between C/EBPα, 
PU.1 and IRF8 (Kurotaki et al, 2014), one can speculate that C/EBPα is involved in early DC 
lineage specification in HSCs. 
 
In our cellular model, CEBPA WT-transduced cells co-express exogenous human WT CEBPA 
with endogenous bi-allelic murine WT CEBPA. This does not mimic physiological CEBPA 
expression but it does provide us with a comparator for transduction of human mutated 
CEBPA. Visualisation of scRNA-seq data with t-SNE reveals a distinct spatial distribution of 
CEBPA WT-transduced cells at Day 0 which corresponds with the distinct cell surface marker 
profile previously identified on flow cytometry. Single-cell analysis demonstrates that CEBPA 
WT-transduced cells are transcriptionally divergent from both EV and CEBPA N321D-
transduced cells within 48 hours of transduction in the presence of nuclear Hoxb8-mediated 
DNA-binding. Gene expression signatures of CEBPA WT-transduced cells suggest ontology of 
granulocytes, with differentially expressed genes suggesting a GMP phenotype. Exogenous 
wildtype CEBPA is able to overcome Hoxb8 transcriptional effects and Flt3L cytokine effects, 
promoting both differentiation and neutrophil specification. Previous work by the Friedman 
group and others has shown that transcription factor ratios for C/EBPα play an important role 
in cell fate decisions of haematopoietic progenitors (Ma et al, 2014). The biological relevance 
of TF ratios is confirmed by our experiments which show a phenotype in CEBPA WT-
transduced cells which is distinct from the phenotype exhibited by endogenous CEBPA 
expression. 
 
Differential expression permits some interesting observations. CEBPA WT-transduced cells 





upregulated suggesting lineage bias towards neutrophil differentiation (Karsunky et al, 2002, 
Hock et al, 2003). Similarly, the upregulated gene IDH1 is known to promote myelopoiesis 
when overexpressed and block myeloid differentiation with knockdown in a zebrafish model 
(Shi et al, 2015). Several other genes associated with myeloid differentiation are upregulated 
by CEBPA WT at Day 2 post-transduction, including ITGAM, SIRPA and GCA (Roes et al, 2003), 
as well as myeloid growth factor receptor genes such as CSF1R (Edwards et al, 2019) and 
CSF3R. Upregulated genes also include genes which are antagonistic to HSPC populations, for 
instance transplantation of KLF7-transduced cells into lethally irradiated mice inhibits bone 
marrow reconstitution and suppresses HSCs and haematopoietic progenitor populations 
(Schuettpelz et al, 2012).  
 
Downregulated genes include genes which are known to play important roles in DC lineage 
restriction, for instance FLT3 (D’Amico et al, 2003, Onai et al, 2006) and GATA2 (Onodera et 
al, 2016), as well as HSC-associated genes such as SOCS2 which preserves stemness of HSCs 
under stress (Vitali et al, 2015) and MEIS1 although not its co-factor HOXA9 (Collins et al, 
2014). Interestingly, CSF3R (upregulated) and GATA2 (downregulated) mutations are amongst 
the most common co-occurring mutations in patients with CEBPA dm (Su et al, 2018, Maxson 
et al, 2016). 
 
By contrast, the CEBPA N321D mutation has a remarkable effect on the WT transcriptional 
signature in Hoxb8-FL cells in self-renewal conditions, with only 15 upregulated and 5 
downregulated genes identified on differential expression with EV-transduced cells, in 
comparison with 636 upregulated and 429 downregulated genes on differential expression of 
wildtype CEBPA against EV-transduced cells. This suggests that C/EBPα N321D has a dominant 
negative effect on exogenous wildtype C/EBPα. 
 
In summary, CEBPA WT-transduced cells demonstrate a distinct transcriptional profile in the 
presence of Hoxb8 nuclear translocation which is characterised by upregulation of genes 
associated with myeloid specification and differentiation, and downregulation of genes 
associated with alternative lineages and HSPC states. Furthermore, the C-terminal N321D 







4.5.2 Effects of mutant C/EBPα on transcriptional wiring and myeloid differentiation, and 
the single-cell expression profile of CEBPA N321D-transduced cells in conditions which 
favour differentiation 
Previously, we have described how Hoxb8 cells transduced with CEBPA N321D demonstrate 
distinct behaviour when differentiated in Flt3L. Specifically, CEBPA N321D-transduced cells 
demonstrate reduced expression of CD11b and SIRPα at Day 5 of differentiation, when 
compared to EV-transduced cells. Correlation with gene expression modules from ImmGen 
data suggests that Hoxb8-FL cells differentiate into both pDCs and type 2 cDCs in the presence 
of Flt3L. Gene set enrichment of genes differentially expressed in CEBPA N321D-transduced 
cells between Days 5 and 0 effectively points towards a pDC precursor cell ontology, both by 
using ASAP’s enrichment tool, and by inputting upregulated genes identified by DESeq2 into 
an independent gene set enrichment tool such as Enrichr. In addition, the following genes 
were upregulated exclusively in CEBPA N321D-transduced cells and were associated to pDC 
cell ontology using Enrichr: SLC44A1, TRAPPC5, MGAT1, FNDC3A, IFFO1, RUNX2, and RAB33B. 
RUNX2 has been shown to be highly expressed in pDCs and is required both for pDC 
maturation and for the expression of IRF7 which in turn regulates type I interferon production 
(Chopin et al, 2016). RUNX2 is highly expressed in HSCs but exhibits rapidly decreased 
expression during myeloid differentiation at the CMP stage. Sustained RUNX2 expression has 
been shown to block myeloid differentiation capacity, decrease expression of core binding 
factor targets CSF1R, MPO, and CEBPD, and decrease expression of gatekeepers of myeloid 
differentiation such as CEBPA and GFI1 (Kuo et al, 2009).  SLC44A1 is upregulated in CEBPA 
N321D-transduced cells with high confidence, and encodes the surface protein CDw92, which 
is known to play a role in DC biology and function including the production of interleukins 
(Wille et al, 2001). Of note, Enrichr associated the upregulated genes NOTCH1 and ZEB2 to NK 
cell ontology, but these genes are known also to play a role in pDC biology. By contrast, genes 
shown to be downregulated exclusively between Days 5 and 0 in the CEBPA N321D-
transduced cell line include genes (FOSB, CSF3R and CLEC5A) which play key roles in 
macrophage and granulocyte differentiation (Hong et al, 2011, Liu et al, 1996, Aoki et al, 2009, 
Batliner et al, 2011). 
 
It is not possible to directly compare the gene expression profiles of CEBPA N321D and CEBPA 
WT-transduced cells in conditions which favour differentiation of Hoxb-FL cells, because 





subsets for differential expression at Day 5 of differentiation in Flt3L are the CEBPA N321D 
and EV-transduced single cells, because these reveal gene sets which characterise two entirely 
different transcriptional trajectories from an initial gene expression signature which is 
originally very similar between CEBPA N321D and EV-transduced cells in the presence of 
estradiol. Comparison of these two gene expression trajectories suggests that CEBPA N321D-
transduced cells switch on a HSPC transcriptional program including SOCS2, and fail to switch 
on genes associated with macrophage and cDC programs including SIRPA (Gurka et al, 2015) 
and genes which encode known partner TFs of wildtype CEBPA such as JUNB and FOS 
(Rangatia et al, 2003, Cai et al, 2008, Rangatia et al, 2002, Hong et al, 2011). Notwithstanding 
reports by Cai et al that AP-1 heterodimers with C/EBPα activate the PU.1 promoter and direct 
monocyte lineage commitment (Cai et al, 2008), differential expression with DESeq2 in our 
experiments shows no significant differences in gene expression of either SPI1 or IRF8 at Day 
5 between cells transduced with EV and CEBPA N321D. This may imply that the N321D 
mutation can exert its phenotypic effects by pathways which are independent of PU.1 and 
IRF8. However, it is important to note that our results are not directly comparable because 
Cai et al employed BM mononuclear cells which were lineage depleted and then cultured in 
IL-3/IL-6/SCF, rather than LMPP-like cells in cytokine conditions which promote DC 
differentiation. 
 
In summary, our expression data confirms that EV-transduced Hoxb8-FL cells differentiate into 
mature pDCs and type 2 cDCs in the presence of Flt3L, and provides new data to suggest that 
CEBPA N321D upregulates HSPC and pDC transcriptional programs and downregulates 
programs associated with granulocyte, macrophage and cDC lineage restriction. Overall, this 
C-terminal mutation generates a pDC precursor gene expression profile when LMPP-like cells 
are differentiated in the presence of Flt3L. This suggests a DC-mediated mechanism which can 
potentially offer novel insights into the biology of C/EBPα-mutated AML, however it requires 
validation by further experiments. For instance, it would be interesting to further characterise 
this effect by taking BM mononuclear cells from a mouse model, lineage depleting them, 
transducing those cells with a range of C-terminal and N-terminal CEBPA mutations, and then 
culturing them in Flt3L. 
 
In addition, single-cell analysis describes heterogeneity within the CEBPA N321D-transduced 





transcriptional signature similar to immortalised Hoxb8-FL cells even in conditions where 
Hoxb8 is translocated to the cytoplasm. One can speculate that it is this small population 
which persists indefinitely in Flt3L differentiation media and which is capable of long-term 
engraftment in vivo, and therefore it would be interesting in a future experiment to employ 
ultra-high-throughput scRNA-seq systems such as 10x Chromium (Zhang et al, 2019) and 





5. ChIP-seq reveals the effect of CEBPA N321D 
mutation on genome-wide binding of CEBP/α and 
identifies direct targets for transcription 
 
5.1 Introduction 
Chromatin immunoprecipitation (ChIP) selectively enriches regions of chromatin which 
present specific antigen and which can be bound by a corresponding specific antibody, 
providing an in vivo snapshot of the interaction between a protein and fragments of DNA 
within a particular cell or tissue type. ChIP-seq builds on ChIP by employing massive parallel 
sequencing to annotate immunoprecipitation data onto a reference genome (Figure 5.1), and 
represents a powerful tool for genome-wide analysis of protein-DNA interactions (Johnson et 
al, 2007). Nevertheless, the biological interpretation of ChIP-seq data can be problematic, with 
a large number of binding sites having no obvious functional significance, leading some 
authors to hypothesise that binding events can be ‘opportunistic’ (Zhu et al, 2012). Further 
difficulties in interpreting ChIP-seq data are caused by evidence which suggests that TF binding 
patterns are commonly cell type-specific (Calero-Nieto et al, 2014). Ultimately, robust 
confirmation of TF-DNA interactions requires functional studies to establish novel 
transcriptional interactions and networks (Wilson et al, 2010).  
 
We have found a dendritic cell phenotype on differentiating CEBPA N321D-transduced Hoxb8-
FL cells in Flt3L, and we have employed single cell RNA-seq to characterise transcriptional 
profiles in EV and CEBPA N321D-transduced cells. Our results suggest that the CEBPA N321D 
mutation promotes an immortalised DC phenotype in conditions of differentiation in Flt3L. 
However, scRNA-seq does not provide any information about the mechanism of this altered 
gene expression profile, in particular it does not identify whether genes are direct targets of 
C/EBPα N321D or provide information about chromatin accessibility. Furthermore, C/EBPα is 
a transcription factor and exerts its biological effects by binding to enhancer and promoter 
regions on DNA to regulate gene expression, and there is evidence that C/EBPα can act as a 
pioneer factor (Di Stefano et al, 2016). For these reasons, it is helpful to integrate gene 







Figure 5.1 ChIP-seq combines ChIP (cross-linking of protein with DNA in chromatin followed by 
immunoprecipitation of DNA fragments bound by specific protein) with massive parallel 
sequencing to identify genome-wide binding of transcription factors  
 
C-terminal in-frame mutations have varied effects on transactivation (Pabst et al, 2001), but 
are characterised primarily by altered DNA-binding at the bZIP region of C/EBPα. The N321D 
mutation is located at the 321st codon which lies within the bZIP’s leucine zipper (LZ). LZs are 
characterised by hydrophobic leucine residues at every d position in an (abcdefg)n  amino acid 
repeat, and they are configured in an α-helical structure which interdigitates with parallel 
residues from a partner protein at their respective LZ domains. The two dimerised TFs then 
bifurcate at their basic region (BR) domains to bind the major groove of DNA. Asparagine 
residues can specify dimer formation (Zeng et al, 1997), and in addition dimerisation profiles 
are particularly affected by amino acids at positions a, e and g in the LZ heptad repeat 
(Schuermann et al, 1992). CEBPA N321D causes asparagine to be replaced by aspartate at 
position a in the heptad repeat, and therefore it would be reasonable to hypothesise that this 
causes LZ reconfiguration and altered DNA-binding with associated transcriptional effects. 
 
Genome-wide binding of C/EBPα N321D constitutes an important linking step between gene 
expression alterations and the altered phenotype seen in Hoxb8-FL cells transduced with the 
CEBPA mutation. This is particularly so because we know that C/EBPα is a transcription factor 





For instance, C/EBPα binds to the SPI1 promoter (Kummalue et al, 2003) and its -14 kb 
enhancer (Yeamans et al, 2007). In addition, evidence of TF binding can provide information 
on whether the genes dysregulated on gene expression analysis are direct or indirect targets 
of mutant C/EBPα.  
 
ChIP-seq for C/EBPα has been previously studied in haematopoietic stem cells (Hasemann et 
al, 2014), haematopoietic progenitor and leukaemic cells (Ohlsson et al, 2014), adipocytes 
(Haakonsson et al, 2013), primary macrophages (Zhang et al, 2013), basophils and mast cells 
(Qi et al, 2013), myeloid cells including neutrophils and monocytes (Avellino et al, 2016) and 
dendritic cell progenitors (Welner et al, 2013). These studies have provided a number of 
interesting findings regarding the role of C/EBPα in haematopoiesis. Firstly, it appears that 
C/EBPα binds to proximal promoter and distal regulatory regions of genes implicated in 
myeloid differentiation as early in differentiation as the LSK cell stage of haematopoiesis 
(Hasemann et al, 2014), suggesting that C/EBPα plays a role in lineage priming before 
expression levels increase at the CMP to GMP junction. Secondly, C/EBPα can play a 
collaborative role with other transcriptional regulators such as MLL fusion proteins to promote 
leukaemic transformation of cells (Ohlsson et al, 2014). Thirdly, C/EBPα continues to modify 
transcriptional programs through later hierarchical cell fate decisions, for instance C/EBPα 
instructs specification in basophil and mast cell progenitors (Qi et al, 2013). Fourthly, C/EBPα-
binding is tissue-specific (Di Stefano et al, 2014) and species-specific across vertebrate 
mammals (Villar et al, 2014). In addition,  CEBPA expression is also tissue-specific, for instance 
+34 kb and +42 kb enhancers of the CEBPA locus are H3K27Ac-enriched only in neutrophils 
and monocytes, and it has been found that deletion of the +42 kb enhancer leads to tissue-
specific neutropenia (Avellino et al, 2016). Lastly, ChIP-seq of murine CMP progenitor cells 
suggests that a number of genes implicated in dendritic cell differentiation are directly 
regulated by C/EBPα (Welner et al, 2013). Our own single cell RNA-seq experiments have 
demonstrated that CEBPA N321D-transduced cells display alterations in DC gene expression 
profiles and therefore it can be hypothesised that C/EBPα-binding to DC-related DNA may be 







5.2 Experimental design 
The objective of our experiment was to analyse the binding profile of endogenous and CEBPA-
mutant Hoxb8-FL cells before and after differentiation for 5 days in Hoxb8 media F+e- . For 
this purpose, we used the following antibodies: C/EBPα (which we expect to bind to both 
endogenous and exogenous CEBPA) and FLAG (binding to exogenous CEBPA in the mutant 
phenotype only). Additionally we also studied in the same settings the distribution of 
H3K27Ac, which is a chromatin modification that marks regions of active chromatin. We 
collected nuclei from EV and CEBPA N321D-transduced cells derived from two distinct 
transfections, both in F+e+ media and after 5 days of differentiation following the withdrawal 
of estradiol. Cells were cross-linked with formaldehyde 1% and quenched with 2M glycine. 
Nuclei were subsequently purified, lysed, sonicated, pre-cleared, and then 
immunoprecipitated with the relevant antibody. The DNA-protein-antibody complexes were 
captured using agarose G beads, then eluted from beads, cross-linking was reversed, and the 
DNA fragments isolated by each antibody were purified. 
 
5.3 Confirmation of ChIP enrichment by qPCR and ChIP-seq read 
quality 
Before proceeding to the generation of a DNA library, the enrichment of the SPI1 -14 kb 
upstream regulatory element (URE), known to be bound by C/EBPα, was analysed by qPCR. As 
a negative control, a region within mouse chromosome 1 (mChrom1) which is not bound by 
C/EBPα (Calero-Nieto et al, 2010) was also analysed. In both cases, the enrichment was 
compared to the DNA obtained with the IgG control, which acted as an indicator for 
background DNA binding. 
 
The qPCR analysis did not evaluate genome-wide enrichment but rather enrichment at a 
specific locus. There was good enrichment at the SPI1 -14 kb URE when precipitating with 
C/EBPα or FLAG, as compared to the mChrom1 region (Figure 5.2). The results of qPCR 
provided reassurance that chromatin immunoprecipitation had been effective and therefore 






Figure 5.2   qPCR evaluation of ChIP enrichment in one of two biological replicates (A) DNA 
enrichment after precipitation with C/EBPα antibody is seen at higher levels at the SPI1 -14 kb 
URE than at an inactive region of Chromosome 1 (Calero-Nieto et al, 2010). Similar results seen 




Input chromatin from all four conditions was used as a control to reduce bias due to chromatin 
fragmentation and variable sequencing efficiency associated with different base composition.  
H3K27Ac antibody was used to map the distribution of histone H3 acetylated at Lysine 27 as 
a marker of active regions of the genome (Creyghton et al, 2010). C/EBPα and FLAG antibodies 
were employed to identify regions bound by C/EBPα and by exogenous C/EBPα N321D 
respectively. Representative tracks at selected enhancer regions SPI1 -14 kb and CEBPB +65 
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Figure 5.3 UCSC Genome Browser screenshots of Input, H3K27Ac, C/EBPα and FLAG binding at 







5.4 Binding events for exogenous mutant C/EBPα, but not 
endogenous C/EBPα,  are markedly increased during differentiation 
of mutant cells in Flt3L  
 
Figure 5.4 represents DNA regions of increased enrichment at Days 5 and 0 for C/EBPα and 
FLAG antibodies. Interestingly, marked alteration in binding was only seen in the FLAG 
antibody for both ChIP-seq replicate experiments.   
 
Figures 5.4 (A) and (B) represent replicate experiments for enrichment by C/EBPα of DNA 
taken from EV cells, comparing enrichment for DNA regions at Day 5 and at Day 0. Figures 5.4 
(C) and (D) represent the same for DNA taken from CEBPA N321D-transduced cells. Figures 
5.4 (E) and (F) represent replicate experiments for enrichment by FLAG of DNA taken from 
CEBPA N321D-transduced cells. Enrichment corresponds to the log2 of normalised read 
counts at C/EBPα and FLAG peaks respectively. 
 
The FLAG sequence was inserted into the N321D construct only, and therefore the FLAG 
antibody enriches only for DNA regions bound by C/EBPα N321D and not for regions bound 
by endogenous C/EBPα.  
 
For C/EBPα, there is no obvious quantitative change in global enrichment of DNA between 
Day 5 and Day 0 in either EV or CEBPA N321D-transduced cells, although specific DNA regions 
are bound differentially between the days and between the conditions (Figures 5.5, 5.6 and 
5.7). In contrast with the bi-modal distribution of global read counts at C/EBPα peaks between 
Days 5 and 0, there were relatively few regions with increased read counts at FLAG peaks at 
Day 0 in estradiol, compared to Day 5 after differentiation in Flt3L. It is possible that at Day 0 
the C/EBPα-bound complexes are relatively stable and inaccessible by the mutant, but upon 
differentiation there is a higher requirement for C/EBPα and its partners for protein synthesis, 
and at this point the mutant TF binds to DNA and exerts a dominant negative effect on the 
wildtype TF. One can also speculate that genes for lineage specification and differentiation are 
preferentially bound by the mutant TF. Interestingly, the wildtype C/EBPα binds equally avidly 
during progenitor and differentiated cell states, whereas the mutant C/EBPα binds more 
avidly during differentiated cell states, supporting the hypothesis that Leukaemia initiating 



















 Figure 5.4 Read count comparison for two biological replicates between Day 0 and after 
differentiation in Flt3L for 5 days, for (A) and (B) C/EBPα antibody in EV cells, (C) and (D) 
C/EBPα antibody in mutant cells, and (E) and (F) FLAG antibody in mutant cells only. Log2 
graph with red dots representing DNA regions with ≥ 4-fold increase in read count and green 
dots representing ≥ 4-fold decrease in read count when comparing Days 5 and 0. Line 
corresponding to direct correlation (no change) is depicted. Blue and pink dots represent regions 





Exogenous C/EBPα WT binding has not been analysed by ChIP-seq, but the altered phenotype 
and gene expression profile suggest that a higher ratio of C/EBPα in CEBPA WT-transduced 
cells may act to open up chromatin in cells even before they are cultured in conditions which 
favour differentiation. This would be consistent with recent reports by Thomas Graf and 
colleagues that pulsed CEBPA expression in B cells can open up chromatin and poise them for 
reprogramming into induced pluripotent stem cells (Di Stefano et al, 2014).  
 
Binding events from both biological replicates in EV and CEBPA-transduced cells were then 
compared to find DNA regions unique to each cell line which demonstrated four-fold 
increased and decreased read counts for C/EBPα-binding between Days 5 and 0 of 








Figure 5.5 Regions of DNA which demonstrate four-fold increased (A) and decreased (B) read 














Figure 5.6 Regions of DNA which demonstrate four-fold increased (A) and decreased (B) read 
counts for C/EBPα-binding in second biological replicate between Days 5 and 0 of differentiation 
in Flt3L 
 
Results from the two biological replicates were then intersected to identify a final list of high 
confidence regions where C/EBPα binding is upregulated (Figure 5.7 A) or downregulated 







Figure 5.7 High confidence regions of DNA which demonstrate four-fold increased (A) and 







5.5 Intersection of differential gene expression and C/EBPα binding 
events 
Following the observation that there is a quantitative shift in FLAG genome-wide binding 
events but not C/EBPα binding events between Days 0 and 5 (Figure 5.4), and bearing in mind 
that there is a phenotypic difference between these two cell lines, it was decided to carry out 
a qualitative analysis of regions bound by C/EBPα. 
 
We examined genome-wide binding profiles of EV and CEBPA N321D-transduced cells at Day 
5 of differentiation, by defining genes which were associated with regions bound by C/EBPα 
in EV and CEBPA N321D-transduced cells, and by FLAG in CEBPA N321D-transduced cells only. 
We identified 4752 genes with an associated C/EBPα peak in both experimental replicates for 
EV cells, and 8843 genes with a C/EBPα peak in both replicates for CEBPA N321D-transduced 
cells. This represents a significant difference in number of genes bound by C/EBPα in EV and 
CEBPA N321D-transduced cells at Day 5 of differentiation in Flt3L, and it is possible that either 
the increased expression ratio of CEBPA in CEBPA N321D-transduced cells or else binding 
effects specific to C/EBPα N321D, for instance conformational changes in the TF, are 
responsible for the quantitative difference. The 8843 genes associated with a C/EBPα peak 
included binding events for both endogenous murine C/EBPα and for exogenous human 
C/EBPα N321D, and therefore we also identified 2747 genes with an associated FLAG peak in 
both experimental replicates for CEBPA N321D-transduced cells. These 2747 genes were 
specifically bound by exogenous C/EBPα N321D. 
 
This data was then correlated with gene expression data from our scRNA-seq experiment. 
During differentiation of EV cells between Days 0 and 5, 1400 genes were upregulated and 
1340 genes were downregulated. By contrast, during differentiation of CEBPA N321D-
transduced cells over 5 days, 594 genes were upregulated and 418 genes were downregulated 
(Figure 5.8). In addition, differential expression between both cell lines at Day 5 gives 224 
upregulated and 633 downregulated genes in CEBPA N321D-transduced cells when compared 






This data can then be interrogated by examining the 1400 genes which are upregulated during 
differentiation of EV cells, identifying those genes which have an associated C/EBPα peak in 
both ChIP-seq replicate experiments at Day 5 of differentiation (Appendix, Table 11), and then 
exploring the binding patterns of those same 653 genes in CEBPA N321D-transduced cells. 
This strategy looks at differential expression in EV cells between Days 5 and 0, and then 




Figure 5.8 Schematic of first strategy to analyse qualitative variations in genome-wide binding 
profiles between EV and CEBPA N321D-transduced cells 
 
From the 653 genes identified as upregulated and having an associated C/EBPα peak in EV 
cells, 230 genes are also upregulated in CEBPA N321D-transduced cells during differentiation 
(Appendix, Table 12), and 126 are bound by the FLAG antibody at Day 5 (Appendix, Table 13). 
Interestingly, 36 of these 126 genes are downregulated in CEBPA N321D-transduced cells 
when compared to EV cells at Day 5. These 36 genes (Appendix, Table 14) are therefore bound 
by exogenous C/EBPα N321D, upregulated during the differentiation process in CEBPA N321D-
transduced cells, but their upregulation is impaired in comparison with EV cells. This means 
that although these genes are upregulated during differentiation of CEBPA N321D-transduced 
cells, exogenous C/EBPα N321D binding events seem to have a dominant negative effect on 






From the 653 genes, 2 genes are downregulated in CEBPA N321D-transduced cells during 
differentiation and 1 of those 2 genes is also bound by the FLAG antibody.  
 
421 of the 653 genes do not significantly change expression levels during differentiation of 
CEBPA N321D-transduced cells, including 218 genes which are bound by the FLAG antibody at 
Day 5 in CEBPA N321D-transduced cells. These 218 genes confirm the general observation that 
ChIP-seq binding events do not necessarily alter expression profiles or biological function in 
each and every cellular context (Calero-Nieto et al, 2014). 
 
In addition to upregulated genes during differentiation of EV cells in Flt3L which have an 
associated C/EBPα peak in EV cells, there are 1340 downregulated genes identified on 
differential expression between EV cells at Days 5 and 0, of which only 3 genes (BC017158, 
AI314180 and AI987944) have an associated C/EBPα peak in EV cells. This suggests that there 
is little evidence of a correlation between C/EBPα-binding and downregulation of gene 
expression during differentiation of EV cells and therefore further exploration of this data set 
was not carried out. 
 
5.5.1 Immunomodulatory and DC genes including NOTCH2 are bound by mutant C/EBPα and 
demonstrate reduced upregulation in CEBPA N321D-transduced cells during differentiation 
in Flt3L  
These 36 genes (see Figure 5.8) represent genes which are bound by both endogenous C/EBPα 
and exogenous C/EBPα N321D, upregulated during differentiation in both EV and CEBPA 
N321D-transduced cells, but their upregulation is impaired in comparison with EV cells. They 
include immunoregulatory genes involved in DC differentiation and function such as AXL, 
which acts as a canonical marker of a discrete population of pDCs which do not produce type 
I IFN (Zhang et al, 2017) and which is upregulated by IFN-α  during differentiation of human 
DCs (Scutera et al, 2009). Expression of CD300a, another of these 36 genes, is expressed by a 
wide range of immunomodulatory cells including NK cells, T and B cells, monocytes and 
dendritic cells (Clark et al, 2009). CD300a is downregulated by exogenous IFN-α, and CD300a 
in turn regulates IFN-α and TNF-α secretion by human pDCs (Ju et al, 2008). 
 
ITGAM encodes CD11b, which is highly expressed in both monocytes and dendritic cells, and 





macrophages. In addition, ITGAM/CD11b promote TLR4 endocytosis and TRIF-mediated 
signalling in myeloid DCs (Ling et al, 2014). CD11b provided the first evidence of a DC 
phenotype in our initial flow cytometry experiments, and shows the important role that can 
be played by genes which are upregulated during differentiation of CEBPA N321D-transduced 
cells but have impaired upregulation in comparison with EV cells. 
 
Genes including TLR2 and CTSB are implicated in tolerogenic DC mechanisms. TLR2 
upregulation in tolerogenic DCs results in a reduced proinflammatory immune program 
(Chamorro et al, 2009) and TLR2 activation promotes tumour DC dysfunction whereas TLR2 
blockade improves the efficacy of immunotherapy (Tang et al, 2015). CTSB is involved in 
apoptosis and lysosomal activation in pDCs (Robbins et al, 2008) and in MHC class II antigen 
presentation in tolerogenic DCs (Schinnerling et al, 2015). 
 
Other genes which demonstrate reduced upregulation in CEBPA N321D-transduced cells have 
not been directly associated with DC differentiation or function, but are involved in 
immunoregulatory mechanisms. For instance, DPEP2 mediates inflammatory effects through 
conversion of leukotriene D4 to leukotriene E4 (Toda et al, 2013). Similarly, IFITM3 is an 
antiviral gene stimulated by type 1 IFN, and expression of IFITM3 is increased by A/Bris/59/07 
infection (Cao et al, 2012).  
 
From the perspective of dendritic cell function, perhaps the most significant gene bound by 
FLAG which has impaired upregulation in CEBPA N321D-transduced cells in comparison with 
EV-transduced cells is NOTCH2. The NOTCH family of transmembrane receptor TFs mediates 
an intercellular signalling pathway which regulates decisions between adjacent cells. Each 
family member comprises a heterodimeric receptor with extracellular subunits on the cell 
surface engaging ligands presented by trans- or opposing cells, and intracellular subunits 
mediating gene expression patterns associated with cell fate decision and differentiation. In 
addition, NOTCH mediates interaction between bone marrow stroma (BMS) and 
haematopoietic progenitor cells. The NOTCH ligand Jagged-1 is highly expressed in BMS and 
stimulates accumulation of DC precursors while preventing terminal differentiation of DCs, 
whereas the Delta-1 ligand is highly expressed in spleen stroma and promotes terminal 
differentiation (Cheng et al, 2007).  Interestingly, deletion of the NOTCH2 receptor causes a 





the effect of NOTCH receptor/transcription factors on DC differentiation is complex and 
dependent on cellular or spatial context. In addition, NOTCH signalling mediates 
immunomodulatory mechanisms in cancer, for instance it mediates functionally altered 
myeloid cells and NOTCH inhibition in DCs can cause abnormal myeloid cell differentiation 
which is implicated in oncogenesis (Cheng et al, 2014). The observation that NOTCH2 is bound 
by FLAG and shows impaired gene expression in CEBPA N321D-transduced cells suggests that 
C/EBPα N321D may directly interact with NOTCH2 cis-regulatory elements and interfere with 
DC differentiation. 
 
Taken together, these data demonstrate that genes directly bound by C/EBPα N321D which 
show decreased expression during differentiation of CEBPA N321D-transduced cells include 
genes specifically associated with both pDC and cDC differentiation and function, as well as 
more generic immunomodulatory mechanisms including tolerogenicity and inflammation. 
 
5.5.2 Loci for important partner TFs (PU.1, RUNX1, IRF8) are bound by exogenous mutant 
C/EBPα but have no altered gene expression  
126 genes are bound by endogenous C/EBPα, upregulated during differentiation in both EV 
and CEBPA N321D-transduced cells, and bound by exogenous C/EBPα N321D. They include 
the 36 genes identified in 5.5.1 above, but also 90 genes which are bound by exogenous 
C/EBPα N321D and have no significant difference in expression levels between EV and CEBPA 
N321D-transduced cells at Day 5 of differentiation. It is important to note that these genes 
are specifically bound by the mutant C/EBPα N321D, because they encode important partner 
TFs for C/EBPα which are known to play a role in dendritic cell function and/or differentiation 
such as IRF8 (Kurotaki et al, 2014, Sichien et al, 2016), PU.1 (Carotta et al, 2010, Merad, 2010) 
and RUNX1 (Guo et al, 2012, Satpathy et al, 2014). It is well-established that TFs act in 
combinatorial networks (Wilson et al, 2010) and it is possible that C/EBPα N321D binding may 
produce secondary indirect effects even if expression of SPI1 is not significantly altered at Day 
5 of differentiation. Previous work by Miller et al has shown that mutations in bZIP TFs 
including C/EBPα alter conformation and binding specificity at the level of amino acid residues 
(Miller et al, 2003), and more recent work has demonstrated that mutations can be 
engineered to alter the dimerisation profiles of bZIP TFs (Pogenberg et al, 2014). In addition, 
Thomas Graf and colleagues have recently shown that TFs can drive topological genome 





can hypothesise that mutant C/EBPα may alter conformational interactions with partner TFs 
even if it does not change the expression level, and this can in turn then change the 
combinatorial effect of C/EBPα with the partner TF. It would be interesting to employ 
crystallography or chromosome conformation capture to examine the conformational effects 
of the N321D mutation but this is outside of the scope of this study. However, it is important 
to recognise that the interplay between TFs and three-dimensional genome topology can drive 
cell fate decisions (Stadhouders et al, 2019). 
 
5.5.3 TGFBI is bound by mutant C/EBPα, upregulated during differentiation in EV cells, but 
downregulated during differentiation of CEBPA N321D-transduced cells 
From the 653 genes which are bound by endogenous C/EBPα and upregulated during 
differentiation in EV cells, 2 genes (FCGR3 and TGFBI) are downregulated in CEBPA N321D-
transduced cells during differentiation and 1 of those 2 genes is also bound by the FLAG 
antibody. This single gene TGFBI represents a reversal of expression profile between CEBPA 
N321D-transduced cells and EV cells which is directly associated with binding of mutant 
C/EBPα N321D. 
 
The role of TGFBI in the pathogenesis of corneal dystrophy has been elucidated in several 
studies (Venkatraman et al, 2019), and altered expression of TGFBI has been implicated in 
non-small cell lung cancer (Yan et al, 2018), glioma cells (Guo et al, 2018, Pan et al, 2018), and 
other cancers (Han et al, 2015, Zhu et al, 2015, Ozawa et al, 2016, Lauden et al, 2014).  TGFBI 
has been characterised as a regulator of HSC specification in a zebrafish model (Charbord et 
al, 2014), and plays a regulatory role in human haematopoiesis that includes cell-intrinsic 
effects but which also involves interplay between both human HSPCs and bone marrow 
mesenchymal cells (Klamer et al, 2018). Specifically, HSPC maintenance was enhanced by 
reduced expression of TGFBI. In addition, TGFBI has been shown in microarray analysis to have 
increased expression in a CD14+ myeloid subset of human dendritic cells (Ahn et al, 2002), and 
to have decreased expression in DCs where maturation was attenuated by regulatory T cells 
(Mavin et al, 2017). It can be hypothesised that reduced expression of TGFBI in CEBPA N321D-
transduced cells associated with exogenous C/EBPα N321D binding mediates HSPC 







5.5.4 Dominant negative effect of C/EBPα N321D affects genes implicated in DC cell fate and 
function, as well as genes involved in cell cycle control  
From the 653 genes which were bound by endogenous C/EBPα and upregulated during 
differentiation in EV cells, 421 genes showed no significant differential expression in CEBPA 
N321D-transduced cells during differentiation over 5 days, and 218 of these genes were bound 
by the FLAG antibody.  
 
These 218 genes represent the genes directly bound by C/EBPα N321D with a failure to follow 
the EV model of gene upregulation during differentiation in Flt3L. These genes are the most 
likely to be subject to a dominant negative effect from the N321D mutation. They include 
genes which are confirmed by other intersections in this chapter (see 5.6.1 below) and which 
play a role in DC lineage specification and/or function, including COTL1, DAB2, FOS, IRAK2, 
JAK2 and SIRPA.  
 
The downregulation of FOS in CEBPA N321D-transduced cells is particularly interesting 
because the AP-1 proteins are known to act as dimerisation partners of C/EBPα. Previous work 
has shown that C/EBPα:C/EBPα homodimers promote granulopoiesis whereas C/EBPα:Fos 
heterodimers induce monocyte lineage commitment, and that the interaction between 
C/EBPα and AP-1 TFs plays a significant role in cell fate decision-making at the CMP to GMP 
junction (Cai et al, 2008).  
 
Zhong et al have shown that JAK2 is essential for bone marrow derived dendritic cells (BMDCs) 
development and maturation, and JAK2 deficiency attenuates innate immune response 
though not adaptive immune response (Zhong et al, 2010). This study did not specifically 
examine cDC or pDC populations, but it suggests that downregulation of JAK2 in CEBPA 
N321D-transduced cells may cause a maturation defect in the DC lineage. 
 
COTL1 alongside AXL acts as a canonical marker of a novel discrete subpopulation of pDCs 
which do not produce type I IFN, but it is not highly expressed in the majority of pDCs which 






IRAK2 plays a role in interferon production by pDCs, with IRAK2-deficient pDCs demonstrating 
increased nuclear translocation of IRF7 which acts as a key TF for interferon gene transcription 
(Wang et al, 2011). 
 
DAB2 is induced during differentiation of murine bone marrow derived DCs and human 
monocyte-derived DCs and appears to act as a negative regulator of DC immunogenicity and 
T cell activation (Ahmed et al, 2015). Downregulation of DAB2 in CEBPA N321D-transduced 
cells may therefore promote DC migration, antigen uptake, T-cell responses and secretion of 
cytokines.  
 
In addition to genes which play a role in cell fate decisions and dendritic cell function, this 
subset of genes also includes three genes which play a role in cell cycle control and therefore 
may be relevant for the pre-leukaemic effects of the CEBPA N321D mutation. Firstly, CXCR4 
has been shown to be associated with cell cycle arrest in leukaemic cells (Burger et al, 2007) 
and furthermore wildtype C/EBPα directly binds to the CXCR4 promoter to activate 
transcription (Kuo et al, 2014). In addition, it has been shown that an N-terminal mutation of 
CEBPA impairs CXCR4 expression (Kuo et al, 2014). Our own observation that CXCR4 
expression is upregulated in EV and not CEBPA N321D-transduced cells suggests that binding 
by the C-terminal mutant C/EBPα N321D may similarly impair expression of CXCR4 in the 
Hoxb8-FL cell line. 
 
KLF4 encodes one of the Yamanaka factors (Takahashi et al, 2006) and is a second gene which 
has been implicated in cell cycle control, mediating p53-activation of the cyclin-dependent 
kinase inhibitor p21 (Zhang et al, 2000). In addition, KLF4 is a target gene of PU.1 and acts as 
a critical regulator of monopoiesis, promoting monocyte differentiation (Feinberg et al, 2007). 
Failed upregulation of KLF4 in CEBPA N321D-transduced cells may impair both monopoiesis 
and cell cycle control in mutant cells. 
 
Finally, E2F2 has been shown to repress the transcription of cell cycle genes and promote a 
quiescent G0 state (Infante et al, 2008). In Drosophila, E2F2 antagonises E2F1 and acts to 
suppress both transcription of E2F-regulated genes and DNA synthesis (Frolov et al, 2001), 
and E2F2 has been shown to act as a tumour suppressor in specific cellular contexts (Opavsky 





established that C/EBPα mediates cell growth arrest through E2F-mediated cell cycle 
mechanisms (Slomiany et al, 2000, Kowenz-Leutz et al, 2016). 
 
5.6 Intersection of mutant C/EBPα (FLAG) binding events and 
differential gene expression between cell lines at Day 5 
The second strategy is to look first at the genome-wide binding profile of the FLAG antibody 
in CEBPA N321D-transduced cells, and then correlate this profile with gene expression data. 
There are 2747 genes with an associated FLAG peak at Day 5 in both replicates of the ChIP-
seq experiments. 160 of these 2747 genes are downregulated (Appendix, Table 15), 49 genes 
are upregulated (Appendix, Table 15), and 2539 out of the 2747 genes do not significantly 
change expression profile in CEBPA N321D-transduced cells when compared to EV cells at Day 
5. Interestingly, it appears that most of the FLAG binding events are not associated with 
altered transcriptional status of directly bound genes, and that the dramatic phenotypic 
difference between the two cell lines is achieved with relatively few downregulated and even 




Figure 5.9 Schematic of second strategy to analyse qualitative variations in 







5.6.1 Regulatory elements for genes involved in myeloid differentiation and DC specification 
are bound by mutant C/EBPα and show reduced expression in mutant cells at Day 5 of 
differentiation in Flt3L 
These 160 genes represent genes which are directly bound by exogenous mutant C/EBPα and 
which are upregulated in EV-transduced cells or downregulated in CEBPA N321D-transduced 
cells on differential expression between these cells at Day 5 of culture in media with Flt3L. 
There is significant overlap with the subset of 36 genes which are bound by exogenous FLAG, 
upregulated during differentiation in CEBPA N321D-transduced cells, but demonstrate 
impaired upregulation in comparison with EV cells, with shared genes between the subsets 
including AXL, CD300a, CTSB, DPEP2, ITGAM, TLR2 and NOTCH2. 
 
Nevertheless, there are some additional genes in this data set which are relevant for DC 
biological processes, and which may be directly regulated by the CEBPA N321D mutation in 
the Hoxb8-FL cell line. These genes include well-established genes involved in myeloid 
differentiation pathways such as CSF3R, JAK2 and FOS, as well as other genes which have been 
shown to play roles in DC differentiation and function. 
 
The role of JAK2 and FOS has been described in 5.5.4 above. CSF3R is downregulated on 
differential expression of CEBPA N321D versus EV-transduced cells at Day 5 of culture in media 
with Flt3L. CSF3R encodes the G-CSF receptor which plays an important role in neutrophil 
ontogeny. Increased expression of CSF3R has also been demonstrated in CD11b+ cDCs 
(Robbins et al, 2008), and downregulation of CSF3R in CEBPA N321D-transduced cells 
compared with EV-transduced cells suggests an altered DC gene expression program. One can 
speculate that the upregulation of CSF3R in the presence of Flt3L contributes to the cDC 
phenotype seen in EV-transduced cells, and that failed upregulation in CEBPA N321D-
transduced cells allows the pDC progenitor-like phenotype to persist. 
 
Other genes upregulated in EV-transduced cells include genes associated with identification 
of DCs or specific DC subsets (CLEC10A, CLEC4A1, COTL1, CD9) and genes associated with DC 
function (DAB2, IRAK2, MARCH1 and CD9 again). The roles of COTL1, DAB2 and IRAK2 have 






CLEC10A is a specific marker for human CD11c+ dendritic cells which are homologous to 
murine CD8- CD11b+ SIRPα+ type 2 cDCs (Heger et al, 2018). Increased expression of CLEC10A, 
and of the SIRPA gene, on differential expression of EV as compared to CEBPA N321D-
transduced cells therefore corresponds with flow cytometry data which suggests that EV cells 
differentiate into type 2 cDCs in Flt3L and that CEBPA N321D-transduction causes a 
differentiation block in this process. 
 
CLEC4A1 encodes Dendritic cell inhibitory factor 4 (DCIR4) and its expression is significantly 
diminished by differentiation of inflammatory monocytes into DCs (Kameda et al, 2016). 
 
CD9 is downregulated on differential expression between CEBPA N321D and EV-transduced 
cells. Importantly, pDCs have reduced surface expression of MHC class II molecules in 
comparison with cDCs, and pDCs do not express CD9 (Asselin-Paturel et al, 2001, Mittelbrunn 
et al, 2009). The downregulation of CD9 in CEBPA N321D-transduced cells may reflect a 
differentiation shift in mutant cells from cDC to pDC phenotype. 
 
In addition to discriminating between cDC and pDC subsets, CD9 also plays a role in DC 
function. It has been shown to facilitate superior antigen presentation ability in murine DCs 
compared to other APCs by playing a role in physically tethering dissimilar MHC class II 
molecules (Unternaehrer et al, 2007). CD9 deletion limits MHC II surface expression and 
significantly impairs CD4+ T cell activation in monocyte-derived DCs (Rocha-Perugini et al, 
2017).  
 
DAB2 and MARCH1 are involved in antigen presentation and T-cell activation mediated by 
dendritic cells. MARCH1-mediated MHC II ubiquitination in DCs regulates MHC class II surface 
expression and immunogenic T-cell activation, but also promotes DC selection of regulatory T 
cells (Oh et al, 2013).  
 
In summary, our results suggest that C/EBPα N321D binds to regulatory elements for genes 
which play significant roles in myeloid differentiation, DC specification and DC function, 






5.6.2 Mutant C/EBPα binds to HSPC genes including MYB and increases their expression in 
Flt3L differentiation media  
These 49 genes represent genes which are directly bound by exogenous mutant C/EBPα and 
which are downregulated in EV-transduced cells (or upregulated in CEBPA N321D-transduced 
cells) on differential expression between these cells at Day 5 of differentiation in Flt3L.  
 
Interestingly, these 49 genes include genes which are important for maintenance of 
haematopoietic progenitor populations. For instance, SDC1 transcripts are upregulated in 
murine MPP cells, in contrast to SDC2 transcripts which are enriched in LT-HSCs (Forsberg et 
al, 2005). CBX2 is another gene in this subset, and is required for both haematopoietic and 
progenitor self-renewal with CBX2 shRNA knock-down resulting in reduced plating potential 
(van den Boom et al, 2013). Perhaps the most interesting gene upregulated by CEBPA N321D-
transduced cells is MYB. Primitive haematopoiesis does not require MYB (Tober et al, 2008), 
but foetal liver haematopoiesis is MYB-dependent (Mucenski et al, 1991) and LT-HSCs express 
the highest levels of MYB with progressive decrease in MYB expression during step-wise 
differentiation to MPP cells and both granulocytes and monocytes (Lieu et al, 2012).  
 
Other genes which play a role in DC maturation include SOCS2 in human monocyte-derived 
DCs (Hu et al, 2009) and IL6ST which encodes a signal transducer for IL-6, which in turn blocks 







5.7 Intersection of chromatin accessibility profile and C/EBPα binding 
events during differentiation in Flt3L  
The third strategy to analyse ChIP-seq data is to describe H3K27Ac coverage in C/EBPα-bound 
regions in both EV and CEBPA N321D-transduced cells to examine qualitative changes in 
chromatin accessibility in the two conditions. This can be achieved firstly by defining C/EBPα-
bound regions in each cell line, and then by intersecting this data with histone acetylation 
data.  
 
C/EBPα-bound regions can be defined as follows:  
(i) identify regions which are enriched four-fold for C/EBPα (Figure 5.4) when comparing 
each cell line at Day 5 versus Day 0, identifying those regions which are differentially 
bound during differentiation in each cell line;  
(ii) intersect results from the two ChIP-seq experiments in each cell line to identify high 
confidence peaks for C/EBPα enrichment during differentiation;  
(iii) intersect the high confidence regions from the two cell lines to identify 3 sets of regions 
(Figure 5.10) which are highly enriched for C/EBPα binding specifically in EV cells (399 
regions) or in CEBPA N321D-transduced cells (669 regions) or which are enriched in 







Figure 5.10 C/EBPα-bound regions enriched four-fold and intersecting two ChIP-seq experiments 







The peak distribution of the regions in Figure 5.10, and the total peak distribution over all 
C/EBPα binding events can be analysed to determine whether the regions enriched by C/EBPα 
binding are more likely to be associated with promoters or enhancers (Table 5.1). 
 
 
Table 5.1 Peak distribution of regions enriched four-fold by C/EBPα-binding 
 Promoter Intragenic Intergenic 
399 up (EV) peaks 7 217 175 
669 up (N321D) peaks 11 321 337 
1078 up (shared) peaks 17 436 625 
All peaks 15317 53225 52933 
 
 
The peak distribution listed in Table 5.1 suggests that, in comparison with all C/EBPα binding 
events, high confidence regions enriched four-fold for C/EBPα are more likely to be associated 
with intragenic and intergenic enhancers than with promoters. 
 
Chromatin accessibility in the C/EBPα-bound regions can then be analysed as follows:  
(iv) examine acetylation coverage with H3K27Ac-binding of the 3 sets of regions (Figure 
5.11); 
(v) identify regions which are highly acetylated (two-fold enrichment of H3K27Ac) in 
C/EBPα-enriched regions;  

















The following regions can then be mapped to genes: two-fold enriched in H3K27Ac in EV cells 
from the 399 regions in Figure 5.10, two-fold enriched in CEBPA N321D-transduced cells from 
the 669 regions, and two-fold enriched in EV cells from the 1078 regions. These are intersected 
between the two experiments to identify genes enriched for H3K27Ac with high confidence 
to give the following results (Table 5.2): 
 
Table 5.2 High-confidence C/EBPα-bound genes associated with regions enriched two-fold for 
H3K27Ac 
399 regions 21 genes in EV versus CEBPA N321D-transduced cells 
669 regions 1 gene in CEBPA N321D versus EV-transduced cells 
1078 regions 35 genes in EV versus CEBPA N321D-transduced cells 
 
These genes are then intersected with genes derived from differential expression of EV versus 
CEBPA-transduced cells at Day 5 of differentiation on single cell RNA-seq, to identify genes 
where chromatin accessibility is associated with C/EBPα-binding and increased expression. 
This intersection gives only 1 high-confidence gene (KLF6) which is highly acetylated and 
bound by C/EBPα exclusively in EV-transduced cells and shows upregulation on differential 
expression of EV against CEBPA N321D-transduced cells at Day 5, and 10 genes (CLEC4B1, 
PID1, PLEKHM3, SLC29A3, PLEKHF2, MARCH1, ATP2B1, RCBTB2, PDE7B, CTSC) which are highly 
acetylated in both cell lines and upregulated on differential expression of EV against mutant 
cells at Day 5 of differentiation in Flt3L. There are no genes which are highly acetylated in 




5.8.1 Choice of cell type and antibody for ChIP-seq 
The experimental hypothesis for our ChIP-seq experiments is that the N321D mutation resides 
in the bZIP domain of C/EBPα and therefore can be predicted to alter coiled-coil heptad 
interactions, C/EBPα binding profile and function (Pogenberg et al, 2014). The choice of cell 
type and antibody was an important consideration in designing a ChIP-seq experiment to 
provide reliable insights into how the altered topology of C/EBPα N321D mediates 
transcriptional effects. Regarding the choice of CEBPA N321D and EV-transduced cells, 
retroviral vectors integrate preferentially into transcribed regions of the genome, and bearing 





two wildtype alleles can reasonably be hypothesised to provide useful insights into the impact 
of mutant CEBPA on TF binding profiles. Theoretically a more useful comparator for the N321D 
model would be the CEBPA WT-transduced cell line, which would integrate an additional WT 
allele, but our early experiments demonstrated that the integration of CEBPA WT into the 
Hoxb8-FL cell line resulted in an altered initial phenotype in the presence of estradiol, meaning 
that the two cell lines started from a different phenotype. An additional experimental 
challenge regarding CEBPA WT-transduced cells was rapid differentiation and clonal selection 
so that it was difficult to obtain sufficient representative cells for ChIP-seq after 5 days of 
differentiation. One possible experiment would have been to compare binding profiles of 
CEBPA WT and EV-transduced cells at Day 0 before differentiation, but this would have failed 
to elucidate the leukaemic effects of the N321D mutation during differentiation. For these 
reasons, it was decided to perform ChIP-seq experiments to compare EV and CEBPA N321D-
transduced cells at Days 0 and 5 of differentiation. It is also important to emphasise that this 
experimental model captures the effects of one specific C-terminal mutant isoform of C/EBPα. 
In fact, CEBPA-mutated leukaemia most commonly combines a C-terminal mutation with an 
N-terminal mutation, and recapitulation of this in vivo co-operative mutational profile would 
require a more complex cellular model with a second non-GFP reporter molecule and an 
alternative epitope tag, and then an analysis of which regulatory regions were bound by 
antibodies to both epitopes but not by C/EBPα antibody. 
 
The other important decision in experimental design was antibody selection. The C/EBPα 
antibody was well-validated by our group and others, but it cannot discriminate between 
wildtype C/EBPα and the single altered amino acid in C/EBPα N321D. For this reason, it was 
decided to add a FLAG tag into the mutant plasmid construct and thereby to identify DNA 
regions bound specifically by the mutant TF rather than by wildtype. The FLAG tag is a 
hydrophilic polypeptide which can theoretically alter conformation and function of C/EBPα 
N321D. However, the tag is short (8 amino acids), and reassurance is provided by the fact that 
it was also included in the CEBPA WT construct, which showed a very different phenotype to 
the mutant, thus suggesting that the FLAG tag (shared between the two constructs) had no 







5.8.2 Qualitative changes are observed in binding events during differentiation of EV and 
CEBPA N321D-transduced cells 
FLAG binding events increase in both experimental replicates during differentiation of CEBPA 
N321D-transduced cells, but interestingly there is no significant global increase in binding 
events for C/EBPα transcription factor during differentiation of either EV or CEBPA N321D-
transduced cells (Figure 5.4). This suggests that closed chromatin opens up specifically to 
mutant C/EBPα N321D during differentiation, but that effects on wildtype C/EBPα binding are 
more subtle. It was therefore decided to subject C/EBPα binding profiles to more nuanced 
qualitative analysis by integrating ChIP-seq results with scRNA-seq expression profiles and 
secondly by looking at H3 Lysine 27 acetylation signatures to ask whether genes bound by 
C/EBPα in EV and CEBPA N321D-transduced cells can be distinguished by transcriptional 
activity.  
 
Our previous gene expression analysis described genes which were dysregulated in EV and 
CEBPA N321D-transduced cell lines, however integrating these results with ChIP-seq allows us 
to determine genes which are direct targets of C/EBPα-mediated transcription.  Two distinct 
approaches identify a common set of genes which can be considered with high confidence to 
be directly bound and transcribed by C/EBPα and which have altered gene expression in 
CEBPA N321D-transduced cells. These include genes which are associated with DC 
differentiation and function (AXL, CD300a, ITGAM, TLR2, CTSB and NOTCH2), with HSPC cell 
state (TGFBI, MYB), and with cell cycle control (CXCR4, KLF4 and E2F2), suggesting overall that 
the CEBPA N321D mutation promotes a transcriptional signature which favours HSPC cell state 
and acts in opposition to DC differentiation. In addition, C/EBPα N321D TF binds directly to 
genes such as SPI1, IRF8 and RUNX1 which show no dysregulated gene expression in our 
experiments but which are known to encode important partner TFs that interact with wildtype 
C/EBPα to direct DC differentiation. 
 
5.8.3 Intersection between C/EBPα-bound regions and H3K27Ac-bound regions identifies 
transcriptionally relevant genes 
It is well-established that the majority of TF binding events do not have functional relevance 
in every tissue-type or cell-type, and therefore we employed H3K27Ac coverage to identify 
those regions where C/EBPα-binding was associated with transcriptionally active chromatin. 





and regions enriched for H3K27Ac is that the regulatory regions selected for by H3 Lysine 27 
acetylation include enhancers which may be located many kilobases distant from the relevant 
transcribed gene. By contrast to enhancers, promoter regions are located around the 
transcriptional initiation site (Smale et al, 2003), bind RNA polymerase II, and can be selected 
by H3 Lysine 4 trimethylation (H3K4me3) (Sharifi-Zarchi et al, 2017). It would be interesting to 
conduct a future experiment with H3K4me3 ChIP antibody to compare promoter-driven 
binding profiles between EV and CEBPA N321D-transduced cells, particularly as these 
promoter regions would correlate more reliably with associated gene loci. Both H3K27Ac and 
H3K4me3 have been employed by others to analyse TF binding in dendritic cells (Wan et al, 
2015). Nevertheless, the Göttgens group has experience of using the H3K27Ac ChIP antibody 
to identify binding sites which are transcriptionally active and therefore likely to have 
functional relevance. 
 
When analysing regions in all cell lines which are bound by C/EBPα and which have increased 
coverage with H3K27Ac, we find these peaks to be enriched for intragenic and intergenic 
locations, suggesting that C/EBPα-binding regions with transcriptionally active chromatin are 
specific for enhancer rather than promoter regions. This corresponds with previous work by 
Heinz et al which showed that the majority of PU.1 and C/EBPα binding sites which localised 
to promoters demonstrated similar occupancy levels in B cell and macrophages, whereas 
differentially bound sites were located in distal enhancer sites (Heinz et al, 2010).  However, 
intersection of C/EBPα-binding and H3K27 acetylation data with gene expression data from 
single cell RNA-seq identifies very few genes which demonstrate differential expression 
associated with increased acetylation in regions identified by C/EBPα peaks. This can possibly 
be explained by the three dimensional folding configuration of DNA, which means that an 
acetylated region or a C/EBPα peak may not correspond to the closest gene which is called by 
that peak. In this case, it is hypothesised that acetylation is happening at enhancers which are 
intergenic and so distal that peak-calling does not correctly identify genes which have 
increased transcriptional activity. This could be tested by chromosome conformation capture-
on-chip methods such as 4C (Simonis et al, 2006) to identify the spatial distribution of 
chromatin in EV and CEBPA N321D-transduced cells. In addition, comparing acetylation 
profiles between the two conditions may not be informative where, for instance, H3K27 
acetylation profiles are similar at a particular gene locus in both conditions, but C/EBPα 





that C/EBPα is thought to be a pioneer factor which is capable of engaging nucleosomes and 
closed chromatin (Hasemann et al, 2014). Another challenge is that we cannot know whether 
C/EBPα-binding events in the CEBPA N321D-transduced cells are caused by wildtype or 
mutant C/EBPα. Lastly, it is reasonable to speculate that some of the transcriptional effects of 
the N321D mutation in the bZIP domain are associated not with DNA-binding profiles but 
rather with sequestering of cooperative transcription factors, and in this case transcriptional 
activity would not necessarily correlate with C/EBPα-binding events. It would certainly be 
interesting to employ co-crystallisation methods to study interactions at the LZ domain with 





6. Restructuring, curating and expanding ChIP-seq 
datasets in CODEX database: New insights into cell-





Following the success of the human genome project, the scientific community has engaged in 
large-scale consortium projects such as ENCODE (ENCyclopedia Of DNA Elements) and 
ImmGen (Immunological Genome Project) to computationally reconstruct gene regulatory 
networks in different cell types. However, an alternative methodology has developed which 
builds up large databases by collating data from multiple small-scale projects and even 
individual experiments. Examples of this approach include Heat*seq which displays interactive 
correlation heatmaps from thousands of experiments using different cell types in human, 
mouse and drosophila (Devailly et al, 2016) and BloodSpot which includes gene expression 
profiles of normal and malignant haematopoiesis in murine and human cells (Machado et al, 
2016). Similarly, SBR-Blood incorporates data from micro-array and NGS (RNA-seq, Methyl-
Seq and ChIP-seq) experiments to describe cell-type specific analysis of regulatory 
mechanisms in mouse haematopoiesis (Lichtenberg et al, 2016). Specific databases have been 
constructed to analyse gene expression in stem cells, such as StemMapper (Pinto et al, 2018) 
which includes 166 transcriptomes generated on Affymetrix microarray technology and 
manually curated from NCBI’s Gene Expression Omnibus (GEO). More recently, CancerSEA has 
collected RNA-seq data from 41,900 single cells for cancer-related scRNA-seq datasets on SRA, 
GEO and ArrayExpress (Yuan et al, 2019).  
 
CODEX (Sanchez-Castillo et al, 2015) is a database constructed by the Göttgens group which 
collects raw data on transcription factor (TF)-binding and histone modification from multiple 
NGS experiments, processes them with a uniform standardised bioinformatics pipeline, and 
permits manual curation to ensure accuracy. Important features of the CODEX database are 
that it is user-friendly, includes a web-crawler which facilitates automated reports of relevant 
new samples from the GEO database, allows individuals to freely interrogate CODEX and 
compare data from their own experiments, and allows visualisation of data on the UCSC 





seq samples (Hannah et al, 2011) and later more than 300 ChIP-seq studies from murine 
haematopoietic cells (Ruau et al, 2013). The latest iteration of CODEX includes data for mouse 
and human cells from over 1000 ChIP-seq, DNase-seq and RNA-seq samples, and is organized 
into two separate databases for blood cells (HAEMCODE) and embryonic stem cells (ESCODE) 
(Sanchez-Castillo et al, 2015). 
 
The integration of TF-binding and histone modification data has provided novel insights into 
cooperative networks of haematopoietic gene regulation, for instance the finding that FLI1 
and RUNX1 pair collaboratively in HSPCs (Beck et al, 2013) and that  GATA2, GFI1B and FOS 
cooperatively induce haemogenic reprogramming in fibroblasts (Gomes et al, 2018). Our 
hypothesis is that an enhanced understanding of transcriptional networks regulating human 
haematopoiesis in general, and haematological malignancy in particular, can be achieved by 
curating the HAEMCODE database and inputting experimental data from more blood cell 
types. 
 
6.2 Manual curation of human blood cells in HAEMCODE 
The first stage of this process was manual curation of the existing database to ensure that all 
included cell types in HAEMCODE were blood cells, and that experimental data was annotated 
correctly. 
 
Initial curation of 648 human datasets in the HAEMCODE database revealed a significant 
number (171) of non-haematopoietic datasets which were subsequently removed, including 
cervical and breast cancer as well as early embryonic tissues such as mesoderm and 
endoderm. The haematopoietic datasets included 18 RNAse and 13 DNAse experiments, 
which were excluded from further analysis. The remaining 446 experiments from HAEMCODE 
described TF-binding and histone modification.  Curation involved detailed study of each cell 
type, subtype, tissue ontology from BRENDA database (BTO), experimental conditions, and 
additional details. For instance, experiments employing the K562 cell line were classified as 
erythrocytic leukaemia cells, but following curation CODEX users can now see additional detail 
that this cell line was originally cultured from a patient with CML in blast crisis and cells are 
positive for BCR:ABL mutation.  In many instances, rigorous curation required literature 





U937 cell line which was originally derived from a patient with histiocytic lymphoma and has 
been described by some authors as a “leukaemic monocyte lymphoma” cell line (Ishikawa et 
al, 2012). However, literature review revealed that it is employed as an immortalised 
monocyte progenitor cell which can differentiate into functional macrophages (Sproston et al, 
2018), and therefore was recategorised as a monocyte in the HAEMCODE database. Literature 
review proved an effective method for curation, although it was difficult to categorise a ChIP-
seq experiment in one instance because it used the Ficoll-Paque method to isolate peripheral 
blood mononuclear cells and this method cannot distinguish between mononuclear cells 
which include T-cells, B-cells, NK cells and monocytes (Wang et al, 2013). 
  
By employing the CODEX web crawler and by manually searching GEO for new human 
haematopoietic cell lines, with a specific emphasis on haematological malignancy, we then 
identified additional 197 datasets. The previous published data (A) and the new collated data 
(B) is summarised below in Figure 6.1. 
 
Since less than 5% of the genome encodes proteins, and many mutations and single nucleotide 
polymorphisms (SNPs) map to the non-coding portion of the genome, there is an urgent need 
to annotate non-coding DNA. A key metric that can be employed to characterise the utility of 
a data resource of ChIP-Seq experiments is the fraction of the genome for which it provides 
annotation, calculated by identifying total bases with non-zero coverage for all TFs in all 
human samples in the database. In terms of TF binding data, annotation of the human genome 
has increased from 9.94% since CODEX was previously published (Sanchez-Castillo et al, 2015) 
to 14.42% after our curation and expansion of the human HAEMCODE database. Of note, this 
is 3-fold higher than the portion of the genome that is coding, and therefore of potentially 
broad interest to the wider haematology research community. The utility of identifying 
regions of TF binding is that it provides evidence of regulatory circuitry at the locus in question, 
and additionally this information can suggest transcriptional relevance if mutations or SNPs 









Figure 6.1 Summary of numbers of ChIP-seq experiments in (A) previous iteration of CODEX and 
(B) additional data incorporated during my review 
 
 
6.3 Constructing global heat maps for human blood cells reveals 
pairwise correlations between cell types in TF-binding data but not 
in histone modification data  
Heat maps were generated by R Hannah from the Göttgens lab. Briefly, she combined peaks 
from all TF samples and generated heat maps where hierarchical clustering was based on using 
a DICE coefficient matrix to establish pairwise correlation between binding patterns across 
regions. This was a binary process based on presence / absence of each peak, and linking these 
peaks to specific genomic loci using Model-based Analysis of ChIP-Seq (MACS) (Zhang et al, 
2008). 
 
The first heat map was generated using TF data from all cell types: 
 












































Figure 6.2 Heat map showing pairwise correlations between ChIP-seq profiles for 
transcription factors in all human blood cells on CODEX (A) is myeloma cells, (B) is T-cell 
lymphoma cell lines, (C) is AML and HPC cells, (D) includes macrophages and dendritic cells, 
(E) is diverse in cell type and TF identity, (F) is erythroblasts, (G) is diverse cell types with 
over-representation of CTCF 
 
 
This first heat map permitted several interesting observations. Firstly, CODEX creates distinct 
TF clusters on heat maps, for instance clusters A, C and F in Figure 6.2 denote myeloma cells, 
AML and haematopoietic precursors cells, and erythroblasts respectively. Secondly, the 
unified standardised CODEX pipeline is capable of clustering TF binding data for similar cell 
types from distinct experimental sources, for instance Figure 6.2B clusters together Jurkat 
cells and CUTLL1 cells which are both distinct T-cell lymphoma cell lines. Thirdly, there are 
clusters where diverse cell lines cluster together with a shared TF, for instance cluster G is a 
cluster of myeloma, erythroid progenitor, Burkitt lymphoma, haematopoietic precursor cell, 
and K562 cell lines based on binding patterns from the shared transcription factor CTCF. CTCF 
is a highly conserved 11 zinc finger TF which binds to about 60,000 sites in the human genome 
(Chen et al, 2012) and there is evidence that it plays important roles in HSCs (Kim et al, 2017), 





that the global binding profile of this TF is able to create pairwise correlations across various 
cell lines. This suggests that CTCF binding, at least in part, is similar across different 
haematopoietic lineages, perhaps in agreement with its role in establishing/maintaining 
coarse-grained chromatin domains.  
 
By contrast, cluster E in Figure 6.2 denotes pairwise correlations between diverse cell lines 
with different TFs that nonetheless show pairwise correlation in their chromatin binding 
profiles. Lastly, cluster D shows a pairwise correlation between the TF binding patterns of 
macrophages, plasmacytoid dendritic (pDC) and conventional dendritic (cDC) cells, with the 
pDC ChIP-seq profile having a closer pairwise correlation with lymphoid experiments and the 
cDC profile being more closely correlated with myeloid experiments. Overall, these results 
show that CODEX’s standardised bioinformatics pipeline is capable of bringing together raw 
data from multiple ChIP-seq experiments carried out under different conditions by different 
centres, and that pairwise correlations can be found based both on cell type and TF. 
 
The Hardison group’s S3norm method (Xiang et al, 2018) was then employed to infer a heat 
map of pairwise correlations between histone modification profiles in HAEMCODE (Figure 
6.3). By contrast with TF binding profiles, which are commonly characterised in binary terms 
as peak present or peak absent, enrichment for a given histone modification is generally 
thought of as a more quantitative process, and therefore it is more challenging to deal with 
sequencing depth (SD) and signal-to-noise ratio (SNR) when modelling chromatin accessibility 
landscapes. S3norm employs nonlinear transformation to simultaneously normalise both SDs 
and SNRs between data sets (Xiang et al, 2018), and therefore provides superior performance 
for H3K4me3 ChIP-seq profiles in comparative studies of normalisation, particularly with 







Figure 6.3 Heat map showing pairwise correlations between ChIP-seq profiles for 
histone modifications in all human blood cells on CODEX (A) is Burkitt Lymphoma 




Initial correlation analysis of histone modification experiments from HAEMCODE is shown in 
Figure 6.3, and gave a very distinct cluster of Burkitt Lymphoma cells bound by H3K4me3. For 
this reason, it was decided to remove the Burkitt cell line experiment from the histone heat 
map and rerun pairwise correlations using the S3norm method to uncover any masked 







Figure 6.4 Heat map showing pairwise correlations between ChIP-seq profiles for histone 
modifications in all human blood cells on CODEX after excluding experiments from cluster 
A in Figure 6.3 (A) is erythroblasts, (B) is NK, T-cell, B-cell and monocyte cell lines 
 
 
By contrast with TF-binding experiments, histone modification experiments do not cluster 
sharply by pairwise correlations. Of note, the Burkitt Lymphoma cluster A in Figure 6.3 is 
derived from one experimental protocol and employs only one histone marker, whereas other 
experiments with Burkitt Lymphoma cells do not correlate on the heat map. This may be 








6.4 Constructing heat maps for normal and malignant human blood 
cells reveals distinct clusters in normal human blood cells but loss of 
pairwise correlation in malignant cells 
We then employed the DICE coefficient matrix to look at subsets of the TF data, initially by 
























Figure 6.5 Heat map showing pairwise correlations between ChIP-seq profiles for 
transcription factors in non-malignant human blood cells on CODEX (A) and (B) are mostly 
HPCs and HSPCs with some megakaryocyte cells, (C) is macrophages, (D) is erythroblasts, (E) is 
macrophages, monocytes, and dendritic cells with PU.1, (F) is HPCs and erythroid progenitors 


































Figure 6.6 Heat map showing pairwise correlations between ChIP-seq profiles for 
transcription factors in malignant human blood cells on CODEX (A) is MM.1S multiple 
myeloma cell line, (B) is mostly AML but a few T-ALL and Jurkat cells, (C) includes 
Burkitt Lymphoma, myeloma and K561 cell lines with over-representation by CTCF 
 
 
Non-malignant cells in Figure 6.5 pair into discrete clusters which are functionally and 
biologically distinct, ranging from HPCs to erythroid cells. For instance, in cluster E several cells 
with immune function cluster together. These pairwise correlations are much more difficult 
to elucidate on TF peak profiles in malignant cells (Figure 6.6), and we can hypothesise that 
this may be because the normal function and transcriptional wiring of these cells is disrupted. 
The only cells which form a distinct and unique cluster are myeloma cells, which despite 
somatic hypermutation and phenotypic diversity are positioned in a very distinct plasma cell 
compartment (Hansmann et al, 2017) within the haematopoietic tree. Intriguingly, some AML 






with aggressive proliferation. In both normal and malignant cells, CTCF seems to exert a 
particularly powerful effect on TF binding profiles across cell lines. 
 
6.5 Constructing heat maps for progenitor, myeloid and lymphoid 
compartments suggests altered TF binding profiles for different cell 
compartments, and an association between AML and pDCs 
Given their phenotypic similarity and early developmental stage, progenitor cells 
demonstrated no obvious clusters based on HSPC, HPC or CD133+ umbilical cord blood cell 
types, although increased pairwise correlation can be seen in cells where DNA is bound by 
ERG, LYL1, and LMO2 (cluster A) or PU.1 (cluster B). One can speculate that TF effects are more 
prominent than cell-intrinsic effects at an early stage of differentiation before lineage 


















Figure 6.7 Heat map showing pairwise correlations between ChIP-seq profiles for transcription 
factors in human haematopoietic progenitor cells on CODEX (A) is HPC cells where DNA is bound 






By contrast, ChIP-seq TF binding profiles for myeloid (Figure 6.8) and lymphoid (Figure 6.9) 
cells demonstrate pairwise correlation based on cell lines, with particularly prominent clusters 
for AML, Burkitt Lymphoma, T-cell lymphoma and myeloma, although a region within cluster 
B in Figure 6.9 shows intense pairwise correlation for cells where DNA is bound by MYB, and 
cluster C shows that CTCF continues to exert a powerful effect on overall binding profile across 




















← C/EBPα, TCF4 
Figure 6.8 Heat map showing pairwise correlations between ChIP-seq profiles for transcription 
factors in human myeloid cells on CODEX (A) is AML cells, (B) is pro-erythroblasts, erythroblasts, 
erythroid progenitors and K562 cells, (C) is diverse cells including AML cells with C/EBPα and 
dendritic cells with TCF4, (D) is erythroid cells and megakaryocytes, (E) is mostly AML and K562 cells 
but also includes two erythroblast cells 
 
 
Intriguingly, cluster C in Figure 6.8 shows pairwise correlation between AML cells where DNA 
is bound by C/EBPα and plasmacytoid dendritic cells where DNA is bound by TCF4. 





sensitive marker for blastic plasmacytoid dendritic cell neoplasm (BPDCN) (Khoury, 2018). 
Unfortunately, my own ChIP-seq data from the CEBPA N321D murine cell line cannot directly 



























Figure 6.9 Heat map showing pairwise correlations between ChIP-seq profiles for transcription 
factors in human lymphoid cells on CODEX (A) is MM.1S cells, (B) T-cell lymphoma, T-ALL and Jurkat 







6.6 Constructing heat maps for myeloid and lymphoid subsets within 
normal and malignant compartments 
These subsets offer more granular data on the interaction between cell-intrinsic effects and 
TF-specific effects in ChIP-seq binding profiles on CODEX. For instance, in normal myeloid cells 
(Figure 6.10), we can observe cell-intrinsic effects for macrophages in cluster B, but we can 
also see TF-specific effects across cell lines with STAT5 and PU.1 in clusters A and C 
respectively. Clusters D and E exemplify this interaction, with cluster E forming a GATA1-
specific subset within the erythroid progenitor cells in cluster D. The PU.1:GATA1 paradigm 
has been well-described (Graf et al, 2009), this paradigm has been recently challenged by 
employing novel reporter mouse lines and live imaging for continuous single cell long-term 
quantification of PU.1 and GATA1 transcription (Hoppe et al, 2016), but GATA1 remains an 

























Figure 6.10 Heat map showing pairwise correlations between ChIP-seq profiles for transcription 
factors in normal myeloid cells on CODEX (A) is erythroblasts and megakaryocytes with STAT5 or 
STAT3, (B) is macrophages, (C) is macrophages and cDCs with PU.1, (D) is pro-erythroblast, 







Figure 6.11 describes pairwise correlations between ChIP-seq binding profiles for normal 
lymphoid cells. The distinct clusters A and C suggest that B lymphocytes and plasmacytoid 
dendritic cells have distinct binding profiles, however it is important to state that the small 
number of samples preclude any definitive conclusions. 
 
It is worth stating here that the developmental biology of cDCs and pDCs remains a 
controversial question, with evidence that these cells can develop through both myeloid and 
lymphoid differentiation pathways. Our decision to place our cDC ChIP-seq profile in the 
normal myeloid compartment (Figure 6.10) and our pDC ChIP-seq profile in the normal 
lymphoid compartment (Figure 6.11) was based on our previous observations under the heat 
map in Figure 6.2 which examined TF binding profiles for all cells together. This is an example 
of how CODEX can be employed to define cryptic cell lines by pairwise correlation. 
 
 
Figure 6.11 Heat map showing pairwise correlations between ChIP-seq profiles 
for transcription factors in normal lymphoid cells on CODEX (A) is B lymphocytes, 






Figure 6.12 shows pairwise correlations between malignant myeloid cells. It is difficult to draw 
conclusions because this subset includes only AML and K562 cell lines, however we can 
observe that the most distinct clusters A and C are formed by AML cells, and that cluster B is 



















← GATA1, RUNX1, FOSB 
Figure 6.12 Heat map showing pairwise correlations between ChIP-seq profiles for transcription 
factors in malignant myeloid cells on CODEX (A) is AML, (B) is K562 cells, (C) is mostly AML cells with 
some K562 cells 
 
Figure 6.13 confirms previous observations that distinct clusters are formed by binding 
profiles for myeloma cells (cluster A), and T-ALL and Jurkat cells (clusters B and C), and that 
CTCF-binding characterises pairwise correlation across Burkitt Lymphoma and myeloma cell 





































Figure 6.13 Heat map showing pairwise correlations between ChIP-seq profiles for transcription 
factors in malignant lymphoid cells on CODEX (A) is MM.1S cell line, (B) is T-ALL and Jurkat cells, (C) 




Several observations can be made through the HAEMCODE database of human blood cells. 
Firstly, TF DNA binding profiles form more distinct clusters on pairwise correlation of peaks 
than are formed by histone binding profiles, even when the S3norm protocol is employed to 
normalise data and account for SNR. Secondly, TF identity seems to exert more influence on 
pairwise correlations for TF binding profiles in progenitors, but cell-intrinsic correlations are 
more evident in lineage committed cells. Thirdly, TFs do nonetheless continue to influence 
binding profiles within clusters of similar cells, for instance we observe that GATA1 forms a 





TF DNA-binding profiles can reveal surprising correlations which merit further exploration, 
such as the correlation between AML cell lines and T-ALL cell lines. Fifthly, clusters are more 
difficult to establish in malignant cells than in normal cells, and this may be related to 
disruption of defined biological processes in normal cells. Lastly, CTCF has a singular capacity 
to maintain a consistent binding profile between different cell types in both normal and 
malignant cells, which may be related to its effects on chromatin looping and architecture 
(Hanssen et al, 2017). 
 
CODEX is a powerful tool to probe DNA-binding profile data. For instance, pairwise 
correlations of human blood cells suggests that our pDC binding profile is closely related to 
lymphoid cell lines and our cDC binding profile is related to myeloid cell lines. 
 
In addition, CODEX is able to harness experimental data from multiple sources and infer novel 
biological relationships. For instance, one of our findings is that CTCF has a very similar DNA 
binding profile in cell types as diverse as myeloma and Burkitt Lymphoma. It is known that 
CTCF has several binding sites within the NANOG locus, and therefore UCSC genome browser 
can be employed to visualise CODEX data for CTCF binding at this locus for myeloma and 
Burkitt Lymphoma cells: 
 
 
Figure 6.14 UCSC genome browser confirms similar binding profiles for CTCF at the NANOG locus 







One of the most useful features of CODEX is that it allows users to freely upload their own 
ChIP-seq data and compare it to existing CODEX profiles. For instance, Jiapaer et al used 
CODEX to identify that the promoter for long non-coding RNA LincU, which maintains 
embryonic stem cells in a naïve state, was bound by KLF4 and SMAD1 as well as NANOG, and 
then tested this transcriptional mechanism with a LincU-promoter luciferase reporter (Jiapaer 
et al, 2018). 
 
In addition, CODEX can be employed to probe results from GWAS. For instance, if a SNP is 
identified which correlates with a clinical condition, then CODEX can inform users if that SNP 
is located at a locus with a particular TF or histone modification profile in a cell type of interest 
or across all cell types. Hodonsky et al performed a GWAS of 12,502 Hispanic people to 
characterise novel SNPs and genomic loci associated with red blood cell traits. They then 
probed this data for loci which were likely to be of functional significance, by cross-referencing 
with CODEX histone modification and ChIP-seq signals for key erythroid TFs (Hodonsky et al, 
2017). Similarly, it can be informative to examine TF or histone binding profiles for mutations 
in non-coding regions of DNA. Another potential use of CODEX is to visualise whether altered 
gene expression in a specific human haematological malignancy correlates with TF binding to 
a particular locus. 
 
In summary, our work has significantly expanded previous iterations of CODEX and we now 
have 459028795 bases with non-zero coverage, resulting in 14.8% of the genome covered 
with histone modification data. This latest iteration has significant potential for improving the 
applicability of CODEX to human disease states, as our focus has been to input data from 
human malignant blood cells. One of the strengths of CODEX is that its standardised pipeline 
permits continued expansion of data sets which will increase the power of pairwise 
correlations. In this regard, future work will include the incorporation of important cell types 
such as normal neutrophils and common malignant blood cells such as chronic lymphocytic 
leukaemia and follicular lymphoma. It will also be important to explore methods other than 
standard hierarchical clustering to identify putative groupings of experiments. Given the high-
dimensional nature of the data contained in CODEX once several hundred experiments are 
considered, techniques now popular with single cell RNA-Seq analysis may be worth exploring, 
such as t-SNE and UMAP. It is also worth noting that CODEX appears to cope well with batch 





demonstrate pairwise correlation. However, this is not always the case, suggesting that 








CEBPA double mutations confer favourable prognosis in patients with cytogenetically normal 
AML in the absence of FLT3 ITD mutations, but it is important to remember that CEBPA-
mutated AML nonetheless carries a significant mortality and morbidity burden, with a five-
year overall survival of only 53% to 60% (Preudhomme et al, 2002, Renneville et al, 2009). 
Bearing in mind that CEBPA is one of the most common mutations implicated in human AML, 
the significant healthcare burden associated with treatment of this aggressive disease 
(Bewersdorf et al, 2019), and the fact that the mainstay of current chemotherapy regimens 
date from the 1970s (Evans et al, 1961), it can be persuasively argued that a better 
understanding of the biology of CEBPA-mutated AML is urgently required. 
 
The cellular model for testing a specific mutational perturbation is particularly important 
when interpreting results of interventions. The impact of distinct models can be appreciated 
by the discordant results of CEBPA deletion on HSC function identified by Porse and colleagues 
who found that C/EBPa promotes HSC maintenance (Hasemann et al, 2014), as compared 
with Tenen and colleagues who employed a different model and concluded that C/EBPa 
inhibits HSC proliferation (Ye et al, 2013).  Investigations of CEBPA-mutated AML have typically 
transduced myeloid-committed cells such as the 32Dcl3 cell line (Guchhait et al, 2003) for in 
vitro studies, and harvested cells from highly heterogeneous haematopoietic compartments 
such as bone marrow mononuclear cells (Togami et al, 2015) or foetal hepatocytes 
(Bereshchenko et al, 2009) for in vivo investigations. We have successfully created a novel 
CEBPA-mutated cell line which has several advantages over previous in vitro models. Firstly, 
our conditional model is based on a  LMPP-like cell line which replicates a relatively early stage 
of haematopoiesis and is capable of reconstituting myeloid, lymphoid, and dendritic cell (DC) 
lineages. This is relevant because CEBPA is implicated as an early driver mutation in de novo 
AML, as evidenced by CEBPA-mutated clones being present in relapse, and we are more likely 
to recapitulate pre-leukaemic changes at the LMPP stage than in committed myeloid 
progenitors. Furthermore, several lines of investigation suggest that C/EBPa-mediated 
lineage specification is a relatively early event, for instance Welner et al found that C/EBPa 
was required for differentiation from HSPCs to common dendritic progenitors, but C/EBPa 





Secondly, the clonal murine Hoxb8-FL model provides a reproducible and homogenous 
cellular model which avoids the uncertainty associated with employing a highly 
heterogeneous cell compartment. Thirdly, we have employed the same model to generate 
Empty Vector and CEBPA WT-transduced cell lines to act as comparators. 
 
The advantages of the precise control offered by this cellular model were initially evidenced 
by comparison of the behaviour of CEBPA WT-transduced cells in Hoxb8-FL conditions, which 
showed a cell marker profile consistent with differentiation. By contrast, CEBPA N321D-
transduced cells failed to differentiate in Hoxb8-FL conditions, suggesting that the mutation 
has a dominant negative effect.  
 
Our cellular model then allowed us to reproducibly test the effect of mutant C/EBPa on early 
differentiation in myeloid, lymphoid and DC lineages. We found that the N321D mutation had 
no appreciable effect on the cell marker profile of transduced cells in cytokine conditions 
which favoured granulocyte or lymphocyte specification, but showed a distinct phenotype in 
Flt3L, strongly suggesting an early DC effect in mutant C/EBPa. Furthermore, on prolonged 
cell culture, it was found that the C/EBPa N321D cell line was immortalised in Flt3L conditions. 
 
Subsequent analysis by single cell RNA-seq (scRNA-seq) confirmed the C/EBPa WT and C/EBPa 
N321D phenotypes suggested by flow cytometry, and captured precisely the gene expression 
profile associated with the N321D mutation during early differentiation in Flt3L conditions. In 
addition, transcriptome analysis at the level of the single cell revealed a small sub-population 
of CEBPA N321D-transduced cells with a distinct gene expression profile, which would not 
have been captured by bulk RNA-seq and which can be hypothesised to represent the 
immortalised fraction of cells transduced with mutant CEBPA. This result underlined the 
importance of single cell analysis to appreciate the rare events implicated in heterogeneous 
pre-leukaemic alterations. ChIP-seq was then performed to identify putative direct binding 
events implicated in those alterations, and identified direct targets of C/EBPa N321D with 
altered gene expression, including NOTCH2, JAK2, SIRPA and FOS which perform significant 
roles in DC lineage specification and differentiation, as well as genes such as MYB and E2F2 
implicated in HSPC cell state and cell cycle control respectively. Interestingly, it was more 
difficult to identify a significant subset of these genes which had two-fold enrichment for 





acetylation profile. This is a surprising result, given that biologically meaningful genes are 
bound by C/EBPa N321D and have altered gene expression in our experiments, and given that 
Pundhir et al have found that chromatin accessibility and activity correlate with C/EBPa’s 
function as a pioneer factor in the context of early GM lineage differentiation (Pundhir et al, 
2018). In this regard, it is important to remember that key genes such as IRF8, RUNX1 and SPI1 
were bound by C/EBPa N321D but did not show altered gene expression, and it is tempting 
to speculate that the phenotypic effects of the N321D mutation may be mediated in part by 
conformational changes and altered dimerisation profiles rather than a direct binding event 
between C/EBPa N321D and cis-regulatory elements, explaining the disconnect between DNA 
binding patterns, acetylation profiles and gene expression. In this regard, Thomas Graf and 
colleagues have found that topological reorganisation often precedes gene expression 
changes during cell reprogramming by transient expression of CEBPA followed by induction of 
the Yamanaka TFs OCT4, SOX2, KLF4 and MYC (Stadhouders et al, 2018).  
 
In mice transplanted with the C/EBPa N321D cell line, we found that mutant cells were 
capable of long-term engraftment in vivo but did not reliably reproduce leukaemia, suggesting 
that co-operating mutations are required for a leukaemic phenotype. This did not correlate 
with results reported by Togami et al when C57BL/6J mice received transplants of BM-derived 
cells tranduced with the N321D mutation (Togami et al, 2015). However, it does agree with 
reports by other groups including Nerlov and colleagues that C-terminal mutations result in 
expansion of multipotent progenitors with no progression to leukaemia (Bereshchenko et al, 
2009). In this regard, the Bonnet group found long-term repopulating activity in human cord 
blood-derived Lin- cells transduced with NC-terminal but not C-terminal mutated CEBPA 
(Quintana-Bustamente et al, 2012). Our results also correspond with several lines of clinical 
data from human patients with CEBPA-mutated AML:  
 
(i) these patients are typically characterised by a bi-allelic mutational profile (Wouters et 
al, 2009);  
(ii) hereditary germline mutations in CEBPA usually affect the N-terminus but do not result 
in a familial AML phenotype until patients acquire a somatic C-terminal mutation 
(Tawana et al, 2015);  
(iii) CEBPA can cooperate with mutations in ASXL1, CSF3R, FLT3, GATA2, RUNX1, TET2 and 





(iv) AML patients with single-allele CEBPA mutations typically carry such a cooperating 
mutation (Wouters et al, 2009). 
 
Recent work by van Galen et al has characterised heterogeneity in AML by performing scRNA-
seq on 38,410 cells from sixteen AML patients and five healthy donors, and identified a 
spectrum of malignant cell types including cells with a DC transcriptional profile, as well as 
demonstrating that leukaemic cells have immunomodulatory properties such as T cell 
inhibition (van Galen et al, 2019). Our own experiments suggested that expression of CEBPA 
N321D at an early LMPP-like stage of haematopoiesis deregulates dendritic cell 
differentiation, specifically that it causes an immortalised CD11c+ B220+ BST2- pDC-like 
progenitor phenotype, correlating with gene set enrichment of differentially expressed genes 
identified by scRNA-seq. In addition, exogenous mutant C/EBPa binding events were 
increased in our cell line after differentiation, suggesting that the pre-leukaemic events occur 
in the HSPC compartment.  
 
The role of C/EBPa in myeloid differentiation has been intensively studied, but relatively little 
is known regarding its function specifically in DC biology. Early work by Thomas Graf and 
colleagues suggested that expression of PU.1 in fully committed pre-T cells induces formation 
of dendritic cells, whereas expression of C/EBPa reprograms T cell progenitors to 
macrophages, and furthermore that NOTCH signalling is able to inhibit these processes (Laiosa 
et al, 2006). Interestingly, our experiments demonstrated that C/EBPa N321D binds directly 
with NOTCH2 and that expression of NOTCH2 is downregulated in CEBPA N321D-tranduced 
cells on differential expression with EV-transduced cells, and it is possible that NOTCH 
deregulation may influence DC lineage specification by the PU.1: C/EBPa axis. Later work by 
the Tenen group showed that there is an early requirement for C/EBPa in DC differentiation 
and that formation of mature DCs through myeloid progenitors is C/EBPa-dependent, 
whereas lymphoid progenitors are able to generate DCs in the absence of C/EBPa (Welner et 
al, 2013). Given that recent work by Rodrigues et al has shown that pDCs develop mostly from 
lymphoid progenitor cells (Rodrigues et al, 2018), it seems reasonable to hypothesise that the 
N321D mutation disrupts the C/EBPa-dependent myeloid pathway and favours the 
generation of pDCs rather than cDCs. This correlates with our experimental results that CEBPA 





progressing to an immortalised pDC-like immunophenotype. It is important to recognise that 
the phenotypic effects of C/EBPa N321D may also be mediated by interactions with other 
transcription factors implicated in lineage specification. For instance, our experiments have 
shown that mutant C/EBPa  binds to IRF8 and SPI1, though gene expression of these two 
genes was not directly altered.  
 
Given that our work suggests for the first time that a pDC phenotype may characterise pre-
leukaemic changes in mutant C/EBPa, it is therefore useful to consider our results within the 
broader context of DC biology. It is well-established that DC subsets include professional 
antigen presenting cells and immunomodulatory cells which secrete IFN-a. More recently, 
evidence suggests that pDCs have a unique TLR7-dependent capability to recognise virus-
infected cells throughout their intracellular replication rather than only during their rare 
extracellular transit events (Takahashi et al, 2010), and this means that pDCs can counter 
effectively the multiple mechanisms of immune evasion deployed by viruses. Marlène Dreux 
and others have shown that sensing of infected cells by pDCs involves viral envelope protein-
dependent secretion and transmission of viral RNA in cell-to-cell interactions (Decembre et al, 
2014), and it is tempting to speculate that pDCs may employ a similar mechanism to play a 
unique role in cancer surveillance.  
 
Regarding pDC function, Rodrigues et al have shown that lymphoid-pathway pDCs produce 
interferon but do not participate in antigen presentation (Rodrigues et al, 2018). It would 
certainly be interesting to perform functional evaluation of the CEBPA N321D immortalised 
pDC-like progenitor cell line, for instance by measuring IFN-a production upon TLR9 
stimulation and T cell proliferation in response to LPS stimulation. Interestingly, T cell anergy 
has also been noted in AML-derived dendritic cells (Narita et al, 2001), and in a broader 
malignant context intratumoral pDCs have been functionally characterised in a murine 
mammary tumour model, favouring tumour progression by secreting IFN-a poorly and by 
inducing differentiation of regulatory T cells (Le Mercier et al, 2013). Besides the direct effects 
of the immortalised pDC progenitor, it is also important to bear in mind that one of our earliest 
experimental findings during culture in Flt3L differentiation media was that CEBPA N321D-
transduced cells reduced expression of cDC type 2 markers CD11b and SIRPα. Conventional 





antigen (Bottcher et al, 2018a, Bottcher et al, 2018b), and therefore N321D-mediated 
leukaemia may be favoured by dysregulation of the cDC compartment. 
 
Further work is required to elucidate the effects of the N321D mutation in a complex biological 
system where cross-talk between IRF8, PU.1, C/EBPa and other TFs informs cell fate decisions 
between neutrophils, lymphocytes and mono-phagocytic cells. Regarding in vitro work, it 
would be important in future experiments to perform functional studies to confirm the 
immortalised pDC progenitor phenotype suggested by cell marker and gene expression 
profiles of CEBPA N321D-transduced cells. It would also be interesting to construct a more 
complex retroviral expression system where Hoxb8-FL cells are transduced with N and C-
terminal mutations, to see if this recapitulates a more aggressive leukaemic phenotype. The 
intersection of scRNA-seq and ChIP-seq data has identified important putative genes 
implicated in pre-leukaemic changes, and ChIP-seq is particularly apt because of C/EBPa’s role 
as a TF, but definitive therapeutic targets may be more clearly identified by CRISPR dropout 
screens (Tzelepis et al, 2016). In addition, scRNA-seq identified a very small subpopulation of 
five Hoxb8-FL cells transduced with mutant CEBPA which had a distinct “non-differentiated” 
transcriptional profile on t-SNE dimensionality reduction after five days of culture in Flt3L 
differentiation media. This subpopulation may represent leukaemia-initiating cells, and it 
would be interesting to employ 10x Chromium or DropSeq technology to process a larger 
number of single CEBPA-mutated Hoxb8-FL cells to capture more of these rare events. For in 
vivo studies, important future work includes (i) next generation sequencing of DNA from BM 
and splenic cells to characterise the full mutational profile of mice which developed latent 
leukaemia after transplantation of mutant cells, (ii) secondary and serial transplantation of 
CEBPA N321D-transduced cells to confirm their self-renewal capacity, and (iii) CRISPR-Cas9 
genome editing to engineer in vivo models of cooperating mutations including CEBPA N321D 
(Heckl et al, 2014). 
 
Lastly, this study opens up potential novel therapeutic options for the significant percentage 
of AML patients who carry CEBPA mutations. Previous targeted therapies for AML, and in 
particular APML, have focused on using CCAAT/Enhancer binding proteins to drive 
differentiation by inserting tamoxifen-responsive C/EBPε into a retroviral vector (Truong et al, 
2003) or using 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid to induce de novo synthesis of 





targets for CEBPA-mutated AML, which include SOX4 and JAK (Zhang et al, 2013, Lavallee et 
al, 2016). Our own experiments have combined an in vitro cellular model with genome-wide 
characterisation of DNA binding events, histone modification and gene expression at the level 
of the single cell to identify NOTCH2, MYB and other genes as putative targets for 
pharmacological intervention by small molecule activators (Ye et al, 2016) or inhibitors 
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Figure 1: Vector map for MSCV-CEBPA-IRES-eGFP. Sal I (1417), FLAG (1429), CEBPA (1456), Bgl II 
(2533), IRES (2562), eGFP (3137). 
 
 
Table 1: 636 differentially upregulated genes on Day 2 CEBPA WT vs Day 2 EV-transduced cells 
comparison 
Chit1 Naip5 Acadsb Stim1 
1700047M11Rik Far2 5730508B09Rik Gns 
Ly6c2 Ccdc125 Fam126b Tmx3 
I830127L07Rik Zscan29 Afap1 Itm2b 
Sgms2 Smurf1 Dhrs7 Cdkn2c 
Tnfsf13b Gda Trim12a Dynlt3 
Slc40a1 Tmem216 Sun2 Ipo5 
CD177 Gstm2-ps1 Dgat1 Arhgdib 
4930438A08Rik Kyat1 Gbe1 Tmem131 
Abca9 Arhgef12 Trappc10 Tank 
Mogat2 Flot2 Dmxl1 Hist1h1c 
Tnfaip6 Nrg1 Gm5251 Cyb5r1 
Tlr7 Gstm1 Arsb Atp2b1 
Cd36 S100a11 Wipi1 Gpd2 
Cybb Per2 Pmm1 Man2b2 
Hsd11b1 Ugp2 Rpia Arhgef3 
Mgst1 Phlda1 Cnn2 Cspp1 
Mgam Wwp1 Bnip3l Gng5 
Chil1 Trem3 Neu1 D930015E06Rik 
Fcnb Gm13416 Pglyrp1 Map2k1 
Aff2 Klf7 Chst12 Myl12b 
Ngp Prkcb Pag1 Gm21738 
Acpp Slc38a5 Ralgapa1 Ebpl 





Lcn2 AA474408 Pcyox1 Snx18 
Abca13 Plpp6 Rsbn1 Ndufaf7 
Xdh Itgb2 Mocs1 Gpsm3 
Slfn4 Lgr4 Plpp5 Med10 
Fmo5 Acsl1 Fcgr2b Ftsj1 
Clec4a2 Gadd45a Gsr Rnf14 
Ffar2 Dock7 Mpp1 Mlx 
Dram1 Nhsl2 Tmx4 Grn 
Gm9733 Nrp2 Arhgap31 Snx20 
C3 Gm12854 Stom Chd7 
Mtus1 Tmem62 Ctsb Flot1 
B4galt6 Sp140 Atrn Prtn3 
Ccno Ago3 Vps13d Ak3 
S100a8 Gm7665 Mbd5 G6pd2 
Gpr84 Entpd1 Sri Adipor1 
Rhou Hlx Csf3r Rock2 
Gm29064 Syne2 Zfp622 Gm10800 
Tmem45a2 Usp2 Bnip3l-ps Gm26809 
Lyz2 Mrgpra2b Tbc1d20 Tmbim6 
AI839979 Auts2 Mgat4a Fuca1 
Klra2 Pygl Kif13b Gtpbp1 
Elane Fosl2 Stx6 Stat3 
Draxin Sort1 Pnpla7 Fam46a 
Mgst2 Gm37354 Cnbd2 Serpinb1b 
Hcar2 Trp53inp2 4930523C07Rik Gm5590 
Olfml2b Naip2 Ppp1cb Klf13 
Itgam Ascl2 Dnajc13 Rpe 
Fcor Dclre1c Sgpp1 Map1lc3b 
Peli2 Mfge8 Irak3 Smim10l1 
Ltb4r1 A530040E14Rik PdCD4 Abtb1 
Grb14 Sorl1 Rab32 Rassf5 
Ctsh Hpse Gm38236 Gm15776 
Alcam Slc31a2 Irf2bp2 Ppp1r12a 
Casp4 Rogdi Osgin2 Tmsb4x 
Mansc1 Tnfaip2 Osbp Sh2b1 
Slc44a4 Gm14699 Lrrfip2 Cyba 
Mgll Miga1 CD1d2 Rnaset2a 
Hp Fcgr3 Degs1 Ankle2 
Lyz1 Mctp1 Mir6236 Apmap 
Igsf6 Prdx5 Crat Gca 
Olr1 Tfec CD1d1 Fli1 
Ncam1 Megf9 Samd8 Kmt5a 
Slc7a11 Cyth3 Pld3 Hcst 
Ccdc109b Mtm1 Plaur Rcsd1 
Wfdc21 Arl15 Plgrkt Tbrg1 
Ptges Gm21975 Papss2 Zfand5 
Gm5960 Hexb Mcee D16Ertd472e 
Serpinb Trib1 Dgkg Ankrd11 
Napepld Rap2a Tst Baz2b 
Vcan Gm37472 Insr Ethe1 
serpinb10 Cep162 Cep85l Gm33707 
Rpgr Ypel5 Sptlc2 Arl11 
Fcgr4 Plekha1 Tmem156 Plin3 
Csf1 Amn1 Tmed3 Ero1l 
Tenm4 Fam134b Vps50 Golim4 
Gng7 Glrx Lamp2 Rgs2 
Ifi206 Scp2-ps2 Gm5914 Faap20 
Crisp3 Tcn2 Zfp36l1 Bhlhe41 
Irak2 Soat1 Gm14032 Arhgap26 
Ccl6 Ikbke Ncf2 Gm14857 
Csf1r Slco4a1 Tom1 Atp8b4 
Fyb Msrb1 AC149090.1 Chmp5 
Gm43858 Gm15466 Cast Plac8 
Plekhg1 Inpp4a Stat4 Tnrc6b 
Aldh3b1 Hdac4 Atp6v1e1 Flna 
Ifi211 Cpq Gpcpd1 Micu1 
Tgm3 Svip Nucb2 Dusp6 
1700020L24Rik Ero1lb Cklf Mbnl1 
Lrrk2 Map1lc3a Gm9025 Tet2 
Scnn1a Acta2 Nfe2l2 Snapin 
Cd300lf Atxn1 Atp2c1 Rbms1 
Arhgef11 B230208H11Rik Ints12 Ccl3 





Slpi Mospd1 Cd24a Bin3 
Smkr-ps Pnkp Micu3 Nars 
Map4k3 Per3 Bend4 Sla 
Dstn Bmx Lpgat1 Vim 
Tbc1d8 Gm4854 Cbr4 Atp6v0c 
Rdh12 Scp2 Plin2 Hdac5 
Syne1 Ppm1h Cyb5r4 Shfm1 
Cd274 Prkd3 Tcp11l2 Plod3 
Lbp Slc22a4 Slc25a37 Pde6d 
Pabpc1l Gm8770 Csgalnact2 Rapgef6 
Homer1 Gm2147 Ankrd28 Zyx 
Atp8a1 Fnip1 Rnase4 Zmpste24 
Mmp8 Anxa3 Gm5884 Smim4 
F630028O10Rik Ptgr1 Spi1 Adssl1 
Lmbr1 Lmtk2 Agtrap Srgn 
Abcc5 1110008P14Rik Elmsan1 Gm13082 
Pld1 Dubr Usp33 Luc7l2 
A430072P03Rik Btg1 Ric1 Cpne3 
Mir7678 Lta4h Rin3 Ptprc 
Pirb Gm5552 Cdadc1 Selenos 
Anxa1 Fgd4 Dram2 Slc50a1 
Fam160a2 Aplp2 Atp6v1a Ctsd 
Zbtb11os1 Gyg Rnaset2b Snhg5 
Abcd2 Agps Npepps Epb41l4aos 
Ifitm6 Ap1s2 Smim12 Tmem165 
Fgl2 Rgcc Gm11868 Wls 
Zdhhc2 Tmem63a 9130401M01Rik Tor1a 
Hsd17b1 Lcmt1 Cd53 Arhgap15 
Abhd5 Il16 Gm10801 Alox5ap 
CD14 Sat1 Gm1840 Atp6ap2 
Cldn15 Mirt1 Phkb Ndfip1 
Nfil3 Tmem38b Gpi1 Pgm2 
Ccm2l Slc17a5 Fam132a Ccdc50 
Lgals3 Aldh3a2 Rab27a Ncoa4 
Cmpk2 Mpp7 BC005561 Serp1 
Vsir Vsig10l Tiam1 Mbnl2 
Mocos Mafg Acad8 Ddx17 
Celsr3 1700123O20Rik Pam Tpp1 
Slc26a6 Tmem159 Gm13342 Rab6a 
Gas7 Tle3 G6pdx Gm6768 
Sqrdl Alas1 Pxylp1 Asnsd1 
Csf2rb2 Mpo Dctn1 Taldo1 
Ceacam1 Dhrs1 Sirpa Akap9 
Gm16139 Gm14005 Gpr160 Cd33 
Znfx1 Pisd-ps1 Sidt2 Fam49b 
S1pr1 Stambpl1 Trip4 Uggt1 
Camsap2 Sgpl1 Gys1 Idh1 
Pex26 Acox3 Bet1l Ostf1 
Rflnb Pon3 Mid1ip1 Rsrp1 
Dach1 Csf2rb Csf2ra Atp6v0b 
Aoah Fam21 Riok3 Lin7c 
Maml1 Gapt Hipk1 Psen1 
B430010I23Rik Dync2h1 Aff1 Stt3b 
Gfi1 Daam1 Tnfaip8 Atp6v0d1 
Cyp4v3 1810037I17Rik Maml3 Gm15487 
Pi16 Pecr Zfp992 Gm12428 
Sash1 Sp100 Edem1 Oxr1 
Serpinb6a Acad11 Pink1 Gmip 
Tlr4 Ginm1 Rnf111 Wbp5 
Slc8b1 Lyst Vamp4 Bckdha 
Afmid Gm3150 Selenop Gm7707 










Table 2: Enrichr GO biological processes from 636 differentially upregulated genes on Day 2 CEBPA 
WT vs Day 2 EV-transduced cells comparison 





1 neutrophil degranulation (GO:0043312) 1.28E-25 4.78 314.97 
2 neutrophil activation involved in immune response (GO:0002283) 1.10E-25 4.74 309.8 
3 neutrophil mediated immunity (GO:0002446) 1.25E-25 4.7 304.75 
4 granulocyte migration (GO:0097530) 0.02793 17.97 185.51 
5 toll-like receptor 4 signaling pathway (GO:0034142) 0.04704 10.48 99.74 
6 positive regulation of reactive oxygen species metabolic process (GO:2000379) 0.003628 7.08 88.78 
7 pattern recognition receptor signaling pathway (GO:0002221) 0.00337 6.42 82.43 
8 ribose phosphate metabolic process (GO:0019693) 0.1228 10.48 81.78 
9 pentose-phosphate shunt (GO:0006098) 0.1159 10.48 81.78 




Table 3: 429 differentially downregulated genes on Day 2 CEBPA WT vs Day 2 EV-transduced cells 
comparison 
Tmem268 Gfi1b Prcc Syce2 
Ighm Ctla2a Ass1 Plek 
Ddx4 Ppp1r13b Gm29397 Apobec3 
Gm15261 Jade2 Dnmt3b Nrm 
Il7r Ccdc9 2610318N02Rik Alyref2 
Cdk18 Plekho1 Hist1h2ai Cfp 
Mmp13 2310075C17Rik Cep78 Msh6 
Ms4a6b Dab2 Csnk1g2 Gm13005 
Rag1 Fam65a Slc2a6 Rpf2 
Itpr3 F2rl3 Gch1 Dhfr 
Pear1 Fkbp7 Socs2 Acap1 
Mzb1 Chl1 Dnajc6 Cfap20 
Crocc Rps6ka3 Cnn3 Gm4849 
C030034L19Rik Cd34 Grwd1 Lgals1 
Spns2 Igkv12-89 Tmem173 Atp1b3 
Gata2 4930427A07Rik Fam212a Bin2 
Mc5r Gata3 Fen1 Smarca5-ps 
Drc7 Coro2a Akap1 Plod2 
CD163 Spp1 Gm28875 H2afy 
Dntt Cerkl Crip1 H2-DMa 
Slc18a1 Cav2 Meis1 Cenph 
Il21r Vamp5 Elk3 Sord 
Prr5 Usp12 Gm9847 Gm21887 
Nlrp10 Psd3 Gm15654 Rfc3 
D630045J12Rik Relt Ttll9 Gm37201 
Cyp4f18 Hdac9 Mtap Sae1 
Rtn4r Flt3 Tmpo Gm10193 





Carns1 Crls1 Fam60a Eef1akmt1 
Tmem176a Adgrg1 Trp53i11 Gm5529 
Zfpm1 Nfya Trim37 Nrp1 
Simc1 Myl4 Rcc1 Aimp2 
Dusp4 Gm15581 Kti12 Parvg 
Hrh2 Igkv4-90 2700099C18Rik Abce1 
Egr2 Etv4 2610524H06Rik Ifitm1 
Car8 S100a6 Gm6169 Nme1 
Ralgds Muc13 Zfp422 Gm42965 
Fam129b Smtn Txndc5 Gm7733 
Tesc Emid1 Bmp2k Aarsd1 
Ttyh2 Slc36a3os Lgals9 Ptpn18 
Gm38345 Carm1 Angpt1 Gm10087 
Pi15 Ptgds Ssbp2 Psme3 
Gm11998 Spaca9 Helb Iars 
Itgb7 Praf2 Gm15658 Pgrmc1 
Gpam Nkg7 Pus10 Gm6652 
Gm16897 2900026A02Rik Gm24452 Isyna1 
Col23a1 Golm1 Nasp Hist1h4i 
Pank1 Nrgn Il17ra Eif3b 
Slc45a3 Kcnn4 Ptprcap Polr3h 
Nr1d2 Sh2d5 Pkig Wdr18 
Gfra2 Serpinf1 Tsc22d1 Rbm38 
Gfra1 Spns3 Trp53 Fkbp3 
Dgkq Tgfb1 Tarbp2 Ftsj3 
Gm43696 Irx2 Lmnb1 Gm20156 
Ctxn1 Pkib Scaf8 Gm5837 
Afap1l1 Nup35 Hmgb3 Gm6640 
Lsmem1 Gm3470 Mcpt8 Plp2 
Pars2 Plcb4 Stmn1 Gins2 
Tmem132a Fbf1 Nmral1 Emp3 
Ighv1-23 Stim2 Mlkl Gm5530 
Spa17 Hist1h2ag Isoc1 Kansl2-ps 
CD180 Rbpms2 Itga6 Pold2 
Tspan6 Mcm10 Rbl1 Alyref 
Thsd1 Adgrl4 Cdk5rap2 Kansl2 
Cd244 Dscc1 Nfatc1 Gm10167 
Il31ra Bahcc1 Gm11223 Ranbp1 
Capn3 4930519L02Rik Blm Gm43578 
S100a4 Supt16 Rpa1 Gart 
Mex3a Gsk3a Ppih Shmt2 
Rbp1 Acss1 Slc11a1 2810004N23Rik 
Gimap5 B3gnt7 Rbbp7 Gm1969 
Nxpe5 H2-Ob Gm6382 Gm5124 
Bex6 Gon4l Gm14769 Gm5256 
Otos Tmem176b Trp53-ps Cdca7 
Gm21807 Slc35d3 Gm12184 Gm4617 
Arhgap6 Flnb Slc16a10 Nop58 
2610307P16Rik Hps5 Gm11246 Cse1l 
Etv5 Stk10 Hells Med29 
Tada2b Cnot6 Smarcc1 Cops4 
Pbx3 Ctla2b Smc2 Gm9800 
AW112010 Ccnd1 Rfc4 Slc35b4 
Nhsl1 Parp9 Steap3 Tuba1b 
Itga9 Lat2 Gm1848 Gm3687 
Cela1 D5Ertd605e Lsm3 Ly6e 
Il6 Ifi203 Slc39a6 Rrm1 
Atp2b4 Dhx33 Topbp1 2810417H13Rik 
Mrgpre Ankrd37 Gcsh Nipsnap3b 
Dgkh Gm17494 Clic4 Lmo2 
Zfp566 3110009E18Rik Arhgap18 Gm6625 
Angptl2 Tmem238 Mcm3 Mcm4 
Rasgef1b Gm5424 Endod1 Hmgb1-ps7 
8430408G22Rik Peg13 Psmb10 CD48 
Zfp729a Gm12470 Gm6104 Mcm2 
Plscr4 Gm12611 Gm2a Higd1a 
Mast4 Adrb2 Slc38a1 Wdr5 
Tmem119 Car2 Gm15428 Mrps23 
Mtmr10 Gm17936 Mcm6 Tipin 
Cd72 Cbfa2t3 Gm5593 Gar1 
Tnfrsf12a Cenpv Gm5385 Gm11914 
Tram2 Lrp5 Zfp36l2 Hmgn5 





Thy1 Gm6960 Dapp1 Gm7901 
Lpar5 Psat1 Ykt6 Ptma 
Rcor2 Tmem229b Nup205 Prmt1 
Kcna3 Rgs1 Gm13521 Rpl21 
Plxnb2 Gm15773 Gins1  
Ccdc51 Knl1 Usp22  





Table 4: Enrichr cell ontology (mouse gene atlas) of 429 differentially downregulated genes from Day 
2 CEBPA WT vs Day 2 EV-transduced cells comparison 
 
Index Name Adjusted p-value Odds Ratio 
Combined 
score 
1 stem_cells__HSC 0.000264 4.01 51.35 
2 common_myeloid_progenitor 0.03158 4.08 26.15 
3 embryonic_stem_line_V26_2_p16 0.005219 2.05 18.7 
4 embryonic_stem_line_Bruce4_p13 0.0104 1.86 14.96 
5 bone_marrow 0.03843 2.14 13.81 
6 follicular_B-cells 0.09355 1.78 9.14 
7 macrophage_bone_marrow_0hr 0.4888 2.07 6.63 
8 mega_erythrocyte_progenitor 0.2659 1.66 6.54 
9 mast_cells_IgE+antigen_1hr 0.6459 1.76 4.93 





Table 5: 15 differentially upregulated genes and 5 differentially downregulated on Day 2 CEBPA 
N321D vs Day 2 EV-transduced cells comparison 
Upregulated Downregulated 
Slc26a6 Mmp12 Gm14328 Spns2 
Mmp8 Lmo1 Gm13998 Gm16104 
Ifi214 Fabp5l2 Fabp5 S100a6 
AA474408 Mir6236 Lsm3 Zfp36l2 








Table 6: Genes upregulated during culture in Flt3L differentiation media 
151 genes differentially upregulated exclusively in CEBPA N321D-transduced cells 
Gm2622 Igfbp4 Sfxn3 Tpm2 
Luc7l2 Six1 1700025G04Rik Mpc2 
Dleu2 Dusp7 Gm17887 Serpinf1 
Gm1848 Trpc4ap Ocel1 Osbpl3 
Bnip3l Atp7a Atxn1l Rnf150 
Scin Tns1 Sh3bp1 D930015E06Rik 
Trappc5 Klrb1c Fli1 Gfod1 
Iffo1 Snx29 Apc Gm8615 
Tmed8 Zfp947 Gm12045 Egfl7 
Rprd2 Trim3 Tmem261 Dcaf10 
Ncoa4 Tmem119 Ivns1abp Serinc3 
Med13l Gm8666 Atp13a2 Shisa2 
Pafah1b3 Borcs6 Zfp933 Rab5a 
Nup210 Gm8752 Tmem8c Fam65b 
Lnpep Ctns Mylpf Slc44a1 
Tubb6 Avl9 Gm7694 Mef2c 
Tmem170b Mef2d Myog Klra1 
Cbfa2t3 H2-M3 Tmem229b-ps Tm6sf1 
Vamp2 Fam234a Mgat1 Tifab 
Cirbp Fabp4 Clec2i Nceh1 
Hoxb8 Ube2a Fam214a Gm8181 
Pigv Ssh2 Znrf1 Satb1 
Map3k5 Hmgn1 Wasf2 Notch1 
Adgre5 Hotairm1 Tnfrsf23 Lhfp 
Atp1b3 Cox6a2 Fam134b 1110059G10Rik 
Zeb2 CD163 Bloc1s2-ps Smim20 
Bcl2 Fam76b Zfp296 Pecam1 
Pink1 Fyn Mroh1 Zbtb18 
Gatsl2 C330007P06Rik Fbxw4 Gm26798 
Parp8 Cmah D930048N14Rik Aagab 
Mtm1 Gab3 Sema6d 2310001H17Rik 
Sh2b2 Rnf130 Klhl30 Gm7862 
Rsrp1 Was Dgkd Gm11663 
Hes6 Fads2 Abcb4 Bmf 
D8Ertd82e Slc27a1 Dap Dr1 
Runx2 Fndc3a Rab33b Cd93 
Adcy7 Gm6088 Sgcg Mtpn 
Kcnk12 H2-T-ps Dhrs3  
 
956 genes differentially upregulated exclusively in EV-transduced cells 
Adap2 Sh3tc1 Trp53i13 Aoah 
Tacc1 Myd88 Gm37347 Zyx 
Med10 Wdr45b Slc7a8 Casp4 
Dram2 Ehbp1l1 Nuak2 CD80 
Crybg3 Parp10 Ftl1-ps1 Gm13077 
Plekhm1 Sertad3 Tbc1d8 Pea15a 
Mthfs Smchd1 H2-DMb2 Aldh3a2 
Tapbpl Lpcat4 Apoc2 Gm7823 
Myo1g Arid5a Phf11d Stxbp3 
Adap2os Dennd1a Tet3 Ncoa7 
Zfyve26 Tmem192 Ciart Acap2 
Spty2d1 Ifit3 Ptpra Hexa 
Hsd17b4 Csf2ra Serp1 Gpr160 
Samd9l Gm5431 Slamf9 Slc29a3 
H2-Ab1 Tmem106a Gna15 Mknk1 
Ifi30 Zdhhc7 Hmgcl Egr1 
Fuca2 Gpr155 Gm8185 Nadk 
Max Gm13597 S1pr2 Mov10 
Hcar2 Erlin1 Tnfrsf14 Snx21 
Rnf213 Sgk3 Cd2ap Cln6 
Cd274 Rcbtb2 S100a11 Rnf34 
Cmtm3 Scarb2 Lipa Tm2d2 
Tlr9 Selplg H2-K2 Pilrb1 
Ggh Arhgef6 Dclre1c Lipe 
Gm18588 Slc15a3 S100a6 Irak2 
Trim26 Rsad2 Psme2 Arl5c 
Rnf115 Mafk Cd244 Cdk14 





Prkch Mfsd5 Zfp36l1 Tnfsf12 
Maf Anxa4 G6pd2 Gm1966 
Gm13392 Prkab2 Gm13212 Ifi214 
Gm15989 Gm6377 Vcpip1 Ppp6r1 
Gm43245 Fkbp1b Bcl10 Oas1a 
Nrp1 Lamp2 Gm6977 Dbnl 
Coro1a F630028O10Rik Arl8a Dck 
Ifit1bl1 HaCD4 Ensa Rasgef1b 
Gm15487 Ccnd1 Pik3ap1 Tmem9b 
Calm1 L1cam Polb Birc3 
Rnh1 Fem1c Cxcr4 Rraga 
Cd22 Gm42786 Renbp H2-Eb1 
Pepd Actg1 Cldnd1 Morc3 
CD48 Psen1 Vps37b Lilra6 
B430306N03Rik Gvin1 Bco2 Picalm 
Spg21 Oser1 Zfp992 Gm23374 
Ier2 Gm12715 Anxa1 Eif2ak1 
Metrnl P2ry14 Gm15361 Gm15534 
Tlr13 Slc25a38 Gm5510 Zfp36 
Gm13453 Dtx2 Gpr18 Kynu 
Snx2 Slfn10-ps Dram1 Gm21738 
Atp6v1e1 Gadd45g Socs1 Cyba 
Add3 Irf1 Nt5c3 Rel 
Gpr108 Clec4n Nfkb1 Myo1c 
Gm7114 2610206C17Rik Il18 Ccdc109b 
Klf10 Slc35c1 Akna Junb 
Etv3 Entpd1 Acot9 Lpl 
Carmil1 Mfsd12 Azi2 Gm26740 
Sorl1 Aff1 Ccl4 Flna 
Clec9a Prkd3 Clta Fnbp1 
Il4ra Sft2d1 Rab3d Arhgap30 
Ptpn22 Txndc15 Lmo1 Vrk1 
Itpr1 Cd300lg Rab32 Spop 
Cstb Elmo2 Slc26a2 Cd53 
Atp2b1 Jak2 A230046K03Rik Stxbp3-ps 
Gng10 Gnaz Zfp382 Chmp1a 
Lpp Ly9 Tpm4 Foxn2 
Brox Galnt10 Lrrc25 Susd3 
Degs1 Tnf Nek7 Trim5 
Smox Stard3 St18 Lgals8 
Rgs1 Hexb Ifi203-ps Sp110 
Amn1 Asgr2 Slc35f6 H2-Aa 
Spaca9 Slamf7 Gm4760 Plxnc1 
1700097N02Rik Sirpa Haus8 Ifit2 
Rtn4 Phf11b Tnfaip2 Sirpb1b 
Capza2 Lrch1 Tmem176b Fry 
9430034N14Rik Gm6615 Lrrfip2 Cmtr1 
Rarg Fbxw17 Ncoa1 Sri 
Gbp4 Taf13 Nub1 Samd8 
Nmi Rps6ka4 Pqlc3 Hmox1 
Il3ra Exoc3 Ppp2r5a Rbms1 
Erp29 Ppp3ca Cnr2 Gm2986 
Psme2b Gm26637 Vwa5a Pttg1 
Clcn5 Nfatc2 Cyp4f16 Ddit3 
Rnpep Coro1b Neurl3 Dyrk1a 
Scn4b Atp6ap1 Rras2 Adgre4 
Malat1 Gpr132 Tmem154 Mgat4a 
Psme1 Ankrd44 Dtx3l CAAA01147332.1 
C3 Rbpj Cic Nfkbib 
Lpar6 Sbno2 Itpripl1 Igtp 
Ly6c1 Gm4918 Sirt7 Ccdc86 
Tfe3 Oasl1 Acss1 Kif1b 
Macf1 Ostm1 Actg-ps1 Gm5763 
Itpripl2 Nipa2 Sgpl1 Acvrl1 
Btg2 Smap1 Fbrsl1 Fam69a 
Mcl1 Anxa2 Plekhg3 Dync1h1 
Lyst Sema4c Dock5 Phf11a 
Gbp9 Arhgap4 Mtf1 Chn2 
Gm7367 Fcgrt Necap2 4930455G09Rik 
Gm7776 Emp3 Mob3a Hcfc1r1 
Dab2 Ascc3 Rn7sk Ifi47 
Fam49b Chmp4b Zfand2a Nampt 





Tor1a Tmem150b Cst12 Ptp4a2 
Hist3h2a Gm8902 1600014C10Rik Tnfrsf1a 
4833421G17Rik Zfp467 Trim36 Cxcl16 
Lamtor1 Arpc5 Ifi209 Ifngr2 
Lacc1 Trim30c P2rx4 Mdm2 
Irgm2 Apobec1 Lyz1 Atp6v1b2 
Gm8641 Spib 4930430E12Rik Ssh1 
Rchy1 Psmb10 Ncoa3 Sap30 
Tmem176a Crlf2 Cyld Cttnbp2nl 
Mndal Gbp2 Plpp6 Scand1 
Szrd1 Atp6v0d1 Plod1 Relb 
Zfp277 Maml1 Tlr1 Eif2ak2 
Aif1 Fam129a Vamp3 Gm8464 
Ptafr 0610012G03Rik Socs3 Ctsd 
Rgl1 Syk Arhgap15 Vhl 
Ap2a2 Armc7 Arhgap25 Gm12428 
1600010M07Rik Hgsnat Tmsb4x Rnf114 
N4bp2l1 Gm15922 Gm16205 Gm7676 
Gm5828 Tmem86a Gm9392 Txndc16 
Cap1 Gm6175 3110043O21Rik Pias1 
Clcn7 Mycbp2 Mob1a Tmod3 
Ep300 Gsdmd Lrrc75a St3gal2 
Gm5578 H2-DMb1 Mapk14 Gm42641 
Plin2 Ccdc88a Klf6 Wdr44 
Hk2 M6pr Gabarap Phactr2 
Gm21975 Pdlim5 Dennd1b Fgl2 
Gm8577 Gm5548 Cass4 Tlr6 
Pfkfb4 Zcchc6 Paqr4 Cast 
Adora3 Dennd1c Ralb Leprot 
Mysm1 Pilrb2 Dock4 Bcl2l11 
Myo9b Aim2 Slc43a2 Mdfic 
Bin3 Raph1 Plekho2 H2-T24 
Naip6 Wwp1 Cln3 Tmem134 
Slc34a2 Zcchc2 Mvb12a Far1 
Swap70 Tlr7 Ttyh3 Nfkb2 
Cxcl2 Azin1 Gna13 Tbc1d9 
Akt3 St8sia1 Gm12250 Foxred2 
Frmd4a Plcl2 Gm15503 Cd9 
Cyb561a3 Fcer1g Tspyl1 Dpysl2 
1110008P14Rik Gm20432 Pml Smpdl3b 
Rabep1 Dusp3 Ccl2 Rnd3 
Vim Rell1 Ifit3b Trim12c 
Hpgds Zc3h12a Gm12791 Slc15a4 
Plaur Tnfsf8 Klf4 Trim14 
Rnf166 Mpc1 Cmip Ptpn1 
Gm15899 Klk1b11 Nedd9 CD86 
Pisd Parp12 Usf1 Mir6236 
Ncf2 Ccdc12 Bin1 Cdc42 
Bet1l Oas1g Prdx5 M6pr-ps 
Plxdc1 Gm5046 Fcgr1 Iqgap2 
Stk38 Atg7 Rap2b Cyp4f18 
Il2rg Gm10801 Ifit1 Slc37a2 
Racgap1 2810405F17Rik Ifngr1 Ptms 
Plekhb2 Pcsk7 CD40 Rab8a 
Dusp10 Dnajb14 Srgap2 Pnkp 
Diaph2 Acta2 Dcaf11 Lpin1 
Slc31a1 P2ry12 Rgs2 Gpr137b-ps 
Ndel1 Cib1 Tle3 Plekhm3 
Herc6 Ctsc Ppp1r18 Slc25a22 
Ifi213 Rgs14 Gpr171 Dnase1l1 
Ppm1h Tcf19 Aldh3b1 Ifi204 
Slc8b1 Fnip2 Arhgdia Arpc2 
Vapb Epb41l2 Pstpip1 Slfn1 
Fcgr4 Atp6v0b Efhd2 AC133103.1 
Tnip3 Keap1 Itm2b Cpne3 
Npc2 AW112010 Gm8369 Cbl 
Sec24b Bcl3 E2f7 Gnai2 
Ero1lb Rassf1 Herpud1 Ier5 
Ms4a4a Card11 Slfn9 Sp2 
Ccr2 Actr3 Sub1 Gm6263 
Arrb2 Grasp Tbc1d13 Pid1 
Fos Msr1 Naaa Gm11405 





Twf2 Ids 9430076C15Rik Kif23 
Dhrs11 Apbb1ip Irgm1 Gm9025 
Rgs3 Ccrl2 Rnf167 Net1 
Clec4a4 Gm14856 Stard9 Lactb 
Dpy19l1 Clec4b1 Cd9-ps Rin3 
Ftl1 Lcp1 Creb3 Alox5 
Synj1 Gngt2 Gm4750 Il12rb2 
Ms4a7 B4galt5 Tnfaip8l2 2310035C23Rik 
Ifi206 Gm3145 Rap1b Vcl 
Taldo1 Gm12543 Elmsan1 Mif4gd 
Tmem184b Ptk2b Nagpa Dpp4 
Map3k3 Gm12226 Atp8a1 Osbpl9 
Gm11189 Cxcl10 Thap6 Rnf31 
Skap2 Rab1b Gm10800 Malt1 
Atf3 Atp6v0c Card19 Crip1 
Zbtb7b Nxpe4 Fam26f March5 
Vps51 Pdxk Sirt2 Skil 
Zfhx3 Tmem219 Helz2 Zfp710 
AC132444.1 Map2k1 Gm9397 Rala 
Atp1b1 Ubc P2ry10 Pik3cd 
Acot10 Emilin2 Gm15448 Gm16026 
Rab3il1 Sdhaf2 Tgfbi Lrrk2 
Sh3glb1 BC005537 Isg20 Gm4962 
Gm12430 Kctd12 Slc35c2 Slc25a45 
Camk1 Tax1bp3 Msrb1 Lmna 
Abhd12 Snx10 Tmem189 Pim1 
C3ar1 Esyt1 Mical1 Nfkbid 
Commd8 Ccdc50 H2-DMa Adgre1 
Actb Pnpla7 Ints4 Lrrk1 
Taf6l Syngr2 C130026I21Rik Padi2 
Gm8399 Lrch3 Sdccag3 Fam46c 
Stat6 Il21r Ttc7 Laptm4a 
H2-T22 Gm17087 Akr1a1 Capn2 
Parp3 Trerf1 Trim30b E2f2 
Actr2 Trem2 Adar Ifih1 
Adam15 Cdk13 Hpcal1 Il15 
5430427O19Rik Rnf13 Grina Klra17 
Sertad1 0610040J01Rik Stard3nl Gm37589 
Ifi208 Ifnar1 Gm20559 Gsap 
Gm7665 Acaa1b Gm6305 Nfkbiz 
Zbp1 Ptprj Aim1 Cdc42se2 
Stam2 Dna2 Sidt2 Rps6ka5 
C1qc Gltp Arf5 Ywhah 
Peli1 Npc1 Iqgap1 Nckipsd 
Arhgap31 Cnn2 Tlr4 Ankfy1 
Gak Fcgr3 B3gnt8 Clec4a1 
Rac1 Gm10717 Gm14000 Daxx 
Ncor2 Igsf6 Hck Gm12164 
Nostrin G6pdx Grb2 Gm7357 
Grap Sema4a Rbfa Sgpp1 
Ostf1 Bhlhe40 Mvp Scimp 
Wdr1 Gm12166 Ddi2 Cotl1 
Dusp1 Gm15753 Pqlc1 Nfe2l2 
Gm8822 Gm5590 Camta2 Fcor 
Gpr146 Sqstm1 Slfn8 Upb1 
Traf5 Antxr2 Fuca1 Rp2 
Smdt1 Gmip Pelo Cav2 
Icosl Uvrag Id3 Fgd3 
Gm6695 C1qb Ifi35 Fnip1 
Sesn2 Tmem173 Hdac4 Vps37a 
Xbp1 Ptger4 Gm12003 Siglec1 
Gm7809 Cndp2 Rhog Mpp1 
Ccdc50-ps Gnpda1 Fth1 Vasp 
Fgr Ltb4r1 Pot1b Abcg1 
Pag1 Map7d1 AB124611 Mgl2 
 
443 genes differentially upregulated in both CEBPA N321D and EV-transduced cells 
Tnfrsf13b Selenop Ppm1m Csf1r 
5730416F02Rik Pmaip1 Ythdf3 Cds1 
Plxnb2 Trafd1 Tubb2a Stk17b 
Slc2a6 Ifi207 Ifi205 Txnip 





Blvrb Cybb Gm15931 Spi1 
Lpxn Myadm Bst2 Cd300c 
Itgb7 Rasa4 P2ry6 Gm13669 
Mbnl1 Il1r2 Parp9 Tmed3 
Gm5398 Gm4875 Hps3 Kdm7a 
Bex6 Snx20 Ccl6 Arhgef12 
Stat2 Gm14699 Cd74 Irf9 
Tyrobp Ctsa Alox5ap Rgs10 
Irf5 Cd28 Sdc3 Hcls1 
Uba7 Tspo Gng2 Ighm 
Inpp4a Alcam Tgtp2 Usp18 
Mycl Xiap Abhd15 Clec10a 
Cdkn1a Arl6ip5 Slc16a7 Tpd52 
Ddx58 St8sia4 Arl4c Prex1 
Axl Laptm5 Runx1 Trpv2 
Slfn5 Myo1f Ccdc180 Ehd4 
Limd2 Sgcb Gm15417 Itm2c 
Filip1l Ms4a6d Cebpd Cnbd2 
Ddx24 Gm5552 Mef2a Ube2l6 
Atp6v1d Prkcd Acer3 Gpr34 
Tapbp Gosr2 Ly86 Msn 
Camk1d Sh3bgrl3 Anxa6 N4bp3 
Napsa Tep1 Capg Lifr 
Il17ra Gm14548 Havcr2 Zc3hav1 
Sdc4 Ptpro Pip4k2a Nptn 
Tlr2 Cnp Fmnl1 Lgals3bp 
Tmsb10 Ctse Prkx Ctnnd2 
Arpc5l Notch2 Stat1 Fam174a 
Acaa1a Sat1 Lilrb4a Gm14608 
Ly6e Selenow Lbh Cd300a 
Plac8 Itgax Plekha1 Fam129b 
Nfkbia Arhgap9 Cmtm6 Arhgap17 
Ubl3 Smim5 Epb41l4b Il6ra 
Cdc42se1 Btg1 Bach2 Pitpna 
P2ry13 Cyth4 Clec4a2 Nfam1 
Pirb Unc93b1 Rassf5 Grn 
Ctsh Whsc1l1 Map3k1 Ap1s2 
Trim12a Evi2a Lst1 Slc14a1 
Tet2 Hmha1 Gas7 Pld4 
Il6st Mir22hg Gpr141 Tifa 
Ms4a4c Mpc1-ps Inpp5k Tmem50b 
Tor3a BE692007 Clec4a3 Rassf4 
Mkrn1-ps1 Oas3 Tec Ogfr 
Cx3cr1 Itgb2 Tmem55b Kmo 
Epn1 Klhl6 Tmem243 Stx7 
Cd52 Ifi203 Neat1 Gpsm3 
Slc37a3 Samhd1 Parp14 Ly6a 
Gm7936 Hlx Tnni2 Fxyd5 
Gng2-ps1 Usp12 D1Ertd622e Nlrp3 
Fads3 Ctnna1 Klf3 Nrros 
Dpep2 H1f0 Cd300lb Anxa5 
Scpep1 2010001K21Rik Gm12345 Lyn 
Klrd1 Gsn Sh2b3 Tulp4 
Ptpn6 Cfh Oasl2 Sp100 
Ighj4 I830127L07Rik Gm3788 Ccr1 
Fes Pisd-ps1 Tor1aip1 Gpcpd1 
Tmem109 Xaf1 Cln8 9930111J21Rik2 
Litaf Abi1 Znfx1 Milr1 
Map3k8 Plec Sik1 Cfp 
Trim30a Themis2 Mkrn1 Tnfsf9 
Ckb Ly6c2 Nfatc1 Zufsp 
Rpph1 Slc44a2 Rogdi Lcp2 
Tmem229b Itga1 Tdrd7 Irf7 
Rnase6 Reep5 Zfp385a Naga 
Gm14032 Pak1 Ifi211 Cysltr1 
Wdr26 Smim3 A530040E14Rik Ifnar2 
Pik3r5 Bcl6 CD14 Trim30d 
Tpst1 Hpse Zfp263 Klrb1f 
Man2b1 9930111J21Rik1 Tiparp Arhgap5 
Fam105a Lair1 Map4 Ypel3 
Cytip Slc9a7 H2-T23 Il13ra1 
Tecpr1 Prr5 Pilra Cd300lf 





Tubgcp5 Naip5 Sft2d2 Cd68 
Cadm1 Csf2rb2 Gm17791 5031439G07Rik 
Gm16372 Psap Rubcnl Nr4a1 
Ypel5 Necap1 Gm8995 Oas2 
St3gal5 Dhx58 Gm12892 Pycard 
Gm15987 Prr13 Kctd14 Rbm47 
Smim14 Mtmr14 Isg15 S100a4 
Fyb Zbtb7a Trim34a Il10ra 
Vsir Lgals3 Acox3 Ahnak 
Lgmn Ms4a6b Gm12854 Bloc1s1 
Wfdc17 E330020D12Rik Ifitm3 Slc46a3 
Nos1ap AI839979 Cst3 Tpd52-ps 
Rasgrp4 Lasp1 Gpr183 Sppl2a 
Zfp36l2 Tmcc3 Ebi3 Ak8 
Shisa5 Bmyc Plp2 Gcnt2 
CD82 Gns Plekhg5 Tcirg1 
Ccl3 Ifi27l2a Tmem51 Ighj2 
Rab7b Asah1 Sp140 Mx1 
Sema4d Cmpk2 CD180 Irf2bp2 
Fkbp15 Epsti1 Frmd4b Lamp1 
Dusp22 Id2 Rara Ifitm6 
P2rx7 Irf8 Itgam Cyfip1 
Lsp1 Mpeg1 Slc6a6 Slc12a9 
Ctss Gcnt1 Clec7a Lyz2 
Tfeb Rtp4 BC147527 Tagap 
Klrk1 Bri3 Plekhf2 Ighj1 
I830077J02Rik Soat1 Cd300c2 Ctsb 
Mx2 Grk2 Klf13 Pira2 
Gm4992 Ptprc Gm11787 Rin2 
Ms4a6c Evl Dusp5 Gm6169 
Pstpip2 Aph1c AbCD1 Gm9844 
Ctsz Pacs2 Rps6ka1 Rmnd5b 
S100a10 Plekho1 Apba1  
 
 
Table 7: Genes downregulated during culture in Flt3L differentiation media 
138 genes differentially downregulated exclusively in CEBPA N321D-transduced cells 
Siglecf Hist1h2ab 1810037I17Rik Abcb1a 
Fam60a AW146154 Srxn1 Rapsn 
Mmp8 Ighv1-77 Spred2 Hsd11b1 
Zfp462 Hist1h2ae Ammecr1 Pvr 
Als2 Pfdn4 Pomgnt2 Zfp704 
Steap3 Rgs18 Nrp2 Ifi214 
P2rx3 Hist1h2an Man1a Ubxn11 
Trim68 Six5 Nudt1 Tmem29 
Ighmbp2 BC003965 BC026585 Flt1 
Homez Pon3 Depdc1b Gm43431 
Zbtb16 Zfp758 Gpr65 Kdm1a 
Adgra2 Hist1h1d Cebpzos Hist1h3b 
Rgs1 Optn Hist1h3g Asb1 
Adcy9 4930486L24Rik Tet1 Rps6ka3 
Vcan Suco Polm Tex30 
Pi16 Gm37354 TlCD1 Hist1h2bg 
Prcc Fpgt Xrcc5 Ifi47 
Smtn Ctla2b Vav3 2810408I11Rik 
Sirt1 Klhdc1 Hist1h3e Clec5a 
Slco3a1 Hist1h4n St3gal6 Rps29 
Dusp19 Actn1 Ube2w Trem1 
AA474408 Tyw3 Ankrd50 Gfpt1 
Gm26597 Gfi1 Atp11b Ift81 
Csf3r Ankrd27 Hpgd Mettl18 
9330175E14Rik Tgfb1 Amz1 4933431K23Rik 
Gtse1 Fcgr3 Erlin2 Mmgt1 
Prdm1 Zfp27 Plcb2 Hivep2 
Cdk5rap2 Tnni3k Tgfbi Tmem132d 
Fam46a Casp7 Atp10a Zbtb34 
Pam Fosb Il11ra1 Rims2 
Gm5424 Hist1h1b Gm7805 Anxa3 





Rsu1 6030408B16Rik Nars2 CD84 
Zc4h2 Rmnd1 Hivep3  
Ebna1bp2 Slc11a1 Rbakdn  
 
1060 genes differentially downregulated exclusively in EV-transduced cells 
Selenbp1 Pum3 Tspan2 Zak 
Sergef Ldlrad4 Fancf Kpnb1 
Bhlha15 Fam114a1 Asf1a Pced1b 
Ruvbl2 Ifi27 Amot Atr 
Ifrd2 B3galnt2 Col11a2 Ninj1 
Gm13502 1110051M20Rik 1110008L16Rik Hemk1 
Angptl4 Fasn Snapc4 Cirh1a 
Gm1976 Gm43213 Cdk4 Gm5593 
Dennd5b Gcsh Fkbp3 Prkca 
Zfp979 Abhd11 Cand1 Rai14 
Cnpy4 Arv1 C030034L19Rik Mroh2a 
Bcl7a Pgm2 Haus1 Pomk 
Kcnq5 Cenpv Jpx Rpl31 
Dlat Ptgir 1110004E09Rik Armcx6 
Gm21807 Gas2 Gm14769 BC055324 
Rps6 Thy1 Ccdc40 Bbs12 
Ak2 Gm37510 Polr1c Rtn4r 
Zbed4 Akap7 Ppcdc Ppfia4 
Snhg4 Gm37666 2610008E11Rik Cry2 
Strbp Polr3g Ssbp1 Tpi-rs11 
Ppfibp1 Lrrc20 Rsl1d1 Zfp335os 
Jade2 Socs5 Ogt Msantd3 
Zfp566 Ktn1 Mei4 Got2 
Psmg2 Pla2g4a Ctnnal1 Gm38391 
Scd2 Atat1 Cd302 Lyrm2 
Cenph Itih5 Cct3 Nck2 
Brinp3 Stam Exo5 Borcs7 
Mns1 Mrpl44 Mybbp1a Haus3 
Gm5837 Gm37124 Spice1 Prep 
Dennd6b Amacr Il31ra Timm10 
Gm27219 Dcun1d5 Chchd5 BiCD1 
Gm12115 Tmem254c Abce1 Mmp14 
Rps12 Gm15659 mt-Nd2 Zfp507 
Cd24a Sort1 Bcap29 Zfp748 
Zfp932 Eif3j1 Thyn1 Gm7244 
Gm4879 Sh2d5 Hyal2 Pdrg1 
Cep57l1 Mgmt Paip2 Gm8459 
Gm6501 Klf16 Tex9 Snora68 
Ercc6 Stk16 Nip7 Cdca7l 
Nutf2 Kctd4 Cisd3 Gm8173 
Ctps 1810014B01Rik Ptprcap Zcwpw1 
Gm3362 CD81 Gm8069 Gart 
Mrto4 Gm12955 Fchsd2 Atp5g1 
Plscr3 Dync2li1 Hsp90ab1 Zfp597 
Utp20 Kdelc1 Cluh mt-Te 
Slc45a3 Trappc13 Gm9824 Pitrm1 
NudCD1 2810002D19Rik Fam78a Utp11l 
Tsen15 Dnmt3b Ovca2 Dnajb4 
Camsap1 Col19a1 Gm8741 Erh 
Mphosph9 Plscr4 Aimp2 Nhsl1 
Slc25a15 Nudt5 Il12a Nme6 
Hdgf Mgarp Blm Acot2 
Rnaseh2c Msrb2 Srr Smad3 
Gm37201 Tnk2 Dand5 Ptpn7 
Zfpm1 Ppp1r14c Emilin1 Fam188b 
Yaf2 Pdlim1 Ndc1 Nolc1 
Hoxa6 Cep89 Gm15528 Mnd1-ps 
Kcnj2 Kansl1l Golgb1 Lins1 
Sox4 Spint2 Rbmxl1 Ilf2 
2610306M01Rik Ccdc88c PdCD4 Rrs1 
Ddx21 Nav2 SCD1 Polr3h 
Mrps31 Gmpr Slc20a2 1190007I07Rik 
Hadh Urb2 Rps13-ps4 Paip2b 
Smim24 Nsun2 Oxnad1 Gm23246 
Pdpr Dzip3 Npm3 Xpnpep3 
Trip13 Bhlhb9 Sdc1 Mccc2 





Pbx4 Ncl Gm15654 Ripk3 
Nme1 Mettl1 Gm5455 Gimap1 
Trub2 Gemin4 Twist1 Pgam1 
Gm5946 2900026A02Rik Pi4k2b Nop10 
Wdr75 Abcb6 Kcnip3 Hspd1 
Zfp606 AI987944 Psmg1 Kti12 
Cdk6 Tmem70 Ska2l-ps Ppif 
D16Ertd472e Cdca7 Prps1 Cmss1 
Sh3rf1 Prelid2 Ttll1 E130308A19Rik 
Gm13700 Spns2 Mex3a Mcm7 
Sos2 Gm23130 Zfat Mesdc2 
Akap1 Gfod2 Wdr34 Unkl 
Ints6 Ube3a Mrpl15 Gm11451 
Nmnat3 Ahcy 2610307P16Rik D630045J12Rik 
Dirc2 Fam220a Polr3d Nol8 
Zfp113 Gm11993 Dusp18 Phgdh 
Tnpo1 Gm13337 Nup43 2810403D21Rik 
Vangl2 Spata7 Gm24452 Tmem69 
Dnph1 Ppargc1b B9d1 Traf4 
Spata24 Dnajc2 Ftsj3 Cbx2 
Gm5297 Ppm1f Tom1l1 Ddx1 
Fam212a Chaf1b Zfp707 Vsig10l 
4930509E16Rik Msh6 Mcee Gm4535 
2810004N23Rik Ipo11 Enkd1 Gpatch4 
Wbscr27 Cacybp Gm5847 Cngb1 
Zscan22 Gm43297 Clpp Pcp4l1 
Ntmt1 Ipp Gm42814 Zfp40 
Armcx2 Ccdc66 Ube2cbp Msi2 
Hspa13 Gm37060 Gsr 6330562C20Rik 
Focad Osbpl5 Snhg6 Gm14857 
Gm20156 Rptor Eif1ax Thsd1 
Plpp5 3110040N11Rik Hsd17b10 Tspan13 
4933404O12Rik Snap47 Kif17 Gng12 
Eef1g Timm9 Hist1h2bk Hoxa5 
Etfbkmt Cep97 Pgam1-ps2 Gm5385 
Anks1 St14 Rpl36 Rsbn1l 
Map9 Pcsk4 Ppan Gm14057 
Gm17251 Gm1818 Nop2 Slc7a6 
Gm17936 Aldoc Mettl4 Pi15 
Gm6960 Akap13 C230034O21Rik Zcchc11 
Mdh2 Zfp239 Lman1 Fto 
Rcl1 Gm5864 Mdn1 Lamp3 
Taf5l Dusp12 Sntb2 Klhdc2 
Idi1 Slc43a1 Gm6640 Pabpn1 
D3Ertd751e Rpgrip1 Nt5dc2 Dok4 
Slc9a3r2 Rcn1 Comtd1 Gm17709 
4921524J17Rik Abhd6 Hoxa7 Gm11914 
Pcbd1 Gprasp1 4930581F22Rik Cd27 
Rnf220 Selenon Bambi Usp31 
Mfsd13a Fam35a Tceanc Icam2 
Prtn3 Aldh6a1 Pear1 Zfp874a 
Gfm1 Layn Gm4735 Znhit3 
Oaz2-ps Gm15770 Xpo7 Sgsm2 
Paip1 Zfp280c Sumf2 Socs2 
Mrpl38 Pde4d Qsox1 Larp1b 
Slc25a29 Fkbp4 Gem Gm11516 
Gm16433 Aak1 Gm9531 Nop58 
Ppp1r14b Rbak Nefh Tia1 
Rps2-ps10 Gm13998 Gm15261 Gadd45gip1 
Nup37 Bmi1 Dhx30 Zfp672 
Rrp1b Gfi1b Gm15800 Spag4 
Miga1 Gm12848 Rpusd2 Tesc 
Pop1 Gm8522 Mcm2 Gm11896 
Zfp146 Gm16465 Susd1 Las1l 
Rpp14 Per3 Phlda3 Slc18a1 
Zfp783 Vwa8 Dnajc10 Gm19031 
Gm4366 Galk1 Gm30074 Ppp1r13b 
Unc13a Gm14681 Gtf3c4 Gm37422 
Kctd1 2610524H06Rik Bora Med29 
Tmem186 Zfp329 Pa2g4 Mnd1 
Tspan5 Mthfd1 Gm4353 Cerkl 
Sord Hspd1-ps3 Exosc2 R3hcc1 





Engase Lamc1 Sdhaf3 Gm16379 
Cmtr2 Prdx6 Dach1 Gm21887 
Tnnt1 Gaa Abhd2 Zfp775 
Uevld Snord22 Scly Mrpl12 
Grwd1 Mrpl50 Fbxo25 Sephs2 
Hmgn5 Gm9260 Etv4 Wdr74 
Ubxn8 Zc3hav1l Ldlrad3 Noc2l 
Calu Ndufb2 Gm17837 Gm15484 
Smyd2 Rapgef3 Zfp512b Bzw2 
Gm10131 Ada Gm5874 Orc2 
C1qbp Polr3k Lyar 2810025M15Rik 
Hddc2 Gm10819 Ankrd13b Htra3 
Gm20342 Gm9755 Prune2 Adsl 
Bsn Dkc1 Abcb8 Cdk7 
Gm13368 Tmem107 Taco1 Gnl3 
1190002N15Rik Tnfsf13os Snhg15 Gata2 
Xk Capn3 Mif-ps3 Lyrm9 
Tnfrsf26 HaCD1 Mtf2 Tdg 
Shmt1 Jmjd8 Ttll5 Mgat5 
Iqsec1 G2e3 Grhpr Nob1 
Hmgb3 Map7d2 Gm8113 Repin1 
Cnpy2 Tnfrsf22 Kremen1 Kcnh7 
Gstp-ps Syncrip Bag2 Frat2 
Pex10 Abcf2 Fam216a Acaca 
Ipo5 Nudt19 Rpl21 Wdr55 
Ndufaf2 Sirt5 Gm42418 Ern1 
Ptcd3 Dnaja3 Rhoj Epha4 
Gar1 Tma16 Nhp2l1 Nlgn2 
Abcd2 Cbx3 Ampd2 Ccdc58 
Mtx3 Eno1b Slc35d3 Gm26917 
Golim4 Drap1 Stk26 Nme4 
Gpam Gm10110 Hibch Smpd4 
Mrps28 Ccdc167 Nomo1 Rint1 
Rpl27 Nudt3 Gm12020 Sssca1 
Gm8520 Cbx5 Gm10020 Gm7666 
Myl4 Thap2 Gm9826 Gstp1 
Ctxn1 Dtx4 Sfxn1 Fgf10 
Gm11847 Gdf11 Gm4349 Exoc8 
Lmo2 Clstn1 Mir5099 Wdr6 
Zbtb38 Luc7l Rhoq Selenom 
Tal1 Wdr12 Gm16341 B230369F24Rik 
Gm17230 Ddx56 Dhx33 Gm7781 
Slc25a43 Ptch1 Stxbp4 Tomm5 
Fmc1 Ell2 Myo19 Fam160a2 
Gm4737 Cdkn2aipnl Fancb B3gnt2 
Cct6a Ippk Gsta4 mt-Tt 
Pold2 Eef1e1 Gm20696 D5Ertd605e 
Tspan32 Wwc2 Micall2 Kdm5b 
Top3b Pcyox1l Fktn Ttc3 
Mvb12b Gm13498 Wdr5b Mrgpre 
Pebp1 Trim28 Rdh13 Gm9256 
Rfc4 Gm17066 Raet1d 4732463B04Rik 
Zfp687 Vpreb1 Elk3 Rrp12 
Gm7901 2610318N02Rik Mrps18b Gspt1 
Zfp101 Car8 Eif3b Mcph1 
Utp14b Fxn Gnpat Guf1 
Gm5069 Dpy19l3 Dnajc12 Ruvbl1 
Hells Tfdp2 Zdhhc24 Slc16a1 
Tcp1-ps1 Rrn3 Afap1 Poli 
Snhg5 Dtymk Hexim2 Prmt5 
Fancd2 Amer1 Dars Trp53rkb 
Rttn Nifk Rbp1 Ahi1 
Bcat1 Rmnd5a Paics BC017158 
Pecr Proser3 Gm13776 Gm13937 
Irak1bp1 Txnrd3 Zfp428 Syce2 
Npm1 Cycs Serf1 9930104L06Rik 
Tfap4 Mmd Trp53bp1 Tufm 
Tmem67 Cnn3 Mycbp Ccnh 
Ccdc181 Fabp5 Umps Asap2 
Rasd1 Irx2 Gm13552 Gm13521 
Cand2 Spry4 Brix1 Tmem97 
Klhl12 Tnik 3110082I17Rik Tarbp1 





Ankrd26 Pde8a Camkk1 Gm5124 
Gclm 2410016O06Rik Fkbpl Spout1 
Tfpi H2-Q6 Prdx3 Ccdc125 
Rpusd3 Bola1 Zfp184 Klhl9 
Trnt1 Srek1ip1 Arap2 Amd1 
Ttc37 Dut Faf1 Senp8 
Gm6166 Ddx18 Fer Pabpc4 
Polr2f Cd99l2 Qtrtd1 9230114K14Rik 
Pam16 Gm14109 Ccdc15 Gm14328 
Aldh18a1 Jmjd4 Gm17494 Rpl12 
Hgh1 Aasdh Phb Cbx6 
Gm5525 Rpl36a Pofut1 Dusp4 
Pom121 Wdr36 Pus7 Lekr1 
Rpl36-ps2 2610002M06Rik Smyd5 Ttc26 
Wdr77 Pcyt2 Mc5r Gm6447 
Stxbp5 Osbpl7 Cd72 Psme3 
Ddah2 Gm5687 Gm5855 Pus10 
Ints3 Ypel1 Zbed3 Xpc 
Mkrn2 Slc29a2 Gm7556 Nudt7 
Idh3a Ap4e1 Simc1 Kcnq1ot1 
Hsd17b14 Lsmem1 Npm3-ps1 Arid4b 
Fam92a Hist1h2bj Nudcd2 Srm 
Rps8 Myb Ubfd1 Yae1d1 
Zfp369 Cep41 Pif1 4930555A03Rik 
Nop56 Gm4258 Adat1 Mlec 
Hcst 4930520O04Rik Atad3a Cbr1 
C920006O11Rik 1700030K09Rik Gemin5 Thop1 
SpoCD1 Mcm6 Gm7332 Mcm3ap 
Nup133 Yod1 Pgk1 Gm7251 
D130058E05Rik Snx27 Mlh3 Maged2 
Snord55 Phc1 Rcc1 Polr1b 
Brwd3 Rai1 Mettl15 Gm12583 
Raet1e 1810022K09Rik Chordc1 Gm16074 
2610301B20Rik Pus7l Rnf219 Pitpnc1 
Gm5611 Chtf8 Gm7289 Gimap6 
Tfb2m Dph5 Msto1 Flt3 
Tctn3 Ppat Zfp799 Pdss2 
Psmd7 Mmachc Pla2g6 P3h1 
Rfx3 Gm26580 Hspbp1 Nlrx1 
Zfand4 Dnm1l Hist1h2ac Gm10384 
Mthfd1l Rad18 Gm6652 Gm7933 
Dnajc27 Bace1 Mzb1 Dctd 
Idh2 Ino80dos Gm6505 Taf1a 
Cad Slc37a1 Zfp503 Fbxo9 
Suv39h2 Nipsnap1 Gm5703 Plppr3 
Katnal1 AI506816 Rasa1 H2-Q7 
Adgrg3 Itgb3bp Gm5251 Vkorc1l1 
Fubp1 Ift27 Prdx6b Zfp219 
Fam133b Pomgnt1 Oaz2 Crnde 
Gm9797 Zc3h7b Tpi1 Trap1 
Eno1 Nt5c3b Atg12 Arpp21 








280 genes differentially downregulated in both CEBPA N321D and EV-transduced cells 
Eya1 Ndufa4 Crtap Gm12158 
Car3 Ebf1 Hmgcll1 Adgrg1 
Ybx3 Papss2 Igfbp7 Tmem108 
Mmp11 Tfrc Arhgap6 Dtnbp1 
Tha1 Ccl9 Mpo Gm3470 
Prkar2b Gm16194 Tsc22d1 Ptger2 
Gm12611 Gm9143 Tspan6 Csgalnact1 
AI314180 Mab21l1 9330159M07Rik Itga9 
Ift57 Ube2o Ftsj1 Gpr12 
Samsn1 Dab1 Ubash3a Nrxn1 
Gnpnat1 Clec4d Ctsg Sptbn1 
Hist1h3f Spry2 Plcb4 Hmga2 
Ttc39c Col4a5 Ms4a3 Slc28a2 
Chchd10 Mtap Gm14450 Afap1l1 
Epha7 Rnf125 Gm12403 Mif 
Meis1 Aebp1 Pcdh7 Gm15658 
Ydjc Prss57 Lsm3 Gm6065 
Kit Ssfa2 Mmp13 Ap3s1-ps1 
Plod2 Erg Nedd4 Sema3a 
F2rl3 1700113H08Rik Slc38a5 Ablim1 
Pfkl Gm10169 Fkbp11 Plxna3 
Sipa1l1 Mt2 Ap3s1-ps2 Wdr60 
Tst Rbpms2 Ctla2a Gm16302 
Rcn2 Chsy1 Lbp Gm5551 
Hoxa10 Ddx4 Ighv1-23 Gm43489 
Olfml2b Gm43096 Chl1 Stat4 
Sh3d19 Endod1 Cul7 Egln3 
Itga6 Acot3 Tacstd2 Dgat2 
Zfp703 Bphl Pglyrp1 Zxdc 
Gse1 Psmd5 Chek1 Gm7389 
Por Bmx Fam136a Trem3 
Cela1 Plscr1 Gfra2 Pde2a 
Pnkd Gm29397 Slc35b4 Galnt14 
3000002C10Rik Hilpda Hoxa9 Emid1 
Sigirr Gtf2f2 Arhgap18 Mmp12 
Gjb3 Gm17149 9630013D21Rik Fndc3b 
Rasgrp2 Gm11349 Ergic1 Slc19a1 
4930519L02Rik Tespa1 Ppic Elane 
Gcnt4 Gm16897 Cd320 Gm4705 
Clec4e Hlf Pfas 2310075C17Rik 
Ocrl Atp11a Tyms Gm15581 
Reps1 Igkv12-89 Gm37818 Timm8a1 
Kcnq3 Bhlhe41 Mcpt8 Cdkn2c 
Calcrl Igll1 Gm6104 8430408G22Rik 
Hist1h1a Il6 Sapcd2 Psd3 
Nrg1 Fam162a Rag1 Rgcc 
Dab2ip G6pc3 Cd34 Dnajc6 
Gab1 Impdh1 Dntt Ttll9 
Ascl2 Dlg2 Lmo4 Gm16104 
Flnb Vat1 Rsph9 Muc13 
Limch1 Anxa9 Armcx1 Ptgds 
Prodh Gimap5 Abhd17c Igkv4-90 
Angpt1 Acot1 Hk3 Mllt3 
Gca Dtd1 Mcfd2 Nkg7 
2300009A05Rik Galc Tmem40 Gstt2 
Hist1h3d Srgn Nfe2 Rbpms 
Slc17a9 Chchd4 Acyp1 Adgrg7 
Nicn1 Nipsnap3b Parp16 Cdc14b 
Gfra1 Lima1 Ptk7 Psat1 
Hmgcr Col23a1 Gda Ap3s1 
Mt1 Slc22a4 B230118H07Rik Zfp934 
Fat4 Ltbp3 Hgf Ednra 
Gimap9 Stap1 Ptprm Car2 
1700012B09Rik Gata3 Ero1l Zhx2 
Ppid Efna5 Gm11998 Cit 
Cited1 Serpinb1a Gm14630 St6galnac3 
Adgrl4 1700003F12Rik Col4a6 Armcx4 
Dok2 Ica1 Aasdhppt Rag2 
Asph Nrgn Rab44 Dus4l 






Table 8: Genes switched on and switched off by the CEBPA N321D mutation  
385 genes switched off by the CEBPA N321D mutation 
Slc7a8 Gm15448 Rab32 Gm15753 
Spib Fcgr1 Atp2b1 Card19 
Gbp2 Fcgr3 Gpr160 Wipf1 
Fam46c H2-Ab1 Gm7676 Lamp2 
Trem2 Rsad2 Slc35f6 Morc3 
Acvrl1 Cass4 HaCD4 Gm12166 
Ms4a7 Arhgap30 Lpcat4 Sec24b 
Fcgr4 Casp4 Zfyve26 Npc2 
Ifit1bl1 L1cam B4galt5 Efhd2 
Smpdl3b Isg20 Mcl1 Actg-ps1 
Cxcl10 Cnr2 Vwa5a Msrb1 
Slfn1 Icosl Gpr137b-ps Ccdc86 
Cxcl16 Gm5431 Peli1 Gm12164 
Adgre4 Adora3 Samd9l CD48 
Fgl2 Naip6 Gm8902 Dpysl2 
Ifit1 Apobec1 Irf1 Gm23374 
Apoc2 Tnf S100a11 Kctd12 
Phf11d Lmln Nmi Atp6v1b2 
Slamf9 Adgre1 Ccnd1 Ms4a6c 
Plxdc1 Gadd45g Jak2 Sp110 
H2-Aa Dock5 H2-K2 Rgs2 
Nfatc2 Mgl2 Herc6 Gm8399 
Tlr13 Slc15a3 B3gnt8 Arrb2 
Gm12250 Naaa Cdk13 Tmem9b 
Rgs1 Oas1a Adam15 Esyt1 
Phf11a Ids Hgsnat Pik3cd 
Tlr7 Lilra6 C130026I21Rik Gm4760 
C3ar1 Hcar2 Pik3ap1 Gngt2 
H2-Eb1 CD40 Slc29a3 Rnf34 
Il18 Tbc1d8 Eif2ak2 Snx2 
AW112010 Clec4a1 Nfkbid Cyb561a3 
Aim1 Lacc1 Sema4a Rnf114 
C1qb Sorl1 Cotl1 Flna 
Fam129a Ciart Myo1c Ftl1-ps1 
Pilrb2 Dab2 Vasp Nampt 
Trim30c Ifi203-ps Plin2 Anxa2 
Slc37a2 Sertad1 Sft2d1 Hexa 
CD80 Hck Crip1 Acta2 
Cd22 Oasl1 Nfkb2 Syngr2 
Gm37347 Ifi204 Gm7665 Cndp2 
Zfp467 Plaur Prkch Dck 
Arl5c Dusp1 Taf13 Cstb 
Fgr P2rx4 Klf6 Tmem219 
Id3 Parp12 Akt3 Acot10 
Siglec1 Irak2 Dennd1b Gm12715 
Tlr4 Atf3 Gm11189 Ppp1r18 
Nxpe4 Zfp36 Slfn8 Taldo1 
Msr1 Anxa1 Gltp Sh3glb1 
Cxcl2 Ifi47 AC132444.1 Rhog 
Bco2 Fry Camk1 Ftl1 
Maf Tmem176b H2-DMa Swap70 
Clec4b1 Trim5 Lipa Gm12791 
Trim30b Zbp1 Rap2c Rel 
Ifit3b Sirpa Mvp Twf2 
Klk1b11 Cyp4f18 Ifi35 Gm12428 
Ltb4r1 Gm15922 Itpr1 Actg1 
Ccdc109b Cttnbp2nl Ero1lb Ywhah 
Tnip3 Gm6377 Pstpip1 Cnn2 
9430076C15Rik Il2rg Pnpla7 Cyba 
Clec4a4 Csf2ra Tmsb4x Rab8a 
Lpl Il15 Selplg Ptpn1 
C1qc Tmem86a Ncoa3 Rnpep 
Dpp4 Fos Dtx3l Gm5548 
Clec4n Bhlhe40 Dusp3 Ddit3 
Tlr1 Lrrc25 Ep300 Gm17087 
Phf11b H2-DMb1 Picalm Scand1 
Cd274 Rnf213 Gm4918 0610012G03Rik 





Rasgef1b Pid1 Ggh Ctsd 
Tnfsf8 Grasp M6pr-ps Gm8185 
Slamf7 Etv3 Plxnc1 Actb 
P2ry12 Gm6175 M6pr Ccdc50 
1600010M07Rik Gsap Mycbp2 Crlf2 
Ifit2 Tmem150b Tnfrsf1a Laptm4a 
St18 Junb Creb3 Iqgap1 
Card11 Fam26f Gm21738 Ttc7 
Ifit3 Ctsc Abhd12 Gm14856 
Tmem106a Skil Hexb Degs1 
Oas1g Ptafr Cd9-ps Necap2 
Kynu Zfp36l1 Acss1 Gm12543 
Tgfbi Zc3h12a Ifngr2 Arf5 
Ifi213 Slfn9 Fam69a Gm4750 
Hpgds Egr1 Gm16026 Gnaz 
Sirpb1b Irgm1 Ly9 Gm8464 
Alox5 Plekhm3 Tnfaip8l2 Gnai2 
Cdk14 Abcg1 Stard3nl Wdr1 
Gm20559 Fbxw17 Nrp1 Atp6v0c 
Clec9a S100a6 Prdx5 Psmb10 
Gbp4 Ptms Ppp2r5a Cst12 
Lyz1 Gm20432 Gm10800 Rap1b 
St8sia1 Pfkfb4 Cd9 Malat1 
Ms4a4a Txndc16 Hist3h2a Gm8822 
Lrp1 Ier5 Ifi214 Itm2b 
Ccrl2 Emilin2 Cln3 Ier2 
Aoah Pim1 Mndal  
Upb1 Ifi30 Vim  
Aif1 Gm1966 Stk38  
 
 
133 genes switched on by the CEBPA N321D mutation 
Zfp329 Fktn Zfp369 Srek1ip1 
Zfp184 Thap2 Myl4 Cdk6 
Tnfrsf26 Pex10 Ldlrad4 Ppp1r14b 
Cbx2 Gm20696 Ino80dos Gm5124 
Cd27 Fabp5 Ada Dkc1 
Abcd2 Tnfrsf22 CD81 Bzw2 
Osbpl5 Gm1976 Cmss1 Ddx1 
Aasdh Gm9847 Tspan13 Lyar 
Abhd6 Spata7 Arap2 1110038B12Rik 
Rcn1 2810403D21Rik 1190007I07Rik Gm17230 
Col19a1 Gm13998 H2-Q7 Mettl1 
Hemk1 Gm14328 Sdc1 Gm16379 
Cbx6 9230114K14Rik Hmgb3 Gm13719 
Htra3 Klf16 Bag2 Snhg15 
Taco1 Gm6166 Dtx4 Gm7332 
Katnal1 Zfp932 Zbed4 Gm4737 
Ccdc66 Tspan2 Elk3 Gm15659 
Afap1 Zfp113 Ptprcap Gm9826 
4930520O04Rik Rrp12 Gm7901 Gm10020 
Ctxn1 Tspan32 Mycbp Ncl 
Ccdc15 Mnd1 Phgdh Nudcd2 
Spice1 Mnd1-ps Gm5847 Paip2b 
Ankrd26 Il12a Xpc Tufm 
Pi15 AI987944 Smpd4 Gm12020 
Zfp160 Myb Cdca7 mt-Te 
Mgmt Kif17 Zfp687 Ahcy 
Rpusd2 Rdh13 3110040N11Rik Ssbp1 
Bhlhb9 Cnn3 Bace1 Gm17837 
Oxnad1 Cep97 B3gnt2 Hspd1 
Gm10384 Gm20342 H2-Q6 Ak2 
Snapc4 Trp53rkb Ifi27 Hspd1-ps3 
Socs2 Jpx Serf1  
Amer1 Yod1 Gm5385  







Table 9: Genes upregulated during culture for 5 days in Flt3L differentiation media 
637 genes upregulated in main population of 78 CEBPA N321D-transduced cells  
Siglech Il6st Ifnar2 Gpsm3 
Ms4a4c Gm42641 Prkx Klf13 
Tpm2 Parp14 Gatsl2 Tnfrsf13b 
Klrk1 Gas7 Gm14699 Gm4875 
Clec7a Id2 Hes6 Uvrag 
Oasl2 Vsir Tapbp Trim25 
Rnase6 Tmcc3 H2-T23 Bloc1s1 
Oas2 Mx2 Naga Pink1 
Lair1 Ighj2 Tyrobp Nfkbia 
Cd300lf Fads3 Gm17791 Fli1 
AI839979 Trim34a Avl9 Dleu2 
Pilra Znfx1 Gm8995 Smim3 
D930048N14Rik Lhfp Plec Rapgef1 
Tmem51 Fyb Bmyc Fmnl1 
Fabp4 Gm12892 D1Ertd622e Myo1f 
Mir22hg Bach2 Necap1 Capg 
Chrng Ckb Epn1 Dap 
Kctd14 Camk1d Fam174a Mpc2 
Smim5 Galnt10 Cnp Satb1 
Cx3cr1 Tdrd7 Trafd1 Pecam1 
Slfn2 Gm15417 Tor3a Tiparp 
Myog Gpr141 Egfl7 Fkbp15 
Ly6c2 Ly6a Iffo1 Xiap 
Klhl30 Cd300c2 Gpcpd1 Ssh2 
Il10ra Rnf150 Adgre5 Sesn1 
Lifr Slc46a3 Scpep1 Gm13669 
Frmd4b Plekha1 Vps37b Aagab 
Itgax Zfp933 Anxa6 Gm8752 
Ptpro Myadm Arhgap9 Gng2-ps1 
Clec10a Pacs2 Stat1 Mtmr14 
Dpep2 9930111J21Rik1 Lamp1 Hmha1 
Alcam Isg15 Serpinf1 Mtpn 
Plekhg5 Ms4a6b Ypel5 Prkcd 
Ifi207 Gm15987 Atp1b3 Ctsz 
Lcp2 Ccdc180 CD82 Alox5ap 
Ahnak Dusp7 Gm11787 Ifi35 
Slc37a3 Tmem229b Lst1 Ythdf3 
Ly86 Rgs10 Spi1 Notch2 
Gpr34 BE692007 Gm1848 Alyref2 
Cd74 Zfp947 Gm26798 Man2b1 
Lsp1 Cd28 Il4ra Ptpn6 
Ccr1 Sgcb Mkrn1 Wdr26 
Epb41l4b Mroh1 Plac8 Runx1 
I830127L07Rik CD163 Klhl6 Nptn 
Gpr183 Mpeg1 Sp100 Mef2c 
Ctsh Neat1 Gm3788 Trappc5 
Csf1r Lbh Tulp4 Heg1 
Cds1 Ctns Pip4k2a Tpd52-ps 
Ifi27l2a Slc12a9 Bcl2l11 Sh3bp1 
Sgcg Ap1s2 Tubb6 Hcls1 
Il1r2 Clec4a3 Bcl2 Gosr2 
Cd300c Ypel3 Hps3 Mef2d 
Pirb Ube2l6 Ctsb Prr13 
Lgals3 Parp11 Fam105a D930015E06Rik 
Dusp22 P2rx7 Plxnb2 Zeb2 
Nlrp3 Fkbp1b S100a4 Pitpna 
Klrd1 N4bp3 Ocel1 Fam168b 
Rbm47 D8Ertd82e Zbtb20 Gm28875 
Sema6d Irf9 Fam65b Man1b1 
Pld4 Rasa4 Soat1 Nfatc1 
Clec4a2 Tmed8 Mef2a Sppl2a 
Gcnt2 Evi2a Hoxb8 Plekhf2 
Oas3 Borcs6 Bst2 Tm6sf1 
Csf2rb2 Filip1l Epsti1 Mpc1-ps 
Tpst1 Fam234a Anxa5 Ivns1abp 
March1 Hotairm1 Gm7285 Gm6169 
Itgb7 Tlr2 Mkrn1-ps1 Gm12854 
P2ry13 Itgb2 Pak1 5730416F02Rik 





Apba1 Cd68 CD180 Smim20 
Tnfrsf23 Sik1 Fbxw4 Ctsa 
Tnfsf9 Prr5 Irf2bp2 Gm12345 
Slc14a1 Cd300lb Ifi203 Syk 
Mx1 Psap Fads2 Ccl3 
Ctnnd2 Slc44a1 Sh2b3 Parp8 
Ctss Grn Prex1 Abi1 
Tagap Gpr137b-ps Gm15989 Lasp1 
Rin2 Nceh1 Stk17b Tmed3 
Ighj1 Ms4a4b Zfp296 Gm8181 
Rubcnl Osbpl3 Sft2d2 S100a10 
Slc9a7 Atp7a Cytip Trpc4ap 
Slc16a7 Tubb2a Gm14032 Gm8666 
Six1 Abhd15 Pafah1b3 Akirin1-ps 
Il13ra1 Rab7b Dr1 Was 
Lgmn Cyth4 Zufsp Ogfr 
Gm7694 Plekho1 Parp9 Cyfip1 
Cysltr1 St3gal5 Gm4992 2010001K21Rik 
Kmo Tecpr1 St8sia4 Whsc1l1 
Scin 5031439G07Rik Lgals3bp Ifitm3 
Abcb4 H2-T-ps Zfp263 Plp2 
Tns1 Notch1 Pisd-ps1 Asah1 
Klrb1c Stat2 Tifa Rps6ka1 
Cfh Inpp4a Arhgap17 Arl6ip5 
Pstpip2 Dcaf10 Arhgef12 Znrf1 
Clec2i Unc93b1 Bex6 Bnip3l 
Pira2 Gm5398 Ppm1m Usf1 
Lilrb4a Tep1 Lyz2 C330007P06Rik 
Ctse Rcan3 Rprd2 Acaa1a 
Itgam Tmem229b-ps Hlx Fndc3a 
Tfeb Lpxn Zfp62 Ubl3 
BC147527 Tmem119 Gns Gm11663 
Tmem8c Blvrb Dhrs3 Slc44a2 
Cmah Selenop Map4 Gm17887 
Nos1ap 9930111J21Rik2 Tspo Cmtm6 
Sdc3 Sdc4 Snx20 Grk2 
P2ry6 Sema4d Mbnl1 Vamp2 
Lilr4b A530040E14Rik Lyn Ddx24 
Slfn5 Gm5552 Fam76b Litaf 
Ighm Cst3 Sp140 Nrros 
Ms4a6d Dusp5 Rpph1 H2-T22 
Mylpf Zbtb18 Fam129b Rassf5 
Wfdc17 E330020D12Rik Tmem55b Rnf130 
Klra1 Sfxn3 Rmnd5b 2610206C17Rik 
Cybb Aldh3b1 Ehd4 Tor1aip1 
Irf7 Usp12 Kcnk12 Nup210 
Gm14548 Cd52 Nfam1 Arpc5l 
Ifi211 Gab3 Tmem109 Fes 
Rasgrp4 2310001H17Rik Atp13a2 Slc6a6 
I830077J02Rik Irf5 Itm2c Msn 
Ifitm6 Cmpk2 Lnpep Ap3b1 
Cox6a2 Cd300a Map3k1 Ncoa4 
Mycl Gfod1 Slc2a6 Pcyt1a 
Arl4c CD14 Cnbd2 Bloc1s2-ps 
Bmf Inpp5k Ctnna1 Nkiras2 
Klrb1f Plcl2 Zbtb7a Luc7l2 
Hpse Mtm1 Milr1 Gm16372 
Fam214a Fam134b Gm6088 1110059G10Rik 
Aph1c Gm14608 Runx2 Setd2 
Ak8 Acox3 Tec Wasf2 
Havcr2 Xaf1 Laptm5 Dgkd 
Kdm7a Trpv2 Cebpd Pycard 
Evl Btg1 Cdkn1a Serinc3 
Tnni2 Trim12a Gm2622 Zfp36l2 
Klf3 Fgd2 Napsa Reep5 
Gm15931 Map3k5 Gm9844 Ptprc 
Rtp4 Trim30a AbCD1 Leng8 
Dhx58 Sat1 Smim14 Limd2 
Gsn Pigv Ccnd1 Tifab 
Map3k8 Il6ra Selenow Sympk 
Pik3r5 Sh2b2 Rsrp1 Cdc42se1 
Ifi205 Pmaip1 Txnip Bin1 





Itga1 Cadm1 Igfbp4 Gabarap 
Bcl6 Apc Gm12045 Pcif1 
Naip5 Gm8615 Tet2 Iqgap1 
Irf8 Csf2rb H2-M3 Arhgef6 
Snx29 Gng2 Ube2a Fxyd5 
Cln8 Samhd1 Tpd52 Hmgn1 
Slc8a1 Med13l Gm7936 Zc3hav1 
Rara Slfn8 Acer3 Gm7823 
Ccl6 Tmem170b Atp6v1d Edem1 
Ighj4 Zfp385a Il17ra Tmem261 
Rassf4 Gcnt1 Tmsb10 Gm12420 
Axl Uba7 Tmem50b Dpysl2 
Srpk3 Ly6e Bri3 Cdc42se2 
Ebi3 Shisa5 Cbfa2t3 Cyb5r4 
Ms4a6c H1f0 Snx30 Flna 
Arhgap5 Stx7 Cd93  
Trim30d Cfp Adcy7  




21 genes upregulated in subpopulation of 5 CEBPA N321D-transduced cells 
Ly86 Gm2965 Mpc1-ps Gm15148 
Csf1r Fcer1g Dynlt1b Rpl30 
Ccl3 Rps15a-ps7 Gm21399 Lgals1 
Plac8 Gm14539 Rps15a-ps5  
Cd52 Ly6e Gm8430  




1399 genes upregulated in EV-transduced cells  
Ly6a Fgd3 Trim12c Trim25 
Mx1 Gsn Bcl6 Tbc1d13 
Axl Rasa4 Ly9 Ppp2r5a 
Ms4a4a Tmem86a Ifi209 Osbpl9 
Ifit1 Naga Nckipsd Atg7 
Trem2 Cyp4f18 Sema4d Pik3ap1 
Spib Sat1 Tifa Hk2 
Slamf7 Shisa5 Daxx Coro1a 
Tmem51 Ddx58 Gm4918 Grina 
Frmd4b 2810405F17Rik Pdlim5 Tle3 
Ifit3b Zfp467 Cebpd Abcg1 
Slfn1 Atf3 Tmem9b Bcl10 
Phf11d Nfkbid Gpr132 Med10 
Cysltr1 9430034N14Rik Pmaip1 Arhgap25 
Tnfsf8 Klf3 Spi1 Slc25a45 
Klra17 Epsti1 Lyn Tet2 
Acvrl1 Slfn8 Mgat4a Ubl3 
Plxdc1 Soat1 Hist3h2a Pitpna 
Tlr1 Sdc4 Fmnl1 N4bp2l1 
Gm12250 Rogdi Lpp Tubgcp5 
Itgax Isg20 Gm8995 Rap2b 
St8sia1 CD14 Nfkbiz S100a6 
Ifit1bl1 Fkbp1b Slc15a4 Nampt 
Nfatc2 Susd3 Tspo Gpcpd1 
Scimp Tlr4 Arrb2 Aff1 
Rras2 Il12rb2 Ypel5 Acss1 
Epb41l4b Crybg3 Rab32 Foxred2 
Apoc2 Irak2 Ptger4 A230046K03Rik 
Mycl Sh3tc1 Eif2ak2 Usf1 
Gbp9 Cd68 Arhgap17 Ubc 
Tlr9 Gm5552 Diaph2 Capn2 
Ifit3 Zfp36 Sik1 Gm13212 
Id3 Zbtb7b Cotl1 Actg-ps1 
Pid1 Trim34a Zc3hav1 Sdccag3 
Oas2 Lmln Sppl2a Sbno2 
Il13ra1 Cln8 Anxa4 Pisd 
H2-Aa Ier5 Il15 Ptk2b 
Siglech Hpgds Tnni2 Sirt7 





Oasl1 Vwa5a Nfkb2 Ccl3 
Lilra6 Rara Prkcd Rnf167 
Ms4a4c Cnr2 Tax1bp3 Ftl1 
Adgre4 Prkch Sft2d1 Gm9025 
Lilr4b Lrp1 Slc43a2 Ifih1 
Clec4a3 Arhgap30 Iqgap1 Wipf1 
Ctnnd2 Pstpip2 Itpripl1 Ostf1 
Trim30b Ighj2 Mcl1 Vrk1 
Dpep2 Lrrc75a Efhd2 Gm3145 
Gbp4 Ctsb Tnfrsf1a Cib1 
Fcgr1 H2-DMb2 Ppm1h Sap30 
Ms4a7 Metrnl Lipe Map3k1 
Bcl3 Ebi3 Ncoa3 Il3ra 
Slc37a3 Adap2os Tcf19 Fcgr3 
Ctsh Gm14699 Gm7665 Atp6v0c 
Ccdc109b Lpin1 Tcirg1 Zfp277 
P2ry13 Rnd3 Arid5a Rnf34 
Fam129a Filip1l Gm7357 Ifngr1 
Tlr7 Tnfaip2 Gm11787 Mob1a 
Ahnak Slc9a7 Akna Pttg1 
Ly86 Raph1 Lpar6 Dbnl 
Pik3r5 Fbxw17 Npc2 Myo1c 
Slfn2 Fry Gm4875 Msrb1 
Rsad2 Il6st Net1 Cd244 
P2ry10 Gm15503 Lasp1 Gm6615 
Oasl2 Gas7 AC133103.1 Sh3bgrl3 
Ifi207 Themis2 Ptpn6 BC005537 
Cybb Slc12a9 Dennd1c Gm10801 
Ly6c2 Ccrl2 Slc25a22 Fcer1g 
Csf1r Ly6c1 Ctsa Bin1 
Lilrb4a Neurl3 Gm15753 Arpc5 
P2rx7 Plpp6 Itm2c Ctnna1 
Clec7a Cd300a Dck Hcls1 
Sdc3 Itga1 Gm16205 Gna13 
Ifi205 Pak1 Fxyd5 Nfe2l2 
Ptpro Naip5 Dtx3l Sgk3 
Clec4a1 9930111J21Rik2 Chmp4b Limd2 
Cxcl16 Ccl4 Nkiras2 Mfsd5 
Klrk1 Slc16a7 Litaf Hmha1 
Phf11b Rasgef1b Map4 Gm7823 
Slfn5 Inpp4a Tnfaip8l2 Psmb10 
L1cam Gm3788 Zyx Elmo2 
P2ry6 Junb Cmtm3 Rbpj 
Cfh Lpxn Itpr1 Tmed3 
Usp18 Cst3 Pag1 Cd2ap 
Ccr1 Gm14032 Acbd5 1600014C10Rik 
Zbp1 H2-T23 AbCD1 Cd53 
Ifi27l2a Aph1c Rgs2 Ncf2 
Ifi211 Sirpa Asah1 Sirt2 
Cd300lf Arhgap5 Gm21975 Akr1a1 
Clec4n Nfam1 Mpc1-ps 0610012G03Rik 
Tpst1 St3gal2 Plekhg3 Gm7936 
Aif1 Maml1 Laptm5 Cln3 
Rnase6 Ccdc180 Plec Whsc1l1 
Pilra Skil Lgals8 Prkd3 
Lgals3 Rgs3 Syngr2 Selenow 
Tlr13 Herc6 Fbrsl1 Cbl 
March1 5031439G07Rik Dab2 Ccdc86 
Irf7 Gm9844 Sh3glb1 Rchy1 
Cttnbp2nl Fgd2 Cdkn1a Plin2 
Cass4 Snx21 Cmtr1 Sec24b 
Fads3 Armc7 Pim1 Racgap1 
Slc15a3 Grasp Nmi Erlin1 
Rin2 Klf4 Snx2 Gabarap 
Nlrp3 Trafd1 Taf13 M6pr-ps 
Clec4a2 Zcchc2 Gm4992 2310035C23Rik 
Gpr34 Slfn9 Peli1 Lrrk1 
Lsp1 Zfp36l1 Epn1 Ppp1r18 
Trim30d Tubb2a Nedd9 Cst12 
Fcgr4 Slc29a3 Tmem229b Cdc42se1 
Gm14548 Tmsb10 H2-T22 Stat6 
Msr1 Ap1s2 Wdr44 Rraga 





Cd300c Camk1d Dnajb14 Gpr108 
CD40 Cd300lb Plac8 Gng10 
Il10ra S100a4 Dock5 Leprot 
Rasgrp4 Mdfic Nuak2 Rpph1 
Isg15 Scpep1 Gm20432 Gm6263 
Gm20559 Zc3h12a Cyp4f16 Hmgcl 
H2-Eb1 Plaur Necap1 Nrros 
Ifitm6 Sp140 Cmtm6 Slc35c2 
Naaa Gpr146 Ankfy1 Aim2 
Cx3cr1 Ifitm3 CAAA01147332.1 Vasp 
Dusp22 Rnf213 Pcsk7 Inpp5k 
Tnip3 Havcr2 Mycbp2 Fnip1 
Mx2 Casp4 Birc3 Arf5 
Gm5431 Lrrk2 Gm13392 Gm17791 
Gbp2 Dusp1 Gm7676 Hpcal1 
Apba1 Galnt10 Ptpn1 Lactb 
Aim1 Fcor Sertad1 Actg1 
Oas1a Rell1 Myd88 Pepd 
Gpr183 F630028O10Rik Mbnl1 Tnfrsf13b 
Cxcl10 Arhgef12 Vim Cnn2 
Itgb7 Il4ra Usf2 Nt5c3 
Ctss Plekho1 Dennd1b Fnbp1 
Lgmn Gsap Dram2 Hcfc1r1 
Pirb AW112010 Tulp4 Ccdc88a 
Smpdl3b Tecpr1 Tmem184b Slc34a2 
Fyb Cadm1 Degs1 Polb 
Slc37a2 Btg1 Zfp992 AB124611 
Dock4 Ifi35 Gng2-ps1 Esyt1 
C3ar1 Csf2ra Slc25a38 Dcaf11 
Phf11a Ltb4r1 Vps37a Gm6977 
Pilrb1 Plekha1 Rnf115 Ttyh3 
Pira2 Dusp5 Gm43245 Cmip 
Clec10a Prr5 Ptpn22 Gm5590 
Il1r2 Sp100 Sp110 Slc44a2 
Btg2 Etv3 Gm5578 Wdr45b 
C1qb Bst2 Rps6ka5 Lcp1 
Cds1 Trpv2 Milr1 Rp2 
Tnf Igsf6 Cyba Hexa 
Kmo Jak2 Antxr2 Zbtb7a 
Pilrb2 Amn1 Pip4k2a Gm8577 
Trim30c Mir22hg Adam15 Gm8822 
AI839979 Lacc1 Lrch3 Tmem173 
Fgl2 Tlr2 Man2b1 Ifnar1 
Hcar2 Ccnd1 Gpr171 Tm2d2 
Ccl2 Tnfrsf14 Fam129b Gm15487 
Itgam Neat1 Gm4760 Max 
Pld4 Myo1f 1110008P14Rik Map7d1 
Oas1g Anxa5 Mov10 Mical1 
Il18 Gm8902 Tfe3 Tmem243 
Id2 Ifi203 Stard3nl M6pr 
Cd22 Sorl1 Ap2a2 Fkbp15 
Ms4a6d Slc46a3 Gng2 2010001K21Rik 
Card11 Gm43330 Cstb Anxa2 
Tnfsf9 Cfp Arhgap9 Epb41l2 
Lyz2 Ncoa7 Klhl6 Renbp 
Arl5c Plxnb2 5730416F02Rik Slc35c1 
Stard9 Gm15417 Rcbtb2 Acaa1b 
Ccl6 Tdrd7 Gm5046 Lrrfip2 
Atp1b1 Slc35f6 Cdk13 Acot10 
Ifit2 Bcl2l11 Stard3 Prr13 
Ifi204 Padi2 H1f0 Ostm1 
3110043O21Rik Frmd4a Gm13535 Ascc3 
Cd300c2 HaCD4 Rnf114 Acap2 
Gadd45g Itpripl2 Stxbp3-ps Actr3 
Ctse Paqr4 Sgpp1 Fth1 
Chn2 Tapbpl Rap2c Nipa2 
Tmem154 Carmil1 Lmo1 Gm12715 
Gpr137b-ps Lyst Prkx Gm6305 
Fgr Gm37589 B4galt5 Psme2b 
Ube2l6 Nr4a1 Capg Gm14856 
Upb1 Plxnc1 Brox Spop 
St18 Prkab2 Rnf166 Sp2 





Rbm47 Ptafr Sh2b3 Grk2 
Tmem106a Tmem176b Picalm Gm12428 
0610040J01Rik Gm5763 Iqgap2 Crlf2 
Evl Tyrobp Klf13 Nfkbib 
Tfeb E2f2 Map2k1 Swap70 
Clec4b1 Acox3 Gm11189 Gm23374 
Oas3 Trim5 Clcn7 Atp6v0d1 
Adgre1 Bmyc Tpm4 Xbp1 
Fam46c Fnip2 Pqlc3 Scn4b 
Dram1 Rubcnl Plekho2 Sqstm1 
Maf Kctd12 Txnip Pstpip1 
Lifr P2rx4 CD48 2610206C17Rik 
Gm37347 Napsa Scarb2 Pisd-ps1 
Ifi208 P2ry14 Gm7809 Ttc7 
Gpr18 Hps3 Rab3d Fuca2 
Adora3 Slc8b1 Snx20 Gm13077 
Siglec1 Tmem109 Parp10 Skap2 
Smim5 Fam26f Rnf31 Sdhaf2 
Gm15987 Lgals3bp Cyld Ftl1-ps1 
Ms4a6b Npc1 Acta2 Actr2 
Adap2 Dclre1c Hsd17b4 Zcchc6 
Kctd14 Dennd1a Mknk1 Acaa1a 
Nxpe4 Tapbp Camk1 Emp3 
9430076C15Rik Gm8369 Ncor2 Atp6v1d 
C3 Ifi203-ps Rgs14 Arhgap4 
Ifi206 Malt1 Smim3 Eif2ak1 
P2ry12 Bri3 Mafk Rel 
Gm15931 AC132444.1 Usp25 Acot9 
Alox5 Apobec1 Twf2 Rabep1 
Wfdc17 Tep1 Arhgef6 Cast 
Cd300lg Zfand2a Abhd12 Fes 
Socs1 Lmna Nfatc1 Abi1 
B430306N03Rik Il6ra Gnai2 Tacc1 
Naip6 Kif1b Tiparp Psme2 
Csf2rb2 Il21r Arl8a Cldnd1 
Klk1b11 Tmem55b Cndp2 Lamtor1 
Cxcl2 Plcl2 Rnf13 Ints4 
Slc14a1 CD82 Cnp Keap1 
Grap Hmox1 Cxcr4 Gm5510 
Cmpk2 Lst1 Klf10 Ier2 
Bco2 Hgsnat Msn Ccdc50 
I830127L07Rik Pelo Mpp1 Itm2b 
Ms4a4b Trim12a Gcnt1 Cap1 
Lcp2 Ifngr2 Haus8 March5 
Bach2 E2f7 Cyfip1 Rbms1 
Lyz1 Rgl1 Pqlc1 Gm14000 
Clec4a4 H2-Ab1 Vcpip1 Bloc1s1 
Znfx1 Ifi214 St8sia4 Pias1 
Gm15922 Aldh3a2 Rhog Vcl 
C1qc Rmnd5b Vps37b Commd8 
Gm15448 Ncoa1 Flna Psme1 
Vsir Ptprj Bet1l Tmod3 
Socs3 Atp2b1 Gnpda1 Rab8a 
Tbc1d8 Hck Gm14608 Myo9b 
Gm5398 S100a10 Fos Sub1 
Dpp4 Plekhg5 Pycard Snap23 
Parp12 Alox5ap Plekhf2 Grb2 
Dusp10 Hdac4 Dpy19l1 Tmem192 
Tagap Usp12 Stam2 Tmem134 
Lpl Irf1 Mvp Rbfa 
Fcgrt Cdk14 Capza2 Wdr26 
Lair1 Zufsp Necap2 Rac1 
Ighj1 Notch2 Mif4gd Smap1 
Kynu Synj1 Gm18588 Gm5828 
Cd274 Rps6ka4 Tmem189 Ndel1 
Myadm Slc26a2 Add3 Gngt2 
Irgm2 Plekhm1 Ypel3 Macf1 
Sirpb1b Tmem50b Rassf1 Rtn4 
9930111J21Rik1 Ctsc Slc6a6 Gm15899 
Ifi213 Stx7 Ifi47 Mysm1 
4930430E12Rik Gpsm3 Il17ra Nadk 
Zfp385a Rgs1 Gm26740 Il2rg 





Ms4a6c 4833421G17Rik Ddi2 Apbb1ip 
Pfkfb4 S100a11 Plekhb2 Cd9-ps 
Traf5 Ciart Rnh1 Smim14 
BC147527 Lamp1 Sft2d2 Tor1a 
Xaf1 Cnbd2 Rnpep Malat1 
Clec9a Aoah Gns Atp6v1e1 
Dhx58 Mndal Dtx2 Spg21 
Blvrb 5430427O19Rik Gnaz Myo1g 
Alcam Ifi30 Mtf1 Gm5548 
Gcnt2 CD180 Tmem219 Ankrd44 
Gpr155 Ctsz Fem1c Uvrag 
CD86 E330020D12Rik Morc3 Atp6v1b2 
1600010M07Rik Cic Stk38 Zfp36l2 
Slc7a8 H2-K2 Dna2 Gm7114 
Tmcc3 Fam105a Gm4962 Gm12791 
Gm6175 Cyth4 Gpr160 Gm7776 
Gm26637 Mef2a Bex6 Syk 
Psap Cav2 Coro1b Vamp3 
Gm1966 Slc2a6 Pml Cpne3 
I830077J02Rik Ddit3 Prdx5 Gm13453 
Hpse St3gal5 Zdhhc7 Mdm2 
Stat2 Ifnar2 Trim26 Cd9 
Rtp4 Gm12854 Cdc42se2 Gosr2 
Asgr2 Tmem176a Gm8464 Laptm4a 
4930455G09Rik Adar Ehd4 Ralb 
Ids Egr1 Gm21738 Nub1 
Samhd1 Wwp1 Spty2d1 Arhgdia 
Gm42641 Sertad3 Gm10717 Ccdc50-ps 
Rgs10 Gm9397 Gm13597 Gm8399 
Map3k8 Csf2rb Gm12166 Mapk14 
Aldh3b1 Tor1aip1 Akt3 Sri 
Rassf4 Tmsb4x Nek7 Ywhah 
Gpr141 Fam174a Arhgap31 Arhgap15 
Kdm7a Prex1 Ptprc Rn7sk 
Ak8 Tnfsf12 Actb Runx1 
H2-T24 Parp9 Dpysl2 Smdt1 
Ighj4 Klf6 Crip1 Xiap 
Entpd1 Selplg D1Ertd622e Rab1b 
Mpeg1 Zfyve26 Lamp2 Fam49b 
Cd52 Gm13669 Gm16026 Azi2 
Txndc16 Mkrn1 Reep5 Azin1 
CD80 Sesn2 Sgpl1 Atp6ap1 
Arl4c Tmem150b Lipa Gm2986 
Lrrc25 Pot1b Card19 Cdc42 
S1pr2 Gm15989 Lrch1 Gm12226 
Irf8 C130026I21Rik Sidt2 Wdr1 
Nostrin Emilin2 Ppp3ca Vps51 
Klrb1f Phactr2 Bin3 Erp29 
Pea15a Smox Gsdmd Gm12430 
Bhlhe40 Dusp3 Gm8641 Tspyl1 
Trim36 Tpd52-ps Pik3cd Far1 
Grn Irf2bp2 Cyb561a3 Ddx24 
A530040E14Rik Crybg3 Gm17087 Cln6 
Ighm B3gnt8 Mpc1 Chmp1a 
Irf5 Acer3 Pdxk Ctsd 
Tor3a Dhrs11 Dyrk1a Ensa 
Stat1 Nfkbia Elmsan1 Gm42786 
Icosl Plp2 Gm12543 Mob3a 
Slfn10-ps Atp8a1 Nptn Gm9392 
Helz2 Gltp Gm16372 Rps6ka1 
Nos1ap Lpcat4 Kif23 Ptpra 
Ckb Relb Gm11405 Gm7367 
Samd9l H2-DMa Ep300 Mvb12a 
Irf9 Mkrn1-ps1 Gm12345 Taf6l 
Cytip Pnpla7 Srgap2 Oser1 
Slamf9 Thap6 Slc31a1 Vapb 
Gm6377 Hlx Nagpa Txndc15 
Unc93b1 Camta2 Nfkb1 Gmip 
Cd28 Parp3 Foxn2 Szrd1 
Abhd15 Plod1 Gm4750 Mir6236 
Selenop Stk17b Rin3 1700097N02Rik 
BE692007 Dnase1l1 Zfp263 Arpc2 





H2-DMb1 Sema4a Mthfs Rap1b 
Clcn5 Tpd52 Zfp710 Herpud1 
Sema4c Uba7 Mfsd12 Rassf5 
Ero1lb Map3k3 Gna15 Ptp4a2 
Mgl2 Hexb Exoc3 Psen1 
Irgm1 Sgcb Ccr2 Gm15361 
Itgb2 Rarg Gm10800 Gm8185 
Igtp Rab7b Rala Dync1h1 
Evi2a Gvin1 Ythdf3 G6pd2 
Rab3il1 Zfhx3 Anxa1 Clta 
Tlr6 Ssh1 Gm6695 Snx10 
N4bp3 Ppm1m Pnkp Nrp1 
Fam69a Mtmr14 Stxbp3 Ccdc12 
Gm12892 Gm6169 Arl6ip5 Gak 
Tgtp2 Anxa6 Scand1 Gm12164 
Ptms Trp53i13 Samd8 Serp1 
Trim30a Sh3bp2 Trim14 Arpc5l 
Pacs2 Ogfr Taldo1 Gm15534 
Tgfbi Ggh Tec  
 
 
Table 10: Genes downregulated during culture for 5 days in Flt3L differentiation media 
432 genes downregulated in main population of 78 CEBPA N321D-transduced cells 
Gpc3 Ankrd37 Tmem108 Dtd1 
Igll1 6030408B16Rik Nrxn1 Hist1h3b 
Zbtb16 1700012B09Rik Plod2 Gm12611 
Armcx1 Gm11998 Ctsg Ero1l 
Pcdh7 9630013D21Rik Gm26597 G6pc3 
Csgalnact1 Amz1 Tst Flnb 
Lbp Zc4h2 Clec4e 2810408I11Rik 
Ptk7 Vcan Gpr65 Ydjc 
Gfra2 Zbtb34 Gm16104 Mtap 
P2rx3 Srxn1 Dab1 Ssbp3 
Tspan6 Cdc14b Col4a5 Tfrc 
St6galnac3 Mmp11 Dusp19 Ifi47 
8430408G22Rik Col23a1 Hsd11b1 Rab44 
Chl1 Ascl2 CD84 Asph 
Mmp13 1700113H08Rik Clec4d Gtf2f2 
Sema3a Ube2o Plscr1 Mmgt1 
Ddx4 Gfra1 Spry2 Gm14038 
Ms4a3 Nrg1 Depdc1b Tgfb1 
Gpr12 Zxdc Gm5530 Gm43096 
Kit Ltbp3 Ttll9 Hilpda 
Ctla2a Dab2ip Gstt2 Chchd10 
Pde2a Cela1 Sirt1 Ap3s1-ps2 
Dlg2 Zhx2 Zfp704 Casp7 
Hmgcll1 Ighv1-77 Fam46a Erlin2 
Fat4 Polm Ptger2 Gm16194 
Hlf Pglyrp1 Gm29397 Ybx3 
Aebp1 Gimap5 Gm37818 Hist1h2ae 
Col4a6 Gm43489 Mpo Ppid 
Rag2 Mettl18 9330175E14Rik Pfkl 
Rbpms2 Hivep3 9330159M07Rik Rmnd1 
Angpt1 Zfp462 Nars2 Chek1 
Trem1 Ankrd50 Gfpt1 Gm4705 
Ebf1 Klhdc1 Galnt14 Psmd5 
Prdm1 Mcpt8 Abcb1a Gm17149 
Ablim1 Il11ra1 Muc13 Endod1 
Gata3 Afap1l1 TlCD1 Gnpnat1 
Tacstd2 Adgrg7 Fpgt Vav3 
Dntt Ppic Adcy9 Por 
Ocrl 1700003F12Rik Zc3hav1l Ap3s1-ps1 
Gab1 Rgs1 Fcgr3 Ap3s1 
Sh3d19 Cul7 Pon3 AI314180 
Hoxa10 Gm37354 Nfe2 Gm5551 
Bmx Rbpms Fkbp11 Rasgrp2 
Bhlhe41 Tmem132d Impdh1 Mt1 
Slc28a2 Rims2 Prodh Lsm3 
Limch1 Atp11a Tespa1 Pfas 





Acot1 Ammecr1 Mt2 Sigirr 
Car2 Ubxn11 Hist1h2an Cit 
Acot3 Tet1 Pvr Crtap 
4930519L02Rik Kcnq3 Dok2 Arhgap18 
Pi16 Hist1h3d Man1a Ftsj1 
Rsph9 Mmp8 Ssfa2 Hist1h3c 
BC026585 AW146154 Sipa1l1 Gm16302 
Gimap9 Galc Gse1 Fam60a 
Adgrl4 Ptprm Smtn Tyms 
Emid1 Rbakdn Hist1h2bg Nudt1 
Mmp12 Wdr60 Spred2 Hist1h2ai 
F2rl3 1110019D14Rik Prkar2b Atp11b 
Rag1 Ubash3a Hist1h3f Gm7389 
Efna5 Olfml2b Rapsn Rsu1 
Il6 Nkg7 Ldlrad3 1810037I17Rik 
Itga9 Dnajc6 Gm7805 3000002C10Rik 
Trem3 Zfp758 Ednra Aasdhppt 
Vamp5 Tmem40 Dtnbp1 Fam136a 
Slc22a4 Hist1h1a Vat1 Ppp1cb 
Tha1 Ttc39c Ifi214 Pfdn4 
Siglecf Atp10a Kdm1a Hmgcr 
Ighv1-23 Plcb2 Fndc3b Mcfd2 
Igfbp7 Adgrg1 Itga6 Slc19a1 
Gda 2310075C17Rik Hist1h4n Hist1h2ab 
Ctla2b Hist1h3e Pam Timm8a1 
Csf3r Crim1 Tgfbi BC003965 
Zfp27 Ptgds Stap1 Lmo4 
Gm3470 Gfi1 Cdkn2c Sptbn1 
Cited1 Tyw3 Abhd17c Ift57 
Zfp703 Rps6ka3 Dgat2 Eya1 
Xrcc5 Gm43431 Rgs18 Gm13313 
Fosb Zfp934 Kdelc1 Rcn2 
Als2 4933431K23Rik Tmem29 Amd1 
Trim68 Plcb4 Nrgn Gm6104 
Gcnt4 Gm15581 Zswim7 Ndufa4 
St3gal6 Gm16897 Hist1h1d Nedd4 
Igkv4-90 Homez Gtse1 Gm14450 
Pomgnt2 Mab21l1 Egln3 Cenph 
Nicn1 Rgcc Gm15658 Mif 
Hgf Pygl Hist1h1b Chchd4 
Six5 Ighmbp2 Anxa3 Rps29 
Armcx4 Arhgap6 Reps1 Cryzl1 
4930486L24Rik Lima1 Hoxa9 Srgn 
B230118H07Rik Ankrd24 Chsy1 Gm6065 
Gm38345 Nrp2 Serpinb1a Gm11349 
Asb1 Cd34 Adgra2 Orc3 
Optn Clec5a Gm9143 Acyp1 
Ica1 Rnf125 Slc17a9 Gm10169 
Tnni3k Slc35b4 AA474408 Gm5251 
Gm12158 Hpgd Prcc Rpl15 
Mllt3 Papss2 Hk3 Pnkd 
Flt1 Epha7 Calcrl 2300009A05Rik 
Slc38a5 4930555A03Rik Psat1 Bphl 
Prss57 Slc11a1 Stat4 Gm14630 
Plxna3 Parp16 Hmga2 Ube2w 
Zfat Erg Steap3 Fam162a 
Lekr1 Car3 Nipsnap3b Cebpzos 
Igkv12-89 Hist1h3g Samsn1 Ebna1bp2 
Ift81 Meis1 Ccl9 Ergic1 
Elane Slco3a1 Tsc22d1 BC028528 
Psd3 Dus4l Tex30 Nop10 
 
1942 genes downregulated in subpopulation of 5 CEBPA N321D-transduced cells 
Mmp13 Mgat4b Rgp1 Phf12 
Tnfrsf1b Nfic Myo18a Nploc4 
Trim16 Ank Cops7b Tmem165 
Gpc3 Letmd1 Htatip2 Ptpn1 
Ankle1 Ankrd13c Mast3 Sharpin 
Flcn Vcl Dhrs4 Gtf2h3 
8430408G22Rik Man1a Traf4 Gk 
Gfra1 Fam120b Ddx19b Wdr75 





Manea Mmab Hsf1 Zwilch 
Plcb3 Tsen54 Ifi206 Gm8546 
Urgcp B4galt7 Apba3 Cdk19 
Osbpl5 Vps18 Abhd10 Cercam 
Lcmt2 Pradc1 Dennd6a Clec4e 
Hlf Hnrnpll Zfp777 Cdkn2aip 
Noct Scarb2 Thap3 Gm9774 
March8 Dnal4 Ptpn9 Gm13803 
Dus2 Rbm33 Mbd4 Rasgrp2 
Slc25a15 Hsdl1 Gpatch11 3000002C10Rik 
Fam179b Spg11 Slc35f5 Zc3h7b 
Trim26 Tfec Pard6a Mmp8 
Csgalnact1 Trappc6b Ppm1b Gm37784 
P2ry2 Pex6 Epc2 Pck2 
Hacl1 Blcap Tbl2 Itga5 
Ipo13 Zfp397 Fam53b C2cd5 
Ap5z1 Prss57 Kptn Snord55 
Pramef8 Socs4 Mier1 Frrs1 
Klhl26 Armt1 Dnajc6 Gabpb2 
Tle6 Med23 Clec4d Pdhx 
Faap100 Prdm1 Cep72 PdCD4 
Tmem18 Nf2 Elp6 2310009A05Rik 
Tango2 Tmem120a Dicer1 Gm12791 
Sepsecs Cited2 Klhl15 Hgf 
Btrc Msi2 Hnrnpul2 Nup50 
3110002H16Rik Ptk2b Dtwd1 Smtn 
Irf1 Pon3 Stim2 Jarid2 
Spryd4 Ndnl2 Fam216a Slc35b4 
Acp2 Adgra2 Dclre1c Fbxw11 
B4gat1 Tspyl3 BC029722 Paf1 
Idua E4f1 Dcp1a Phkg2 
Ikbke Pex3 Tnrc18 Hspa4 
Mtmr3 Myd88 Ercc6 Gm2810 
Polr3a Nbeal2 Cntln Dirc2 
Dstyk Ankfy1 Kdelc2 Supt6 
Tubd1 Ints3 Optn Rptor 
Rufy1 Tgoln1 Isoc2b Helz 
Klhl22 4833420G17Rik Antxr2 Stim1 
Zscan21 Limk1 Sbno2 Uap1l1 
Zfp574 Acadvl Inf2 Gm1969 
Fam160b2 Chek2 Tnip2 Gm29462 
Slc25a44 Rab43 Tnip1 Rapgef1 
Ltbp3 Clec5a Mlst8 Ppcdc 
Samd10 Irak3 Tmub1 Aurka 
Usp11 Mospd1 Tsen15 Rrp8 
Tk2 Rad51d Gmeb2 Zhx1 
Vhl Rbsn 2410004B18Rik Rrp7a 
Gpr160 Kif21b Emilin2 Zcchc6 
Igll1 Zfp608 Snapc5 Wdr5 
Plekha7 Aars2 Dab2ip Bhlhe41 
Zgpat Nfrkb Tbc1d7 Gm7162 
Zscan12 Osbpl9 Arhgap32 Bcl7b 
Dennd1c Dtx2 Myo9b Gm15530 
GuCD1 Trim11 Ift74 Vprbp 
Scrn2 1810043G02Rik Tbc1d1 Mcph1 
Det1 Klhdc4 Rtf1 Gm8818 
Parp10 Zfp639 Rsph9 Yif1b 
Mutyh Brf1 Ythdc1 Pik3ip1 
Fbxl4 Fpgt Paox Rbms1 
Ezh1 Fbxw8 Cntrob Gm13517 
Hsd17b7 Akap8l Slc35a3 Mt2 
Zbtb16 Nsl1 Xpa Ska1 
Pomk Pddc1 Kpna6 Nr2c2 
Ubash3a Atg16l1 Mia3 Ing1 
Socs5 Asb6 Wasl Scamp2 
Pcdh7 Kdm4c Coa4 Ate1 
Lss Trem1 Kdm5c Mapkap1 
Tbc1d25 Mettl3 Anxa9 Rabepk 
Tjp2 Prosc Hck Scaf1 
Wipi1 Erbin Kat6a Ccdc43 
Zfp523 Arhgap19 Tbp Akt1 
Pcp4l1 Srsf4 Mcm3ap Fasn 





Sdccag8 Map4k5 Champ1 Cenpe 
Wrap53 Cast Tcta Ifitm1 
Spice1 Nfatc3 Atat1 Actn4 
Dhx34 Oip5 Cdc37l1 Mapk14 
Ddx59 Fem1a Zmym4 Tpm1 
Ilvbl DHRSX Prkag2 Acot7 
Nrp2 Tyk2 Pip5k1a Mrps5 
Slc25a25 Cdk5 Rnf125 Dnajb12 
Gfra2 Tmem214 Lrif1 Yif1a 
Zswim1 Hibch H2-Ab1 Golga5 
Daglb Dhx29 Kif18b Pdpk1 
Mon1a Gpr180 Arnt Kdm6a 
Bbs2 Fam3a Pura Dctd 
Slc2a3 Nol6 Arrdc3 Naa60 
Brat1 Ctso Kdm2b Tagap1 
Mettl8 Man1c1 Aco1 C330027C09Rik 
Insig2 Trmt5 Nars2 Vav3 
Pdik1l AC149090.1 Tle3 Gm6158 
Hps6 Zfp869 Insig1 Cdk16 
Mr1 Etv5 Troap Fam126b 
Gsg2 Rint1 Oxnad1 Arhgap31 
Ppp1r16a Mllt10 Trmt61b Gm6623 
Cyp4f13 Dgcr14 Hps4 Ddx49 
Cep131 Sgms1 Pigl Ncf4 
March2 Herc2 Gtf2ird2 Asl 
Glipr2 Mab21l1 Polr3gl Gm15800 
Gclc Phf14 Rnf213 Sppl2a 
Fam174b Azi2 Prune2 Raly 
Armcx1 Brpf1 Fam219b Sdc1 
Tmem110 Eme1 Map1lc3a Cnot1 
Fam185a Pigc Xrcc2 Dhx36 
Alg12 Gas2l3 Zfp668 Mthfd1l 
Zfp729b Lrp6 Nfkb2 Nudcd3 
Spryd3 Utrn Ubxn2b Lonp1 
9130011E15Rik Nr2c1 Papss1 Dctn2 
Pgpep1 Dennd4b Ankra2 Micu2 
Slc38a7 Caml Cdk13 Arid1a 
Slc37a1 Rtn4ip1 Lin37 Nomo1 
Usp28 Ppfia4 Scyl2 Suco 
Pomgnt2 Gyg Smg8 Stx8 
Nedd9 Ints6 Relt Cul2 
Pex12 Bloc1s5 0610009B22Rik Cdca7l 
Aifm2 Tceanc2 Grb2 Sptbn1 
P2rx3 Secisbp2l Plekhg3 Mogs 
Trp53i13 Serpinf1 Arid5a Fbl 
Cyb5rl Pop1 Spag5 Map2k3 
Lima1 Golim4 Amz2 2610206C17Rik 
Snrk PdCD11 Nt5dc1 Ube2g2 
Sgk1 Morc2a Oxld1 Numa1 
Snupn Exosc4 Fkrp Prkd3 
Hook2 Trappc8 Tsr1 Ptcd3 
Cdk5rap1 Qpctl Mtf1 Ebp 
Cep89 Cenpo Rbm45 Setd2 
Alkbh4 Nphp1 Erich1 Guca1a 
Osbpl7 Rnf123 Rhebl1 Hist1h1c 
Hcfc2 Bicd2 Tmtc3 Nr1h2 
Fut4 Zfp692 1700109H08Rik Mdm2 
Rsad1 Phf7 Pqlc1 Tap1 
Aldh7a1 Dguok Dhx38 Fam192a 
Pim3 Zzef1 Ndst1 Celf1 
Slc2a8 Mgat4a Ipo4 Kit 
Unc45a Sft2d2 Irak1bp1 Haus4 
Ccdc77 Hps5 Kmt5c Tomm40l 
Myadm Irx2 Ahi1 Ltbr 
Fam160a2 Tti1 Fdxacb1 Cluh 
Lbp Trappc3 Dhdh Hnrnph2 
S1pr3 Commd5 Csgalnact2 Wdr82 
Tmem268 Clasrp Slx1b Arfgap2 
Baiap2 Chchd6 Twsg1 Usp22 
Hyal2 Fam195a Gm19680 4921524J17Rik 
Sh3bp5l Klf2 Dlg1 Gm15519 
E130307A14Rik Lztr1 Prepl Os9 





4933404O12Rik Atp5s Primpol Hk1 
B3galt6 Arfgap3 Sec24b 4930453N24Rik 
Wbscr27 Ash1l Tbc1d22b Nrgn 
Wdr91 Mtmr12 Ube2d-ps Gm26917 
Txnrd3 Gzf1 Vezt Fads1 
Cog3 Mul1 Mospd2 Nkiras2 
Coq8b Tacstd2 Dus4l Sigirr 
Ndor1 Mto1 Gm13328 Cpsf7 
Nuak2 Hgh1 Cluap1 Setd5 
Appl2 Pdlim7 Arl10 Notch2 
Gem Rb1cc1 Tpcn1 Cdc34 
Gba2 Zfp157 Sos2 Acot2 
Slc25a29 Polr3d Scrib Nosip 
Tmem237 Poc1b Usp36 Dapp1 
Vps8 Nagk Cacfd1 Ankrd11 
Taf8 Ppp2r5e Sik2 Gtf2i 
Terf2ip Pcnx Abl2 Tbl3 
Slc35e1 Selenoi Dse Cdc20 
Arrdc2 Poli Hps3 Dusp6 
Gbp7 Gm20342 N4bp2l1 Epha7 
Zfp775 Rffl Rag1 Dnase2a 
Tmem185a Fgd4 Csf2rb Zmpste24 
Recql4 Rfx7 Fam118b Pik3r1 
Git1 Nsun4 Wwc2 Mrpl58 
Irf2bp1 Hdac5 Dcaf4 Fam172a 
Tepsin Unc13d Rab5b Crtap 
Cbx2 Rpusd4 1110038F14Rik Dok3 
Aff1 Rnpepl1 Dhrs11 Gm10051 
Zfp407 Entpd6 Gm12454 Itgal 
Plscr4 Ipo8 Gfpt1 Cdk11b 
Hace1 Gpatch1 Pspc1 Ap3s1-ps2 
Dnajc14 Rnf145 B4galt3 Pxn 
Recql5 Panx1 Prelid2 Cdc27 
Syne2 Cep57l1 Gadd45a Rrp9 
Tmtc4 Cdc25c Cbfa2t3 2410002F23Rik 
Arhgap6 Lactb Mesdc1 Acin1 
Tbc1d10a Supt7l Fez2 Gpbp1l1 
Mmp12 Kctd10 Mterf3 Fam46a 
Rab44 Rbm28 Rbm6-ps1 Eif2d 
Dntt Rraga Ptpn4 Rcn2 
Plod2 Plod1 Ccdc88c Plscr1 
Angpt1 Akap9 Rbbp6 Csnk2a1 
Emid1 Yipf2 Nfkbil1 Anxa1 
Ssfa2 Map3k4 Focad Adprh 
Sema3a Iws1 Tmem156 Tctex1d2 
Slc11a1 Mcm9 Sfxn2 Bckdha 
Chl1 Stat5a Psd3 Cnot9 
Gaa Tmc6 Dennd1b Mmadhc 
Sapcd2 Pik3ap1 Mgme1 Ppp1r8 
Muc13 Gramd3 Shprh Ubr4 
Por Pus7l Upf1 Jagn1 
Ppm1f Epb41l2 Fam76a Gm8010 
Mllt3 Traf3ip3 Tex264 Gm5530 
Idh1 Coq7 Tnks Yeats4 
Ddx4 Aldh4a1 Mapk3 Suv39h1 
Galnt14 Nrp1 Gin1 Lyz2 
Pde2a Faap20 Dusp19 Srprb 
Ccnf Pi15 Prr11 Btk 
Emilin1 Itgb3 Nubp1 Itpr1 
Gys1 Dnajc13 Fra10ac1 Acap1 
Stxbp2 Rap2c Camk2d Selenom 
Pfkp Gca Gcc2 Tmed7 
Rgs18 Nfat5 Cyb561a3 Gm38078 
Papss2 Golph3l Afg3l2 Prr14 
Preb Dvl2 Pcyt1a Tmem39a 
Bin2 Gpn2 Endog Impdh1 
Lpcat2 Cpped1 Thap4 Gm7389 
Stk11 Wrnip1 Vps13b Anxa3 
Reep4 Rgs1 Xndc1 Dlst 
Zfp703 Sumf2 Osbpl2 Pdia4 
Aebp1 Ikbip Cenpl Nudt3 
Erlin2 Sphk2 Tal1 Apobec3 





Lmo4 Mctp1 Dusp12 Mia2 
Ikbkap Pcsk4 Vamp5 Rbm5 
Trabd Ocrl Praf2 Ahsa2 
Zfr Ppp1r14c Gab2 Pdxdc1 
Gpr12 Pex16 Gigyf1 Zdhhc20 
Smg5 Ttk Tmem259 Cd72 
Tmed1 Pex1 Sun1 Stom 
Nat10 Hmbox1 Thg1l Usp9x 
Ankrd27 Hmg20b Gm18284 Smc2 
Prkar2b Ncoa6 Tfb1m Ccar1 
Nfe2 Tmem218 Phf8 Ift20 
Acot1 Cipc Aida Atp6ap1 
Anapc7 Ankrd28 Dedd2 Lpcat3 
Vps26b Cox18 Bud13 Myc 
Armc5 Zpr1 Ccdc186 Leng8 
Mfge8 Cpne2 Fam49a Hmgcs1 
Wars A230050P20Rik Slc22a4 Ifrd2 
Ctla2a Abhd6 Purb Mars 
Ednra Pecr 5730480H06Rik Tpp2 
Skiv2l Manbal Sirpa Ube2w 
Polrmt Yeats2 Bahcc1 Dpp3 
Miip Tpgs1 Furin Pgd 
Sart3 Bsn Ermard Tm9sf4 
Dhodh Nprl2 Lamc1 Gm2a 
Gstz1 Hmces Gm6493 Pigu 
Atp13a1 Kmt5b Brwd1 Elk3 
Hmgcll1 Med26 Wdr62 Alkbh5 
Pcyox1 Vcpip1 Sfmbt1 Herpud1 
Col4a6 Zfp282 Igsf6 Timm17a 
Gorasp1 Pstk Hist1h1d Tln1 
Ptprm Gab1 Arhgap10 Mir5099 
Hilpda Wdyhv1 Srf Tacc3 
Chid1 Ccdc18 Plcg1 Acly 
Dlg2 Nbas Ighv1-23 Nipbl 
4930427A07Rik Sugp2 Cdk5rap2 Ewsr1 
Man2c1 Mrpl45 Inpp5f Arhgap18 
Cant1 Fam188a Scly Pwp1 
Orai3 Usp42 Nudt13 Rnf181 
Wwp2 St7 Actr6 Gnpat 
Pitpnm1 Aldh6a1 Trak2 Dcaf7 
Stat6 Grpel2 Pafah1b3 Xpc 
Clip1 Sh3glb2 Gse1 Tmem183a 
Narf Ccdc191 Ick Gm7556 
Fut7 Tjap1 Ints8 Stk4 
Pml Mical1 Sufu Gm7676 
Inpp5b Uros Csnk2a2 Map1lc3b 
Fat4 Tirap Gapvd1 Vasp 
Tgfbi Sh3d19 Rpia Dld 
Dmtf1 Snap29 Kcnj2 Tmx2 
Slc9a9 Map2k7 Ncor2 Cd34 
Ttll12 Parp16 Rnf216 Tmem242 
Ggta1 Csnk1g3 Gm5874 Tbcb 
Aldh3a2 Bcor Slc25a12 Gm9923 
Eif2b2 Polr3c Ppp1r9b 2810403A07Rik 
Fastk Birc2 Adgrl4 Eprs 
Sipa1l1 Klhl7 Ubqln1 Zfp622 
Hoxa10 Thap7 Slc35e2 Glud1 
Gch1 Ptch1 Gm12166 Fbxo9 
Slc39a11 Agps Map2k4 Eif3d 
Rdh11 Tmem199 Fbxw2 Arl6ip4 
Safb AU040320 Strn Cdca8 
Col4a5 Zbtb41 Fam26f Dcun1d5 
Clpx Phyh Ap1g2 Huwe1 
Fbxo18 Arap1 Ranbp10 Gm12716 
Ciao1 Tmco6 Plcb4 Cd33 
Slc17a9 Nfe2l1 Zfp81 Nedd4 
Ubtd1 Sbf1 Gm7512 Ddx46 
Ldlrap1 Zfp646 Dpy19l1 Actr1a 
Vps39 Trem3 Zbtb45 Bcat2 
Cyth1 Arsa Depdc1b R3hdm1 
Jmjd6 Gnaq Dctn1 Ncstn 
Bag5 Serinc5 Gm9517 Rpl28 





Glt8d1 Rmnd5a Galc Rp9 
Sipa1 Gata3 Ptafr Pdcd6ip 
Dhx30 Xxylt1 Gm20696 Tfrc 
Mettl2 Gna15 Fcgr3 Gm8806 
B230219D22Rik Ptger2 Arl8a Rpl7a-ps3 
Neu1 Map2k6 Plk-ps1 Raver1 
Xbp1 Fbxo28 Chd3 Fip1l1 
Tbc1d17 Ralbp1 Pcnx3 Paip2b 
Akr7a5 Nusap1 Htt Mrps12 
Rprd1b Atg2b Nkg7 Pnn 
Fam63a Mfng Polr1a Trf 
Tst Lgals3bp N6amt1 Nisch 
Ebf1 Mdm1 Cyb5r1 Ppig 
2510039O18Rik Snip1 Gm21738 Ep400 
Gla Pnpo Safb2 Fubp1 
Opa3 Amz1 Necap2 Ctsg 
Dgcr2 Fam96b Plxnd1 Dtnbp1 
Prodh Tmem68 Glul 4930519L02Rik 
Prpf38b Plpp2 Pcdhgc3 Gm6560 
Atad3a Slc9a1 Fam126a Ubald2 
Akr1b10 Dmap1 Stxbp5 Hoxa9 
Keap1 Ccdc61 Lsm10 Cd63 
Atf7ip Ctdsp1 Tarsl2 Aldoart2 
Ints5 Pelp1 Rabl3 Eno1b 
Eml3 Fam98a Akirin2 Thrap3 
Ccdc71 Ing2 2310075C17Rik Man2b1 
Kif2c Ifi204 Gm3470 Hk3 
Rbpms2 Tada2a Smad5 H2-K1 
Gne Mettl5 Ring1 Pdap1 
Btbd10 Dffb Tob2 Pold2 
Poldip3 Msrb2 Gtpbp1 Ctsd 
Letm1 Prpf3 Cox11 Brd3 
Mrps31 Erg Hist1h1a Prrc2c 
Meis1 Asb3 Fchsd2 Gm10819 
Rere Arhgef3 Kif18a Hdlbp 
Rad9a Cwc22 Gemin8 Calr 
Myo1c Extl3 Eps15 Gm5814 
Cpt1a Tiam1 Pced1a Srrm2 
Telo2 Rassf1 Zfp277 Rrbp1 
AI467606 Hinfp Dhx33 Gm9826 
Hist1h2bc Gga3 Naa40 Ccdc124 
Pde4a Polr3b Tm7sf2 Srp72 
Rwdd4a Rnf214 Prkaca Rnh1 
Pvr Klhl12 Ugt1a7c Sf3b2 
Kansl3 Ipp Rexo4 Ing4 
Nudt9 Rnf166 Kat5 Eya1 
Ampd2 Naa25 Gpr89 Nipsnap3b 
Tmem40 Dhcr24 Actr8 Mff 
Ccnl2 Mettl7a1 Dolpp1 Adgrg1 
Leo1 Fadd Lrrc24 Pkm 
Agpat4 Ggact Rapgef2 Iqgap1 
Afap1 Stau2 H2-Q5 Sucla2 
Mettl16 Tgfbr1 Dus3l Smarca4 
Gm17018 Rpap2 Rnf44 Ero1l 
Gcdh Tespa1 Asph Gm42418 
Wdr73 Xrcc1 Hdgfrp2 Prdx5 
Gpr65 Bet1l Tmem184b Gm5276 
Naglu Cutc Igkv4-90 Nfu1 
Gga2 Fnbp1 Fam222b Dctn3 
Mavs Rdh13 Otud5 Lyl1 
Usp21 Mfsd12 Otulin Sdf2l1 
Hmg20a Fbf1 Sptan1 Dnmt1 
Cpt2 Pus10 9330159M07Rik Gm5424 
Eaf1 Cep120 Mid1ip1 Hist1h1e 
Mvd Mpi Tmem203 Eno1 
Ablim1 Nemp1 Gm5578 Mrfap1 
Rbpms Slain2 Midn Ddx1 
Gjb3 Tspan5 Zfp36l1 Gm13612 
Kctd5 Slc35a2 Jmjd8 Slc39a7 
Mcat Acox1 Hipk2 Cd63-ps 
Mars2 Ubp1 Sec24a Sec61a1 
Wdr3 R3hcc1l Crtc3 Ctsc 





Hdac10 Irf3 Fam3c Rbmxl1 
Srbd1 Ttc17 Ywhag Foxp1 
Fam175b Add3 Sugp1 Stoml2 
Cep250 Rnf31 Zdhhc21 Ap3s1-ps1 
Lig3 Bmx Prrc2b Tram1 
Dhx16 Mbd1 Mettl4 Uba1 
Shkbp1 Rbm6 Gm20604 Gm4735 
Ube2c AI597479 Abi3 Plscr3 
Sec22a Slc19a2 Tbk1 Ndufs2 
Chd1l Car9 Mtfr2 Dhx9 
Wls Stxbp4 Pan2 Gm9575 
Tmem161a Tm2d1 SmarCD1 Ccl9 
Ccdc137 Qsox1 Itpk1 Gm4784 
Tbc1d14 Bcr Prcc Ube2i 
Ngrn Ubash3b Sla Gm11964 
Txnrd2 Mov10 Stk11ip Eif4a2 
Cry1 Adprm Gm12158 Edf1 
Card9 Trim8 Csf2ra Rab11b 
Atr 2700097O09Rik Bpnt1 Myb 
Sel1l Mtmr14 Npepps Gm7180 
Msmo1 Vgll4 Dmxl1 Anp32b-ps1 
Sec23a Tmem19 Kif4 Ccnd3-ps 
Slc25a24 Tnpo2 Trim14 Phb 
Triobp Rhoq Pam Rab11b-ps2 
Hyou1 Gm9144 Ano6 Arl1 
Gbe1 Ckap4 Zfp800 BC031181 
Btd Ppp1r10 Plk1 Drg1 
9630013D21Rik Eral1 Gnpda2 1110008F13Rik 
Dnase1l1 Stxbp3 Spry1 Lsm6 
Cd200r1 Kdm5b Casc3 Prtn3 
2610301B20Rik Ctdsp2 Gm5303 Rnaseh2c 
Gtf2h2 Zyg11b Msl1 Calr-ps 
Fance Dhx40 Setd7 Rbm25 
Pgghg Smcr8 Tcof1 Malat1 
Bscl2 Orc1 Mrps30 Lars2 
Spast Traf2 Abhd2 Hmgb3 
Cog4 Tsc1 Krt10 Sdhc 
Mvk Khnyn Eif4g1 Elavl1 
Agpat1 Ncoa2 Gm28417 Vim 
Cstf1 Phrf1 Foxm1 Hsp90b1 
Tvp23b Rnf41 Rab28 Lman2 
Ccdc86 Gpatch2l Slc19a1 Pfdn6 
Wdr24 Aspm Sft2d1 Chchd10 
Jak3 Rwdd2b Ube2h Pebp1 
Tmem184c Ankrd26 Rin3 Tmem59 
Ubl7 Pemt Tssc1 Gm4737 
Creb1 0610009O20Rik Gm18588 Psmc1 
Plekho2 Vmp1 Tmbim1 Ap2m1 
Lgals8 Wash1 Pcgf6 Gm12611 
Dhx35 Gatb Sars2 Psmd7 
Atp6v0a2 Tmco4 Tmem5 Cuedc2 
Arhgap27 Lclat1 Aldh16a1 Surf4 
Zfp180 Ppp4r1 Lrpap1 Gm13509 
Mipep Ccnb2 Ppt2 Aldoa 
Slc35a1 Pla2g6 Gm4258 Anp32b 
Cd27 Mrs2 Ripk1 CD164 
Wdr6 Rabggta Mbip Csde1 
Akt1s1 Nfyc Gm13880 Npm3-ps1 
Cog1 Cstf2t Gm10801 Anp32e 
Nrf1 E2f6 Ncoa3 Gm6517 
Banp Slc28a2 Rasa3 Pdia6 
Wrap73 Ddx54 Igkv12-89 CD47 
Ppox Mknk2 Rangap1 Psat1 
Fem1b Ipmk H2-M3 Akr1b3 
Dnaja3 Mettl13 Elmsan1 Cox7c 
Taok1 Snx15 Rcbtb2 Tmbim6 
Diaph1 Usb1 Ndrg3 Eif4h 
Srd5a3 Zmym5 Faf2 Gm9824 
Scamp3 Mvp Gga1 Aldoart1 
Kcnab2 Ggh Fntb Selenok 
Pggt1b Ppp1r12c Arhgef12 Nono 
Dnmt3b Iqce Ppp2r5a Pgk1 





Fam207a Cby1 1810044D09Rik Cct2 
Dcaf17 Rnpc3 Pmm2 Rsu1 
Arntl Lpcat1 Supt20 Manf 
Rag2 Ip6k1 Cxxc5 Pgam1-ps2 
Ice2 Nudt22 Ppwd1 Tkt 
Pum1 Kctd1 Gm23130 Itm2b 
Agtrap 2610020H08Rik Sfswap Gm7901 
Smyd3 Nus1 Scap Rpn2 
Klc4 Scmh1 6330562C20Rik Etfb 
Wdr83 Zfp146 Saal1 Arpc1b 
Strip1 Dpy19l3 1700003F12Rik Rnaset2b 
CD84 Rapgef6 Sumf1 Ubc 
Armc8 Cebpg Fzr1 Rbm8a 
Decr1 Rnmtl1 Spsb3 H2-D1 
Ado Lman2l Slc25a1 Serpinb1a 
Rpap1 Kif14 Pisd-ps1 Prdx6b 
Gm16194 Trdmt1 Ino80dos Rbm39 
Slc25a19 Il3ra Ccdc69 Gm5637 
Tmx4 Gpank1 Mtmr6 Glrx3 
Tusc3 Pgam5 Klf6 Gm12669 
Ngly1 Ttc39c Heatr6 Gm12020 
Chek1 Exo5 Bod1l Atp5a1 
Wbscr16 Dbt Gm12397 Pgam1 
Zfp266 Tapbpl Ehbp1l1 Ucp2 
Dis3l S1pr4 Hint2 Cct6a 
Tbc1d19 Vars2 Cmtr1 Tomm20 
Rgs14 Ddx31 Oxr1 Gm6368 
Selenbp1 Trp53bp1 Wdfy2 Srgn 
Pgm3 Cmas Gm9200 Hsp90ab1 
Aim2 Fbxo6 Snord100 Clic1 
Sec14l1 Ighmbp2 Pycr2 Park7 
Ska3 Vegfb Mark2 Capzb 
Urb2 Tns3 Gm7856 Ldha 
Vipas39 Vkorc1l1 Arid5b Tdpx-ps1 
Ddx11 Ccdc94 Net1 Selenoh 
Pqbp1 Kmt2a Gm7334 Serbp1 
Katnb1 Kctd13 Gm3436 Vdac2 
Tusc2 Mapk8ip3 Myh9  
Golga4 Ddx55 Cdkn2c  
 
 
1340 genes downregulated in EV-transduced cells 
Gjb3 Pdss2 Chchd4 Fubp1 
Cd99l2 Gm12158 Pla2g4a Ampd2 
Slc25a29 Gm21807 Ift57 Utp11l 
Thsd1 8430408G22Rik Fer Gfm1 
Ptgir Fndc3b R3hcc1 Ptprcap 
Ppic Gm4349 Gm24452 Gm11847 
Zfp775 Cd302 Zfp101 Gm14109 
Gm807 Jpx H2-Q7 Nme1 
Gpc3 Dab1 Zfp512b Ndc1 
Adgrl4 Adat1 Gm5385 Gm5069 
Slc45a3 Gm37666 Snord22 Mrps28 
Gfra2 Zfp566 Itga6 Znhit3 
Igll1 Mt2 Snx27 Trim28 
Dntt Galc Tspan13 Ifrd2 
Gfra1 Vpreb1 Gm5124 Ripk3 
Angpt1 Vangl2 Aldh18a1 Cdk7 
Emid1 Mrgpre Mfsd13a Ndufaf2 
Cand2 Dennd5b Bzw2 Cad 
Chl1 1700003F12Rik Phgdh Endod1 
Slc43a1 Zdhhc24 Zak Chchd5 
Cul7 Gdf11 Acaca Gm6640 
Hmgcll1 Slc18a1 Unkl Nme6 
Ptk7 Kcnq5 Srgn Wdr77 
Hgf Pla2g6 Bambi Pus10 
Gpr12 Tmem40 Ttc37 Gm11914 
4930519L02Rik Il6 3110082I17Rik Gm7781 
Ptprm Zfp507 Zfand4 Trappc13 
Ablim1 Prkca Mif Pgam1-ps2 
Rbpms2 Tnfsf13os Fancd2 Rps2-ps10 





Rag2 Xpnpep3 NudCD1 Gar1 
Aebp1 Qtrtd1 Guf1 Oaz2-ps 
Dlg2 Zfp934 Tma16 Gcsh 
Hoxa10 G2e3 Gm13998 Hadh 
Ica1 Dnmt3b Mcph1 Mrpl50 
Fat4 Brinp3 Spint2 Gm7666 
Muc13 D130058E05Rik Zbtb38 Pgk1 
Sh3d19 Clstn1 Kctd1 Ybx3 
Ebf1 Fam35a Orc2 Gm16074 
Pear1 Ppfibp1 Gm10169 Ruvbl1 
Col4a5 Ttc39c Gpatch4 Aasdhppt 
Gimap6 Prss57 Zfp672 Snhg4 
Rcn1 Tst Wdr6 Gm9143 
Ddx4 4732463B04Rik Bphl Abhd11 
Gata3 Simc1 Gm4353 Rps6 
Csgalnact1 Gm8113 Gm5455 Slc7a6 
Sema3a Fancb Ppp1r14b Gm16433 
Car2 Unc13a Nudt7 Selenom 
Hlf Mmp13 Gm14328 Bcap29 
Galnt14 Ppp1r13b Grhpr Ubxn8 
Tacstd2 Gm9847 Gm5946 Comtd1 
Mcpt8 Uevld SCD1 Pi4k2b 
Limch1 Camsap1 Stat4 Sssca1 
Aldoc Ube2cbp Rpp14 D16Ertd472e 
Plod2 Katnal1 Qsox1 Mrpl38 
Erg Txnrd3 Ints3 Gm13700 
Ms4a3 Col23a1 E130308A19Rik Pom121 
Ctla2a Gm30074 Strbp Chordc1 
Psd3 9930104L06Rik Kti12 Nudt5 
Nefh Taf1a Gm43297 Ntmt1 
Ubash3a Cep41 Dnajc12 Ergic1 
Cd27 Mnd1-ps Suv39h2 Taf5l 
Ppp1r14c Pomk Ddx1 Eef1g 
Vamp5 Klhl12 Samsn1 Mrps31 
Tnfrsf26 Pde8a Mgat5 Por 
Dnajc6 2610008E11Rik Wdr55 Blm 
Car3 C230034O21Rik Cd24a Pum3 
Tmem108 Msantd3 Gclm Anks1 
Gab1 Nav2 Bmi1 Gm8522 
Arhgap6 Selenon 3000002C10Rik Gm15484 
Plscr4 Mnd1 Gm7332 Gm6501 
Pcdh7 Spry2 Gm1818 Rrs1 
Slc28a2 Kcnq3 BC017158 Atg12 
Armcx1 Tspan32 Mns1 Rpl36 
St6galnac3 Zfp40 Plppr3 Ubfd1 
Atp11a Hyal2 Ftsj1 Gm26917 
Ptgds Zfp748 Fam92a Smyd2 
Rag1 Pdpr Tspan2 Top3b 
Ltbp3 Kctd4 Ints6 Fbxo9 
F2rl3 Trem3 Plpp5 Gm11896 
Afap1 Fam114a1 Pus7 Gstp-ps 
Fam160a2 Dach1 Galk1 Paip2 
Pecr Gm16104 Akap1 Gm4735 
Dync2li1 Pus7l Srm Clpp 
Cbx2 Ankrd13b Spout1 Mcm2 
Tnik Sapcd2 Sergef Fkbp3 
Rhoj Hmgb3 Gemin4 Stam 
Wbscr27 Mlh3 BC055324 Mvb12b 
Ednra Pced1b Gm10020 Gm17837 
Acot3 Layn Nipsnap1 Gm4366 
Rgcc Kremen1 Selenbp1 Ddx56 
Mab21l1 Ctnnal1 Gm43096 Stk26 
Gm15261 Thy1 Yod1 Cluh 
C030034L19Rik 2610306M01Rik Abcb8 D5Ertd605e 
Itga9 Ahdc1 1110008L16Rik Cenph 
Oxnad1 Zhx2 Eya1 Pabpn1 
Armcx2 Gca Adgrg3 Mir5099 
B230118H07Rik Smim24 Itgb3bp H2-Q6 
Kit Chchd10 Gm6652 Gaa 
Zfp239 Zfp932 Bcl7a Eif1ax 
Lbp Cep97 Gtf2f2 Lman1 
Gstt2 Stxbp5 Kansl1l Ipo11 





Bmx Gm6104 Pbx4 Psme3 
Adgrg1 Il31ra Gm5847 Mthfd1 
Gm10384 Prelid2 Gm5864 Mesdc2 
Traf4 Larp1b Smpd4 Borcs7 
Fgf10 6330562C20Rik AI987944 Gm13719 
Ocrl Ube2o Pam16 Emilin1 
Map9 1190007I07Rik Snord55 Gstp1 
Nrgn Exo5 Gm23246 Gm7556 
Pglyrp1 Hist1h1a Polr1b Mycbp 
Mc5r Spice1 Dirc2 Gm17709 
Hmga2 Hyls1 Ccdc167 Ninj1 
Slc22a4 Cmss1 Gm15659 Cdk4 
Bhlhe41 Mtx3 Pitrm1 Rfc4 
Dpy19l3 Tnnt1 Fam136a Cbx5 
Lima1 Akap7 Rrp1b Hmgcr 
Gimap9 Slc35d3 1110004E09Rik Gm8173 
Tal1 Osbpl7 Gm17494 Tia1 
Rpusd2 Etfbkmt Grwd1 Srek1ip1 
Bcat1 Ccdc181 Fam216a Ftsj3 
Gm3470 Gm9256 Lyar Icam2 
Hoxa9 Gas2 Gm14769 Gm10819 
Plcb4 Bhlhb9 Sord Eno1 
Rai14 Sirt5 Rint1 Asf1a 
Dab2ip Tfrc Kcnq1ot1 Dhx30 
Phlda3 Slc37a1 Enkd1 Cit 
Epha7 Gm37818 Gm14450 Pebp1 
Abhd6 Capn3 Hist1h2bj Gm13368 
Igkv4-90 Gm16341 Nup37 Gm9824 
Col19a1 Gm37422 Gm13502 Bola1 
Cbx6 Prkar2b Reps1 Gm12115 
Ptger2 Gemin5 Fam162a Trap1 
4930555A03Rik Impdh1 Trp53bp1 Hddc2 
Efna5 B230369F24Rik Pdlim1 Rpl27 
Spry4 Gm37510 Cdkn2aipnl Nomo1 
Gimap1 Rpusd3 Gm17066 Prep 
Ighv1-23 Gfi1b Mettl1 Rpl31 
Ccdc15 Aak1 Abcb6 Tpi-rs11 
Plxna3 Dok2 Gm5703 4921524J17Rik 
Mmp11 Abhd17c Nolc1 Rps12 
Pi15 Ippk Snhg15 Klhdc2 
Mettl15 Gtf3c4 Spata24 Pold2 
1700030K09Rik Lins1 G6pc3 Gm6447 
Mzb1 Angptl4 Acot2 AI314180 
Gcnt4 Urb2 Utp20 Tmem254c 
Igfbp7 Rrp12 Gm4737 Tomm5 
Dnajc27 Dctd Cdk6 Gm5593 
Ahi1 Zfp219 B3galnt2 Ktn1 
Lsmem1 Mettl4 Las1l Gnl3 
Aasdh Sh3rf1 Wdr12 Aimp2 
2810002D19Rik Rbak Cerkl Gm5611 
Gsta4 Zfp979 Dnph1 Gart 
Htra3 Gm37124 Lmo4 Gm13552 
Spns2 Dtx4 Jmjd8 Tfap4 
Tspan6 Exoc8 Rai1 Nsun2 
Zfp783 Slc35b4 Nt5c3b Nop56 
Gata2 Gse1 Nob1 Tpi1 
Mpo Utp14b Gm13337 Haus1 
Kcnj2 Tceanc Rasgrp2 Clec4e 
Maged2 Etv4 Exosc2 Oaz2 
Mei4 Tmem67 Trub2 Tufm 
Jmjd4 Micall2 Flnb Mrto4 
Kcnip3 Wdr5b 2900026A02Rik mt-Nd2 
Senp8 Lrrc20 Nme4 Ptpn7 
Amer1 L2hgdh Ahcy Drap1 
9630013D21Rik Gm29397 Wdr75 Nifk 
Gda Bag2 Eef1e1 Mrpl15 
Stxbp4 Kif17 Dnaja3 Tyms 
Tnk2 Mroh2a Mdn1 Gm37201 
Socs5 Crnde Cdkn2c Gadd45gip1 
Sort1 Sox4 Gnpnat1 Rnf220 
Gm26580 Poli Sptbn1 Tmem70 
Cngb1 2610301B20Rik Xpo7 Gm7244 





Arpp21 Rbpms Pcp4l1 Ptcd3 
Gm38391 Lamc1 Rmnd5a Adsl 
Dennd6b Polr3g Pitpnc1 Gm4705 
Rtn4r Ankrd26 Gm7512 Polr2f 
Map7d2 Ap4e1 Smyd5 Gsr 
Olfml2b Ino80dos Gm4879 Cisd3 
Pde2a Arap2 Gm20156 Clec4d 
Cited1 Usp31 Sumf2 Ttc3 
D630045J12Rik Ypel1 Ifi27 Ppan 
4930509E16Rik Dzip3 Gm9826 Rpl12 
Nck2 Rdh13 Dtnbp1 Gm9755 
Tha1 Pofut1 Fasn Tmem97 
2310075C17Rik Prodh Ccl9 Ddx18 
Mmp14 Zfp428 Nt5dc2 Gm21887 
Tarbp1 Zscan22 Hspd1-ps3 Stk16 
Abcd2 Spata7 Msi2 Gm13937 
Ctxn1 Lyrm9 Pfkl mt-Te 
Camkk1 Ppm1f Fam65a Psmd5 
Slc25a43 Amot Abhd2 Gm7289 
Rapgef3 Cnn3 PdCD4 Cnpy4 
C920006O11Rik Anxa9 Nfe2 Rsl1d1 
Gm20696 Msrb2 Mthfd1l Syncrip 
Rnf125 Gm5530 Pabpc4 Gspt1 
1700012B09Rik Rptor Gm23130 Ssbp1 
Mgmt Golim4 Nipsnap3b Gm8520 
Myo19 Dnajb4 Zbed4 Arid4b 
Fam220a Gm16897 Tfb2m Gm5297 
Gem Slc17a9 Lyrm2 Gm15654 
Taco1 Fancf 1810032O08Rik Cnpy2 
Car8 Calcrl Gm5251 Gm7389 
Armcx4 Ero1l 3110040N11Rik Syce2 
Slc38a5 Myl4 Mtap Dnajc2 
Zfp874a Cbr1 Susd1 Atp5g1 
Hsd17b14 Brwd3 Sigirr Rps8 
Slc9a3r2 Hist1h3d Hspd1 Gm27219 
Nkg7 Kdm5b Hibch Eif3j1 
Spag4 Mphosph9 Ppif Nop2 
Cdc14b Polr3d Gm16465 Paip1 
Pcbd1 Meis1 Gm9260 Dtymk 
Arv1 Zfp703 Gm6166 Gm12583 
Engase Gm17936 Dkc1 Sfxn1 
Dusp18 Rttn Pop1 Noc2l 
Nrxn1 Iqsec1 Pcyox1l Hdgf 
Srr Cep57l1 HaCD1 Golgb1 
Gm15658 Ldlrad3 2610318N02Rik Gm13776 
Zxdc Cep89 Snora68 Cbx3 
Bhlha15 Gprasp1 Timm9 Rps13-ps4 
Cela1 Snapc4 Ruvbl2 Rsbn1l 
Amacr Ttll5 Cdca7l Hspbp1 
Fkbp11 D3Ertd751e Sos2 Cct3 
Gm15581 Bsn Bora Psmg1 
Sipa1l1 Dgat2 Cycs Cand1 
Ttll1 Wwc2 Prps1 Gm5687 
Wdr60 Cmtr2 Gm17230 Nop10 
Ccdc66 Plscr1 Rpl21 Gm19031 
Dok4 Ptch1 2610002M06Rik Ndufb2 
Dusp4 Hoxa6 Ndufa4 Hmgn5 
Afap1l1 CD81 Mif-ps3 Ipo5 
Igkv12-89 Elk3 Trip13 Fto 
B9d1 Tsen15 Stap1 Zbed3 
Nlrx1 Ppfia4 Gm4258 Msh6 
Fkbpl Atat1 Mt1 Rcn2 
Serpinb1a Shmt1 Lmo2 Pfas 
Thap2 Hoxa5 Mkrn2 C1qbp 
Zfp503 Gm6505 Gm6960 Gm42814 
Zfp184 1810014B01Rik Crtap Gm11993 
Rasd1 Ovca2 Phb Gm8459 
4933404O12Rik Ydjc Sh2d5 Pgam1 
Zfp329 Psat1 Hk3 Gm13498 
Egln3 Mmd Hoxa7 Gm15770 
Ttll9 Zfp799 Ssfa2 Ift27 
Gm11998 Mccc2 Ncl Eno1b 





Slc29a2 Snap47 2410016O06Rik Gm5525 
Hemk1 Ldlrad4 Rfx3 Eif3b 
Tnfrsf22 Ada Ctps Akap13 
Zfp160 Cry2 Gm11451 Rnaseh2c 
Spa17 Repin1 Zcchc11 Mrps18b 
Ascl2 Acyp1 Mtf2 Tnpo1 
Pif1 Parp16 Msto1 Polr3k 
Fam188b Gm14057 Gm5551 Npm3 
Gm37060 Dtd1 Hcst Wdr74 
Fktn Ap3s1-ps2 Mrpl44 Mcfd2 
Raet1d 1190002N15Rik Gm5855 Mdh2 
Gpam Slc19a1 Lamp3 Idi1 
Ctsg Arhgap18 Ppp1cb Pa2g4 
Rsph9 Aldh6a1 Dlat Gm11516 
Lekr1 Cd34 Fchsd2 Chaf1b 
2810403D21Rik Gm5874 Nedd4 Got2 
Itih5 Hist1h3f 1110038B12Rik B3gnt2 
9230114K14Rik Ccdc40 Nutf2 Med29 
Armcx6 Rnf219 Ska2l-ps Sephs2 
Sntb2 Tmem69 Bace1 Fmc1 
Raet1e Fam212a Hsd17b10 Ilf2 
Nrg1 Cd320 Snhg5 Nhp2l1 
Per3 Gm17149 Tmem107 Mcee 
Zfp113 Trp53rkb Gm5837 Cct6a 
Mex3a Cenpv Ppid Flt3 
Tom1l1 Nol8 Gm12020 Calu 
Ttc26 Slc25a15 Asph Gm42418 
Gm1976 Ercc6 2810004N23Rik Ogt 
Zfpm1 Pde4d Umps Gm9531 
Tesc Hgh1 Nop58 Paics 
Rbp1 Cdca7 Gm14630 Kpnb1 
Gmpr Wdr34 Fkbp4 Wdr36 
Rab44 Il12a Hells Hspa9-ps1 
Col11a2 1110051M20Rik Dusp12 Pcyt2 
Acot1 Gm9797 Lsm3 Fxn 
Ppargc1b Mcm3ap Hist1h2ac Mlec 
Zc3hav1l Hilpda Pdrg1 Prdx6 
Asap2 Smad3 Psmg2 Gm14857 
Ccdc125 Zfp280c Gm14681 mt-Tt 
SpoCD1 Nup43 Fam133b Dars 
Irx2 Ipp Slc16a1 Brix1 
Jade2 Dhx33 Dnajc10 Snhg6 
Chsy1 Tsc22d1 Ak2 1810022K09Rik 
Rhoq Plscr3 Gm17251 Yaf2 
Epha4 Zfp369 Dph5 Tcp1-ps1 
Kcnh7 Rpgrip1 Haus3 Prdx3 
Dus4l Fabp5 Gm7933 Ube3a 
Zcwpw1 Fam78a Rpl36a Rrn3 
Vkorc1l1 Ap3s1 Idh3a Nudt19 
Tctn3 Sdhaf3 Rasa1 Prmt5 
Mgarp Cirh1a Pgm2 Hsp90ab1 
Fbxo25 Timm8a1 Ppat Twist1 
4930520O04Rik Hspa13 Etfb Mrpl12 
1700113H08Rik Vwa8 Cd72 Npm3-ps1 
Pomgnt1 Ap3s1-ps1 Tfdp2 Dnm1l 
Nicn1 Tex9 Ppcdc Gm8069 
Pcsk4 Proser3 Gm13521 Gm8741 
Sgsm2 Frat2 Npm1 Gm12955 
Gm20342 Osbpl5 Gm10110 Nudt3 
Mmp12 Tfpi Atad3a Gnpat 
Mllt3 Irak1bp1 Paip2b Psmd7 
Zfp606 St14 Timm10 Thyn1 
Dand5 Serf1 Klhl9 Gm7251 
Socs2 Mmachc Rcc1 Prdx6b 
Myb Tmem186 Tspan5 2810025M15Rik 
Hexim2 Papss2 Chek1 Dut 
Adgrg7 Gm4535 Gng12 Rbmxl1 
Pex10 Scly Polr1c Gm12848 
Gfod2 Ddah2 Gm11349 Dcun1d5 
Zfat Zc3h7b Abce1 Chtf8 
Bbs12 Zfp687 Rcl1 Gm10131 
Zfp597 Miga1 Pnkd Luc7l 





Vsig10l Zfp146 Gm43213 Abcf2 
Phc1 Alg2 Kdelc1 Cacybp 
Gimap5 Gm12611 Atr Tdg 
Ell2 2300009A05Rik Rad18 Gm6065 
Elane 4930581F22Rik Gm3362 Rpl36-ps2 
Nlgn2 Nmnat3 Ern1 Nip7 
P3h1 Sdc1 Gm15800 Ccnh 
Ccdc88c 9330159M07Rik Amd1 Faf1 
Gm16194 Vat1 Thop1 Erh 
2610307P16Rik Hist1h2bk Gm15528 Ddx21 
Zfp335os Gm7901 Prtn3 AI506816 
Zfp707 Slc20a2 Polr3h Scd2 
Mterf2 Gm16302 Mybbp1a Ccdc58 
 
 
Table 11: 653 genes which are upregulated during differentiation of EV cells, identifying those genes 
which have an associated C/EBPα peak in both ChIP-seq replicate experiments at Day 5 of 
differentiation 
1600014C10RIK DPP4 LPP RNF166 
2310035C23RIK DPY19L1 LPXN RNH1 
3110043O21RIK DPYSL2 LRCH1 RNPEP 
5031439G07RIK DRAM1 LRP1 RPS6KA1 
AB124611 DTX2 LRRC25 RSAD2 
ABCG1 DUSP1 LRRC75A RTP4 
ABHD12 DUSP10 LRRFIP2 RUNX1 
ABHD15 DUSP22 LRRK1 S100A11 
ABI1 DUSP3 LSP1 SAMD8 
ACAA1A DYRK1A LST1 SAMHD1 
ACBD5 E2F2 LY6E SAT1 
ACER3 EGR1 LY86 SBNO2 
ACOT9 EHD4 LY9 SCARB2 
ACSS1 ELMO2 LYN SCIMP 
ACTA2 ELMSAN1 LYZ1 SDC3 
ACTR3 EMILIN2 LYZ2 SDC4 
ADD3 ENSA MACF1 SEC24B 
ADGRE1 ENTPD1 MALAT1 SELPLG 
ADGRE4 EPB41L2 MALT1 SEMA4A 
AFF1 EPB41L4B MAML1 SEMA4D 
AHNAK ERLIN1 MAP3K1 SESN2 
AI839979 ETV3 MAP3K3 SGK3 
AIM2 EVL MAP3K8 SGPL1 
AKR1A1 F630028O10RIK MAP4 SGPP1 
AKT3 FAM105A MAPK14 SH3BP2 
ALDH3A2 FAM129A 36951 SH3GLB1 
ALOX5 FAM129B MAX SIDT2 
ALOX5AP FAM174A MBNL1 SIGLEC1 
ANKRD44 FAM46C MCL1 SIRPA 
ANXA1 FAM49B MDFIC SKIL 
ANXA2 FAM69A MEF2A SLAMF7 
ANXA6 FAR1 METRNL SLAMF9 
AP2A2 FBRSL1 MFSD5 SLC15A3 
APBA1 FCGR3 MGAT4A SLC15A4 
APBB1IP FCGR4 MICAL1 SLC16A7 
APOBEC1 FEM1C MILR1 SLC29A3 
ARHGAP15 FES MKNK1 SLC2A6 
ARHGAP25 FGD3 MOB3A SLC31A1 
ARHGAP31 FGR MPEG1 SLC35C1 
ARID5A FILIP1L MS4A4A SLC37A2 
ARL4C FKBP15 MS4A4B SLC43A2 
ARL5C FKBP1B MS4A4C SLC44A2 
ARL6IP5 FLNA MS4A6B SLC6A6 
ARPC5 FMNL1 MS4A6C SLC7A8 
ARRB2 FNBP1 MS4A6D SLFN1 
ASGR2 FNIP2 MSRB1 SLFN2 
ATF3 FOS MTHFS SMIM3 
ATG7 FOXN2 MYADM SMOX 
ATP2B1 FOXRED2 MYD88 SMPDL3B 
ATP6V1B2 FRMD4B MYO1C SNX10 
AXL FTH1 MYO1F SNX2 





AZIN1 FYB N4BP2L1 SOAT1 
B430306N03RIK G6PDX NAGPA SOCS1 
B4GALT5 GAS7 NAIP5 SOCS3 
BACH2 GBP2 NAPSA SORL1 
BC005537 GCNT1 NCF2 SP100 
BCL2L11 GCNT2 NCKIPSD SP2 
BCL3 GGH NCOR2 SPG21 
BCL6 GM1966 NDEL1 SPI1 
BEX6 GM6377 NEAT1 SPOP 
BHLHE40 GM7367 NECAP1 SPTY2D1 
BIN1 GM8369 NEDD9 SQSTM1 
BLVRB GNA15 NEK7 SRGAP2 
BROX GNG2 NFAM1 SSH1 
BTG2 GNS NFATC1 ST18 
C3 GPR108 NFE2L2 ST3GAL2 
C3AR1 GPR132 NFKBIA ST8SIA1 
CADM1 GPR141 NFKBIZ ST8SIA4 
CAMK1D GPR146 NLRP3 STAT1 
CAP1 GPR155 NOS1AP STAT6 
CAPG GPR160 NOTCH2 STK17B 
CAPN2 GPR183 NPC2 STX7 
CAPZA2 GPR34 NPTN STXBP3 
CARD11 GRB2 NR4A1 SUB1 
CARD19 GRN NRP1 SUSD3 
CASP4 GSAP NRROS SYK 
CAST GSDMD NUAK2 SZRD1 
CBL GSN NUB1 TAGAP 
CCDC109B HACD4 NXPE4 TALDO1 
CCDC12 HCAR2 OSBPL9 TBC1D13 
CCDC180 HCFC1R1 P2RX4 TBC1D8 
CCDC50 HCK P2RX7 TBC1D9 
CCDC86 HDAC4 P2RY6 TDRD7 
CCL2 HERPUD1 PADI2 TEC 
CCL3 HEXA PAG1 TECPR1 
CCL6 HEXB PAK1 TEP1 
CCR1 HK2 PDXK TET2 
CCR2 HLX PELI1 TFEB 
CCRL2 HMHA1 PFKFB4 TGFBI 
CD14 HMOX1 PHACTR2 THAP6 
CD22 HPCAL1 PIAS1 THEMIS2 
CD244 I830077J02RIK PID1 TIFA 
CD28 ICOSL PIK3AP1 TIPARP 
CD300A ID3 PIK3CD TLE3 
CD300LB IDS PIK3R5 TLR1 
CD300LF IER2 PILRA TLR13 
CD48 IER5 PIP4K2A TLR2 
CD52 IFI205 PIRB TLR4 
CD53 IFITM3 PISD TLR6 
CD68 IFITM6 PLAC8 TMEM106A 
CD74 IFNAR1 PLAUR TMEM150B 
CD82 IFNAR2 PLCL2 TMEM154 
CD86 IFNGR1 PLD4 TMEM184B 
CD9 IFNGR2 PLEC TMEM189 
CDC42SE1 IGSF6 PLEKHA1 TMEM192 
CDC42SE2 IL10RA PLEKHF2 TMEM229B 
CDKN1A IL13RA1 PLEKHG3 TMEM243 
CFH IL15 PLEKHM1 TMEM50B 
CHMP4B IL17RA PLEKHM3 TMOD3 
CHN2 IL18 PLEKHO2 TMSB10 
CIB1 IL1R2 PLIN2 TMSB4X 
CKB IL21R PLXDC1 TNFAIP2 
CLCN7 IL3RA PLXNC1 TNFRSF13B 
CLEC4A2 IL4RA PMAIP1 TNFRSF14 
CLEC4B1 IL6RA PNKP TNFRSF1A 
CLEC4N IL6ST PNPLA7 TNFSF8 
CLEC7A INPP4A POT1B TOR1A 
CLN8 IQGAP1 PPP2R5A TOR1AIP1 
CMIP IQGAP2 PRDX5 TOR3A 
CMPK2 IRAK2 PREX1 TPD52 
CMTR1 IRF2BP2 PRKAB2 TRAFD1 
CNDP2 IRF5 PRKCD TREM2 
CNR2 IRF8 PRKCH TSPYL1 





CORO1B ITGA1 PRKX TUBGCP5 
COTL1 ITGAM PRR13 TULP4 
CRLF2 ITGAX PSAP TXNDC16 
CTNNA1 ITGB2 PSEN1 TYROBP 
CTNND2 ITM2B PSTPIP1 UBC 
CTSB ITPR1 PSTPIP2 USP12 
CTSC JAK2 PTAFR USP18 
CTSD JUNB PTGER4 USP25 
CTSE KDM7A PTK2B UVRAG 
CTSZ KIF1B PTPN1 VAPB 
CTTNBP2NL KLF10 PTPN22 VASP 
CX3CR1 KLF13 PTPRA VCL 
CXCL16 KLF3 PTPRC VIM 
CXCL2 KLF4 PTPRJ VPS37B 
CXCR4 KLF6 RAB3D VRK1 
CYB561A3 KLHL6 RAB8A VSIR 
CYBA KLRA17 RACGAP1 WDR1 
CYBB KLRB1F RALA WDR26 
CYFIP1 KLRK1 RAP1B WHSC1L1 
CYP4F16 LACC1 RAP2C WIPF1 
CYP4F18 LACTB RAPH1 XBP1 
CYTH4 LAIR1 RARA YTHDF3 
CYTIP LAMP1 RARG ZBP1 
D1ERTD622E LAPTM4A RASGEF1B ZBTB7A 
DAB2 LASP1 RASSF4 ZBTB7B 
DBNL LBH RASSF5 ZC3H12A 
DCAF11 LCP1 RBM47 ZC3HAV1 
DCK LCP2 RBMS1 ZCCHC2 
DCLRE1C LGALS3 RCBTB2 ZDHHC7 
DDIT3 LGMN RCHY1 ZFHX3 
DEGS1 LIFR RELL1 ZFP263 
DENND1A LILRA6 RGL1 ZFP277 
DENND1B LILRB4A RGS2 ZFP36L2 
DHX58 LITAF RGS3 ZFP710 
DIAPH2 LMLN RHOG ZFYVE26 
DNA2 LMNA RIN2 ZYX 
DNAJB14 LPCAT4 RIN3  
DOCK4 LPIN1 RMND5B  
DPEP2 LPL RNF115  
 
 
Table 12: Subset of 230 genes from Table 11 which are also upregulated in CEBPA N321D-
transduced cells during differentiation in Flt3L 
 
5031439G07RIK FAM105A LST1 RMND5B 
ABHD15 FAM129B LY6E RPS6KA1 
ABI1 FAM174A LY86 RTP4 
ACAA1A FES LYN RUNX1 
ACER3 FILIP1L LYZ2 SAMHD1 
AHNAK FKBP15 MAP3K1 SAT1 
AI839979 FMNL1 MAP3K8 SDC3 
ALOX5AP FRMD4B MAP4 SDC4 
ANXA6 FYB 36951 SEMA4D 
APBA1 GAS7 MBNL1 SLC16A7 
ARL4C GCNT1 MEF2A SLC2A6 
ARL6IP5 GCNT2 MILR1 SLC44A2 
AXL GNG2 MPEG1 SLC6A6 
BACH2 GNS MS4A4B SLFN2 
BCL6 GPR141 MS4A4C SMIM3 
BEX6 GPR183 MS4A6B SNX20 
BLVRB GPR34 MS4A6C SOAT1 
CADM1 GRN MS4A6D SP100 
CAMK1D GSN MYADM SPI1 
CAPG HLX MYO1F ST8SIA4 
CCDC180 HMHA1 NAIP5 STAT1 
CCL3 I830077J02RIK NAPSA STK17B 
CCL6 IFI205 NEAT1 STX7 
CCR1 IFITM3 NECAP1 TAGAP 
CD14 IFITM6 NFAM1 TDRD7 
CD28 IFNAR2 NFATC1 TEC 
CD300A IL10RA NFKBIA TECPR1 





CD300LF IL17RA NOS1AP TET2 
CD52 IL1R2 NOTCH2 TFEB 
CD68 IL6RA NPTN THEMIS2 
CD74 IL6ST NR4A1 TIFA 
CD82 INPP4A NRROS TIPARP 
CDC42SE1 IRF2BP2 P2RX7 TLR2 
CDKN1A IRF5 P2RY6 TMEM229B 
CFH IRF8 PAK1 TMEM243 
CKB ITGA1 PIK3R5 TMEM50B 
CLEC4A2 ITGAM PILRA TMSB10 
CLEC7A ITGAX PIP4K2A TNFRSF13B 
CLN8 ITGB2 PIRB TOR1AIP1 
CMPK2 KDM7A PLAC8 TOR3A 
CTNNA1 KLF13 PLD4 TPD52 
CTNND2 KLF3 PLEC TRAFD1 
CTSB KLHL6 PLEKHA1 TUBGCP5 
CTSE KLRB1F PLEKHF2 TULP4 
CTSZ KLRK1 PMAIP1 TYROBP 
CX3CR1 LAIR1 PREX1 USP12 
CYBB LAMP1 PRKCD USP18 
CYFIP1 LASP1 PRKX VSIR 
CYTH4 LBH PRR13 WDR26 
CYTIP LCP2 PSAP WHSC1L1 
D1ERTD622E LGALS3 PSTPIP2 YTHDF3 
DHX58 LGMN PTPRC ZBTB7A 
DPEP2 LIFR RARA ZC3HAV1 
DUSP22 LILRB4A RASSF4 ZFP263 
EHD4 LITAF RASSF5 ZFP36L2 
EPB41L4B LPXN RBM47  
EVL LSP1 RIN2  
 
 
Table 13: Subset of 126 genes from Table 12 which are also bound by FLAG antibody at Day 5 
ACER3 FRMD4B LY86 RASSF4 
AHNAK FYB LYN RBM47 
AI839979 GAS7 MAP3K1 RIN2 
APBA1 GCNT1 MAP4 RPS6KA1 
AXL GCNT2 36951 RTP4 
BLVRB GNG2 MBNL1 RUNX1 
CADM1 GNS MEF2A SDC4 
CAMK1D HLX MILR1 SEMA4D 
CCL3 I830077J02RIK MPEG1 SLC16A7 
CCL6 IFITM3 MS4A6B SLC2A6 
CCR1 IFITM6 MYO1F SMIM3 
CD14 IFNAR2 NAIP5 SOAT1 
CD28 IL17RA NECAP1 SPI1 
CD300A IL6RA NFAM1 ST8SIA4 
CD300LB IL6ST NFATC1 STK17B 
CDKN1A INPP4A NLRP3 STX7 
CLEC7A IRF2BP2 NOS1AP TAGAP 
CMPK2 IRF8 NOTCH2 TDRD7 
CTSB ITGAM NR4A1 TEC 
CTSE ITGAX NRROS TEP1 
CTSZ KLF13 PILRA TET2 
CYFIP1 KLF3 PIP4K2A THEMIS2 
CYTH4 KLHL6 PLAC8 TIPARP 
D1ERTD622E KLRB1F PLD4 TLR2 
DPEP2 LAIR1 PLEKHA1 TMEM229B 
DUSP22 LAMP1 PLEKHF2 TMEM243 
EHD4 LBH PMAIP1 TPD52 
EPB41L4B LCP2 PREX1 WHSC1L1 
FAM105A LGALS3 PRKCD ZC3HAV1 
FAM174A LGMN PSAP ZFP263 
FES LITAF PSTPIP2  







Table 14: Subset of 36 genes from Table 13 which are downregulated on differential expression 
between CEBPA N321D versus EV-transduced cells at Day 5 
ACER3 DPEP2 LY86 PREX1 
AHNAK FYB MPEG1 PRKCD 
AXL IFITM3 MS4A6B PSAP 
CCL6 IFITM6 MYO1F RTP4 
CCR1 IRF2BP2 NFAM1 TDRD7 
CD300A ITGAM NOTCH2 THEMIS2 
CMPK2 LGALS3 NR4A1 TLR2 
CTSB LITAF PLD4 TPD52 
CTSZ LY6E PLEKHF2 ZC3HAV1 
 
 
Table 15: Genes which have an associated FLAG peak at Day 5 in both replicate ChIP-seq experiments 
160 genes with high-confidence FLAG peak at Day 5 which are also downregulated on differential 
expression between CEBPA N321D and EV-transduced cells at Day 5 
ABCG1 DCK LACC1 PSTPIP1 
ABHD12 DEGS1 LAPTM4A PTAFR 
ACER3 DENND1B LGALS3 PTPN1 
ACTA2 DPEP2 LITAF RAP1B 
AHNAK DPP4 LMLN RBPMS 
ALPK1 DUSP1 LPCAT2 RCBTB2 
AMZ1 EMILIN2 LPCAT4 RGS2 
ANXA2 EP300 LY6E RHOG 
AOAH ESYT1 LY86 RSAD2 
APOBEC1 FAM129A LYZ1 RTP4 
ATF3 FAM69A MAN1A SEC24B 
ATP10A FCGR4 MAPK14 SIK3 
ATP2B1 FOS MARCH1 SIRPA 
ATP6V1B2 FYB MCTP1 SKIL 
AW112010 GBP2 MPEG1 SLC15A3 
AXL GM1966 MS4A6B SLC7A11 
B4GALT5 GPR160 MS4A7 SLC7A8 
C3AR1 GSAP MSRB1 SMPDL3B 
CCL6 HACD4 MYCBP2 SORL1 
CCR1 HCAR2 MYO1F ST8SIA1 
CD180 HIST1H1C NABP1 STK38 
CD22 HMOX2 NAMPT TBC1D8 
CD300A ID3 NFAM1 TDRD7 
CD84 IER2 NOTCH2 TGFBI 
CD9 IFITM1 NPC2 THEMIS2 
CDK14 IFITM3 NR4A1 TLR1 
CLEC10A IFITM6 NXPE4 TLR13 
CLEC4A1 IFNGR2 PDE7B TLR2 
CLEC4N IL15 PID1 TMEM150B 
CLEC5A INF2 PIK3AP1 TMSB4X 
CMPK2 IQGAP1 PIM1 TNFRSF1A 
CNDP2 IRAK2 PLD4 TNFSF8 
COTL1 IRF2BP2 PLEKHF2 TPD52 
CSF3R ITGAM PLEKHM3 TTC7 
CTSB ITM2B PLIN2 WIPF1 
CTSC ITPR1 PPP2R5A XDH 
CTSZ JAK2 PREX1 ZBP1 
CTTNBP2NL KCNK13 PRKCD ZC3H12A 
CYP4F18 KLF6 PRKCH ZC3HAV1 
DAB2 L1CAM PSAP ZYX 
 
 
49 genes with high-confidence FLAG peak at Day 5 which are also upregulated on differential 
expression between CEBPA N321D and EV-transduced cells at Day 5 
8430429K09RIK COL19A1 INSL6 SLC44A1 
ABCD2 CTR9 KATNAL1 SLPI 
ABHD6 CTSG LDLRAD4 SOCS2 
AFAP1 D930015E06RIK MYB SORCS2 
AK2 DHRS3 MYOG TACO1 





ATP1B3 DTX4 PI15 TRP53RKB 
AW209491 EPHA7 RAB44 XPC 
B3GNT2 FNDC3B RCN1 ZFP369 
BACE1 GAS2 SDC1 ZNRF1 
CBX2 HTRA3 SERPINB1A  
CHSY1 IL6ST SGCG  
COBLL1 INO80DOS SIX1  
 
 
 
 
 
 
 
 
